0000721371-19-000127.txt : 20191107 0000721371-19-000127.hdr.sgml : 20191107 20191107162042 ACCESSION NUMBER: 0000721371-19-000127 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 89 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191107 DATE AS OF CHANGE: 20191107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CARDINAL HEALTH INC CENTRAL INDEX KEY: 0000721371 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 310958666 STATE OF INCORPORATION: OH FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11373 FILM NUMBER: 191200639 BUSINESS ADDRESS: STREET 1: 7000 CARDINAL PLACE CITY: DUBLIN STATE: OH ZIP: 43017 BUSINESS PHONE: 6147573033 MAIL ADDRESS: STREET 1: 7000 CARDINAL PLACE CITY: DUBLIN STATE: OH ZIP: 43017 FORMER COMPANY: FORMER CONFORMED NAME: CARDINAL DISTRIBUTION INC DATE OF NAME CHANGE: 19920703 10-Q 1 a20q110q093019form10-q.htm 10-Q Document
false--06-30Q12020000072137175500000075500000032700000032700000080000000002500000500000002800000034000000 0000721371 2019-07-01 2019-09-30 0000721371 2019-10-31 0000721371 2018-07-01 2018-09-30 0000721371 2019-06-30 0000721371 2019-09-30 0000721371 us-gaap:TreasuryStockMember 2019-06-30 0000721371 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000721371 us-gaap:RetainedEarningsMember 2019-09-30 0000721371 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0000721371 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000721371 us-gaap:RetainedEarningsMember 2019-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2019-09-30 0000721371 us-gaap:CommonStockMember 2019-06-30 0000721371 us-gaap:CommonStockMember 2019-09-30 0000721371 us-gaap:NoncontrollingInterestMember 2019-07-01 2019-09-30 0000721371 us-gaap:NoncontrollingInterestMember 2019-06-30 0000721371 us-gaap:TreasuryStockMember 2019-09-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000721371 us-gaap:CommonStockMember 2018-09-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000721371 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0000721371 us-gaap:TreasuryStockMember 2018-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2018-06-30 0000721371 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0000721371 us-gaap:TreasuryStockMember 2018-07-01 2018-09-30 0000721371 us-gaap:TreasuryStockMember 2018-09-30 0000721371 2018-09-30 0000721371 us-gaap:NoncontrollingInterestMember 2018-09-30 0000721371 us-gaap:RetainedEarningsMember 2018-09-30 0000721371 2018-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0000721371 us-gaap:RetainedEarningsMember 2018-06-30 0000721371 us-gaap:CommonStockMember 2018-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0000721371 2019-07-01 0000721371 us-gaap:EmployeeSeveranceMember 2019-09-30 0000721371 us-gaap:EmployeeSeveranceMember 2019-07-01 2019-09-30 0000721371 us-gaap:FacilityClosingMember 2019-06-30 0000721371 us-gaap:EmployeeSeveranceMember 2019-06-30 0000721371 us-gaap:FacilityClosingMember 2019-09-30 0000721371 us-gaap:FacilityClosingMember 2019-07-01 2019-09-30 0000721371 cah:EnterpriseWideCostSavingMeasuresMember 2019-07-01 2019-09-30 0000721371 cah:EnterpriseWideCostSavingMeasuresMember 2018-07-01 2018-09-30 0000721371 cah:IPRDTrademarksandOtherMember 2019-06-30 0000721371 cah:TrademarksAndPatentsMember 2019-06-30 0000721371 us-gaap:CustomerRelationshipsMember 2019-06-30 0000721371 us-gaap:DevelopedTechnologyRightsMember 2019-06-30 0000721371 cah:MedicalMember 2019-06-30 0000721371 cah:PharmaceuticalMember 2019-07-01 2019-09-30 0000721371 cah:PharmaceuticalMember 2019-06-30 0000721371 cah:MedicalMember 2019-07-01 2019-09-30 0000721371 cah:MedicalMember 2019-09-30 0000721371 cah:PharmaceuticalMember 2019-09-30 0000721371 us-gaap:DevelopedTechnologyRightsMember 2019-09-30 0000721371 us-gaap:DevelopedTechnologyRightsMember 2019-07-01 2019-09-30 0000721371 cah:IPRDTrademarksandOtherMember 2019-09-30 0000721371 us-gaap:CustomerRelationshipsMember 2019-09-30 0000721371 cah:TrademarksAndPatentsMember 2019-09-30 0000721371 cah:TrademarksAndPatentsMember 2019-07-01 2019-09-30 0000721371 us-gaap:CustomerRelationshipsMember 2019-07-01 2019-09-30 0000721371 cah:NaviHealthMember 2018-08-01 0000721371 cah:NaviHealthMember 2018-07-01 2018-09-30 0000721371 cah:NaviHealthMember 2018-08-01 2018-08-31 0000721371 cah:NaviHealthMember 2019-06-30 0000721371 cah:NaviHealthMember 2019-09-30 0000721371 2019-07-01 2019-07-01 0000721371 srt:MinimumMember 2019-09-30 0000721371 srt:MaximumMember 2019-09-30 0000721371 cah:OperatingLeaseMember 2019-09-30 0000721371 cah:FinanceLeaseMember 2019-09-30 0000721371 cah:ASC842Member 2019-07-01 2019-07-01 0000721371 us-gaap:CommercialPaperMember 2019-06-30 0000721371 us-gaap:RevolvingCreditFacilityMember 2019-06-30 0000721371 cah:ShortTermCreditFacilitiesMember cah:CommittedReceivablesSalesFacilityProgramMember 2019-06-30 0000721371 cah:OpioidLitigationlessCuyahogaandSummitCountiesMember 2019-07-01 2019-09-30 0000721371 cah:ProductLiabilityLawsuitsMember cah:AlamedaCountyMember us-gaap:SubsequentEventMember 2019-11-01 0000721371 cah:ClassActionLawsuitsMember cah:PrivatePartiesMember cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember 2019-11-01 0000721371 cah:OpioidLitigationCuyahogaandSummitCountiesMember 2019-09-30 0000721371 cah:PrivatePartiesMember cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember 2019-11-01 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember 2019-11-01 0000721371 cah:CVSHealthMember 2019-07-01 2019-09-30 0000721371 cah:TotalOpioidLitigationMember 2019-09-30 0000721371 cah:ProductLiabilityLawsuitsMember cah:AlamedaCountyMember us-gaap:SubsequentEventMember 2019-11-01 2019-11-01 0000721371 cah:ProductLiabilityLawsuitsMember cah:OtherJurisdictionsMember us-gaap:SubsequentEventMember 2019-11-01 0000721371 cah:OpioidLitigationlessCuyahogaandSummitCountiesMember 2019-09-30 0000721371 cah:TotalOpioidLitigationnetoftaxMember 2019-09-30 0000721371 us-gaap:SubsequentEventMember 2019-10-21 0000721371 cah:ProductLiabilityLawsuitsMember cah:OtherJurisdictionsMember us-gaap:SubsequentEventMember 2019-11-01 2019-11-01 0000721371 cah:CareFusionMember 2019-06-30 0000721371 cah:PatientRecoveryBusinessMember 2019-09-30 0000721371 cah:CareFusionMember 2019-09-30 0000721371 srt:MinimumMember us-gaap:InternalRevenueServiceIRSMember 2019-07-01 2019-09-30 0000721371 cah:PatientRecoveryBusinessMember 2019-06-30 0000721371 cah:TotalOpioidLitigationMember 2019-07-01 2019-09-30 0000721371 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000721371 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000721371 us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000721371 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000721371 us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000721371 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000721371 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000721371 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000721371 us-gaap:FairValueInputsLevel2Member 2019-06-30 0000721371 us-gaap:FairValueInputsLevel2Member 2019-09-30 0000721371 us-gaap:CurrencySwapMember 2018-09-30 0000721371 us-gaap:CurrencySwapMember 2019-09-30 0000721371 us-gaap:CashFlowHedgingMember 2019-09-30 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-06-30 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-09-30 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-09-30 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-06-30 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-07-01 2019-09-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2019-07-01 2019-09-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2019-06-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2019-09-30 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-07-01 2019-09-30 0000721371 2018-10-25 0000721371 us-gaap:CorporateNonSegmentMember 2018-07-01 2018-09-30 0000721371 us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0000721371 us-gaap:NonUsMember 2019-07-01 2019-09-30 0000721371 us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0000721371 us-gaap:CorporateNonSegmentMember 2019-07-01 2019-09-30 0000721371 country:US 2019-07-01 2019-09-30 0000721371 us-gaap:NonUsMember 2018-07-01 2018-09-30 0000721371 country:US 2018-07-01 2018-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2018-07-01 2018-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2018-07-01 2018-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2019-07-01 2019-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2019-07-01 2019-09-30 0000721371 us-gaap:CorporateNonSegmentMember 2019-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2019-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2019-09-30 0000721371 us-gaap:CorporateNonSegmentMember 2019-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2019-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2019-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:MedicaldistributionandproductsMember 2018-07-01 2018-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:NuclearPrecisionHealthServicesMember 2019-07-01 2019-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:CardinalHealthAtHomeMember 2019-07-01 2019-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:PharmaceuticalDistributionandSpecialtyMember 2019-07-01 2019-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:PharmaceuticalDistributionandSpecialtyMember 2018-07-01 2018-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:MedicaldistributionandproductsMember 2019-07-01 2019-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:CardinalHealthAtHomeMember 2018-07-01 2018-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:NuclearPrecisionHealthServicesMember 2018-07-01 2018-09-30 0000721371 us-gaap:PerformanceSharesMember 2019-07-01 2019-09-30 0000721371 us-gaap:PerformanceSharesMember 2019-06-30 0000721371 us-gaap:PerformanceSharesMember 2019-09-30 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2019-06-30 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2019-09-30 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2018-07-01 2018-09-30 0000721371 us-gaap:PerformanceSharesMember 2018-07-01 2018-09-30 0000721371 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-09-30 0000721371 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0000721371 us-gaap:EmployeeStockOptionMember 2018-07-01 2019-06-30 0000721371 us-gaap:EmployeeStockOptionMember 2019-09-30 0000721371 us-gaap:EmployeeStockOptionMember 2019-06-30 0000721371 srt:MinimumMember us-gaap:PerformanceSharesMember 2019-07-01 2019-09-30 0000721371 srt:MaximumMember us-gaap:PerformanceSharesMember 2019-07-01 2019-09-30 xbrli:pure cah:StateAG cah:segment iso4217:USD xbrli:shares cah:Reportable_Segments iso4217:JPY iso4217:USD cah:plaintiff iso4217:EUR xbrli:shares cah:lawsuit

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
☑
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2019
or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________ to ________
Commission File Number: 1-11373
Cardinal Health, Inc.
(Exact name of registrant as specified in its charter)
Ohio
 
31-0958666
(State or other jurisdiction of
incorporation or organization)
 
(IRS Employer
Identification No.)
 
 
 
 
 
 
 
7000 Cardinal Place
,
Dublin
,
Ohio
 
43017
(Address of principal executive offices)
 
(Zip Code)
(614) 757-5000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common shares (without par value)
CAH
New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☑    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☑    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☑
 
Accelerated filer
☐
 
Non-accelerated filer
☐
 
Smaller reporting company
☐
 
 
 
 
Emerging growth company
☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☑
The number of the registrant’s common shares, without par value, outstanding as of October 31, 2019, was the following: 292,488,354.


Cardinal Health  
Q1 Fiscal 2020 Form 10-Q

Table of Contents
 

About Cardinal Health
 
Cardinal Health, Inc. is an Ohio corporation formed in 1979 and is a globally integrated healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices. We provide medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. We manage our business and report our financial results in two segments: Pharmaceutical and Medical. As used in this report, “we,” “our,” “us,” and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2020 and fiscal 2019 and to FY20 and FY19 are to the fiscal years ending or ended June 30, 2020 and June 30, 2019, respectively.
Forward-Looking Statements
 
This Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 (this "Form 10-Q") (including information incorporated by reference) includes "forward-looking statements" addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. Many forward-looking statements appear in Management’s Discussion and Analysis of Financial Condition and Results of Operations ("MD&A"), but there are others in this Form 10-Q, which may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results, trends or guidance, statements of outlook and various accruals and estimates. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those made, projected or implied. The most significant of these risks and uncertainties are described in this Form 10-Q, including Exhibit 99.1, and in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2019 (our “2019 Form 10-K”). Forward-looking statements in this Form 10-Q speak only as of the date of this document. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.
Non-GAAP Financial Measures
 
In the "Overview of Consolidated Results" section of MD&A, we use financial measures that are derived from our consolidated financial data but are not presented in our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These measures are considered "non-GAAP financial measures" under the Securities and Exchange Commission ("SEC") rules. The reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures are included in the “Explanation and Reconciliation of Non-GAAP Financial Measures” section following MD&A in this Form 10-Q.



 
 
 
 1
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
 

MD&A
Overview
 



Management's Discussion and Analysis of Financial Condition and Results of Operations
The discussion and analysis presented below is concerned with material changes in financial condition and results of operations between the periods specified in our condensed consolidated balance sheets at September 30, 2019 and June 30, 2019, and in our condensed consolidated statements of earnings/(loss) for the three months ended September 30, 2019 and 2018. All comparisons presented are with respect to the prior-year period, unless stated otherwise. This discussion and analysis should be read in conjunction with the MD&A included in our 2019 Form 10-K.


 
 
 
 
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
2


MD&A
Overview
 

Overview of Consolidated Results
Revenue
 
chart-986746bac297519d8c3.jpg
Revenue for the three months ended September 30, 2019 increased 6 percent to $37.3 billion due to sales growth from pharmaceutical distribution and specialty pharmaceutical customers.

GAAP and Non-GAAP Operating Earnings/(Loss)
 
 
Three Months Ended September 30,
(in millions)
2019
 
2018
 
Change
GAAP
$
(5,264
)
 
$
816

 
N.M.

State opioid assessment related to prior fiscal years
5

 
29

 
 
Restructuring and employee severance
30

 
32

 
 
Amortization and other acquisition-related costs
132

 
156

 
 
Impairments and (gain)/loss on disposal of assets
1

 
(511
)
 
 
Litigation (recoveries)/charges, net
5,673

 
19

 
 
Non-GAAP
$
577

 
$
542

 
6
%
The sum of the components may not equal the total due to rounding.
We had a GAAP operating loss of $5.3 billion during the three months ended September 30, 2019 due to a $5.63 billion pre-tax charge we recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications. As described further in the Significant Developments in Fiscal 2020 section in this MD&A and Note 7 of the "Notes to Condensed Consolidated Financial Statements", in October 2019, we agreed in principle to a global settlement framework with a leadership group of four state attorneys general that is designed to resolve all pending and future opioid lawsuits and claims by states and political subdivisions. GAAP operating earnings during the three months ended September 30, 2018 were favorably impacted by a $508 million pre-tax gain from the divestiture of our naviHealth Holdings, LLC ("naviHealth") business.
The 6 percent increase in non-GAAP operating earnings to $577 million was primarily due to the beneficial impact of enterprise-wide cost-savings measures, higher contribution from our Medical distribution and products businesses and growth from our specialty pharmaceutical products distribution and services business, partially offset by the adverse impact of pharmaceutical customer contract renewals.


 
 
 
 3
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
 

MD&A
Overview
 

GAAP and Non-GAAP Diluted EPS
 
 
Three Months Ended September 30,
($ per share)
2019 (1) (2) (3)
 
2018 (1) (2)
 
Change
GAAP
$
(16.65
)
 
$
1.94

 
N.M.

State opioid assessment related to prior fiscal years
0.01

 
0.07

 
 
Restructuring and employee severance
0.08

 
0.08

 
 
Amortization and other acquisition-related costs
0.33

 
0.39

 
 
Impairments and (gain)/loss on disposal of assets
—

 
(1.23
)
 
 
Litigation (recoveries)/charges, net
17.51

 
0.05

 
 
Non-GAAP
$
1.27

 
$
1.29

 
(2
)%
(1) The sum of the components may not equal the total due to rounding.
(2) The reconciling items are presented within this table net of tax. See quantification of tax effect of each reconciling item in our GAAP to Non-GAAP Reconciliations in the "Explanation and Reconciliation of Non-GAAP Financial Measures".
(3) First quarter fiscal 2020 GAAP diluted loss per share attributable to Cardinal Health, Inc. ("GAAP diluted EPS") and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 296 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the quarter. First quarter fiscal 2020 non-GAAP diluted EPS is calculated using a weighted average of 297 million common shares, which includes potentially dilutive shares.

We had a $(16.65) GAAP diluted loss per share attributable to Cardinal Health, Inc. ("GAAP diluted EPS") during the three months ended September 30, 2019 due to the charge we recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications. The charge had a $(17.40) after tax impact on GAAP diluted EPS. GAAP diluted EPS during the three months ended September 30, 2018 was favorably impacted by a $1.24 gain from the divestiture of naviHealth.
During the three months ended September 30, 2019, non-GAAP diluted EPS decreased 2 percent to $1.27 per share. This decrease was primarily due to the prior-year benefit from discrete tax items, largely related to international legal entity changes. The unfavorable year-over-year impact of the discrete tax items was largely offset by the factors discussed above impacting non-GAAP operating earnings and a lower share count as a result of share repurchases.

Cash and Equivalents
 
Our cash and equivalents balance was $1.2 billion at September 30, 2019 compared to $2.5 billion at June 30, 2019. The decrease in cash and equivalents during the three months ended September 30, 2019 was due to $653 million of net cash used in operating activities, $350 million paid for share repurchases and $146 million paid in dividends. Cash used in operating activities for the quarter was primarily driven by changes in working capital associated with the timing of payments to vendors. We expect our operating cash flow to be higher in the quarter ended December 31, 2019 due to expected working capital improvement.






 
 
 
 
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
4


MD&A
Overview
 

Significant Developments in Fiscal 2020

Opioid Lawsuits Development
 
In October 2019, we agreed in principle to a global settlement framework with a leadership group of four state attorneys general from the multi-state task force that is designed to resolve all pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). This Settlement Framework is subject to contingencies and uncertainties as to final terms, but is the basis for our negotiation of definitive terms and documentation. The Settlement Framework includes (1) a cash component, pursuant to which we would pay up to $5.56 billion over eighteen years, (2) development and participation in a program for free or rebated distribution of opioid abuse treatment medications for a period of ten years, and (3) industry-wide changes to be specified to controlled substance anti-diversion programs. In order to continue working on the Settlement Framework, we also agreed, with two other national distributors, to a $215 million settlement with two plaintiffs counties in a trial that had been scheduled for October 2019; our portion of that settlement is $66 million, which will be payable upon execution of a final settlement agreement.
In connection with these matters, we recorded a total pre-tax charge of $5.63 billion ($5.14 billion after tax) during the three months ended September 30, 2019 for the cash component. We accrue for contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. Moreover, the global Settlement Framework is in its early phases, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. We will regularly review these opioid litigation matters to determine whether our accrual is adequate. We are unable to reasonably estimate the liability associated with any potential distribution of treatment medications and any incremental costs for changes to our controlled substance anti-diversion program that we may agree to under the Settlement Framework. The amount of ultimate loss may differ materially from this accrual. See Note 7 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
Also in connection with these matters, we recorded a tax benefit of $487 million, which is net of unrecognized tax benefits of $468 million, during the three months ended September 30, 2019, reflecting our current assessment of the estimated future deductibility of the amount that may be paid under the $5.63 billion accrual taken in connection with the opioid litigation. Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination of the technical merits of the position, including resolutions of any related appeals or litigation. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement. For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits. Our assumptions and estimates around this benefit and uncertain tax position require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was changed by the U.S. Tax Cuts and Jobs Act (“Tax Act”). We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act which is subject to further interpretation by the U.S. Internal Revenue Service ("IRS"). Further, it is possible that the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates. See Note 8 of the “Notes to the Condensed Consolidated Financial Statements” for additional information.

Cost-savings Initiatives
 
We are implementing certain cost-savings initiatives intended to optimize and simplify our operating model and cost structure. As a result of these initiatives, we recognized $20 million in restructuring and employee severance expense during the three months ended September 30, 2019. We expect these cost-savings initiatives, which will affect various functional and commercial areas across the Company, to be substantially implemented during fiscal year 2020.





 
 
 
 5
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
 

MD&A
Results of Operations
 

Results of Operations
Revenue

chart-0e7efb26c0365e6cb47.jpgchart-5f32bf9b0ca256e99b2.jpg
 
Three Months Ended September 30,
(in millions)
2019
 
2018
 
Change
Pharmaceutical
$
33,428

 
$
31,416

 
6
%
Medical
3,917

 
3,801

 
3
%
Total segment revenue
37,345

 
35,217

 
6
%
Corporate
(4
)
 
(4
)
 
N.M.

Total revenue
$
37,341

 
$
35,213

 
6
%

Pharmaceutical Segment
Pharmaceutical segment revenue increased during the three months ended September 30, 2019 due to sales growth from pharmaceutical distribution and specialty pharmaceutical customers, which together increased revenue by $2.0 billion.
Medical Segment
Medical segment revenue increased during the three months ended September 30, 2019 primarily due to sales growth from our distribution and products businesses and Cardinal Health at-Home Solutions. The increase was partially offset by the divestiture of naviHealth in the prior year.
Cost of Products Sold
 
Cost of products sold increased 6 percent to $35.7 billion due to the factors affecting the changes in revenue and gross margin.








 
 
 
 
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
6


MD&A
Results of Operations
 

Gross Margin
 
chart-ff3385a010ad5ef68c1.jpgchart-f4d60677c0e25c84939.jpg
 
Three Months Ended September 30,
(in millions)
2019
 
2018
 
Change
Gross margin
$
1,679

 
$
1,667

 
1
%
Gross margin during the three months ended September 30, 2019 was essentially flat versus the prior-year period.
Gross margin rate declined 23 basis points during the three months ended September 30, 2019 mainly due to the adverse impact of pharmaceutical customer contract renewals and pharmaceutical distribution product mix.
Distribution, Selling, General, and Administrative ("SG&A") Expenses
 
 
Three Months Ended September 30,
(in millions)
2019
 
2018
 
Change
SG&A expenses
$
1,107

 
$
1,155

 
(4
)%

During the three months ended September 30, 2019, SG&A expenses decreased due to the beneficial impact of enterprise-wide cost-savings measures and lower state assessments on sales of prescription opioid medications. In the three months ended September 30, 2018, we accrued $34 million for an assessment on prescription opioid medications that were sold or distributed in New York state, which was reversed in the three months ended December 31, 2018 when the New York state assessment was declared unconstitutional.


 
 
 
 7
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
 

MD&A
Results of Operations
 

Segment Profit
 
We evaluate segment performance based on segment profit, among other measures. See Note 13 of the "Notes to Condensed Consolidated Financial Statements" for additional information on segment profit.
 
Three Months Ended September 30,
(in millions)
2019
 
2018
 
Change
Pharmaceutical
$
398

 
$
409

 
(3
)%
Medical
170

 
135

 
26
 %
Total segment profit
568

 
544

 
4
 %
Corporate
(5,832
)
 
272

 
N.M

Total consolidated operating earnings/(loss)
$
(5,264
)
 
$
816

 
N.M

 
Pharmaceutical Segment Profit
The decrease in Pharmaceutical segment profit during the three months ended September 30, 2019 was primarily due to the adverse impact of customer contract renewals. This decrease was partially offset by the beneficial impact of cost-savings measures and growth from our specialty pharmaceutical products and services business.
Medical Segment Profit
The increase in Medical segment profit during the three months ended September 30, 2019 was primarily due to the beneficial impact of cost-savings measures and higher contribution from the segment's distribution and products businesses.
Corporate
The changes in Corporate during the three months ended September 30, 2019 are due to the factors discussed in the Other Components of Consolidated Operating Earnings/(Loss) section that follows.


 
 
 
 
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
8


MD&A
Results of Operations
 

Other Components of Consolidated Operating Earnings/(Loss)
 
In addition to revenue, gross margin, and SG&A expenses discussed previously, consolidated operating earnings/(loss) were impacted by the following:
 
Three Months Ended September 30,
(in millions)
2019
 
2018
Restructuring and employee severance
$
30

 
$
32

Amortization and other acquisition-related costs
132

 
156

Impairments and (gain)/loss on disposal of assets, net
1

 
(511
)
Litigation (recoveries)/charges, net
5,673

 
19

Restructuring and Employee Severance
During the three months ended September 30, 2019 and 2018, we recognized $20 million and $26 million, respectively, of expenses in connection with our implementation of certain enterprise-wide cost-saving measures.
Amortization and Other Acquisition-Related Costs
Amortization of acquisition-related intangible assets was $129 million and $133 million for the three months ended September 30, 2019 and 2018, respectively. Transaction and integration costs associated with the Patient Recovery Business acquisition were $1 million and $22 million for the three months ended September 30, 2019 and 2018, respectively.
Impairments and (Gain)/Loss on Disposal of Assets, Net
During the three months ended September 30, 2018, we recognized a pre-tax gain of $508 million related to the divestiture of our naviHealth business.
Litigation (Recoveries)/Charges, Net
During the three months ended September 30, 2019, we recognized a pre-tax charge of $5.63 billion ($5.14 billion after tax) associated with the opioid litigation. See Significant Developments in Fiscal 2020 section in this MD&A for additional information.
Earnings/(Loss) Before Income Taxes

In addition to the items discussed above, earnings/(loss) before income taxes was impacted by the following:
 
Three Months Ended September 30,
(in millions)
2019
 
2018
 
Change
Other (income)/expense, net
$
14

 
$
3

 
N.M.

Interest expense, net
66

 
77

 
(14
)%
Other (Income)/Expense, Net
The increase in other (income)/expense, net during the three months ended September 30, 2019 was primarily due to fluctuations in foreign exchange rates.
Interest Expense, Net
The decrease in interest expense during the three months ended September 30, 2019 was primarily due to less debt outstanding.
Provision for/(Benefit From) Income Taxes
 
During the three months ended September 30, 2019 and 2018, the effective tax rate was 7.9 percent and 19.4 percent, respectively. The decrease in the effective tax rate from fiscal 2019 to fiscal 2020 is primarily due to the net tax benefit of $487 million related to the opioid litigation pre-tax charge of $5.63 billion, as described further in the Significant Developments in Fiscal 2020 section in this MD&A, partially offset by the prior-year benefit of discrete tax items.
 


 
 
 
 9
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
 

MD&A
Liquidity and Capital Resources
 

Liquidity and Capital Resources
We currently believe that, based on available capital resources (cash on hand and committed credit facilities) and projected operating cash flow, we have adequate capital resources to fund working capital needs; currently anticipated capital expenditures; currently anticipated business growth and expansion; contractual obligations; tax payments; and current and projected debt service requirements, dividends and share repurchases as well as potential opioid litigation settlement payments associated with the Settlement Framework. If we were to decide to engage in one or more additional acquisitions, depending on the size and timing of such transactions, we might need to access capital markets for additional financing.
Cash and Equivalents
 
Our cash and equivalents balance was $1.2 billion at September 30, 2019 compared to $2.5 billion at June 30, 2019. At September 30, 2019, our cash and equivalents were held in cash depository accounts with major banks or invested in high quality, short-term liquid investments.
During the three months ended September 30, 2019, net cash used in operating activities was $653 million, primarily driven by increases in working capital associated with the timing of payments to vendors. We also deployed $350 million for share repurchases and $146 million for cash dividends. We expect our operating cash flow to be
 
higher in the quarter ended December 31, 2019 due to expected working capital improvement.
Changes in working capital, which impact operating cash flow, can vary significantly depending on factors such as the timing of customer payments, inventory purchases and payments to vendors in the regular course of business, as well as fluctuating working capital needs driven by customer and product mix.
The cash and equivalents balance at September 30, 2019 included $710 million of cash held by subsidiaries outside of the United States.
Other Financing Arrangements and Financial Instruments
 
Credit Facilities and Commercial Paper
In addition to cash and equivalents and operating cash flow, other sources of liquidity at September 30, 2019 include a $2.0 billion commercial paper program, backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. At September 30, 2019, we had no amounts outstanding under our commercial paper program, revolving credit facility or our committed receivables sales facility. Under our commercial paper program, we had maximum amounts outstanding of $190 million and an average daily amount outstanding of $6 million during three months ended September 30, 2019.
In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2022. Our revolving credit facility and committed receivables sales facilities require us to maintain, as of the end of every fiscal quarter from September 30, 2019 through December 2020, a consolidated net leverage ratio of no more than 4.00-to-1. The maximum quarter-end permitted ratio will reduce to 3.75-to-1 in March 2021 and as of the end of every fiscal quarter thereafter. As of September 30, 2019, we were in compliance with our financial covenants.

 
Long-Term Debt
At September 30, 2019, we had total long-term obligations, including the current portion and other short-term borrowings, of $8.0 billion at both September 30, 2019 and June 30, 2019. During the three months ended September 30, 2019, we repurchased a total of $74 million of notes due in 2022 and 2047 with available cash. We plan to repay our outstanding 2.40% notes at maturity in November 2019 with $450 million of available cash.



 
 
 
 
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
10


MD&A
Liquidity and Capital Resources
 

Capital Deployment
 
Opioid Settlement Framework
In October 2019, we agreed in principle to a Settlement Framework which includes a cash component, pursuant to which we would pay up to $5.56 billion over eighteen years. We currently expect payment amounts under the Settlement Framework to be spread through the 18-year period subject to participation by states and political subdivisions. See Significant Developments in Fiscal 2020 section in this MD&A for additional information.
Capital Expenditures
Capital expenditures during the three months ended September 30, 2019 and 2018 were $72 million and $58 million, respectively.
Dividends
On each of May 8, 2019 and August 7, 2019, our Board of Directors approved a quarterly dividend of $0.4811 per share, or $1.92 per share on an annualized basis, which were paid on July 15, 2019 and October 15, 2019 to shareholders of record on July 1, 2019 and October 1, 2019, respectively.
On November 6, 2019, our Board of Directors approved a quarterly dividend of $0.4811 per share, or $1.92 per share on an annualized basis, payable on January 15, 2020 to shareholders of record on January 2, 2020.

 
Share Repurchases
During the three months ended September 30, 2019, we deployed $350 million to purchase our common shares under an accelerated share repurchase ("ASR") program. We funded the ASR program with available cash and short-term borrowings. At September 30, 2019, we had $1.0 billion remaining under our existing share repurchase authorization. The ASR program is expected to conclude in the second quarter of fiscal 2020, which will reduce the amount remaining under our existing share repurchase authorization to $943 million. See Note 11 of the "Notes to Condensed Consolidated Financial Statements" for additional information on our ASR program.







 
 
 
 11
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
 

MD&A
Other Items
 


Other Items
The MD&A in our 2019 Form 10-K addresses our contractual obligations and off-balance sheet arrangements, as of and for the fiscal year ended June 30, 2019. There have been no subsequent material changes outside of the ordinary course of business to those items except for the agreement in principle on a global settlement framework designed to resolve all pending and future opioid lawsuits and claims brought by states and political subdivisions described in the Significant Developments in Fiscal 2020 section in this MD&A and Note 7 of the "Notes to Condensed Consolidated Financial Statements".
Critical Accounting Policies and Sensitive Accounting Estimates
The discussion and analysis presented below are supplemental disclosures to the critical accounting policies and sensitive accounting estimates specified in our consolidated balance sheets at June 30, 2019. This discussion and analysis should be read in conjunction with the Critical Accounting Policies and Sensitive Accounting Estimates included in our 2019 Form 10-K.
Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and (ii) require the use of complex and subjective estimates based upon past experience and management’s judgment. Other people applying reasonable judgment to the same facts and circumstances could develop different estimates. Because estimates are inherently uncertain, actual results may differ.
Goodwill
 
Purchased goodwill is tested for impairment annually or when indicators of impairment exist. Goodwill impairment testing involves a comparison of the estimated fair value of reporting units to the respective carrying amount, which may be performed utilizing either a qualitative or quantitative assessment. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If it is determined that it is more likely than not that the fair value does not exceed the carrying amount, then a quantitative test is performed. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. A reporting unit is defined as an operating segment or one level below an operating segment (also known as a component).
Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit. Our qualitative evaluation considers
 
the weight of evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount.
Medical Unit Goodwill
For our annual impairment test in fiscal 2019, the fair value of our Medical Unit exceeded its carrying value of $10.8 billion by approximately 4 percent. Although we believe the assumptions used to arrive at the estimate of fair value during the fourth quarter of fiscal 2019 continue to be reasonable and appropriate, changes in key assumptions during fiscal 2020, including a failure to meet expected earnings or other financial plans, or other unanticipated events and circumstances, such as an increase in interest rates or a significant change in industry or economic trends, may affect future estimates. Adverse changes in key assumptions may result in a decline in fair value below the carrying value in the future resulting in an impairment in our Medical segment in future periods, which could adversely affect our results of operations.

Loss Contingencies
 
In connection with the opioid litigation as described further in the Significant Developments in Fiscal 2020 section in this MD&A, we recorded a pre-tax charge of $5.63 billion ($5.14 billion after tax) during the three months ended September 30, 2019. We accrue for contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.
Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur the assessment is highly subjective and requires judgments about future events. Moreover, the global Settlement Framework is in its early phases, and there is no assurance that the necessary parties will agree to a
 
definitive settlement agreement or that the contingencies to any agreement will be satisfied. We will regularly review opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual.


 
 
 
 
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
12


MD&A
Other Items
 


Provision for Income Taxes
 
Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination of the technical merits of the position, including resolutions of any related appeals or litigation. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement. For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.
In connection with the $5.63 billion pre-tax charge for the opioid litigation, we recorded a tax benefit of $487 million, which is net of unrecognized tax benefits of $468 million, reflecting our current assessment of the estimated future deductibility of the amount that may be paid. We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible that the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates. See Note 8 of the Notes to the "Condensed Consolidated Financial Statements" for more information regarding these matters.
We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2008 through the current fiscal year. Tax laws are complex and subject to varying interpretations. Tax authorities have challenged some of our tax positions, including IRS challenges to our international transfer pricing for the periods from 2008 to 2014, and it is possible that they will challenge others. These challenges may adversely affect our effective tax rate or tax payments.









 
 
 
 13
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
 

Explanation and Reconciliation of Non-GAAP Financial Measures
 
 

Explanation and Reconciliation of Non-GAAP Financial Measures
The "Overview of Consolidated Results" section within MD&A in this Form 10-Q contains financial measures that are not calculated in accordance with GAAP.
In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, evaluate the balance sheet, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated.
Exclusions from Non-GAAP Financial Measures
Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors’ assessment of the business for the reasons identified below:
•
LIFO charges and credits are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies’ financial results.
•
State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the fiscal year of the initial assessment. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Reversals of these accruals have occurred when certain assessments were declared unconstitutional.
•
Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business.
•
Amortization and other acquisition-related costs, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity’s initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity and size of acquisitions.
•
Impairments and gain or loss on disposal of assets are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results.
•
Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.
•
Loss on extinguishment of debt is excluded because it does not typically occur in the normal course of business and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt extinguishment transactions.
•
Transitional tax benefit, net related to the Tax Cuts and Jobs Act is excluded because it results from the one-time impact of a very significant change in the U.S. federal corporate tax rate and, due to the significant size of the benefit, obscures analysis of trends and financial performance. The transitional tax benefit includes the initial estimate and subsequent adjustments for the re-


 
 
 
 
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
14


Explanation and Reconciliation of Non-GAAP Financial Measures
 
 

measurement of deferred tax assets and liabilities due to the reduction of the U.S. federal corporate income tax rate and the repatriation tax on undistributed foreign earnings.
The tax effect for each of the items listed above, other than the transitional tax benefit item, is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations.
Definitions
Growth rate calculation: growth rates in this report are determined by dividing the difference between current-period results and prior-period results by prior-period results.
Non-GAAP distribution, selling, general and administrative expenses or Non-GAAP SG&A: distribution, selling, general and administrative expenses, excluding state opioid assessments related to prior fiscal years.
Non-GAAP operating earnings: operating earnings excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) impairments and (gain)/loss on disposal of assets, and (6) litigation (recoveries)/charges, net.
Non-GAAP earnings before income taxes: earnings before income taxes excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) impairments and (gain)/loss on disposal of assets, (6) litigation (recoveries)/charges, net, and (7) loss on extinguishment of debt.
Non-GAAP Net Earnings attributable to Cardinal Health, Inc.: net earnings attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) impairments and (gain)/loss on disposal of assets, (6) litigation (recoveries)/charges, net, (7) loss on extinguishment of debt, each net of tax, and (8) transitional tax benefit, net.
Non-GAAP effective tax rate: provision for/(benefit from) income taxes adjusted for (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) restructuring and employee severance, (4) amortization and other acquisition-related costs, (5) impairments and (gain)/loss on disposal of assets, (6) litigation (recoveries)/charges, net, (7) loss on extinguishment of debt, and (8) transitional tax benefit, (net) divided by (earnings before income taxes adjusted for the first seven items).
Non-GAAP diluted earnings/(loss) per share attributable to Cardinal Health, Inc.: non-GAAP net earnings/(loss) attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding.


 
 
 
 15
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
 

Explanation and Reconciliation of Non-GAAP Financial Measures
 
 

GAAP to Non-GAAP Reconciliations
(in millions, except per common share amounts)
SG&A1
SG&A1 Growth Rate
Operating Earnings/(Loss)
Operating Earnings Growth Rate
Earnings/(Loss) Before Income Taxes
Provision for/ (Benefit from) Income Taxes
Net Earnings/(Loss)2
Net Earnings2 Growth Rate
Diluted EPS2,3
Diluted EPS2
 Growth Rate
 
Three Months Ended September 30, 2019
GAAP
$
1,107

(4
)%
$
(5,264
)
N.M.

$
(5,344
)
$
(423
)
$
(4,922
)
N.M.

$
(16.65
)
N.M.

State opioid assessment related to prior fiscal years
(5
)
 
5


5

1

4


0.01


Restructuring and employee severance
—

 
30

 
30

8

22

 
0.08

 
Amortization and other acquisition-related costs
—

 
132

 
132

34

98

 
0.33

 
Impairments and (gain)/loss on disposal of assets
—

 
1

 
1

—

1

 
—

 
Litigation (recoveries)/charges, net 4
—

 
5,673

 
5,673

498

5,175

 
17.51

 
Non-GAAP
$
1,102

(2
)%
$
577

6
 %
$
496

$
117

$
378

(4
)%
$
1.27

(2
)%
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended September 30, 2018
GAAP
$
1,155

9
 %
$
816

211
 %
$
736

$
142

$
593

416
 %
$
1.94

439
 %
State opioid assessment related to prior fiscal years
(29
)
 
29


29

8

21


0.07


Restructuring and employee severance
—

 
32


32

8

24


0.08


Amortization and other acquisition-related costs
—

 
156


156

36

120


0.39


Impairments and (gain)/loss on disposal of assets
—

 
(511
)

(511
)
(134
)
(377
)

(1.23
)

Litigation (recoveries)/charges, net
—

 
19


19

5

14


0.05


Non-GAAP
$
1,126

6
 %
$
542

(11
)%
$
461

$
65

$
396

14
 %
$
1.29

18
 %
1 
Distribution, selling, general and administrative expenses.
2 
Attributable to Cardinal Health, Inc.
3 
First quarter fiscal 2020 GAAP diluted loss per share attributable to Cardinal Health, Inc. ("GAAP diluted EPS") and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 296 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the quarter. First quarter fiscal 2020 non-GAAP diluted EPS is calculated using a weighted average of 297 million common shares, which includes potentially dilutive shares.
4 
Litigation (recoveries)/charges, net includes a pre-tax charge of $5.63 billion ($5.14 billion after tax) recorded in the first quarter of fiscal 2020 related to the opioid litigation.
The sum of the components may not equal the total due to rounding.
We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.






 
 
 
 
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
16


Other
 


Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in the quantitative and qualitative market risk disclosures included in our 2019 Form 10-K since the end of fiscal 2019 through September 30, 2019.
Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of September 30, 2019. Based on this evaluation, our principal executive officer and principal financial officer have concluded that as of September 30, 2019, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended September 30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Legal Proceedings
In addition to the proceeding described below, the legal proceedings described in Note 7 of the "Notes to Condensed Consolidated Financial Statements" are incorporated in this "Legal Proceedings" section by reference.
In June 2019, Melissa Cohen, a purported shareholder, filed an action on behalf of Cardinal Health, Inc. in the U.S. District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances. The derivative complaint seeks, among other things, unspecified money damages against the defendants and an award of attorneys' fees.


 
 
 
 17
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
 

Other
 

Risk Factors
You should carefully consider the information in this Form 10-Q, including the risk factors below, and the risk factors discussed in "Risk Factors" and other risks discussed in our 2019 Form 10-K and our filings with the SEC since June 30, 2019. These risks could materially and adversely affect our results of operations, financial condition, liquidity, and cash flows. Our business also could be affected by risks that we are not presently aware of or that we currently consider immaterial to our operations.

The public health crisis involving the abuse of prescription opioid pain medication and our efforts to resolve related claims could have additional or unexpected material negative effects on our business.
Our Pharmaceutical segment distributes prescription opioid pain medications. In recent years, the abuse of prescription opioid pain medication has become a public health crisis.
A significant number of counties, municipalities and other plaintiffs, including a number of state attorneys general, have filed lawsuits against pharmaceutical manufacturers, pharmaceutical wholesale distributors (including us), retail chains and others relating to the manufacturing, marketing or distribution of prescription opioid pain medications. In addition, we are currently being investigated or sued by most other states for the same activities and expect to be named as a defendant in additional lawsuits. The defense and resolution of current and future lawsuits and events relating to these lawsuits are subject to uncertainty and could have a material adverse effect on our results of operations, financial condition, cash flows, liquidity, our ability to pay dividends or repurchase our shares, or have adverse reputational or operational effects on our business.
In October 2019, we agreed in principle to Settlement Framework and in connection with this development we recorded a pre-tax accrual of $5.56 billion in the quarter ended September 30, 2019. This Settlement Framework is subject to contingencies but is the basis for our negotiation of definitive terms and documentation. Moreover, the Settlement Framework is in its early phases, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. We will regularly review opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual. See Note 7 of the "Notes to Condensed Consolidated Financial Statements" for more information regarding these matters.
Other legislative, regulatory or industry measures related to the public health crisis involving the abuse of prescription opioid pain medication and the distribution of these medications could affect our business in ways that we may not be able to predict. For example, several states have now adopted taxes or other fees on the sale of opioids, and several other states have proposed similar legislative initiatives. These laws and proposals vary in the tax amounts imposed and the means of calculation. Liabilities for taxes or assessments under any such laws could have an adverse impact on our results of operations unless we are able to mitigate them through operational changes or commercial arrangements where permitted.
Ongoing unfavorable publicity regarding the abuse or misuse of prescription opioid pain medications and the role of wholesale
 
distributors in the supply chain of such prescription medications, as well as the continued proliferation of the opioid lawsuits, investigations, regulations and legislative actions, and unfavorable publicity in relation to those lawsuits could have a material adverse effect on our reputation or results of operations.
We could be subject to adverse changes in the tax laws or challenges to our tax positions.
We are a large multinational corporation with operations in the United States and many foreign countries. As a result, we are subject to the tax laws of many jurisdictions.
From time to time, initiatives are proposed in the United States and other jurisdictions in which we operate that could adversely affect our tax positions, effective tax rate or tax payments. Specific initiatives that may impact us include the repeal of the LIFO (last-in, first-out) method of inventory accounting for income tax purposes, the establishment or increase in taxation at the U.S. state level on the basis of gross revenues, recommendations of the recently completed base erosion and profit shifting project undertaken by the Organization for Economic Cooperation and Development and the European Commission’s investigation into illegal state aid.
Additionally, in connection with the $5.63 billion pre-tax charge for the opioid litigation, we recorded a tax benefit of $487 million, which is net of unrecognized tax benefits of $468 million, reflecting our current assessment of the estimated future deductibility of the amount that may be paid. We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible that the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates. See Note 8 of the "Notes to Condensed Consolidated Financial Statements" for more information regarding these matters.
We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2008 through the current fiscal year. Tax laws are complex and subject to varying interpretations. Tax authorities have challenged some of our tax positions, including IRS challenges to our international transfer pricing for the periods from 2008 to 2014, and


 
 
 
 
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
18


Other
 

it is possible that they will challenge others. These challenges may adversely affect our effective tax rate or tax payments.
Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Equity Securities
Period
Total Number
of Shares
Purchased (1)
 
Average Price Paid per Share (2)
 
Total Number of Shares
Purchased
as Part of Publicly Announced Programs (2, 3)
 
Approximate
Dollar Value of
Shares That May
Yet be Purchased
Under the Program (3)
(in millions)
July 2019
1,203

 
$
47.26

 
—

 
$
1,293

August 2019
6,400,332

 
43.76

 
6,398,537

 
1,013

September 2019
285

 
47.36

 
—

 
1,013

Total
6,401,820

 
$
43.76

 
6,398,537

 
$
1,013

(1)
Reflects 1,203, 1,795 and 285 common shares purchased in July, August and September 2019, respectively, through a rabbi trust as investments of participants in our Deferred Compensation Plan.
(2)
On August 20, 2019, we entered into an accelerated share repurchase ("ASR") program to purchase common shares for an aggregate purchase price of $350 million and received an initial delivery of 6.4 million common shares using a reference price of $43.76. The program is expected to conclude in the second quarter of fiscal 2020. See Note 11 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
(3)
On February 7, 2018, our Board of Directors approved a $1.0 billion share repurchase program that expires on December 31, 2020. On November 7, 2018, our Board of Directors approved a new $1.0 billion share repurchase program that expires on December 31, 2021. As of September 30, 2019, we have $1.0 billion authorized for share repurchases remaining under these programs. The approximate dollar value of shares that may yet be purchased under these programs has been reduced by the initial delivery of 6.4 million shares under the ASR program.



 
 
 
 19
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
 

Financial Statements
 
 

Condensed Consolidated Statements of Earnings
(Unaudited)
 
Three Months Ended September 30,
(in millions, except per common share amounts)
2019
 
2018
Revenue
$
37,341

 
$
35,213

Cost of products sold
35,662

 
33,546

Gross margin
1,679

 
1,667

 
 
 
 
Operating expenses:
 
 
 
Distribution, selling, general and administrative expenses
1,107

 
1,155

Restructuring and employee severance
30

 
32

Amortization and other acquisition-related costs
132

 
156

Impairments and (gain)/loss on disposal of assets, net
1

 
(511
)
Litigation (recoveries)/charges, net
5,673

 
19

Operating earnings/(loss)
(5,264
)
 
816

 
 
 
 
Other (income)/expense, net
14

 
3

Interest expense, net
66

 
77

Earnings/(loss) before income taxes
(5,344
)
 
736

 
 
 
 
Provision for (benefit from) income taxes
(423
)
 
142

Net earnings/(loss)
(4,921
)
 
594

 
 
 
 
   Less: Net earnings attributable to noncontrolling interests
(1
)
 
(1
)
Net earnings/(loss) attributable to Cardinal Health, Inc.
$
(4,922
)
 
$
593

 
 
 
 
Earnings/(loss) per common share attributable to Cardinal Health, Inc.:
 
 
 
Basic
$
(16.65
)
 
$
1.95

Diluted
(16.65
)
 
1.94

 
 
 
 
Weighted-average number of common shares outstanding:
 
 
 
Basic
296

 
305

Diluted
296

 
306

 
 
 
 
Cash dividends declared per common share
$
0.4811

 
$
0.4763

See notes to condensed consolidated financial statements.


 
 
 
 
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
20


Financial Statements
 
 

Condensed Consolidated Statements of Comprehensive Income/(Loss)
(Unaudited)
 
Three Months Ended September 30,
(in millions)
2019
 
2018
Net earnings/(loss)
$
(4,921
)
 
$
594

 
 
 
 
Other comprehensive income/(loss):
 
 
 
Foreign currency translation adjustments and other
(17
)
 
(3
)
Net unrealized gain/(loss) on derivative instruments, net of tax
(5
)
 
(1
)
Total other comprehensive income/(loss), net of tax
(22
)
 
(4
)
 
 
 
 
Total comprehensive income/(loss)
(4,943
)
 
590

 
 
 
 
Less: comprehensive income attributable to noncontrolling interests
(1
)
 
(1
)
Total comprehensive income/(loss) attributable to Cardinal Health, Inc.
$
(4,944
)
 
$
589

See notes to condensed consolidated financial statements.



 
 
 
 21
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
 

Financial Statements
 
 

Condensed Consolidated Balance Sheets
(Unaudited)
(in millions)
September 30, 2019
 
June 30, 2019
Assets
 
 
 
Current assets:
 
 
 
Cash and equivalents
$
1,212

 
$
2,531

Trade receivables, net
8,190

 
8,448

Inventories, net
12,458

 
12,822

Prepaid expenses and other
1,855

 
1,946

Total current assets
23,715

 
25,747

 
 
 
 
Property and equipment, net
2,324

 
2,356

Goodwill and other intangibles, net
11,658

 
11,808

Other assets
1,482

 
1,052

Total assets
$
39,179

 
$
40,963

 
 
 
 
Liabilities and Shareholders’ Equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
19,724

 
$
21,535

Current portion of long-term obligations and other short-term borrowings
631

 
452

Other accrued liabilities
2,194

 
2,122

Total current liabilities
22,549

 
24,109

 
 
 
 
Long-term obligations, less current portion
7,360

 
7,579

Deferred income taxes and other liabilities
8,367

 
2,945

 
 
 
 
Shareholders’ equity:
 
 
 
Preferred shares, without par value:
 
 
 
Authorized—500 thousand shares, Issued—none
—

 
—

Common shares, without par value:
 
 
 
Authorized—755 million shares, Issued—327 million shares at September 30, 2019 and June 30, 2019, respectively
2,669

 
2,763

Retained earnings
371

 
5,434

Common shares in treasury, at cost: 34 million shares and 28 million shares at September 30, 2019 and June 30, 2019, respectively
(2,039
)
 
(1,790
)
Accumulated other comprehensive loss
(101
)
 
(79
)
Total Cardinal Health, Inc. shareholders' equity
900

 
6,328

Noncontrolling interests
3

 
2

Total shareholders’ equity
903

 
6,330

Total liabilities and shareholders’ equity
$
39,179

 
$
40,963

See notes to condensed consolidated financial statements.



 
 
 
 
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
22


Financial Statements
 
 

Condensed Consolidated Statements of Shareholders' Equity
(Unaudited)

 
Common Shares
 
 
 
Treasury Shares
 
Accumulated Other
Comprehensive
Loss
 
Noncontrolling Interests
 
Total
Shareholders’
Equity
(in millions)
Shares Issued
 
Amount
 
Retained
Earnings/(Deficit)
 
Shares
 
Amount
 
 
 
 
Three Months Ended September 30, 2019
Balance at June 30, 2019
327

 
$
2,763

 
$
5,434

 
(28
)
 
$
(1,790
)
 
$
(79
)
 
$
2

 
$
6,330

Net loss
 
 
 
 
(4,922
)
 
 
 
 
 
 
 
1

 
(4,921
)
Other comprehensive income/(loss), net of tax
 
 
 
 
 
 
 
 
 
 
(22
)
 
 
 
(22
)
Employee stock plans activity, net of shares withheld for employee taxes


 
(24
)
 
 
 


 
31

 
 
 
 
 
7

Share repurchase program activity
 
 
(70
)
 


 
(6
)
 
(280
)
 
 
 
 
 
(350
)
Dividends declared
 
 
 
 
(141
)
 
 
 
 
 
 
 
 
 
(141
)
Balance at September 30, 2019
327

 
$
2,669

 
$
371

 
(34
)
 
$
(2,039
)
 
$
(101
)
 
$
3

 
$
903


 
Three Months Ended September 30, 2018
Balance at June 30, 2018
327

 
$
2,730

 
$
4,645

 
(18
)
 
$
(1,224
)
 
$
(92
)
 
$
—

 
$
6,059

Net earnings
 
 
 
 
593

 
 
 
 
 
 
 
 
 
593

Other comprehensive income/(loss), net of tax
 
 
 
 
 
 
 
 
 
 
(4
)
 
 
 
(4
)
Employee stock plans activity, net of shares withheld for employee taxes


 
(20
)
 
 
 


 
26

 
 
 
 
 
6

Share repurchase program activity
 
 
(120
)
 
 
 
(9
)
 
(480
)
 
 
 
 
 
(600
)
Dividends declared
 
 
 
 
(143
)
 
 
 
 
 
 
 
 
 
(143
)
Other
 
 
 
 
2

 
 
 
 
 
 
 
 
 
2

Balance at September 30, 2018
327

 
$
2,590

 
$
5,097

 
(27
)
 
$
(1,678
)
 
$
(96
)
 
$
—

 
$
5,913

See notes to condensed consolidated financial statements.




 
 
 
 23
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
 

Financial Statements
 
 

Condensed Consolidated Statements of Cash Flows
(Unaudited)
 
Three Months Ended September 30,
(in millions)
2019
 
2018
Cash flows from operating activities:
 
 
 
Net earnings/(loss)
$
(4,921
)
 
$
594

 
 
 
 
Adjustments to reconcile net earnings/(loss) to net cash provided by/(used in) operating activities:
 
 
 
Depreciation and amortization
234

 
245

Impairments and (gain)/loss on sale of investments
—

 
2

Impairments and (gain)/loss on disposal of assets, net
1

 
(511
)
Share-based compensation
20

 
19

Provision for bad debts
29

 
21

Change in operating assets and liabilities, net of effects from acquisitions and divestitures:
 
 
 
(Increase)/decrease in trade receivables
229

 
(302
)
(Increase)/decrease in inventories
356

 
(178
)
Increase/(decrease) in accounts payable
(1,812
)
 
559

Other accrued liabilities and operating items, net
5,211

 
(84
)
Net cash provided by/(used in) operating activities
(653
)
 
365

 
 
 
 
Cash flows from investing activities:
 
 
 
Additions to property and equipment
(72
)
 
(58
)
Purchase of available-for-sale securities and other investments
(3
)
 
(4
)
Proceeds from sale of available-for-sale securities and other investments
2

 
1

Proceeds from divestitures, net of cash sold, and disposal of property and equipment
—

 
740

Net cash provided by/(used in) investing activities
(73
)
 
679

 
 
 
 
Cash flows from financing activities:
 
 
 
Net change in short-term borrowings
(2
)
 
—

Reduction of long-term obligations
(74
)
 
(1
)
Net tax proceeds/(withholdings) from share-based compensation
(13
)
 
(13
)
Dividends on common shares
(146
)
 
(150
)
Purchase of treasury shares
(350
)
 
(600
)
Net cash used in financing activities
(585
)
 
(764
)
 
 
 
 
Effect of exchange rate changes on cash and equivalents
(8
)
 
2

 
 
 
 
Net increase/(decrease) in cash and equivalents
(1,319
)
 
282

Cash and equivalents at beginning of period
2,531

 
1,763

Cash and equivalents at end of period
$
1,212

 
$
2,045

See notes to condensed consolidated financial statements.


 
 
 
 
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
24


Notes to Financial Statements
 
 

Notes to Condensed Consolidated Financial Statements

1. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation
Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. Investments in business entities in which we do not have control, but have the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. Refer to Note 4 for further information on our equity method investments.
References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.
Our fiscal year ends on June 30. References to fiscal 2020 and 2019 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2020 and June 30, 2019, respectively.
Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. To conform to the current year presentation, certain prior year amounts have been reclassified. In addition, financial results presented for this fiscal 2020 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2020. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2019 (the "2019 Form 10-K").
Recently Adopted Financial Accounting Standards
Derivatives and Hedging
In October 2018, the Financial Accounting Standards Board ("FASB") issued amended accounting guidance related to derivatives and hedging which permits the use of the Secured Overnight Financing Rate ("SOFR") Overnight Index Swap ("OIS") as a Benchmark
 
Interest Rate for Hedge Accounting Purposes. This guidance is effective beginning the first quarter of fiscal 2020 and must be applied on a prospective basis. The adoption did not have a material impact on our consolidated financial statements.
Leases
In February 2016, the FASB issued amended accounting guidance that requires lessees to recognize most leases on the balance sheet as a lease liability and corresponding right-of-use asset. The guidance also requires disclosures that meet the objective of enabling financial statement users to assess the amount, timing and uncertainty of cash flows arising from leases. We adopted this guidance during the first quarter of fiscal 2020 and elected the transition option which allows us to apply the guidance prospectively. The adoption resulted in the recognition of lease liabilities in the amount of $422 million and did not have a material impact on our results of operations, liquidity or debt covenant compliance under our current debt agreements. The majority of our lease spend relates to certain real estate with the remaining lease spend primarily related to vehicles and equipment. The adoption required certain changes to our systems and processes. See Note 5 for additional information regarding leases.
Recently Issued Financial Accounting Standards Not Yet Adopted
Financial Instruments - Credit Losses
In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. This guidance will be effective for us in the first quarter of fiscal 2021. We are currently evaluating the impact of adoption on our consolidated financial statements.


 
 
 
 25
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
 

Notes to Financial Statements
 
 


2. Restructuring and Employee Severance
The following table summarizes restructuring and employee severance costs:
 
Three months ended September 30,
(in millions)
2019
 
2018
Employee-related costs (1)
$
20

 
$
29

Facility exit and other costs (2)
10

 
3

Total restructuring and employee severance
$
30

 
$
32


(1)
Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods.
(2)
Facility exit and other costs primarily consist of product distribution and lease contract termination costs, lease costs associated with vacant facilities, accelerated depreciation, equipment relocation costs, project consulting fees, costs associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs.
During fiscal 2020 and 2019, we implemented certain enterprise-wide cost-saving initiatives affecting various functional and commercial areas intended to optimize and simplify our operating model and cost structure. We incurred $20 million and $26 million for the three months ended September 30, 2019 and 2018, respectively, in expenses related to these cost savings initiatives, which are reflected in restructuring and employee severance in the condensed consolidated statements of earnings.
The following table summarizes activity related to liabilities associated with restructuring and employee severance:
(in millions)
Employee-
Related Costs
 
Facility Exit
and Other Costs
 
Total
Balance at June 30, 2019
$
64

 
$
8

 
$
72

Additions
19

 
6

 
25

Payments and other adjustments
(10
)
 
(2
)
 
(12
)
Balance at September 30, 2019
$
73

 
$
12

 
$
85


3. Goodwill and Other Intangible Assets
Goodwill
The following table summarizes the changes in the carrying amount of goodwill by segment and in total:
(in millions)
Pharmaceutical
 
Medical
 
Total
Balance at June 30, 2019
$
2,663

 
$
5,715

 
$
8,378

Goodwill acquired, net of purchase price adjustments
(5
)
 
—

 
(5
)
Foreign currency translation adjustments and other
—

 
(13
)
 
(13
)
Balance at September 30, 2019
$
2,658

 
$
5,702

 
$
8,360


 
Other Intangible Assets
The following tables summarize other intangible assets by class at:
 
September 30, 2019
(in millions)
Gross
Intangible
 
Accumulated
Amortization
 
Net
Intangible
 
Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
 
 
 
 
 
 
 
IPR&D, trademarks and other
$
22

 
$
—

 
$
22

 
N/A
Total indefinite-life intangibles
22

 
—

 
22

 
N/A
 
 
 
 
 
 
 
 
Definite-life intangibles:
 
 
 
 
 
 
 
Customer relationships
3,555

 
1,592

 
1,963

 
13
Trademarks, trade names and patents
673

 
307

 
366

 
13
Developed technology and other
1,603

 
656

 
947

 
11
Total definite-life intangibles
5,831

 
2,555

 
3,276

 
12
Total other intangible assets
$
5,853

 
$
2,555

 
$
3,298

 
N/A
 
June 30, 2019
(in millions)
Gross
Intangible
 
Accumulated
Amortization
 
Net
Intangible
Indefinite-life intangibles:
 
 
 
 
 
IPR&D, trademarks and other
$
22

 
$
—

 
$
22

Total indefinite-life intangibles
22

 
—

 
22

 
 
 
 
 
 
Definite-life intangibles:
 
 
 
 
 
Customer relationships
3,562

 
1,517

 
2,045

Trademarks, trade names and patents
672

 
295

 
377

Developed technology and other
1,602

 
616

 
986

Total definite-life intangibles
5,836

 
2,428

 
3,408

Total other intangible assets
$
5,858

 
$
2,428

 
$
3,430


Total amortization of intangible assets was $129 million and $133 million for the three months ended September 30, 2019 and 2018, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2020 through 2024 is as follows: $382 million, $442 million, $408 million, $358 million, and $328 million.


 
 
 
 
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
26


Notes to Financial Statements
 
 


4. Investments
In August 2018, we sold our 98 percent ownership interest in naviHealth Holdings, LLC ("naviHealth") to investor entities controlled by Clayton, Dubilier & Rice in exchange for cash proceeds of $737 million (after adjusting for certain fees and expenses) and a 44 percent equity interest in a partnership that owns 100 percent of the equity interest of naviHealth. We also have certain call rights to reacquire naviHealth. We are accounting for this investment using the equity method of accounting and on a one-month reporting lag.
During the three months ended September 30, 2018, we recognized a pre-tax gain of $508 million related to this divestiture in impairments and (gain)/loss on disposal of assets in our condensed consolidated statement of earnings. 
The carrying value of this investment was $329 million and $334 million as of September 30, 2019 and June 30, 2019, respectively. For the three months ended September 30, 2019, our proportionate share of naviHealth’s net loss, which was recorded in Other (income)/expense, net in the condensed consolidated statement of earnings, was immaterial.
5. Leases
We primarily have operating leases for corporate offices, distribution facilities, vehicles, and equipment. We determine if an arrangement is a lease at inception by evaluating whether the arrangement conveys the right to use an identified asset and whether we obtain substantially all of the economic benefits from and have the ability to direct the use of the asset. Our lease agreements generally do not contain any material residual value guarantees or material restrictive covenants.
Beginning July 1, 2019, operating leases are included in other assets, other accrued liabilities, and deferred income taxes and other liabilities in our condensed consolidated balance sheet. Operating lease right-of-use assets and corresponding operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Operating lease expense for operating lease assets is recognized on a straight-line basis over the lease term. As most of our leases do not provide an implicit rate, we use our collateralized incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate if it is readily determinable.
Finance leases are included in property and equipment, net, current portion of long-term obligations and other short-term borrowings, and long-term obligations, less current portion in our condensed consolidated balance sheet.
Our lease agreements include leases that contain lease components and non-lease components. For all asset classes, we have elected to account for both of these provisions as a single lease component. We also, from time to time, sublease portions of our real estate property, resulting in sublease income. Sublease income and the related assets and cash flows are not material to the condensed
 
consolidated financial statements at or for the three months ended September 30, 2019.
We also have elected to apply a practical expedient for short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months. Short-term lease expense recognized in the three months ended September 30, 2019 was not material. In addition, we elected the package of three practical expedients permitted under the transition guidance, which include the carry forward of our leases without reassessing 1) whether any contracts are leases or contain leases, 2) lease classification and 3) initial direct costs.
Our leases have remaining lease terms from less than 1 year up to approximately 23 years. Our lease terms may include options to extend or terminate the lease when it is reasonably certain and there is a significant economic incentive to exercise that option.
The following table summarizes the components of lease cost:
 
Three Months Ended September 30,
(in millions)
2019
Operating lease cost
$
31

Finance lease cost


Amortization of right-of-use assets
4

Total finance lease cost
4

Variable lease cost
1

Total lease cost
$
36


The following tables summarizes supplemental balance sheet information related to leases:
(in millions)
September 30, 2019
Operating Leases
 
Operating lease assets
$
394

 
 
   Current portion of operating lease liabilities
103

   Operating lease liabilities
312

Total operating lease liabilities
415

 
 
Finance Leases
 
Property and equipment, net
18

 
 
Current portion of long-term obligations
5

Long-term obligations, less current portion
12

Total finance lease liabilities
$
17





 
 
 
 27
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
 

Notes to Financial Statements
 
 


The following tables summarizes supplemental cash flow information related to leases:
 
Three Months Ended September 30,
(in millions)
2019
Cash paid for amounts included in the measurement of lease liabilities:


Operating cash flows paid for operating leases
$
31

Financing cash flows paid for finance lease
2

Non-cash right-of-use assets obtained in exchange for lease obligations:

New operating leases
15

New finance leases
17

Amended lease standard adoption impact as of July 1, 2019 (1) 
400


(1)
Includes the effect of $22 million from reclassifying deferred rent as an offset in accordance with the transition guidance.
Our operating leases had a weighted-average remaining lease term of 6.2 years and a weighted-average discount rate of 3.0 percent.
Future lease payments under non-cancellable leases as of September 30, 2019 were as follows:
(in millions)
Operating Leases
 
Finance Leases
 
Total
Years Ending September 30,

 

 

Remainder of 2020
$
91

 
$
4

 
$
95

2021
101

 
6

 
107

2022
79

 
4

 
83

2023
58

 
4

 
62

2024
41

 
1

 
42

Thereafter
149

 
—

 
149

Total future lease payments
519

 
19

 
538

Less: leases not yet commenced (1) 
61

 
—

 
61

Less: imputed interest
43

 
2

 
45

Total lease liabilities
$
415

 
$
17

 
$
432

(1)
As of September 30, 2019, we had certain leases that were executed but did not have control of the underlying assets; therefore, the lease liabilities and right-of-use assets are not recorded in the condensed consolidated balance sheets.
As previously disclosed in our fiscal 2019 Form 10-K under the prior accounting guidance, the future minimum rental payments for operating leases having initial or remaining non-cancelable lease terms in excess of one year at June 30, 2019 for fiscal 2020 through 2024 and thereafter were as follows: $126 million, $100 million, $76 million, $54 million, $33 million and $94 million.

 
6. Long-Term Obligations and Other Short-Term Borrowings
Long-Term Debt
We had total long-term obligations, including the current portion and other short-term borrowings, of $8.0 billion at both September 30, 2019 and June 30, 2019. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $19.7 billion and $21.5 billion at September 30, 2019 and June 30, 2019, respectively.
During the three months ended September 30, 2019, we repurchased a total of $74 million of notes due in 2022 and 2047 with available cash.
Other Financing Arrangements
In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $2.0 billion commercial paper program backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility.
In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2022. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors.
Our revolving credit facility and committed receivables sales facilities require us to maintain, as of the end of every fiscal quarter from September 30, 2019 through December 2020, a consolidated net leverage ratio of no more than 4.00-to-1. The maximum permitted ratio will reduce to 3.75-to-1 in March 2021 and as of the end of every fiscal quarter thereafter. As of September 30, 2019, we were in compliance with our financial covenants.
7. Commitments, Contingent Liabilities and Litigation
Commitments
Generic Sourcing Venture with CVS Health Corporation ("CVS Health")
In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. Due to the achievement of predetermined milestones, we are required to make quarterly payments of $45.6 million to CVS Health for the remainder of the initial term.


 
 
 
 
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
28


Notes to Financial Statements
 
 

Legal Proceedings
We become involved from time to time in disputes, litigation and regulatory matters.
We are named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.
From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information have led, and may in the future lead, to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.
From time to time, we determine that products we manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions can lead to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, action by regulators and product liability claims and lawsuits, including class actions. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.
We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.
We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.
 
We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our condensed consolidated statements of earnings.
Opioid Lawsuits
Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately 2,400 lawsuits relating to the distribution of prescription opioid pain medications. These lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as negligence, public nuisance and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.
The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the “MDL”).
In addition, 21 state attorneys general have filed lawsuits against distributors, including us, in various state courts.
Additionally, 43 state attorneys general have formed a multi-state task force to investigate the manufacturing, distribution, dispensing and prescribing practices of opioid medications. We have received requests related to the multi-state investigation, as well as separate civil investigative demands, subpoenas or requests for information from these and other state attorneys general offices.
In October 2019, we agreed in principle to a global settlement framework with a leadership group of four state attorneys general from the multi-state task force that is designed to resolve all pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). This Settlement Framework is subject to contingencies and uncertainties as to final terms, but is the basis for our negotiation of definitive terms and documentation.
The Settlement Framework includes (1) a cash component, pursuant to which we would pay up to $5.56 billion over eighteen years, (2) development and participation in a program for free or rebated distribution of opioid abuse treatment medications for a period of ten years, and (3) industry-wide changes to be specified to controlled substance anti-diversion programs. The Settlement Framework is in its early phases, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. We have included a $5.56 billion accrual related to the Settlement Framework in deferred income taxes and other liabilities in the condensed consolidated balance sheets and litigation (recoveries)/charges, net, in the condensed consolidated statements of earnings.
On October 21, 2019, we and two other national distributors agreed to a $215 million settlement with two Ohio counties, Cuyahoga and


 
 
 
 29
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
 

Notes to Financial Statements
 
 

Summit, to resolve all claims in the first bellwether trial in the MDL that had been scheduled for trial in October 2019. In connection with this settlement, we have accrued $66 million, which is included in other accrued liabilities in the condensed consolidated balance sheets and litigation (recoveries)/charges, net, in the condensed consolidated statements of earnings.
In connection with these matters, we recorded a total pre-tax charge of $5.63 billion ($5.14 billion after tax) during the three-months ended September 30, 2019 for the cash component. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. Moreover, the global Settlement Framework is in early stages and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. We will regularly review these opioid litigation matters to determine whether our accrual is adequate. We are unable to reasonably estimate the liability associated with any potential distribution of treatment medications and any incremental costs for changes to our controlled substance anti-diversion program that we may agree to under the Settlement Framework. The amount of ultimate loss may differ materially from this accrual. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.
The Settlement Framework does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals. Private parties had brought approximately 325 lawsuits as of November 1, 2019. Of these, 97 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We will continue to vigorously defend ourselves in these matters.
Product Liability Lawsuits
As of November 1, 2019, we are named as a defendant in 280 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 3,463 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava (IVC) filter products. Another 24 lawsuits involving similar claims by approximately 28 plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. We are vigorously defending ourselves in these lawsuits.
At September 30, 2019, we had a total of $414 million, net of estimated insurance recoveries, accrued for losses and legal defense costs related to the Cordis IVC filter lawsuits which are presented on a gross basis in the condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range
 
to be approximately $836 million, net of estimated insurance recoveries.
Shareholder Securities Litigation
In August 2019, the Louisiana Sheriffs' Pension & Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. We believe that the claims asserted in this complaint are without merit and intend to vigorously defend against them. Due to the early stage of this proceeding, it is not possible to reasonably estimate the amount of any possible loss or range of loss in this matter.
8. Income Taxes
Fluctuations in our provision for income taxes as a percentage of pre-tax earnings (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.
Opioid Settlement Framework
In connection with the $5.63 billion pre-tax charge for the opioid litigation, we recorded a tax benefit of $487 million, which is net of unrecognized tax benefits of $468 million, reflecting our current assessment of the estimated future deductibility of the amount that may be paid. We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible that the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates. See Note 7 for more information regarding these matters.
Effective Tax Rate
During the three months ended September 30, 2019 and 2018, the effective tax rate was 7.9 percent and 19.4 percent, respectively. The change in the effective tax rate from fiscal 2019 to fiscal 2020 is primarily due to the net effects of the Settlement Framework, partially offset by the prior-year benefit of discrete tax items.


 
 
 
 
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
30


Notes to Financial Statements
 
 

Unrecognized Tax Benefits
We had $943 million and $456 million of unrecognized tax benefits at September 30, 2019 and June 30, 2019, respectively. The September 30, 2019 and June 30, 2019 balances include $795 million and $303 million, respectively, of unrecognized tax benefits that, if recognized, would have an impact on the effective tax rate.
At September 30, 2019 and June 30, 2019, we had $126 million and $122 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.
It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of $10 million, exclusive of penalties and interest.
Other Tax Matters
We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2008 through the current fiscal year. Tax laws are complex and subject to varying interpretations. Tax authorities have challenged some of our tax positions, including IRS challenges to our international transfer pricing for the periods from 2008 to 2014, and it is possible that they will challenge others. These challenges may adversely affect our effective tax rate or tax payments.
We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), which has been acquired by Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $168 million and $165 million at September 30, 2019 and June 30, 2019, respectively, and is included in other assets in the condensed consolidated balance sheets.
As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition. The indemnification receivable was $23 million and $22 million at September 30, 2019 and June 30, 2019, respectively, and is included in other assets in the condensed consolidated balance sheet.
Future adjustments to the financial statements may be necessary as final tax regulations related to U.S. Tax Reform are issued. We will assess any impact as additional guidance is issued.
 
9. Fair Value Measurements
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:
 
September 30, 2019
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
Other investments (1)
$
109

 
$
—

 
$
—

 
$
109

Forward contracts (2)
—

 
95

 
—

 
95

 
June 30, 2019
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
Other investments (1)
$
118

 
$
—

 
$
—

 
$
118

Forward contracts (2)
—

 
53

 
—

 
53

(1)
The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
(2) The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.
10. Financial Instruments
We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.
Interest Rate Risk Management
We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes


 
 
 
 31
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
 

Notes to Financial Statements
 
 

in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.
Currency Exchange Risk Management
We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce volatility in earnings, cash flow and net investments in certain subsidiaries to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.
Commodity Price Risk Management
We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.
Fair Value Hedges
We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings. For the three months ended September 30, 2019 and 2018, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.
Cash Flow Hedges
We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.
During the three months ended September 30, 2019, we entered into a forward interest rate swap with a total notional amount of $50 million to hedge probable, but not firmly committed, future transactions associated with our debt.
 
Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three months ended September 30, 2019 and 2018. All gains and losses currently included within accumulated other comprehensive loss associated with our foreign exchange forward contracts to be reclassified into net earnings within the next 12 months are immaterial.
Net Investment Hedges
We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.
During three months ended September 30, 2019, we entered into a ¥64.0 billion cross-currency swap maturing in 2022.
During three months ended September 30, 2018, we entered into a €200 million cross-currency swap maturing in 2023.
Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive income/(loss) until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. There was no ineffectiveness in our net investment hedges during the three months ended September 30, 2019.
Economic (Non-Designated) Hedges
We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. The gain and losses recognized in the three months ended September 30, 2019 and 2018 were immaterial. The principal currencies managed through foreign currency contracts are the euro, Canadian dollar, British pound, Japanese yen, and Chinese renminbi.
Fair Value of Financial Instruments
The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at September 30, 2019 and June 30, 2019 approximate fair value due to their short-term maturities.


 
 
 
 
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
32


Notes to Financial Statements
 
 

The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:
(in millions)
September 30, 2019
 
June 30, 2019
Estimated fair value
$
8,001

 
$
8,065

Carrying amount
7,991

 
8,031


The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.
11. Shareholders' Equity
During the three months ended September 30, 2019, we entered in an accelerated share repurchase ("ASR") program to purchase common shares for an aggregate purchase price of $350 million and received an initial delivery of 6.4 million common shares having an aggregate cost of $280 million. The average price paid per common share was $43.76. The ASR program began on August 20, 2019 and is expected to conclude in the second quarter of fiscal 2020. We funded the repurchases with available cash and short-term borrowings.
During the three months ended September 30, 2018, we entered in an ASR program to purchase common shares for an aggregate purchase price of $600 million and received an initial delivery of 9.5 million common shares having an aggregate cost of $480 million. The average price paid per common share was $50.45. The ASR program began on August 16, 2018 and was completed on October 25, 2018 when we received the final delivery of 2.0 million common shares. We funded the repurchases with available cash and short-term borrowings.
The common shares repurchased are held in treasury to be used for general corporate purposes.
Accumulated Other Comprehensive Loss
The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:
(in millions)
Foreign
Currency
Translation
Adjustments
 
Unrealized
Gain/(Loss) on
Derivatives,
net of tax
 
Accumulated Other
Comprehensive
Loss
Balance at June 30, 2019
$
(95
)
 
$
16

 
$
(79
)
Other comprehensive income/(loss), before reclassifications
(17
)
 
—

 
(17
)
Amounts reclassified to earnings
—

 
(5
)
 
(5
)
Other comprehensive income/(loss), net of tax
(17
)
 
(5
)
 
(22
)
Balance at September 30, 2019
$
(112
)
 
$
11

 
$
(101
)

The sum of components may not equal the total due to rounding.
 
12. Earnings Per Share Attributable to Cardinal Health, Inc.
The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:
 
Three Months Ended September 30,
(in millions)
2019
 
2018
Weighted-average common shares–basic
296

 
305

Effect of dilutive securities:
 
 
 
Employee stock options, restricted share units, and performance share units
—

 
1

Weighted-average common shares–diluted
296

 
306


For the three months ended September 30, 2019, 6 million employee stock options, restricted share units and performance share units were excluded from the calculation of diluted shares outstanding, 1 million of which would be anti-dilutive as a result of the net loss for the period.
The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive for the three months ended September 30, 2018 were 6 million.
13. Segment Information
Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.
Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products.
Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment


 
 
 
 33
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
 

Notes to Financial Statements
 
 



also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.
Revenue
The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:
 
Three Months Ended September 30,
(in millions)
2019
 
2018
Pharmaceutical Distribution and Specialty Solutions (1)
$
33,212

 
$
31,209

Nuclear and Precision Health Solutions
216

 
207

Pharmaceutical segment revenue
33,428

 
31,416

Medical distribution and products (2)
3,446

 
3,380

Cardinal Health at-Home Solutions
471

 
421

Medical segment revenue
3,917

 
3,801

  Total segment revenue
37,345

 
35,217

Corporate (3)
(4
)
 
(4
)
Total revenue
$
37,341

 
$
35,213

(1)
Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services".
(2)
Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.
(3)
Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
The following table presents revenue by geographic area:
 
Three Months Ended September 30,
(in millions)
2019
 
2018
United States
$
36,310

 
$
34,245

International
1,035

 
972

  Total segment revenue
37,345

 
35,217

Corporate (1)
(4
)
 
(4
)
Total revenue
$
37,341

 
$
35,213

(1)
Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit
We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial, and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.
 
We do not allocate the following items to our segments: last-in first-out, or ("LIFO"), inventory charges/(credits); restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; state opioid assessment related to prior fiscal years; other (income)/expense, net; interest expense, net; loss on extinguishment of debt; and provision for income taxes.
In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $3 million and $7 million for the three months ended September 30, 2019 and 2018, respectively.
In connection with the opioid litigation as discussed further in Note 7, we recognized a pre-tax charge of $5.63 billion during the three months ended September 30, 2019, which was retained at Corporate.
In connection with the naviHealth divestiture, we recognized a pre-tax gain of $508 million during the three months ended September 30, 2018, which was retained at Corporate.
The following table presents segment profit by reportable segment and Corporate:
 
Three Months Ended September 30,
(in millions)
2019
 
2018
Pharmaceutical
$
398

 
$
409

Medical
170

 
135

Total segment profit
568

 
544

Corporate
(5,832
)
 
272

Total operating earnings/(loss)
$
(5,264
)
 
$
816


The following table presents total assets for each reportable segment and Corporate at:
(in millions)
September 30,
2019
 
June 30,
2019
Pharmaceutical
$
21,755

 
$
22,446

Medical
15,462

 
15,284

Corporate
1,962

 
3,233

Total assets
$
39,179

 
$
40,963


14. Share-Based Compensation
We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees.
The following table provides total share-based compensation expense by type of award:


 
 
 
 
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
34


Notes to Financial Statements
 
 


 
Three Months Ended September 30,
(in millions)
2019
 
2018
Restricted share unit expense
$
17

 
$
14

Employee stock option expense
1

 
4

Performance share unit expense
2

 
1

Total share-based compensation
$
20

 
$
19


The total tax benefit related to share-based compensation was $4 million and $5 million for the three months ended September 30, 2019 and 2018, respectively.
Restricted Share Units
Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to restricted share units under the Plans:
(in millions, except per share amounts)
Restricted Share Units
 
Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 2019
2

 
$
51.65

Granted
2

 
42.09

Vested
(1
)
 
60.92

Canceled and forfeited
—

 
—

Nonvested at September 30, 2019
3

 
$
45.29

At September 30, 2019, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $125 million, which is expected to be recognized over a weighted-average period of two years.
Stock Options
Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.
The following table summarizes all stock option transactions under the Plans:
(in millions, except per share amounts)
Stock
Options
 
Weighted-Average
Exercise Price per
Common Share
Outstanding at June 30, 2019
6

 
$
63.78

Granted
—

 
—

Exercised
—

 
—

Canceled and forfeited
—

 
—

Outstanding at September 30, 2019
6

 
$
63.75

Exercisable at September 30, 2019
6

 
$
63.67


At September 30, 2019, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $3 million, which is expected to be recognized over a weighted-average period of one year.
 
The following tables provide additional detail related to stock options:
(in millions)
September 30, 2019
 
June 30, 2019
Aggregate intrinsic value of outstanding options at period end
$
10

 
$
10

Aggregate intrinsic value of exercisable options at period end
10

 
10

(in years)
September 30, 2019
 
June 30, 2019
Weighted-average remaining contractual life of outstanding options
5
 
5
Weighted-average remaining contractual life of exercisable options
5
 
5

Performance Share Units
Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
(in millions, except per share amounts)
Performance
Share Units
 
Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 2019
0.9

 
$
51.45

Granted
0.5

 
43.68

Vested
(0.1
)
 
48.40

Canceled and forfeited
(0.1
)
 
50.59

Nonvested at September 30, 2019
1.2

 
$
50.84


At September 30, 2019, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $25 million, which is expected to be recognized over a weighted-average period of three years if the performance goals are achieved.


 
 
 
 35
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
 

Exhibits
 
 

Exhibits
Exhibit
Number
Exhibit Description
3.1
3.2
10.1
10.2
10.3
31.1
31.2
32.1
99.1
101.SCH
Inline XBRL Taxonomy Extension Schema Document
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
Inline XBRL Taxonomy Definition Linkbase Document
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document
104
Cover Page Interactive Data File - formatted in Inline XBRL (included as Exhibit 101)
Cardinal Health Website
Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive e-mail alerts when we post news releases, SEC filings and certain other information on its website.



 
 
 
 
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
36


Form 10-Q Cross Reference Index
 
 



Form 10-Q Cross Reference Index
Item Number
 
Page
 
 
 
 
Part I. Financial Information
 
Item 1
Item 2
Item 3
Item 4
 
 
 
 
Part II. Other Information
 
Item 1
Item 1A
Item 2
Item 3
Defaults Upon Senior Securities
N/A
Item 4
Mine Safety Disclosures
N/A
Item 5
Other Information
N/A
Item 6
 
N/A
Not applicable
 




 
 
 
 37
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
 

Additional Information
 
 

Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
Cardinal Health, Inc.
 
 
 
Date:
November 7, 2019
/s/ MICHAEL C. KAUFMANN
 
 
Michael C. Kaufmann
 
 
Chief Executive Officer
 
 
 
 
 
/s/ DAVID C. EVANS
 
 
David C. Evans
 
 
Chief Financial Officer



 
 
 
 
Cardinal Health | Q1 Fiscal 2020 Form 10-Q
38

 EX-31.1 2 a20q110q93019exhibit311.htm EXHIBIT 31.1 Exhibit
 
 
Exhibit 31.1


I, Michael C. Kaufmann, certify that:
1.
I have reviewed this Form 10-Q of Cardinal Health, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 7, 2019
/s/ MICHAEL C. KAUFMANN
 
Michael C. Kaufmann
 
Chief Executive Officer
 



 EX-31.2 3 a20q110q93019exhibit312.htm EXHIBIT 31.2 Exhibit
 
 
Exhibit 31.2


I, David C. Evans, certify that:
1.
I have reviewed this Form 10-Q of Cardinal Health, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 7, 2019
/s/ DAVID C. EVANS
 
David C. Evans
 
Chief Financial Officer
 



 EX-32.1 4 a20q110q93019exhibit321.htm EXHIBIT 32.1 Exhibit
 
 
Exhibit 32.1


Certification of the Chief Executive Officer and the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Michael C. Kaufmann, Chief Executive Officer of Cardinal Health, Inc. (the “Company”) and David C. Evans, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that:
(1)
the Periodic Report on Form 10-Q for the quarter ended September 30, 2019 containing the financial statements of the Company (the “Periodic Report”), which this statement accompanies, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
(2)
the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: November 7, 2019
 
/s/ MICHAEL C. KAUFMANN
 
Michael C. Kaufmann
 
Chief Executive Officer
 
/s/ DAVID C. EVANS
 
David C. Evans
 
Chief Financial Officer



 EX-99.1 5 a20q110q93019exhibit991.htm EXHIBIT 99.1 Exhibit
 
 
Exhibit 99.1




Statement Regarding Forward-Looking Information
As used in this exhibit, “we,” “our,” “us” and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our filings with the Securities and Exchange Commission, including this Annual Report on Form 10-K for the fiscal year ended June 30, 2019 (the “2019 Form 10-K”), our quarterly reports on Form 10-Q and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement is first made) about future events, prospects, projections or financial performance. The matters discussed in these forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied in or by such statements. These risks and uncertainties include:
•
competitive pressures in the markets in which we operate, including pricing pressures;
•
uncertainties relating to the pricing of generic pharmaceuticals;
•
uncertainties relating to the timing, frequency and profitability of generic pharmaceutical launches;
•
our ability to maintain the benefits of our generic pharmaceutical sourcing venture with CVS Health Corporation;
•
with respect to our distribution services agreements with branded pharmaceutical manufacturers, changes in the amount of service fees we receive or, in cases where part of our compensation under these agreements is based on branded pharmaceutical price appreciation, changes in the frequency or magnitude of such price appreciation;
•
changes in manufacturer approaches to pricing branded pharmaceutical products and risks related to our compensation under contractual arrangements with manufacturers being set as a percentage of the wholesale acquisition cost of branded pharmaceuticals;
•
changes in the timing or frequency of the introduction of branded pharmaceuticals;
•
risks associated with the resolution and defense of the lawsuits and investigations in which we have been or will be named relating to the distribution of prescription opioid pain medication, including the risk that the outcome of these lawsuits and investigations could have a material adverse effect on our results of operations, financial condition, cash flows or liquidity;
•
potential damage to our reputation, adverse operational impacts or other effects that may result from the national opioid epidemic, the allegations that have been made about our role in such epidemic and the ongoing unfavorable publicity surrounding the lawsuits and investigations against us;
•
risks associated with the ongoing discussions regarding a potential global settlement of certain opioid lawsuits and investigations against us, including the risk that we could fail to reach a final settlement, that any final settlement reached could require us to pay more than we currently anticipate or could have a negative effect on our liquidity or ability to return money to shareholders, and the risk that any injunctive or non-monetary remedies we may agree to could have unintended consequences;
•
potential adverse impact to our financial results resulting from enacted and proposed state taxes or other assessments on the sale or distribution of opioid medications;
•
our high sales concentration with certain key customers, including CVS Health Corporation and OptumRx;
•
actions of regulatory bodies and other governmental authorities, including the U.S. Drug Enforcement Administration, certain agencies within the U.S. Department of Health and Human Services (including the U.S. Food and Drug Administration, Centers for Medicare and Medicaid Services, the Office of Inspector General and the Office for Civil Rights), the U.S. Nuclear Regulatory Commission, the U.S. Federal Trade Commission, the U.S. Customs and Border Protection, various state boards of pharmacy, state controlled substance authorities, state health departments, state insurance departments, state Medicaid departments or comparable regulatory bodies or governmental authorities or foreign equivalents that, in each case, could delay, limit or suspend product development, manufacturing, distribution, importation or sales or result in warning letters, recalls, seizures, injunctions or monetary sanctions;
•
any compromise of our information systems or of those of a third-party service provider, including unauthorized access to or use or disclosure of company or customer information, disruption of access and ancillary risks associated with our ability to effectively manage any issues arising from any such compromise or disruption;
•
uncertainties related to our Medical segment's Cardinal Health Brand products, including our ability to manage infrastructure and cost challenges, and to improve its performance;
•
risks associated with the realignment of our Medical segment's supply chain and other businesses, including our ability to achieve the expected benefits from such realignment;
•
uncertainties with respect to our cost-savings initiatives or other restructuring activities, including the ability to achieve the expected benefits from such initiatives, the risk that we could incur unexpected charges, and the risk that we may fail to retain key personnel;
•
difficulties or delays in the development, production, manufacturing, sourcing and marketing of new or existing products and services, including difficulties or delays associated with obtaining requisite regulatory consents or approvals associated with those activities;
•
manufacturing disruptions, whether due to regulatory action, production quality deviations, safety issues or raw material shortages or defects, or because a key product is manufactured at a single manufacturing facility with limited alternate facilities;
•
risks arising from possible violations of healthcare fraud and abuse laws;



•
costs or claims resulting from potential errors or defects in our manufacturing of medical devices or other products or in our compounding, repackaging, information systems or pharmacy management services that may injure persons or damage property or operations, including costs from remediation efforts or recalls and related product liability claims and lawsuits, including class action lawsuits;
•
risks arising from possible violations of the U.S. Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws;
•
risks arising from our collecting, handling and maintaining patient-identifiable health information and other sensitive personal and financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information;
•
risks arising from certain of our businesses being Medicare-certified suppliers or participating in other federal and state healthcare programs, such as state Medicaid programs and the federal 340B drug pricing program, which businesses are subject to accreditation and quality standards and other rules and regulations, including applicable reporting, billing, payment and record-keeping requirements;
•
risks arising from certain of our businesses manufacturing pharmaceutical and medical products or repackaging pharmaceuticals that are purchased or reimbursed through, or are otherwise governed by, federal or state healthcare programs, which businesses are subject to federal and state laws that establish eligibility for reimbursement by such programs and other applicable standards and regulations;
•
changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications;
•
material reductions in purchases, pricing changes, non-renewal, early termination, or delinquencies or defaults under contracts with key customers;
•
unfavorable changes to the terms of key customer or supplier relationships, or changes in customer mix;
•
risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges;
•
uncertainties due to possible government healthcare reform, including proposals related to Medicare drug rebate arrangements, possible repeal or replacement of major parts of the Patient Protection and Affordable Care Act, proposals related to prescription drug pricing transparency and the possible adoption of Medicare-For-All;
•
reductions or limitations on governmental funding at the state or federal level or efforts by healthcare insurance companies to limit payments for products and services;
•
changes in manufacturers' pricing, selling, inventory, distribution or supply policies or practices;
•
changes in legislation or regulations governing prescription drug pricing, healthcare services or mandated benefits;
•
changes in hospital buying groups or hospital buying practices;
•
changes in distribution or sourcing models for pharmaceutical and medical and surgical products, including an increase in direct and limited distribution;
•
changes to the prescription drug reimbursement formula and related reporting requirements for generic pharmaceuticals under Medicaid;
•
continuing consolidation in the healthcare industry, which could give the resulting enterprises greater bargaining power and may increase pressure on prices for our products and services or result in the loss of customers;
•
disruption, damage or lack of access to, or failure of, our or our third-party service providers' information systems, our critical facilities, including our national logistics center, or our distribution networks;
•
risks to our business and information and controls systems in the event that business process improvements, infrastructure modernizations or initiatives to use third-party service providers for key systems and processes are not effectively implemented;
•
the results, costs, effects or timing of any commercial disputes, government contract compliance matters, patent infringement claims, qui tam actions, government investigations, shareholder lawsuits or other legal proceedings;
•
possible losses relating to product liability lawsuits and claims regarding products for which we cannot obtain product liability insurance or for which such insurance may not be adequate to cover our losses, including the product liability lawsuits we are currently defending relating to alleged personal injuries associated with the use of Cordis inferior vena cava filter products;
•
our ability to maintain adequate intellectual property protections;
•
the costs, difficulties and uncertainties related to the integration of acquired businesses, including liabilities relating to the operations or activities of such businesses prior to their acquisition, and uncertainties relating to our ability to achieve the anticipated results from acquisitions;
•
our ability to manage and complete divestitures or other strategic business combination transactions, including our ability to find buyers or other strategic exit opportunities and risks associated with the possibility that we could experience greater dis-synergies than anticipated or otherwise fail to achieve our strategic objectives;
•
increased costs for commodities and other materials used in the Medical segment manufacturing, including various components, compounds, raw materials or energy such as oil-based resins, pulp, cotton, latex and other commodities;
•
shortages in commodities, components, compounds, raw materials or energy used by our businesses, including supply disruptions of radioisotopes;


•
the loss of, or default by, one or more key suppliers for which alternative suppliers may not be readily available;
•
bankruptcy, insolvency or other credit failure of a customer or supplier that owes us a substantial amount;
•
risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations;
•
uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business;
•
risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures;
•
our ability to introduce and market new products and our ability to keep pace with advances in technology;
•
significant charges to earnings if goodwill or intangible assets become impaired;
•
uncertainties relating to general political, business, industry, regulatory and market conditions; and
•
other factors described in the “Risk Factors” section of the 2019 Form 10-K.
The words “expect,” “anticipate,” “intend,” “plan,” “believe,” “will,” “should,” “could,” “would,” “project,” “continue,” “likely,” and similar expressions generally identify “forward-looking statements,” which speak only as of the date the statements were made, and also include statements reflecting future results or guidance, statements of outlook and expense accruals. We undertake no obligation to update or revise any forward-looking statements, except to the extent required by applicable law.



 EX-101.SCH 6 cah-20190930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2101100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Commitments, Contingent Liabilities and Litigation link:presentationLink link:calculationLink link:definitionLink 2409401 - Disclosure - Commitments, Contingent Liabilities and Litigation Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1014000 - Statement - Condensed Consolidated Statement of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 1015000 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Statements of Earnings link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Fair Value Measurements Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Financial Instruments Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Goodwill and Other Intangible Assets Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - Income Taxes Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 2406401 - Disclosure - Investments Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Leases Narative (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Leases Summary of Lease Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Leases Summary of Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2407405 - Disclosure - Leases Summary of Minimum Lease Committments (Details) link:presentationLink link:calculationLink link:definitionLink 2407406 - Disclosure - Leases Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Restructuring and Employee Severance link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Restructuring and Employee Severance Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Restructuring and Employee Severance (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 2415405 - Disclosure - Segment Information (Assets by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 2415406 - Disclosure - Segment Information Disaggregated Revenue Within Reportable Segments (Details) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Segment Information Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2415407 - Disclosure - Segment Information Revenue by Geographical Segments (Details) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 2415404 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Share-Based Compensation Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2416405 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details) link:presentationLink link:calculationLink link:definitionLink 2416404 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details) link:presentationLink link:calculationLink link:definitionLink 2416407 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) link:presentationLink link:calculationLink link:definitionLink 2416406 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Shareholders' Equity Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 cah-20190930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 cah-20190930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 cah-20190930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Earnings Per Share [Abstract] Weighted-average common shares–basic (in shares) Weighted Average Number of Shares Outstanding, Basic Effect of dilutive securities: Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract] Weighted Average Number Diluted Shares Outstanding Adjustment Weighted Average Number Diluted Shares Outstanding Adjustment Weighted-average common shares–diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] IPR&D, trademarks and other IPR&D,TrademarksandOther [Member] Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style. Indefinite-lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Net Intangible Indefinite-lived Intangible Assets (Excluding Goodwill) Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name Finite-Lived Intangible Assets, Major Class Name [Domain] Customer relationships Customer Relationships [Member] Trademarks, trade names and patents Trademarks And Patents Member The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law. Developed technology and other Developed Technology Rights [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Gross Intangible Finite-Lived Intangible Assets, Gross Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Net Intangible Finite-Lived Intangible Assets, Net Weighted- Average Remaining Amortization Period (Years) Finite-Lived Intangible Assets, Remaining Amortization Period Gross Intangible, Total other intangible assets Intangible Assets, Gross (Excluding Goodwill) Net Intangible, Total other intangible assets Intangible Assets, Net (Excluding Goodwill) Equity [Abstract] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Treasury Shares Treasury Stock [Member] Class of Stock [Line Items] Class of Stock [Line Items] Payments for Repurchase of Common Stock Payments for Repurchase of Common Stock Treasury shares acquired (using cost method), shares Treasury Stock, Shares, Acquired Payments for Repurchase of Common Stock Treasury Stock, Value, Acquired, Cost Method Treasury shares acquired, average price per share (in usd per share) Treasury Stock Acquired, Average Cost Per Share Final Shares Received from ASR Program Final Shares Received from ASR Program Final Shares Received from ASR Program Commitments and Contingencies Disclosure [Abstract] Loss Contingencies Loss Contingencies [Table] Lawsuit Type [Axis] Lawsuit Type [Axis] Lawsuit Type [Axis] Litigation Type [Domain] Litigation Type [Domain] [Domain] for Litigation Type [Axis] Class Action Lawsuits [Member] Class Action Lawsuits [Member] Class Action Lawsuits [Member] Plaintiff Type [Axis] Plaintiff Type [Axis] Plaintiff Type [Axis] Plaintiff Type [Domain] Plaintiff Type [Domain] [Domain] for Plaintiff Type [Axis] Private Parties [Member] Private Parties [Member] Private Parties [Member] Tax Matters Agreement [Axis] Opioid Litigation [Axis] Opioid Litigation Tax Matters Agreement [Domain] Tax Matters Agreement [Domain] [Domain] for Tax Matters Agreement [Axis] Total Opioid Litigation [Member] Total Opioid Litigation [Member] Total Opioid Litigation Opioid Settlement Framework [Member] Total Opioid Litigation, net of tax [Member] Total Opioid Litigation, net of tax Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] Alameda County [Member] Alameda County [Member] Alameda County [Member] Other Jurisdictions [Member] Other Jurisdictions [Member] Other Jurisdictions [Member] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Opioid Lawsuits [Member] Opioid Lawsuits [Member] Opioid Lawsuits [Member] Product Liability Lawsuits [Member] Product Liability Lawsuits [Member] Product Liability Lawsuits [Member] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] CVS Health CVS Health [Member] CVS Health [Member] Litigation Case Litigation Case [Axis] Litigation Case Type Litigation Case [Domain] Opioid Litigation, less Cuyahoga and Summit Counties [Member] Opioid Litigation, less Cuyahoga and Summit Counties [Member] Opioid Litigation, less Cuyahoga and Summit Counties Cuyahoga and Summit County [Member] Opioid Litigation, Cuyahoga and Summit Counties [Member] Opioid Litigation, Cuyahoga and Summit Counties Loss Contingencies [Line Items] Loss Contingencies [Line Items] Long-term Purchase Commitment, Period Long-term Purchase Commitment, Period Maximum quarterly payment Maximum Quarterly Payment Maximum Quarterly Payment for pharmaceutical sourcing venture if certain milestones are achieved. Loss Contingency, Lawsuits, Number Loss Contingency, Lawsuits, Number Loss Contingency, Lawsuits, Number Number of plaintiffs Loss Contingency, Number of Plaintiffs Loss Contingency Accrual, Net of Insurance Recoveries Loss Contingency Accrual, Net of Insurance Recoveries Loss Contingency Accrual, Net of Insurance Recoveries Lawsuits Against Distributors Number of State Attorneys General filing lawsuits Number of State Attorneys General filing lawsuits InvestigationbyMultitateTaskForce InvestigationbyMultitateTaskForce Investigation by Multitate Task Force litigation settlement liability recorded Estimated Litigation Liability Cash Component For Settlement Framework, Term Cash Component For Settlement Framework, Term Cash Component For Settlement Framework, Term Opioid Total Settlement, Cuyahoga and Summit Counties Opioid Total Settlement, Cuyahoga and Summit Counties Opioid Total Settlement, Cuyahoga and Summit Counties Restructuring Charges [Abstract] Restructuring and Employee Severance Restructuring and Related Activities Disclosure [Text Block] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative [Table] Derivative [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative, Name [Domain] Derivative Contract [Domain] Cash Flow Hedging [Member] Cash Flow Hedging [Member] Currency Swap [Member] Currency Swap [Member] Derivative [Line Items] Derivative [Line Items] Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Foreign Currency Contract, Asset, Fair Value Disclosure Derivative Liability, Notional Amount Share-based Payment Arrangement [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Restricted Share Units Restricted Stock Units (RSUs) [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Restricted Share Units Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Nonvested at beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Canceled and forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Nonvested at end of period (in shares) Weighted-Average Grant Date Fair Value per Share Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Nonvested at beginning of period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Canceled and forfeited (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Nonvested at end of period (in usd per share) Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Statement of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and equivalents Cash and Cash Equivalents, at Carrying Value Trade receivables, net Receivables, Net, Current Inventories, net Inventory, Net Prepaid expenses and other Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Goodwill and other intangibles, net Intangible Assets, Net (Including Goodwill) Other Assets Other Assets, Noncurrent Total assets Assets Accounts Payable, Current Accounts Payable, Current Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Current portion of long-term obligations and other short-term borrowings Long-term Debt and Lease Obligation, Current Other accrued liabilities Other Accrued Liabilities, Current Total current liabilities Liabilities, Current Long-term obligations, less current portion Long-term Debt and Lease Obligation Deferred income taxes and other liabilities Deferred Tax and Other Liabilities, Noncurrent Shareholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred shares, without par value: Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract] Authorized—500 thousand shares, Issued—none Preferred Stock, Value, Issued Common shares, without par value: Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract] Authorized—755 million shares, Issued—327 million shares at September 30, 2019 and June 30, 2019, respectively Common Stock, Value, Issued Retained earnings Retained Earnings (Accumulated Deficit) Common shares in treasury, at cost: 34 million shares and 28 million shares at September 30, 2019 and June 30, 2019, respectively Treasury Stock, Value Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total Cardinal Health, Inc. shareholders' equity Stockholders' Equity Attributable to Parent Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Total shareholders' equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total liabilities and shareholders’ equity Liabilities and Equity Cover page. Document Type Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Segment Reporting [Abstract] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Operating Segments Operating Segments [Member] Corporate Corporate, Non-Segment [Member] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Pharmaceutical Pharmaceutical Member Pharmaceutical [Member] Medical Medical Member Medical [Member] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Total operating earnings Operating Income (Loss) Schedule of Total Share-based Compensation Expense by Type of Award Share-based Payment Arrangement, Cost by Plan [Table Text Block] Schedule of Stock Option Transactions Under the Plans Share-based Payment Arrangement, Option, Activity [Table Text Block] Schedule of Additional Data Related to Stock Option Activity Additional Stock Option Plan Data [Table Text Block] A disclosure of additional data related to all stock option activity Schedule of Transactions Related to Restricted Share Units Under the Plans Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Schedule of Transactions Related to Performance Share Units Under the Plans Schedule of Nonvested Performance-based Units Activity [Table Text Block] Segment Information Segment Reporting Disclosure [Text Block] Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Leases [Abstract] Operating lease assets Operating Lease, Right-of-Use Asset Current portion of operating lease liabilities Operating Lease, Liability, Current Operating lease liabilities Operating Lease, Liability, Noncurrent Total operating lease liabilities Operating Lease, Liability Net property, plant and equipment Finance Lease, Right-of-Use Asset Current portion of long-term debt Finance Lease, Liability, Current Long-term debt Finance Lease, Liability, Noncurrent Total finance lease liabilities Finance Lease, Liability Amortization of intangible assets Amortization of Intangible Assets Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Finite-Lived Intangible Assets, Amortization Expense, Year Two Finite-Lived Intangible Assets, Amortization Expense, Year Two Finite-Lived Intangible Assets, Amortization Expense, Year Three Finite-Lived Intangible Assets, Amortization Expense, Year Three Finite-Lived Intangible Assets, Amortization Expense, Year Four Finite-Lived Intangible Assets, Amortization Expense, Year Four Finite-Lived Intangible Assets, Amortization Expense, Year Five Finite-Lived Intangible Assets, Amortization Expense, Year Five Investments [Abstract] Investment [Table] Investment [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] naviHealth [Member] naviHealth [Member] naviHealth [Member] Investment [Line Items] Investment [Line Items] Noncontrolling Interest, Ownership Percentage by Parent Noncontrolling Interest, Ownership Percentage by Parent Proceeds from Divestiture of Businesses Proceeds from Divestiture of Businesses Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Partnership Indirect Ownership Partnership Indirect Ownership Partnership Indirect Ownership Pre-Tax Gain on Divestiture Pre-Tax Gain on Divestiture Pre-Tax Gain on Divestiture Equity Method Investments Equity Method Investments Accounting Policies [Abstract] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Recent Financial Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Basis of Presentation and Summary of Significant Accounting Policies [Abstract] Basis of Presentation and Summary of Significant Accounting Policies [Abstract] Lease Liabilities established as a Result of the adoption of ASC 842 Lease Liabilities established as a Result of the adoption of ASC 842 Lease Liabilities established as a Result of the adoption of ASC 842 Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Employee- Related Costs Employee Severance [Member] Facility Exit and Other Costs Facility Closing [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Beginning Balance Restructuring Reserve Additions Restructuring Costs Payments and other adjustments Payments for Restructuring Ending Balance Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net earnings/(loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Adjustments to reconcile net earnings/(loss) to net cash provided by/(used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Impairments and (gain)/loss on sale of investments Loss on Sale of Investments Impairments and (gain)/loss on disposal of assets, net Gain (Loss) on Sale of Assets and Asset Impairment Charges Share-based compensation Share-based Payment Arrangement, Noncash Expense Provision for bad debts Accounts Receivable, Credit Loss Expense (Reversal) Change in operating assets and liabilities, net of effects from acquisitions and divestitures: Increase (Decrease) in Operating Capital [Abstract] (Increase)/decrease in trade receivables Increase (Decrease) in Receivables (Increase)/decrease in inventories Increase (Decrease) in Inventories Increase/(decrease) in accounts payable Increase (Decrease) in Accounts Payable Other accrued liabilities and operating items, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Net cash provided by/(used in) operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Additions to property and equipment Payments to Acquire Property, Plant, and Equipment Purchase of available-for-sale securities and other investments Purchase of available-for-sale securities and other investments The cash outflow from purchases of available-for-sale securities and other investments. Proceeds from sale of available-for-sale securities and other investments Proceeds from sale of available-for-sale securities and other investments The cash inflow from sales of available-for-sale securities and other investments. Proceeds from Sale of Property, Plant, and Equipment Proceeds from Sale of Property, Plant, and Equipment Net cash provided by/(used in) investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Net change in short-term borrowings Proceeds from (Repayments of) Short-term Debt Reduction of long-term obligations Repayments of Long-term Debt Net tax proceeds/(withholdings) from share-based compensation Net proceeds/(tax withholdings) from share-based compensation The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately. Dividends on common shares Payments of Ordinary Dividends, Common Stock Purchase of treasury shares Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash and equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net increase/(decrease) in cash and equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and equivalents at beginning of period Cash and equivalents at end of period Share-Based Compensation Share-based Payment Arrangement [Text Block] Weighted Average Number Diluted Shares Outstanding Adjustment Number of shares excluded from calculation of diluted shares Number of shares excluded from calculation of diluted shares shares that would be antidilutive as a result of net loss shares that would be antidilutive as a result of net loss shares that would be antidilutive as a result of net loss Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Stock Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding at beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Canceled and forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Outstanding at end of period (in shares) Exercisable at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted-Average Exercise Price per Common Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding at beginning of period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Canceled and forfeited (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Outstanding at end of period (in usd per share) Exercisable at end of period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Reconciliation of Revenue from Segments to Consolidated [Table] Reconciliation of Revenue from Segments to Consolidated [Table] Medical Segment [Axis] Medical Segment [Axis] Medical Segment [Axis] Medical Segment [Domain] Medical Segment [Domain] [Domain] for Medical Segment [Axis] Medical distribution and products [Member] Medical distribution and products [Member] Medical distribution and products [Member] Cardinal Health At Home [Member] Cardinal Health At Home [Member] Cardinal Health At Home [Member] Pharmaceutical Segment [Axis] Pharmaceutical Segment [Axis] Pharmaceutical Segment [Axis] Pharmaceutical Segment [Domain] Pharmaceutical Segment [Domain] [Domain] for Pharmaceutical Segment [Axis] Pharmaceutical Distribution and Specialty [Member] Pharmaceutical Distribution and Specialty [Member] Pharmaceutical Distribution and Specialty [Member] Nuclear Precision Health Services [Member] Nuclear Precision Health Services [Member] Nuclear Precision Health Services [Member] Subsegments [Axis] Subsegments [Axis] Subsegments [Domain] Subsegments [Domain] Subsegments Consolidation Items [Axis] Subsegments Consolidation Items [Axis] Subsegments Consolidation Items [Domain] Subsegments Consolidation Items [Domain] Segment Reporting, Revenue Reconciling Item [Line Items] Segment Reporting, Revenue Reconciling Item [Line Items] Revenue Revenues Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Condensed Consolidated Statement of Shareholders' Equity Condensed Financial Statements [Table] Common Stock Common Stock [Member] Retained Earnings Retained Earnings [Member] AOCI Attributable to Parent AOCI Attributable to Parent [Member] Noncontrolling Interest Noncontrolling Interest [Member] Statement of Stockholders' Equity Condensed Financial Statements, Captions [Line Items] Balance at beginning of period (in shares) Common Stock, Shares, Issued Balance at beginning of period Treasury, balance at beginning of period (in shares) Treasury Stock, Shares Treasury, balance at beginning of period Net Earnings/(Loss) Net Income (Loss) Attributable to Parent Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Employee stock plans activity, net of shares withheld for employee taxes Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Treasury Stock, Shares, Acquired Dividends Dividends Stockholders' Equity, Other Stockholders' Equity, Other Balance at end of period (in shares) Balance at end of period Treasury, balance at end of period (in shares) Treasury, balance at end of period Operating Lease, Cost Operating Lease, Cost Finance Lease, Right-of-Use Asset, Amortization Finance Lease, Right-of-Use Asset, Amortization Total Finance Lease Cost Total Finance Lease Cost Total Finance Lease Cost Variable Lease, Cost Variable Lease, Cost Lease, Cost Lease, Cost Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Lessee, Operating Lease, Term of Contract Lessee, Operating Lease, Term of Contract Operating Leases, Future Minimum Payments Due, Next Twelve Months Operating Leases, Future Minimum Payments Due, Next Twelve Months Reclassification of deferred rent in accordance with ASC 842 Reclassification of deferred rent in accordance with ASC 842 Reclassification of deferred rent in accordance with ASC 842 Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent Operating Leases, Future Minimum Payments, Due in Two Years Operating Leases, Future Minimum Payments, Due in Two Years Operating Leases, Future Minimum Payments, Due in Three Years Operating Leases, Future Minimum Payments, Due in Three Years Operating Leases, Future Minimum Payments, Due in Four Years Operating Leases, Future Minimum Payments, Due in Four Years Operating Leases, Future Minimum Payments, Due in Five Years Operating Leases, Future Minimum Payments, Due in Five Years Operating Leases, Future Minimum Payments, Due Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Preferred Shares, authorized Preferred Stock, Shares Authorized Preferred Shares, issued Preferred Stock, Shares Issued Common Shares, authorized Common Stock, Shares Authorized Common Shares, issued Common Shares in Treasury Schedule of Lease Costs Lease, Cost [Table Text Block] Leases Supplemental Balance Sheet Information LeasesSupplementalBalanceSheetInformation [Table Text Block] [Table Text Block] for LeasesSupplementalBalanceSheetInformation [Table] Schedule of Lease Payments Lease Payments [Table Text Block] [Table Text Block] for Lease Payments [Table] Schedule of Future Lease Payments Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Income Statement [Abstract] Cost of Goods and Services Sold Cost of Goods and Services Sold Gross margin Gross Profit Operating expenses: Operating Expenses [Abstract] Distribution, selling, general and administrative expenses Selling, General and Administrative Expense Restructuring and employee severance Restructuring Charges Amortization and other acquisition-related costs Amortization and other acquisition-related costs The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. Litigation (recoveries)/charges, net Gain (Loss) Related to Litigation Settlement Operating earnings/(loss) Other (income)/expense, net Other Nonoperating Income (Expense) Interest expense, net Interest Expense Earnings/(loss) before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Provision for (benefit from) income taxes Income Tax Expense (Benefit) Net earnings/(loss) Less: Net earnings attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Net earnings/(loss) attributable to Cardinal Health, Inc. Earnings/(loss) per common share attributable to Cardinal Health, Inc.: Earnings Per Share, Basic [Abstract] Basic (in shares) Earnings Per Share, Basic Diluted (in shares) Earnings Per Share, Diluted Weighted-average number of common shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Basic (in shares) Diluted (in shares) Cash dividends declared per common share Common Stock, Dividends, Per Share, Declared Debt Disclosure [Abstract] Debt and Lease Obligation Debt and Lease Obligation Notes Payable Repurchased Notes Payable Repurchased Principal Amount of Notes Payable Repurchased during the year Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Commercial Paper [Member] Commercial Paper [Member] Revolving Credit Facility [Member] Revolving Credit Facility [Member] Short Term Credit Facilities Member Short Term Credit Facilities Member Other short-term credit facilities and an unsecured line of credit Committed Receivables Sales Facility Program [Member] Committed Receivables Sales Facility Program [Member] Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables. Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Debt Instrument [Line Items] Debt Instrument [Line Items] Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Schedule of Goodwill by Reportable Segment Schedule of Goodwill [Table Text Block] Schedule of Definite and Indefinite-Lived Intangible Assets Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block] Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block] Stock Options Share-based Payment Arrangement, Option [Member] Performance Share Units Performance Shares [Member] Vesting Period in years for Shares Vesting Period in years for Shares Vesting Period in years for Shares Tax benefit related to share-based compensation Share-based Payment Arrangement, Expense, Tax Benefit Award vesting period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Exercisable period of plans (in years) Exercisable period of plans, in years The instrument's contractual term. Target performance goal (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Investments Investment Holdings, Schedule of Investments [Text Block] Leases Leases [Text Block] Leases [Text Block] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Total assets Goodwill [Table] Schedule of Goodwill [Table] Operating and Reportable Segment Goodwill [Line Items] Goodwill [Line Items] Goodwill, Transfers Goodwill, Transfers Goodwill [Roll Forward] Goodwill [Roll Forward] Beginning balance Goodwill Foreign currency translation adjustments and other Goodwill, Foreign Currency Translation Gain (Loss) Ending balance Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Performance Share Units Weighted-Average Grant Date Fair Value per Share Commitments, Contingent Liabilities and Litigation Commitments and Contingencies Disclosure [Text Block] Segment Revenue by Geographic [Table] Segment Revenue by Geographic [Table] Segment Revenue by Geographic [Table] Corporate UNITED STATES UNITED STATES Non-US [Member] Non-US [Member] Segment Revenue by Geographic [Line Items] Segment Revenue by Geographic [Line Items] [Line Items] for Segment Revenue by Geographic [Table] Summary of Minimum Lease Payments [Abstract] Summary of Minimum Lease Payments [Abstract] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Domain] Lease Arrangement, Type [Domain] Operating Lease [Member] Operating Lease [Member] Operating Lease Finance Lease [Member] Finance Lease [Member] Finance Lease Remainder of 2020 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year Remainder of 2020 Finance Lease, Liability, Payments, Remainder of Fiscal Year Remainder of 2020 Lessee Lease Liability Payments Remainder Of Fiscal Year Lessee Lease Liability Payments Remainder Of Fiscal Year 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two 2021 Finance Lease, Liability, Payments, Due Year Two 2021 Lessee Lease Liability Payments Due Year Two Lessee Lease Liability Payments Due Year Two 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three 2022 Finance Lease, Liability, Payments, Due Year Three 2022 Lessee Lease Liability Payments Due Year Three Lessee Lease Liability Payments Due Year Three 2023 Lessee, Operating Lease, Liability, Payments, Due Year Four 2023 Finance Lease, Liability, Payments, Due Year Four 2023 Lessee Lease Liability Payments Due Year Four Lessee Lease Liability Payments Due Year Four 2024 Lessee, Operating Lease, Liability, Payments, Due Year Five 2024 Finance Lease, Liability, Payments, Due Year Five 2024 Lessee Lease Liability Payments Due Year Five Lessee Lease Liability Payments Due Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Thereafter Finance Lease, Liability, Payments, Due after Year Five Thereafter Lessee Lease Liability Payments Due After Year Five Lessee Lease Liability Payments Due After Year Five Total future lease payments Lessee, Operating Lease, Liability, Payments, Due Total future lease payments Finance Lease, Liability, Payment, Due Total future lease payments Total Lease Liability Payments Due Total undiscounted Lease Liability Payments Due for both operating and financing leases Less: leases not yet commenced (1) Lessee Operating Lease Liability Not Yet Commenced, Amount Lessee Operating Lease Liability Not Yet Commenced, Amount Less: leases not yet commenced (1) Lessee Finance Lease Liability Not Yet Commenced, Amount Lessee Finance Lease Liability Not Yet Commenced, Amount Less: leases not yet commenced (1) Total Lease Liability Not Yet Commenced, Amount Total Lease Liability Not Yet Commenced, Amount Less: imputed interest Operating Lease Imputed Interest Operating Lease Imputed Interest Less: imputed interest Finance Lease Imputed Interest Finance Lease Imputed Interest Less: imputed interest Total Lease Liability Undiscounted Excess Amount Total Lease Liability Undiscounted Excess Amount Total lease liabilities Total lease liabilities Total lease liabilities Total Lease Liability Total Lease Liability Long-Term Obligations and Other Short-Term Borrowings Debt Disclosure [Text Block] Employee-related costs Severance Costs Facility Exit and Other Costs Facility Exit and Other Costs Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services. Total restructuring and employee severance Revenue from External Customers by Geographic Areas [Table Text Block] Revenue from External Customers by Geographic Areas [Table Text Block] Revenue by Reportable Segment Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Schedule of Segment Reporting Information, by Segment [Table Text Block] Disaggregation of Revenue [Table Text Block] Segment Profit by Reportable Segment Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Assets by Reportable Segment Reconciliation of Assets from Segment to Consolidated [Table Text Block] Schedule of Segment Reporting Information, by Segment [Table] Total revenue Restricted Share Unit Employee Stock Option Performance Share Unit Total share-based compensation Share-based Payment Arrangement, Expense Fair Value Measurements, Recurring and Nonrecurring Fair Value, Recurring and Nonrecurring [Table] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Level 2 Fair Value, Inputs, Level 2 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Estimated fair value Debt Instrument, Fair Value Disclosure Carrying amount Financial Instruments Financial Instruments Disclosure [Text Block] Fair Value Disclosures [Abstract] Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Recurring Fair Value, Recurring [Member] Level 1 Fair Value, Inputs, Level 1 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Assets: Assets, Fair Value Disclosure [Abstract] Other investments Investments, Fair Value Disclosure Liabilities: Liabilities, Fair Value Disclosure [Abstract] Derivative Assets (Liabilities), at Fair Value, Net Derivative Assets (Liabilities), at Fair Value, Net Reclassification out of Accumulated Other Comprehensive Loss [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Foreign Currency Translation Adjustments Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Unrealized Gain/(Loss) on Derivatives, net of tax Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member] Accumulated Other Comprehensive Loss AOCI Including Portion Attributable to Noncontrolling Interest [Member] Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] AOCI, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Balance at beginning of period Other comprehensive income/(loss), before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Amounts reclassified to earnings Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Total other comprehensive income/(loss), net of tax Other Comprehensive Income (Loss), Net of Tax Balance at end of period Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Opioid Settlement Framework [Member] Opioid Settlement Framework [Member] Opioid Settlement Framework [Member] Number of Reportable Segments Number of Reportable Segments Estimated Litigation Liability Number of operating segments Number of Operating Segments Project Costs On Investment And Other Spending Project Costs On Investment And Other Spending Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses. Restructuring and Related Activities [Abstract] Restructuring Plan [Axis] Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] Enterprise Wide Cost Saving Measures [Member] Enterprise Wide Cost Saving Measures [Member] Enterprise Wide Cost Saving Measures Restructuring Costs Severance Costs Summary of Restructuring and Employee Severance Restructuring and Related Costs [Table Text Block] Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Shareholders' Equity Stockholders' Equity Note Disclosure [Text Block] Goodwill and Other Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Statement of Comprehensive Income [Abstract] Other comprehensive income/(loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Foreign currency translation adjustments and other Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Net unrealized gain/(loss) on derivative instruments, net of tax Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax Total comprehensive income/(loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Less: comprehensive income attributable to noncontrolling interests Total comprehensive income attributable to Cardinal Health, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share Schedule of Weighted Average Number of Shares [Table Text Block] Income Taxes Tax Credit Carryforward [Table] Tax Matter [Axis] Tax Matter [Axis] Tax Matter [Axis] Tax Matter [Domain] Tax Matter [Domain] [Domain] for Tax Matter [Axis] Patient Recovery Business [Member] Patient Recovery Business [Member] Patient Recovery Business [Member] CareFusion [Member] CareFusion [Member] CareFusion [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Income Tax Authority Income Tax Authority [Axis] Income Tax Authority Income Tax Authority [Domain] Federal Internal Revenue Service (IRS) [Member] Income Taxes Tax Credit Carryforward [Line Items] Income Tax Expense (Benefit) Effective Income Tax Rate Reconciliation, Percent Effective Income Tax Rate Reconciliation, Percent Unrecognized tax benefits Unrecognized Tax Benefits Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized tax benefits, interest and penalties accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Estimated range of decrease in unrecognized tax benefits within the next 12 months Decrease in Unrecognized Tax Benefits is Reasonably Possible Open Tax Year Open Tax Year Indemnification receivable Indemnification Receivable Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes. Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] ASC 842 ASC 842 [Member] ASC 842 Amended lease standard adoption impact as of July 1, 2019 New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification Operating cash flows paid for operating leases Operating Lease, Payments Financing cash flows paid for finance lease Finance Lease, Principal Payments New Operating Leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability New financing leases Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Earnings Per Share Attributable to Cardinal Health, Inc. Earnings Per Share [Text Block] Fair Value Measurements Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Aggregate intrinsic value of outstanding options at period end Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate intrinsic value of exercisable options at period end Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term EX-101.PRE 10 cah-20190930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 10-Q 11 a20q110q93019form10q.pdf 10-Q FY 20 Q1 (PRINT READY) begin 644 a20q110q93019form10q.pdf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�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�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Ò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

6"SA5R.?6'(%I(.#*Q M=,R92V0@? E_;*JMK4U7)5P9")B+)=)>,$]@J7.2<& :WEPBEZA*Y+PY+[JZ MTGXNI\$D6=4OF5!2@;)TPM\\-LTQ/::NI**DHJ)_OO^1A/J*L4)P;75Z6]@W(<44XD*C#M6E9(IKI?L+I_E8LUELXAJ"(3+^$-*[[G(X\'2 M3K=45%175V3[5WL2%>F!U?TK^J-47=%449%%WW@ZD$XGT#:=EN6$/)#[!1*> M= (>+X&3=1EZ5U3WK]8X)C2V?0=1SVK!5+:FICD0R#?W;\ "3U=E&IKSN#HV M#M-)R M12*;<%>GL;NER\I0@\TTVS_MJ8" U8ET-E"1KDA7EU=SDI8Q#7]UNCK=/UT= MJ Z@JR<;Y'(63$K[#RQ-1S.A7#8=&CLURS$[N;&LIJRFIJ&VX4C"X)JI4Q!J M:FJF'3-NR)!<774V.Z1_M,H>;"JNB41J(I (PK%(%1"%(PO1]!XI!L=759)5 !(V?+ZRJJ\T.'U@_-58[$':\$UJZ,I]/Q=&6*;3\0L30Y M<%"VMJ08KC4=3B1DCSQD0#J>2B<"S4?E58/Q9&1@LVVNCW"=5J":&DNK@8!UZ6P^5).MR=95 MUG&2=6$:H;IL7;8A6Q>J"Z&K+Z]P&:LC7=XPM#Q;G"^JSF>+CF[+<\P?.SQ7 MGQLP8-C 84<21@QHFXDP8," V7./;FFI;JROS+!]=NR(AGQH5!U'E+/9>DQ[ M*"NDIK$ITCBLP5=34PLK(AE:5PV#5N21&^BK*2^&"LK3R6S&!S2F$]GR5#93 MW\#V:JAI*N\/+:J>BQ*OX0TJ^)P0"V"/S4^OK&QKJ:YH: IGZ?'-# M4WT32@WUX^OK:QCG.$7D,VC+QYF,NYG[*9E /M. 34/Q*57H7=_0U*!QS&AL M^PZ2YZ-0)%?3V#A%4>JG-(VJKZ_/#ZH>-:4>)YWQ@!U8Y.L'Y_-3ZNN;IHS/ MHY7;75^=J>=/1YE,/N!6\ :!V38U-0&> :4GY-WUF9J,KR%?#^&KJE#3W-Q< MTY0/U$/ ADQ%C0+F>?@]3O)N3$-IR#?DF_(-2H."KH&:")=KP*2RJ:4R7U(3 MP\J,SIQ?P[%FWNBJQJK&QE%#1AU)&-,X_SB$QL;&A4O:QH[M/[RAMF9L4\E M9V1\66,RV9B$1!".1:J'*!Q9B*ZM %JNQ[S=FIPL*S0NJ'M<2'C6H*L,9J&I T-_2'0:MKD!L2J*\LR04KL?$U-@7@99OJ6RH'0/2 ?+Z\K"(_()W/E^8'5+#MFS,MF5E0W+Y M?"R3<0?<8YOSI;E\6=&4UGK58#P9=]=_QM'U_W9XU?]W@X0P'B/U_F<>HMKF MIP$O=7J#T62V6"6;W2$[76Z/U^ M.[-MUNPY[7-IWG'S%RQL/?6TT\\X\ZQU M9Y^S?L.YYYU_P84;+]IT\267;K[L\BNNO.KJ:Z[=N[7S[_P MXDLOO_+J;UY[G=YX\ZVWWWGWO3V__=W>]_=]L)_TAALPT\=H'1FIDF[TZ[A/_5Z6CE?%:^.# MXHWQ(?'F^%GQV^-WQ>\M-A1[BOW%B>)T<;YX=O%5Q=L28L*(RY8[X<,%.X:C M97EB=&)N8D%23#J3Q2E*B2E;RIGRIH*I(MP\U([4(ZG'4K]*O9QZ+?7;U*?IQG13>GBZ/7U<>F'ZA!_$0H'_2@]MA?1_ M%X/BKR']'DB_ =)?HKM-+^@=^LGZV?K-T771O\8]\0 NORQ]37Q@C_2W_9/T M,XLW]TCO@O0AW!DTZ=L3\U7IX_^)])-ZI-^GC M?Q *A<+'1 5OX7TZE>@PMOI_;$6ZA$%XN/QP]G#F<-F/WW\\ZZ.O-& >./? M51_./+#AP-\^W'9@S8&'4;/Y@// Q@-G?+AJ__'[UQYXY, E^[?MO_J#JS^X M]8.+B#ZXDWOM#WRPXH,Y*%5]T/1![0]GWD^\ MK[SO?5_8^Y>]G^W]P]Z#>S_B7GM_O??)O4_LQ1A[G]M[Q][[][;L';YWV-Z2 MO8F]Q7NCAB?4)?1(UR([N>O!+,0-XCT_74[B7\5O=?J?K3$2OZ?_(H@?\",> MZ"J]3_]R$!\0'^K)[_A/F^GH-MI YXJ7T=7T*9U'E]!%="/=3;>3DS9B:NOI M"OJ2OJ*+Z1JZ0!#H??J";J)[Z&OZ*QVB6^E>>H%^3??1/#J.-M-\>HD6T//T M(OV&7J97Z%7Z/2VD-^@U>IU^28OH+W09O4UOTENTF/Y(G]&%=#PMH1-H*9U( M)]%66D8K:#F=3!VTBE;2:EI#?Z!3@(FU=!J=0:?3PW0+G45G8K6>37^B/]-N MX6KA&D$4=()>,- /] _A6F&+<)UP/?U(AP6C8!+,5!!N$&X4;A)N%K8*MP@6 MP2I(@DVX5;B-OJ7OA-N%.X0[A;N$;<+=PCW"+X1[A?N$7PKW"YW"=F&'L).^ MIW>$C<)%P@/"@\)#PL/"+L$N.(3=PB."+#@%E^"F _2AX!&\PJ/"8X)/\ N; MA,>%)X0GA:>$IX5GA( 0I/NI4P@)8>%9X5>"(A0)$2$J/"?\FOY&?Z>/Z&,A M)L2%8B$A/"^\(+PHO"2\++PBO"K\1D@*)4)*2 NO":\+;PAO"F\);],C0JE0 M)F2$+'U"!X5WZ%W:3[^EW]%>^H#>HWW"%\*7PE?"^\)?A:^%0\*WPG?"]\+? MA+\+Y<(/PC^$'X7#0@[^C41!%$6=J.=?@B&:1+-H$:U"A2B)-M$N.D19=(HN MT2UZ1*^0%WVB7Z@4JL0 /$M(#,,[%HD1,2K&Q+BX22P6$T*U4",FA5JQ1$R) M:;%4+!,S8E8LI^VT0]PH]*,'Z2%Z5CA(.^D!^A6=0T_3^?2-\'O:0I_3,W0' M72X,I4N%8<)JX3)XL"N$-;1+.)VHJ7'HD,&- P?4]ZNMJ:ZJS%?DRK.9LM)T MJB29*(['HI$B)1P*!OP^K\?-?Z.;__$$_V-R@UXG"I1K28YLCW>FVSOUZ>3H MT15<3LY%Q=P^%>V=<52-_&F;SGB[VBS^TY9-:+GP9RV;M)9-/2T%9[R1&BMR M\99DO//5YF1\EW#LY!G(7]R<;(UW?J[FQZMY?5HMV%$H+D:/>$MP<7.\4VB/ MMW2.7+UX8TM[,_AMEZPCDB,66"MRM-TJ(2LAUSDRN7R[,'*(H&;$D2V#MHMD MMD.JSJ.2S2V=8Y+-+$*G+M4R=W[GI,DS6IJ5XN+6BERG,.*XY+Q.2@[OE,O5 M)C1"':;3.*+3I X37\+3H8OBVW-/;=RTRTGSVLMM\Y/SY[;-Z-3-;>4Q7.6= MHY+-G:-._218D=LEW'GTC$[+B%T"'3UC-QU56+=]S+KFYE8>S3UBQOE]FRNZ MC2W!)7$N;MQX?KQSZ^09?=\6,VUM!=.*W-@I,XHA=;)E4YRG,66&.@,P%8*5 M$)+K>)K:A!Z-$UO=\A=&9N];V9!SSLU MIS;G'*3N5K7 $B7' "*=\>/BD&1&LE-,#6"R8 !M/&Z HOZ$OE6 1I= ?^T; MG8/8$(84-M:-W\!IM"<___-/:^9VU1A3SF^(LPR7'LCA?7>^L[R\,YMEI)A& MP+20;(A:[E^16]TY-KG<&>\<"Y71I!GHU#JH$BHO+F8K7[2KB>:AT+EN\@RM M'*=YR@YJJBQO[13;^/(9'SDQO:- MTJ["D]=I'0V;6I=+$"IG;6:-CH](V;H%+%5 MRXF*#KFQ4Y-C)Q\[8T#7^K"6)Z'"S@ 6!PS520,ZR\HW0OVO)SN=Y9V&$3.> M4AI;XTY7)[D%MH28?!K[A:>3O,Y.H5&57N@D3Z< ^X_IU 4&X&7%+G'] M0_/GQYZ;]D)LEWC.SA.K8\N&V<7E]"0>D2:"7HJG@$=']XO+FV+"UH.=!Y\Z MJ%M^<-W!K0=UL8-5!R<=U%D(J3C0;MEEIATQ@TY-]**:"%J)N-14B%ED74Q7 MJ1NJFZB;HUNF,PV\67>_[DG=:[K]NB]T!9W)0A:G)6ZILC19)EG:+::!FRU; M+9V6IRRO6PY8OK3@O>24XE*5U"1-DMHEO)>V2IW24]+KT@'I2\EDD4TQ4Z5I MJ&FB:8YIF0G\3?>;GC2]9MIO^L)4,)EBH8DA,1:<&!0IY P-#36%EH<,%'0& MAP:;@LN#!@N%! H*YCF^93YQCG>95R2?TS?4U^1;[C- E]ZAWB;O0^+:51>NVK+J[E7Z;:MVK1)?6+5G ME;CVF@NOV7+-W=?HMUVSZQKQA6OV7".N;;^P?4O[W>WZ;>V[VL47VO>TBVL[ M+NS8TG%WAWY;QZX.\86./1WBVC47KMFRYNXU^FUK=JT17UBS9XUH,;3YVL2! M:]LN;-O2=G?;-VV&;6V[VL07VO:TB;N$8W;LT\<>%XZA?87/24]^X:\['M?% M=@E_;0H\;M;YS[S@.%DC2SX?%%OR><,@_RZA! M6I&[9^?*S@R8MNZ8'HT-LPK3:+IX'<6$\6@QG(Y"BZ-VKOQ3'5J,V;GRF0JD MP2;[]&SL6W#^='HF]M'\789^.V)OK=PE'&QR+O,_A[IGIX^(/3/]RMCC7+ES MF?_^E;O$ZW;$;GU[=V"WH=]#_BW3*V)7X=U).X_V;T#JW]GD/XW;/!P[=>6' M_?RKIZOM3\*KY,X1_A.1WK:SW;]HY6[_'S&8?S8JS \/]L^?Q?=^R69D%(_U<=^_OY M/VG;S;P?\O^J;5#LZ36[F?T.?^>:W>9GA<=V^*_I4.=P?L=N_Y,L\_KVW4:K M,'Z'?U5W9EG;+AYB7ELR-J=CEU#3Y!CE'TD8-B\U;5Y@VGR<:7.KJ<2<,,?-47.1.6P. MFOUFK]EM=IH=9IOZ#^/Y7]R+9@#EE-T B"!T>G1CQ;%3APNKQG8^=1R-G1?O M_'9J$2./<+ MU+U]EQ#B\KD*;^N[P39Q[L4*IX5S+VX%MLK_.01_4A+&3EJ[&V::O],4^]Y4 M7CYV*HJ;N;B9B\%(Y]5CI\[HO"?2VEG#F4*D=6SGLJGQMAF[Q7(QT]*\&Z=* M)*TS=@L_BN4X$Z!>^!%'C;&='ZC-:"6JF[EUN=I,]QVMY&:T4O<=-X,%M';3 MU'8TOZN=] 5-4]M-D[Y0V^D%K=UT,&3+1T:>E.4;("8.U*<>MPOW/Y$!5MUE>'^I1'Z#[=5R3AN&'%^55*#J>A M0X/ESD:ATFCK-*+*A(=;-Q0'SU0>T9.P36UM0[6]ZU7%L(IA_ H7<7[EX(-P MUZO@F0W%RB/"MJY73E2[L#CZ3(8Z5JZ:W3$;]#_^0[,[\+9CY/[ Z>$EA;_PN\/+"A^)WQ0^,SQ!/G&?6NW?7\Q^$*NIGNI*MPK[^2[D+.CKO\6I2GT*MT"&\_I#;:1"D: M /?7ACO]7_%V&Q713;C%;Z*+Z3+<]&\5UM-$ZJ!+<222:0-9:#B-1[O+Z!2Z MD2KI(OI8S)*39M%B6D'7%6XM/ "SVDD!QS-H/?@\0(_3#[BQEQ5>!>\\>I^# MWK?3Y[H7"N,*^W'P+'P'3K-I'JVB ML]'S(LA](Z3<":Y/X=[Z KTNEND:"@>UW]M,_:F>9M)RM+TZ^D6R'!G?248,#-^@?=.+T>\RN&%$-I#)U,Y]%&VJK> ME)_##=^"N_ZEB+\0OL"-^UI=6E>AGU-H*-Q6^![2FZ 3&V90CXU[+LW''!9# M7U?!+M=AE)WT)")_>_F'X!."0KDP$G$<+@Q+A).%]>H7CZ>$9W%C'RPN%\\3 MS]?Y=:?KKM*7'GZMX"ML*#Q<>*SP$N8F8"0=93!.)5718&K!:)-I.LW!T6(9 MK40\E4ZCTZ'S=8@70H\W8?X[Z EZ7OT&Q!*\0Q_0 ?I,< @>(2ODA3IAE#!- MF"4<)YPK;!9N%^X7'A >%_8A?BQ\*?Q#-(EED&JP^)SXIKA'/"!^+'ZO$W5. M7:-NE&Z=;KON!=UK^B#B./V[^D.&)M,Y__CR\(;#A8*G,*JPH'!G87_A3Y"; M]>.F&"4A]0B:0). OS;$6;!J.RU"7 R$G@K)SP0&-ZC(NQQ6OI9N@*5OIWL0 M?P%+/(CX,.;S"NVG@\#O]XA_ [)$P0O-9H5JQ"9A.&8T#=H]05@EK!;.$,X3 M+A&N$JZ#EG<*CZE?=]X2WA4^$[X3?A!%T2'&L)M5B0/$(8A'B6/%5G&V.%]< M(BX3.[ *3Q4O$"\7KQ)_*3XD/BH^([X@OBB^J9,099U+E]!5Z/*Z%FBC33=+ MMT1W K1RAZZ@]^E;].WZ#?K+]5?K._6OZ=\UD,%JB!JF&!88;C0ZC2YCB3%M MG&J\U*0S%9F30./-F.]//_L?IG&T4%PL&G17"FOH*_J:WC$LT0OT9V&Q,%/X M7F>B'R'),N%Q^KOX#6T3'X75RZ#/LX6D<.7A,;#XF;A?%*A4R-)G=+9N,>W0 MZ>DC<:=83B^+4=AWL_ .A6EDX1-H9YQNH'@,Z41%[*\_15>O>T*0A39#2'>5 M;B@=1^.Q%J-4KULG_H"MWJL[G4["RCKQ\$.%M^D=X9#(?WU[8%?<2/N$F\3+ M=*WZE+Y5?X7^=<,TP_F&EPP'#05CF?%RX[>FJ\Q5YHLD6 MMLVS76Q[US[:H7-<)C?)>YV3G ^[_*Y'W;7N]>[O/>=Y7O+^X-OE'^M_-W!] ML"5D#BT*?1T^6NFG["U:6O1:)!89$]D2.1#Y(1J.'HB=']?'=Q:/+OY5XIRD M,[DZ62BYH61_ZNIT47I;Z?C2[\J.S40R#V0G9*\KOSI7GKNF0JPXK^+V?&E^ M??[Z_ /YY_/[\E]72I7)RH&5$RL75)Y1>47E+RH?KWRK\H^5A:I 5:YJ6-7T MJJ55ZZNV5-U?]5S5OJJOJRW5L>K^U>.K=U1_6?-0[>Q^NG[)?DOZ)_M_6K>R MWE)?77]\_=X!)PST#]P\\+U!%8/.:QC6\'[CQ,;[&@\,S@Z^9$C)D%.'RDW> MIC\/FS7LOF'O#B\>?N^(_B/6COBH>43SNN:KF^]M?J;EFI%GCMPR\L%1HT?M M'YT>?=+H^T:_//J]T1^/\8S9/N;@4:5'?3'VUG$#QTT:MV5\?D+%A!$36B)3DXR31DYJG[1Q4N>D/T^N MF'S*Y'LG_W7*BJGQJ753QTV=-W7-U+N//@J+*#"M8MJST]NFKYW^[3'SCGEA MQO 9K3-6S+BP56Y-M3:T3FZ=W[JZ=5/KK:V[6G]S[/7'/G+LV\?^:2;-],Q, MSVR>/,G3-?G+E_YC=M@;9D6V5;2]O,MA5MY[?=W/9PVZMM M'[5]/\L^*SEKP*RC9K7-.GG6>;-NFO70K-_,^G36/V:[9I?.;IQ]]IRB.5O; M4^T/SATY]^FY/\R[==Y#\YXYKFS^@OGGSK]C_G/S/UG@63!\P=H%%RYX?,&A MA?+"\,)A"Q.WB*Q8_L/B5Q9\N,2TI7C)HR7'UJ17''TBO85)ZXX9<6Z%1>/ACE<[/N[X?J5C9GKUR-5MJU>L/G_U#:MWK'Y^]6]7?[9&6+,:U][KU]RV MYJ$U+ZYY?\U?3CE^K; VL+9B[8BUK6M/7'OFVBO7WG.J?.I-ISYPZDNG'CCU MV]-LIR5.ZW_:Z--FG[;RM(VG;3WML]-CIT\Y??'I9YY^Y>GWG/[4Z>^>_N=>=9#9[VYSKTNMZYE MW:QUJ]9=NNZ.=4^NV[/NP+H_G-U\]KBSCSZ[[>SY9Y]X]CMG[SO[X#E#SAEY MSBWGW+V^:'W)^MSZ?NM_O^&L#==LN&W#_1L>V?#K#6]LV'?NJ>?^X;Q9Y[U_ M_JSS%YS_Z06-%[QWP?X+C[_PY OW;YRQ<=]%TS=9-UVVZ89-VS8]L.FI3:]L MVG/QR(NG7/SLQ2]?_-;%GUW\]27++_G'I8LO/?/2*R_][-*O-T_>W+IY[N;W M-N^_[-'+^U]^S>7W73'\BBU7W'+%W5=LOV+W%4]?\>(5;UR9N/*V*W]QE>6J MDZYZ_NJ&JZ^_^JZK_W;-XFO>N;;UVKG7[MLR<\L7UTV_;O;UDZ]__/KGKM][ MPTDW/'GC]!L?O_&Y&U^]\9T;]]UX\,;/;[KUIGMN'GCSEJVIK>_=4GY+_2T7 MW_+W6\^Z]9O;;+?==MN^VX^Z?K=C+<_#Q.PS\LQ\3C=EN MT.\2ANX@H^E182C_F%@,/ZC3D=6$ZJ8'!1IC-AJ0>TC4W6PY[RZ_H%,?_U6_KGR'(Q8 MP$G4@/WXY*9&_NV2.L%DM.ATSXI&KRCRKP,N,]#')I-YGL5H+1.-3MVWXGM& MPY5Q[.*/6&8:C6.L%F-@X3U\H3QU@O-+(5@Y_O-#LSYW'OH<%X#RH8T_4B-$ M0^9\0[[\#.>OG/^'LS>!CZ)(^\>KJN^>[IF>LR:^323?WH]8H6F>[C2X!F*))<):QGJRH@^E_%S#@\ M"Q_$##Z/QR%%^Z$^'(E&BNR.D#T4E67UZO:^1I-B%BMJBK+$D3A&CKZ\@2W&IW\\3Z''X-Z4C%KYWQHAU^B;Y$R(UK#;N^P_NU?P=9 M5@!#>C#E"5.7PMT9HT^@TR^0C'9:-?'AL>&042M+^$T/K2K\[WT M\.\[>5%9ZLZT+L7FHY@)PJ/8G68^TIQ!QAET!H?U77>DQ^<_]KN_'V;Z/M!O M\[$>UR)]'^@;C?:MP:1'-)J 3^S TW;@IZ+WT,>.Z(X=T4I\(EI)RO T:C&5 M+:7,2WPB(,I<5(3+SDU-Q'NMF&]J^?RTS1X*-+5\8^3;'"&OU^8*.1-\>1V" MJ:D.+2-=%%!:FKV#D"?ZTA.$#!3LF.+4,FR.U-0FW.?9-+L+/G78F_"!>X[^#[Z[JE?T8VGBW^*3;!!_SJZ>53$] M>B/2C(_.&S8;@0\XTO);;A?8&8/LP,P*@)E=,0:=3;@0/%MRH8RM]4Y-J>TZ M]#C&O_05Y> M2MY=H;QL^* K+_WT+[9CY8TEZS9O_O'>K0^-Z).4_79][_*D[-_>O#3BQE+S M[2T/#83U)_@[Y^2,]7I?'XTVQH"[Y'?P^ MKX=/RIIK:#CI'X&_I729RUCR54^'7.1-3PDD^7U<-^?D2^G?I9/TKW/YR65% M0XJV%!TL>JOHVR*^KF@9O&!2B@J+*HIJBMBB]>ID([@)& M%J(V1%U:&.PDPQP",)&2S"QZ,(>%%SQZUQ*='H1,W-4<&# 59V86+U"3*2YB M>M[W\(C];SWZ:)ZD'%\U<]M#3]PWL4?7!TO&A8;5#8^^_W;O_&ZCK^RNG%-@ M+!]U_^:IY7\Z?^++RCDYH1YK/GGT@?LN3?GKGC'SAZY?.:INQBAFX8.K>PR9 M.73K MRB NDB&8QL5E$!DY,S+R-#(V4V4-%4% ;(;.ULV5'2M:28E[%;)FD8BB MS5Y<$ Y?;W;<]LL.NXL(O)#6U8>[: P>]-#TF>4[YDS^0_58[@_1$]&=/T7' MO+7BRFK\!C[Q$1Z$Q].JNQ>9">2/W#O(BYXV)(>N,B+'N6P]9=P7:1!*^R(7 MLN"A2(:V0PV7?!S_@]..TPFS%!;_ZR9_Q) C;W-S;X$ MB-#-K5X=>F:78EYHTTS0QBS0VQ'.T_GAT)OQ&3O1# MG(W>!!&,-3I+/(L!WB'PX"-C'EQ$_$+N$="M"4C.YL+\%$2J,)9JT$5$QL&? MKY>H&N>58I#"S6MY98"*07I:*;5ISC3E$#5C$%8QJ#810 VKTYY(+OZ5=7S* MFZ>C'R0,"3;!UPS&3:03F0'#X3<41.MR<#6#'GS FP?=B91B>['#E&Y0&!S MKP1PT]FS\%=473K M=._4LD$@.W,RZ@_6_NI-Q:]D6E6](?'IQU/ Z +>GVB MY1ORM!G;.AL>C-!8AKCH_58PO",CAL6$NX#_@L@0(&Y4 MDE4/1A9YN?_]V4W1_7Q I>>X2Z"<*6B*H0N\:"/W>28ESW,N\LQ+7BVOUH[) M(D>#G,?I"EE%>$J<"RH]UZHF:'97R-[4\IUA@9.$A@JQ#FRIB M#T)!L&> %\TFVBB#@VE93@TLVO2#])8F;0&JJR,6H'@R_YDEXV:L?KYTT+K) M*U>\L&5JQ3UWS:R=-'14[YHZ_ 5V$ZYNQ/??_O7KZ"=;I[>\^=CN$1N(]NB! M=<,71/Y$?_@G 'N9T"<9[3;T(^)Y?%9D+L*XR_*[,;W (GL!/XL8_(W10Q(Y M&2G96*1;P;*HC,$,HUBPA@ XE*-*M 5=0E?0YT@, )88C&:8+WC)U"[0X(]. M6R2D Z_1O@1: YIBZI,90!P40>71 4"1B#W4+H#C<-#)4VT"M\;@'2\N^CQQ M\^89!2-OLO?,Z_M8^8/CQ_YL0#_NA7XT0C\2T9?/KN1VN0G'V>/CB[A@J TI"^%E("2"SI,%*,DD3/7-H0)@ M!:$""! FXG2$8/@I'0# "3)!>:U!,V9"A=3:<0A"GB=.'PQM_4+"O>F M#"^[L6?.PF'#E_BW>M[>?N3%D5UOOM"-^)*>7S+N^^WG)TQ=N^F [[MLGI+/+P0 MP]JIF=5;M=FCIS[^P'@E+<'M6K"E86#%@XZ',]Y>O?'%>R>6E_]X>-\5O,RS M_Z$+R^:L87>Q6^=.6;5^>?J%E]XY/N>I4/&V<:]'OWF?^H/!H'-; !7(2$6_ M-SIL4 XHIY07%'8/NX?;JS0I+$\WJ;: [U'H;:G HA07/5=4E:J9BV'!(;$* MPV6SG*!>%T]!8&_"[QD^F5J9RA!LH5MWTYN;*4@3!!L8$5ED>*0 &4)FD5/D M(GF+7"7?$C% _Y(L?,8*YJ4!%,M;1!,'=A"/5HKU.!,'?VWRS+Q2%#(M;/7B M5HH)SIN2%OJ@XD1@<\$2#+122+-@)\;_,J*> #FTZ. 3_A-&MRG1GGC>:6;K MS>J#T77$0R9&'H&!FPLZ]!)W%*6BJT;7;#%'ZR9VT[JY1R1-$:=8%H@++.O$ M=W1[&Y=U=;9FO";AE6=J^O)3M=UAYTUE>K3 M9_FYR6H?'P9SNV[X)#GD=MFH06X&^H[7_,6^;!MZV?C;E?:!GX?KF8M,)@?6%8UH& MDJ)*9NH:X%4SQL5-T%DBN*BRM9*$+&=0"#*FD]:HB\['7>;M(CVJBLO635@4 M?FC2@V?(P,1HR9A)LU>>>WCQA7&[:O 11T'_5<9]G\U?NF6WA?SM:'3]F(]> MC7Y[9N_XW\R%:]P LKQ@>K,<]($QY+[$BSE$UP[DG,IAYOCF!![(7&O9H&_( MW)]YUGI6]2#\!)>U,$I42%RH%S-I &WS#8<"V7 F4V+ MA=?A5J@?QC&[-"4&K#@6Y0!'F:R+B06YF GC867WEZXZMV[.HUM_MW'YC,T+ M'E76Z1MZ=*FH[;OL[C%#)BRZ9\()9EA9V=576]#3VS 7^1)'UM2=.ZU]D=_[ M9N3+I4=GKCJUZL#7,/"_ XO]"^BH@AXRE/W, ?8IYA3[N(43J1!HJN$B4,X4 MFR/$,8[C/E ;*FCI.*[77P-F>JU;V 08@''RPF9H+P:L7!($I,,SA+GN>_)_ MET:.)S$HZ84-S]QU$=_$C3N.'GTC^KOHO.A:FI%9W/(5TSQ@+ M83I3[*\/R!VM5^5.RI[2<5[VPHX;N)665=EK\_?BO=P.=5]P>_93P2?RCG:Z M&'PN[URG5_'[^"OL5U#BW(("1^IG0\+D-@RTN M.>U.:&"H9\YL #CNIE931#&*:3&Q?$DSN!9SB,WA#<6)3)[+AR]$9,7CTPZXFB[EO'?QG]TZ=/3WMQ!@Y,F/7PG/'U/9?<_&'Z M\N85TY?\AGKG>K"A1T%>"2@;'32,%[C3F60IMS2->-RZQQ-@]@K[ CNS3@@G M A<$?JJP4%@G,#N8QYGS.B/(H#;[S04;P M!1MJG)\[R24G=E(;&C#TFVC-O6I>0ND4P-^\$4VT\R-WVWD(8YE,;W!(4% RC#/\1,$5B93F"H\ M!5WBIK#\%*&*[2_6QI(Q@VDN\_JUR+485($'34''XP=-[U)Z^T^ XM%7X(D9 M_>:;-X]15$Y,%G+>_%T%U1HEMWY74'B60?2W(>8ME!Z!B#D!KL#\?58*RW ) M5?2^'_W5^#4 =!QL+"@8#L8Q$?%Z37S;3H!N/O7" M"^R"W1)V5S&)D;5D/GGP.-Y[.GHY^M)ID%<8'X+KXB& M@!2-I)6G&/$,RX[D>!>](1WTDDEAOS>X*!--(=]CIHI' T2.WA80W^JEF;/^ M 3J+"OYK'R7QC#]:9+B[ MDQ!+D@.!D8E)KL3$)/51FQ4#_,XV\N4:._:C/R4E)4\(),K9PF37@*!_,EJ6 MF%R5E)0HJ57698&JPD2MU.BB#F^D\BBDNTQC;V :& MH$1^$5A;LKHT/Y&=Q[J"<:@AXTNMDT($ZV M0;K=[\H;>D?!\JQ'<@/+2_"@Y?1NID01D(8U/E?6KY7U6+Y/],^]8/[1X M9AK-D&KBY+MN(-?V_LL0JAA*+<($R=#!R _-V@]@#W#>7%86+@N#;\'0-#/?JN&;/QY:J['\CW;Y_O3=/S#L_<&_W[X0O1 MMRZ=Q,8?7\&Y=V_O]$7TNV>BT>B.*U_CL5__!G=__M2V$\/[1*?/*.^V86)= M1>G]$X_<4Y ^Z;WE)W#9GNKJ?9'Q&VQ)&1NP9<B,EA^C3SSS^-J% MGTY_&^_ 09R'__K5I>B6+Z*?7+LX%$]:OW/NO]9LWC8E>AVDWG(5(58!E"X@ M*_K8&"0!:]>(V%7\K4)$(*;T;I3T'DKTQB 2X'11H7=:.JM@D@+ O5)07(*@ M@(57LHJ+WHA(!*C-\=726Q08X/F&F]Y_@V$0?)>@V)AY!GM5JN,N .,E>("A M(453"I0:99FR1;FJ",H+>!&RH12X; YY\\!4(N&(]_MKUWUFTJFX=5(H$IL1 MGV*8 @UPC)ABW!0:!2$ MJP(6A"92;]BE A.HUP!47X8NP7@UX8//Y)B,)IRWZ"<@-,"7 6904[8#H4&E M>1%,IU=*8^>( O8PG:1-"!6 W$R)"3%&DX?R\HJ=P2*=PI$8*(%0B]LB:Y ) M%I7<2:@J!_O?P'/7W%4SM6[FN(D++\R*_N_UQM[W=*Z8VH)>QH[IZ3WO->HV M1G_/7?"F'EM\_]F"S+TSEGP^F^G7X^YE/:O2;VP3K7)W=(V MSWF^R?:CSS% BWTP4^-LO[=^9)]O8=#O,:U'+]/GLQ*:AZ_:3M59KUB_LS*: MM<:ZS-IHO00O/[>"KJ=8#6L%O%D';V\QW_[.:I%H,Q*R-A&'X7?5 YRM@7$@ MFO"=0"0-AN5S@0D)?_9K/X!&F5 ^?J01-LZ]6P$\U@E*2T5VK<01I,"=T!^?.@G^^&_WYPJ9%U?6$]4>C+0C0?PF>=@/; M__&)'9=&AT0__.HOHZ93+SD =/(DZ*058L%FHXMHP>L<%QQ$L.@6XK?9XCKH M\\>43K-59UN[N_N[][K!!K-!R]SUHMA$9AOZ;?KT+&B4>(6NQ0&M.IT8ST/] MPU2JF'+%YM=Q.*9*K2K5+C9 GV,J!'Z14.>91;T?S<-E9>;A 3?PM$7&V&T5 MRU]Z<,+:ZQ=7/;=]QKAA=RQYC[O@]&__X>![T<>_[)AV-/0XSGWQV"NI"7 I M@^(]M:"]QI!C[/L2 :9/[Z$6[R//58LB76I"! $Q;*S#LE2=;8GUU"++\#ZA M=P166WOZ+.+:>JFTR[;5A^W%BPN\H0)S'J(@9';V]JZV6D^\RW'+*3;);>PQ MZ 8S,3%2>C=I3(Q4C"+?)W$7CD6['8N2H_'>#(?>2#!J@XYRQ\1?ZLUF<^D, M[[*),[GZ7(@G, 0Q[QE]D8[L=N#R2G9 :TPV4@^EV'JH./^H[_'ZULH*6E%1?N/0%#)KRJ$;A^9%ML[C+D0.D/$_EY/3D<'P6Y1)W83^ M,FBE,;S0S LT:"PZ M@)@ '(AD V4DH9C^L[K#],)K;ARZ0<,]'8\2X,'+ MX?IFPDP];%5FX;XJ'9R$K)XJ*W [2 POX>?<3/UR3DQ#(C MN;,A9"BOJI97U3T%4IE$)*D)SS82)*:^P+G4>=9)QSEGPZH"3=3:1 M!\ZZ)5URQ]65QHZ8PLYN!LK85EIA3AV"KM(ZIMLTU%D2 Z$0'J ?<3K<>X=U M9'FG(46>9PX]FW5N_<:#^*0Z(O>><.=IRUG;C;?_?/'0@5[0TX&@>9^:FO>% ML7*]C$4VFQW(KF<_8ND=LLU;S'$,P\H6F;,0\\:HE0+OHC=WA1&2.9?,$+F= M$LH2T"$+C!^H8+:I@Q9&QH2E=]66F!:*6V"L,:=BK0/JUDX1?XT^0M+;O^R% MZ81'<;@ K%:/37F@TM(\.NU16NK0V] >G1_GXIHI4M44M5*Q-/9,!QF9ZHF+ M)< P%CSPQJ&%9..7D7?PGM/1QVX.!06]D[P<.7ES'_DZ^GTTG6I!+^!7=>8, M]F0CZ99&TH@"II;-Q722K>.X)L(:3HB=(T$EGP6EY )H'$V;PM">YMO%S=D0 M-W^&X[7;0LFM@&D:D-#KQJ&KI"X1E/&O1^EU0'3GSL-U> ECM%SAKEJONAF. MR")G=]G9/)PCIMM':I7Z-'&:-%.=X)FDR_/Q K5!7VE;J7'/:F?L%YR-GK,Z MMYWLT+;;'R?'I"/:(<]1790QI\G.D'. VLLVP#G -5*B]5EL5B)V^%8P1%XDV"WUQN7NINS,D@2C9YF0+?8'5XD6NF= M3RU>C(C#S4GTCI$P'MTL RRC+%,M"RQ;+1-R'0V^A?2%Z-=J,K MZ#O$;HGKZ-D$R6(ZR]:A!3WU 2A*@$$.Q\T7WJ+,!!<7%-MCQ7UTN@I1=UH: M\ZQQ_;W%^N-^-?X*AV/I\]FSZ^OKS:07F@TZXJ3%'9CZV:Y.7L!I)GMA!MQX M99%7*&[ 1U^_\>CB#D,[#X[VW+=0$YVN0]R%FP->.+'C)K,!7/#K/^*BS8_? M[,D\^<#3S\V_.1HZ-!2\P ^@84[*D[MXBJW0LU?[J M:'6SRMK4<7"XJK*JVD26 $ZEWJ-7&U)]Z19./>N2U/;C4A]N"_ZQL3!K,$+M MXIK^;X0Q?C!I/XZ5-<0JU>ACM?7R:FNKXPW'QH*.!HUZV!R&H3?V_W9,<7JN M'MS^R(T#T?>&=+2D[P'W\O$_'ZO_U0LO,6-_+F>&?/G$YBLW5X*+V L8RF%6 MDB2BEXUA$"T87N)E-H%X)-WN];)&,AZ27.V\QW>2N4">R\G6TYGWDJ[!(N TA(4H1$I: MUT]C_"%.>S'ZV<'U5S<]^N[6F>\]_-:V$VN.DEJ\[<;5Z&/1W_X4G?:[[;C# MV?>BAW'5FY^U'#.S0)1S[P#]5)".?FV,R-:Z:?VT$>(>[81VW'5!$RVJKNB@ M7S&MLJK5 )*01S?1L@):I5IT!=3)49_"E_%U_#)^"]_( W@NY"O@E+W*8YYO M(HN-5"F_'?\Y9)J_=!$,GT@UZ& ;LO"V<^FQ*?D8U9X=CA'MF'[=PM>EOX"N MB\PD/Y]&:T_-A!!EU$"C__70TM&;OSX2?;?V(2QMV3*^J+(N^CON0M]?S=D1 M_=?XR%/DI[[')PZNS@2I/-(RBG.![CA1%F:-63P(H='-[%'/JT14O$IC#E.9 M.-6RT#+/N3+K2=>)M%,9CV5)'.MFYU"2O\ MJQ-7I.QS[TO8D7A<.>D^ZV_*^#3+2_]@2,X(?-[]:1;$KUFQQ7V&GN=G0)X+L5> M:#?@]*#]HIT/V"OL6^R,G2J=/;E>D\?)I$;>(C?*C/SG;*IO,66+T.!O*EQ9 M<[Q^U*SW,&?X8Z5PL9HB2JH[4Z1.]3#+3,W=0NN9624>YL?N]_6M&UZW_H/H MI\_AQ*,?X=1'_C1NV>^WS?ITX[N[>_4:-+C[I'F5PQM&+^J#Q^'0CWC7JU0W MOXBN44;A_F>_PNAH],P[UZ+!X9T6=:;Z.03T\PT:H5$Z^J,Q3E">L?S.PCCT MA/1TKPK\6W.X-. .;<%,]GG\"=6Z[O&@M'132[T:T'+;.0&#MB;HZ5Z'ILHL MLH'2!NHKP%9IWN>2P%V,97YLAOL/I,%AA[=24-//L[#C!/@)XDI\9 ;^*?' MMJ85OO%&KXQ^':K/5';JD35BW(6Z]9\VK;BW>Z&:%IB8 MO]C5X'V@4!PCCK%7!89G#LOA\NS] Q7%#XAUQ1O$=:Y5F7MM>[/.95I$UUF. MJ#E964WX12/!IKKH7;VRU!RV8*D?^S\*SOKVS";N,-#R/SG89 M, P'P5WPMT:%:Z0#HM':%7S2G :<':8U&G2&,W+==)[7PF7-S6$:@N(5*S@_ M'EKHA+D>+\_(RLRB8C:+.\%MV'").;,%J!_&@*96J+.=OQ]G)V^^=^W!COE/ MK2H<><\7EU=?JL>/X+XK*N]?V[GS[W9,NR,:??O+_\$?.SI-&-2]_];I@[J5 M5/5-[[E_4N.'M9?K K9@WT6]%DP875@X<^BDC:.:OO\[7/[;H-D'S4SP3J,/ MI9WQQ 0F7#5+JB'X"S$8S$G+V"WL0;:1O<1R=2QF62E%JI&629O&/?H',[BNLG] MY%I^JCB/7RCNXHYQ9[A&_CE14:W62EEQR;*"":GT(!=8IJHH&*!EMC#?(7ED M+T 3Y-$L\E+0A*LR>U'&LDRQB%\J\-SEJ?!,\,SV/.C9Z3GJ.>>YY)&O>+#' M \9HR%Y)AF&2/5[*[TIO R:?T]1,O0E,@.-= H6(K_YH)7AP]+8Q/13&K?,- M)5W]]-R<[>S2N00//K3/N7/>(Q,&%J\[N"UWR]L/O?9-*H"^^^M*ZKN[GP>Y7(%1_9=9A;/94$;*$\E9AI%L"IVV'VJD<$A.01A7 MQDNZ)"F>:Y!$D=!,?A/V&ZFRC$11E@AF$,M9)$DQN$JNQJ3R!SF>!ZR M)&C7*._V%L1JG&FNOCG>Q=NS]'%''F1:T2W&SWZ];WV697 A?O)H9#KT9N?? M'KXXC;D$%!VC=Q#B*6+UX='&-15)@BK"\+FY1)0@^ER9SDQ?5V=77[FSW-=$ M;VU.G*ROM[.WCULCKG:N]KWK_%!_U\=KS@1=\S&C\#BQPCG:7>'C=C'[^%WR M/F6[OMUW46QT-KD;??+#UH>U ][]"8W\&>M9VUE-'*)?U8E&[TFL!G16=^D^ MU_V*Y%(4R>EP5-H5E]VNB+K/=S\ONGA>-&5I+F7B%9T1D<,NT1D1GPL +RVM M]/N '+MTI]WA2"Q7)BIS%$;9,U"?IM^O7])9K&.GCO4F,M/P&(!7:@# F/"E M)_\@3YX&Z'(>?XS\9MU$!#!8,XC;'FHM*(_3C1CEL-^.=6^G&V*L>!"^!<^F M?",<&PNWX,2Q(3$')<8U,$X<<"11QEOPS*/9 K&E]4C&(X]$]C^9P[&= ]$: M@+MY?UM;@VN803>/[7^E:/S1?DQWP+T+&A[;TN]F/X1;W@!.:Z&, _UL3)8Q M%G$"[FN9BEG)YL8B"U*S*!998< "-:L*@(;G64RW(I4L%D4#GB$#ON59@ABB MJI4* \)G))D2"W-Y$B@MK5NE-Y@'_(0.L]0QBF7 M0-07B .(3]BP#4%O(6)#5]&W=)K'=0%WPSHRIT/KPX-IE2F=+3>+N.-33K<4 M^1:!0Z:0@2E<%B^OILF'R]92RA@NBZ6M+^.JCL)I$F[5=JE5LEW(G=$GG]Y7 MD7'G$BR^'7D>]S_U:W]6!R/:2/Y,WHN>.7GOI,/XGH@E<@=^ZH[)_>Z)#@)K M> 6DZ33Q\=?&1M$RQ$)*^+>L1!1 .Q@LL1QO87@@%DQE;&9>XOE*B^RR\(Q% MMK3A9FSA.580A;CPE)ACQ_#7BD40)6D+Q#\ 98:\#"*@#'2<$#45XG-/2$F9Y=/B:Q]8W/935Q+8E=?7(*[E@#VA\B%A:[%02''1C[,3!W4(?+/)*:'-7+_KJQ< M,B-I&YO5K:-R;,_-T1\!PH,?LT1GD:UF-)YOE+$<-RHV< P[!S"DELUS<[(% MY,@6>!L,/ *?3F*3!5HK6&01.DB#+!+-9&/K[$ \+UY<8$YXAPM"_S[/T19O MG3@HI.%BP8)+\0#];/2[LWITEC!P_4]OK(?KV]SR#7[#K!\O,0)>NB?5;27D M%KR(K$>+F*W<%1IF MT*A8"2C+S1&R>8TA('C!$;,9C4D: (!*H(8:,(<$24&/&]; MG\.TTK/XUG2 J9".6*\UZ&Y97NEMG0Z6@.Q=H9+QX0G;6>[[*> MCDE'\@SY!OK,HRE&(@&5'X4):!-A>!@?EG&Q+ .^BZ,U*(6&Q8#KY!CP6YB] M0!H03QH,*64SOH()*!@@1%]"I-EANN[80@KPVN;$[.W%+VFF)[Z\"Z?.QZG; MWR#/,,&;5\D(D-;U%L2<:J%+-Q(-*T9_)PSS5Y:$N=\] *_IGUO%KMT*A2" M[J#"/'>SS]Y:VH?OV6- UV@^/FA83H!"_;0,A@ZP&EGV#/Z:U7YHINKL:S;+ M/>@([3AXIH8]AIW19CK[V/(-T\#>B=)0(?K1R.=$'K@!,]>Y621>,4\9")Z9 ME@2NTK'-%PB,0#;069L\1[)E8C&SB0PVK.J<]'2=<2T.N*^ZB;L)IQAW.&IT M(9@J=YS#6'A-MH92 X7I*F-#G;)M2/.]'1AC>SL;]0:E;D K6DOH"7*965?< M;.@04<<4N+'[[=R)A3QNY+_C2:%9F5E^MA/H?Z=VR?;K--^NQ3C2M4A;PIT" M%K,6L_16-2:=VVUNQ>HH/]Q*/V\MP[H3E\#_\9KJ+#K-ZW8)%+7I:9E.7K"2 M>*J>+!^V94##GE$'MB\.!QWCJ\^7[!R'"W M%97E1S?7[AXJ")HVJ+#7T)"_FS,%@1=F&5;:MMLXPXRF!<]8@Y.MW1EBBP3G0W.]:[M3GD7 M- M2I.M"1.'2'7FUH#?2MQ2ZA:;"#+2I%EH*=J,CJ)S9O[T<_0/)#E0$2IOY:MT MD)33P5^84JXW)L!I\9&EJ^>ZLTQ.R+;8VX;1SCAJ+@!:#[6<:@80YK&4A,/PQ M%X%WGK2-*;0:UAKK%FNCE=M,2[5(+\/AF7A)^%P@!=#,3,PQPGE5-YO!5[N_,U+'[_U!AZT\_G'E"FSID;__.2RE:M CT9!S_\*>D0G MU+X_[4V&RVOY\33TS]G4\LUINS.$:=>[V[10E5 A3Y1K/;7)#?)NJ-C[ MS,,5\3A8%Q0SVY-7SYCU;A'JC?^;OZNBY;($F9VQ:!MT47X+W4CQ^['4QW[ MYHR?_.:FYW#O'5^]<_>PE(2=^Q;A11F;-AVD:]] 7+3&T8.>-";4LI/MA - MRB&'V^.Q ZS@D,ON!/CNM"O;+!:[QS,"<1!>.,5IM2C61@G3+.LNIP."L(8D>/DS>GQ!"(4'9LJAM)2&X3)S MM5$;1L5%7G.!30PR%;35SK;FR=)*BND"+% >6I[/VP SI3&#'UWI7>GS9W5K M*)GN'U34H:/===1[=#^S=\.N_45]DQ[U=ITP>\--6MO9(3J2.0,:DH(*4/-Y MU!'\#2A'&E6.GO![G2U%6:2CO8=]L/TNUVC[,->4W"=R185:EIR=D^OF/)+N M]8Z0/"Y)\LA9N6XVHT.-4] ]?#9>#+T\:N1FU"@R5Y-HDPJS/5JVU%4:*M5* M\Z1UTB[IF/2V)-TA]9&(%G/ITXT$*3C11L8$ H7!B84V' "K(ZT65WZV4-*E MPGA$I:86-FO;M>98AF-VO/#"5*3HM9C]V6,Y+Z[- &-+]_+R CB>X2C#[2R0 M5EH*L==.?<^#I;FIMH:''CR[_I6))\/)JT]E#ZT]=?3Q%XI' M%_5:-W'AB#ZK1]38O7W*AW2_7+GY+Y_^"A?O>O57-UJ^J5VV;9F7#)^_JL\L MS*Q9M?O^"$5#W1!B%IC9W->,"EW,84FF!RB3Q'N(J#$@5R(IR@A5/W-QO\@.^:3MF>LFMM]9V0C6;X^ MHZLQ]O25:#?JN8J@IR^92%% !XS[S.4/K07I 'F)@, ^)2(((UCLHF^CUX@- MTS)ICA=8&:B(C2U@0^Q =@9[/[N9?9A]G(VP<@X;9F>R2^&- ^QQ]B+[+W#G MT.XYEF'[BZP^]:@WC_)P"()Y,<98%BY%@]NF5?):5Q\+;>4HU#G1ZF,ZYR^G M;4^+;C^W_1S;_.:;-YQLYHV/:95KY^A(?,GLBP.]?C:VP=D9R>;"XAEDD65\ MAE%40LY 1()S%[S!G;&P@ITY8_;I#'1*L9SAA4:[[8SLS,;R&8W;QNX]4R5/ MD^\_(V^4#\AGWI;YB_*9JS*QR6?\!Z4Q-$KK7$TPU&I _]EK^T53[*%-TZ],W \:'X(-/\P MK0;!C#%;0CR?@'2>]? X1WI 7BA*]EKP7LN85O/X%7H1 M\39 8 5H"-C%+/0)$JK@< "=0A<1A_HK2)_Z7%P]:)X&C.1:.+:&C_(YEO\S$ G=;M0A-,=!J$3,+%H[5BV!G&B,PH1L['L&-KT0W?'[XJ;,] MN LWY^"?H@V16A)\,;H?)$?W37K>U*5IQI *[A1'@'F-:-OH@T%4]5O[]%2L M3S[H4V\T'!U!SZ%K2/2C*G0&,5( E4&;Y]!;B NADRR-1M?C^"6F^VV\U+S" M#C=VM-4M=87(-QRB1@[ZFQ&>ES@O:15AN*2"/"./\:0F)DG)V5G Q24F(\?F M<(QP>EQ.IT=*EN3D$8%4>N-&DI,3O^:,&CZA1E' J#&?$P@D)SN=#@=TPN-, M#X]I<&9TP?1_P_G=(*02T3P(P7! G$(:>Y#KU0&QF MOK4_UV/NS$P":?%_9L2E&PK\TDA9V^;E8\M^0R@_O[6 2S#]F_Z+7J[UG!>8 MKN>V)U<^U+]BIN.N[4,GSW'-W;[ UJW@SC5#DT?MN%\MR;GWZ>R1;.:I>4-K MQT^\=U%#<7UD.'FQ,K-KJ.K DY$(>;-_2I<[7_^?J!R/$_-!VCI@N(%KV34N M4DY6$D(CA9M&"H^NMX\4NMX:*70:)4"P>CQ00)30)'@*_?\($=YV(>):/<@U M[Y8\8X'VWT.#F8UL"PWHENS:2PTDU>WE0G;;7L=^SP[$L1:VU3'5$]MPCS;0L="S[P$,9=D MBKF.[J2K&'(,(.7B&%(IREI3RU^- @J17?1I#B-HAO]_WYPUU[ MYV!YP^[]LZ,_T1CS;70JLQSD8@?9\^+XEXKUAPI#$OL]K@":0Z&<2?%= BX MD=7215KH.R M6NE$,X?"(YH7#,9R9'3:V*3CX?C63F6E.-S&G6[Y47"R*%;\D1=F;NF1N>M" M%N-LO^T"3^PWU_J&++AKX;'5LRK'[J^\=\N,83T[E=?.N/O.91.C4[D7MD_L M]_$[KT8OC.[SU M5[4/M*^T?VG*'5I_K4I;JFW6#FC\.'BZ"BQ*:\(+@,:9Q',(AULTDWZ>#6JZ M%KRMJK,]'"Z[14;_C8F:R8UZ,[O1CH6:RXW2\+]M94&F+:U;='+%Y=J[5V0' M'[RY/?K1]+M+2P9/K!O4N[CWY 5;_OC^:_BNO=-G_?KG7DS? SLZ]<+.KP+)5A%45"!)6@1,9F5BMK3&\D:/J9@5W!=%; M R6CP9C8(%@--.=ON5@D:/59 NIO X6:>AX_@^C&?'=KU\+UL\WRF.*"^+85 M98-;>XY,IHEC^\28D5=HHTX6W.W<\HSE*SKV[)&5-^Q(_@ V\Z._9QU/_2#Z M7;221CT#?$\?Z$4N%HS\1N:BEP0#@5<4V:4H\N/L$PEDFK)062OOD9^0+\B\ M'%0"; +K61QP8S/5Z$R8XQ#PXHK8+'1LYPV:K[&Q<[(L%VQGTXE- S--I\MS M/)(<4@)!F4VWN<=X#(LKY/$($^&C2S0=1(^&KMI"=>D8I6OI%>E;TB^F(@3*8K+QO+Q( MJ""O.9:D,/,_Y@X[\<0D-<)PNSTO:$6PI[5R(+9]6E%KT;I9,Q KX:":9>S M#1.K[@NFUC]T3_Z3&_:=81]F9E3W&^/WSWPBO_RYH\=>Q-,L#RVKZENZY\\ND#RL3I0[OD!U-#H[O<,W_%BY=.(3-7]C?BYXZC!/2A(65:>UFO MR>9"!+>1Z)3L.VWR3LGF<#JMB@3ZH]H<5B><21#LGC0\5I1M=5I5YPA!!12I MVN5=FH6'O]UE%'OQ8F\-8Q%\U"B% 4*U,%U8*FP67A;^(%P3OA?D/*&KT%]8 M)YP7N( PCJ[[@+!XSB<)NN!K/\G1CH5>T[ZBBQFIQ"BT>"#/6^:]EF>/4PA@ M3O$-Z3#=NRC^YU2L&7$&6D+9O;.$;O40GX_'VWQ=BNX9[YDZUSNWXXF[MGJW M3G*F!#MMVVX?-2!M"9FZ 7.+HTLV1,[6N])2J+2F@LX>9S/!X_[)&-C5\ZR' M( ?=A='C=H]PZ2Z72Y< /L?GCUUN%_!XD=<]A\FDR*C1^27]5QZ\1!^@_(U##$*,2= 9C*:U-0RT"B*URF,:*M3&!&K M4X!3LU*!EZ$IP8Q%A,^4669)PGUF24)\BEPW)UEB5_\?RP8[%;:O17!NWC)0 M<>3UPJG[HU8V,_+LQ/=F;R5+X<(P>@A0MY?NN8_W&BU 212;FU&11UI#UO*[ MR>O\JUXA"1F^&A_C%P*BIFEVCZYY>2D!^3F_XG(_@4YR)Y7'W&*H]9W1J(JK M4H:[]Z%]W#YEN_L3[A/E7?N[[G>]=G!@@DWD]-Y:7WNY_B'^A/M(D?LR [G^ MPD"EC[NW9PU>SZUP2Q_QGPA7Q2O:%?N[7KY*'&$?[F4&BGWL?;S,'6(7>VVS5MA$UQV6R*Y'8XIL=*&;R<*$YW>UUNM_>6D-VO:39:O, K MB[G7O X[DFUVS2$IHI?N^LDD<(9+\REC6+?+34ZY+[J_=3/OF&YVJA'4.%S' M'>0:N=>X*]P7W'><('$:5\AMX:YR\$1')Q4EQ!AOA!:7PB#%BG5CM0RQ3-RU M6"E#\W_6,=PJ9VC=(:"^WJQ5G0V1M+XX/IC.UD-KV?2G59NRK7QVZ*W#23S) MJ7YN1[1R;PJ+4_._8C.C:4]]>& /R8TTU[^SNAE_>>-C,JOGH>GW1W;2F=X@I!$Y)]TN:@33M^_C>(O]/I0NQRH7+<1Y\.?Y, MWXF)- TSQ;3JCW)BB"R8P?=_]%C_W)0;YZ(/?_)895):-$+\Q/+"M!J\)O)U MY)\?]I\076S>*S8ZE/D52,J%UAL=))L'BR*X?JM5$,&K22-D%7JNVD +!2OX M?ZOZFBC;K++$XPN8[C @&3K3:#AM5AL6P)8U'B&WS3-+Q1 ]/GS:G4)7S],B M(WNH0#<3UK[F[YO-LI?F]A[)I)%LC.%3[F,OB><93=4 *Z<3*%)^7D=_9F[! MUH?O6/PN>G0KR!H0#7TRXZV M&OI]S%K@UH"Z99N35OD(*J[4L$8Y4(:DAC2G)+.RJHZ(%1M(.0G>_^ZJ[9D84E M-=(!Z%4]C!;+_0'EH\5&7\[N=(YB.!?#BD_/ZB^I-A37@HZ/8R3LX.W MFZ*JA;9";&X;&YR29 MB'NO/'^N=+Q1F+,_8_BC[YV8E-/S2%7T?_IWZ)2S/Z>ZU\"/'NM^=Z<,>D_D M?=&A.-&L9D@]CQB\T0#42Y@_X(,F6&/0$18Z5$JWNFZ&BX41V/=@=*CPT(]+ MP#NHY6U?0N MZY+NZ]3;EP@B+,A(S$HB$X\0$.&9LO%& 17A@?>>G):2,V7XZ+<>S@,19E?W M'OS!X3N&=$H'"?8C'9G-S%SD03.,V/XR;@H\LRB3ZC=R8/Z.VJKA3?L_. MM8L+1XV>WK-H+.GXYH+4+@6).;W?G>WK=$=7U-(2V_] L)"NB"X$T]$F/ +/ M01Y#88@MA2$(/!@IQGE=NJ"R+EW:V@\EF69[ 7UBMM<-%=IZO=!68X@WA3;. MHW_4TH)V1X?2=>[P%YGF7_P1%[7\C"SG,$I,HMLHYIFMS-7.0D>XCFSS.C;B M2OA>AR%C)04CQ1J["OA>:&NNX1%\T+:3V?8#O PWF&U=T-85P)9;; %;:MSMA=H_:VV19W_6]OWT7/MO_<7VNYN:[L) MG82V9A\[I4(?.W6+M6Y_S1NXHVWM/Z!5=;>^N]3U']_]65O;3]!O6K^[N_G= M);=_]]CH2%I' *-=;MY;_8_W(7.LDY)OC;4Y)VSVK5]<9GOBOY\&OY^6(6FW M?O_?V]Z2&6V;GOG?VK[?UB_S>S/]_]%V=UO;3>:XF?U*H_U*RW5K[?LU&2&2 M:W[W>]#>@S9>,+\9LZD8"5Q[[:0MI78M>Z%;+3GVWUO6MVOY_E>W6LK2O[>\ MW[S:6,M-OT,QG61302<%\38;-;.U2\SQ'1H?WV?CU^"%;_:F8>G6-YO93/,: MAL7'XI&XS/P@,W\2XO_OMKW01^W:)B:K_Z7M^^A$^^_]A;:[V]IN0OM:Q\)/ MQ\*?&FO=VK]8^Z-M[3] A]I_=V;[[S;9IWD=H^+]>Z6]+'R2^_]NVPN]UJYM M@E]R_=]MWT?GVG^O7_R/[]W=UG831-7X^'E339\2:VWVC^X,$CW"_($[BBSH M82.;;H+ L8"R:+F?A9>)9.$)@Q0@?BIOL8R*%0%0H)QI)'+9$EDM,A&>YU V M41A&D501*=F<1O,3M>?H:F.DM.8**,-MK8>,[1$0VP<2 GW>K6T23,!%TP7Q MNPO050CFXMT@@VUO1YM\N%__[?UQGX3HA2O1(^S+._')Z(B=-^X$E<5VYCA3 M"MC C];>-8V#DE8:B(UANP>QV#'.%J["2^?4<:A\S@9>;4?:.VQN>T2+&[+3L=WP[.?F1VP^$C9][[^U3?B_[XIS#A^?,.7*XH?S>>\OA M 4!B:70J\P#W>T 7V9@QPMTDGM!.>XPG',L[CYS6+Q>Y(2DZ6 MQ6 *"@2 PP0"OTJ67?".S$L!?W**PXN27'Y[4+6(J;QH"=I3'"A)M"8'L@#] MJA*V+K8!.+^ TU J=C[+"_KB0B_VTJ1:DFN.WY)LU<=X3UK'(!5K=,8#&DOP M$%5: F7+FHC(9O(=86(WD3A/QM -X^CQPS MN2^8D)"$D$":^R;< 7(A D'N@!! (@C*C8 0.50.4<$SR!E0%SSPQF-51'== MW)6%W=\NJ[O+L@J9SEM5W3.9(.YO_Y_W_1-FIH_JZJJGGJIZGJKG^3YTU8LB M4((R#1..?$%K-*( B#K:1GZ(S096 M:8&M5-\?9@ W1E(LVJF?BX&6HTE0[I MUBDUIDIGTNV0VI Y'="UXZ$/EGF\ZRL>/( >"28I/]HM Q],;>KVR0/I:0]- M:,%"W?#&C$+_3"@1&"V[;&WP'/'7-?-,+L%/B&+ MF2G7S7F)>2BO!0Z0,S.O=^X,I"28X$_T"GH#9G:8/3UGO[WI6QN4;9-L*VS[ M;*S%!FTM\"$Y 28V<=.]=66&ZW4BEFC(5DBL=!P*I?+J,BIXD!$3/#>]^7>NYX<8$GAI+\U(+DPJ1N%FO0"CUQWA8X M_43<*B?LM JK7.?D L!"J3 I@Q&"284%N2*?*-1E9>5;N@6L;&*=S=;=[#%[ M47Y=:JJWTN,I TT0=J\S$H6F)S&,#5W#(CGYJ<:#Q36B?X8HSCN1S&W%UPF\ MB)5P)B56%'!7=>_!6^.'IEQU_IN>[OBCV9OV3)[SI:M^'D.CS*;J15J^1&#T7(:60&$#\@FK-;/%75 OU\R?&8R M$E VT8Q5Y,\LU/1JVG%VD/5#%8!N&&8XS&4W*&@[19X+7Z8,9R6$ZPGS@\YD M*_F#([>W3'KV/L0OW'A"N8=UBA>//_1&[8L_5?%/_51%ZM(#][)3M)=]+>=P MC)M!W5"AT%^HL*U-YN*\J4*JBX'Y7;MJ^QR=%\@<[ KT&;[3L _PH@FRN")^ MDIL8N_I:X""YRQGOQU[D]8*T*8DF:#*!["GS="MT6W3?Z]ITG$X7F$+ JS]V M,),47 [GJ)%8^_.'US M5=[BZ7<-#21V';5H1J]-'_]EU.0!]Y>G])@PWMUZ5,YM//R5CP4 ML0"U_8V]B&E.M-A"((-79;=@T[ET/B&![>P)I77)SF1*"C,S"[JVP"$GBKIU M8PUE,CE,$D$0ZH(M2);U<;4LTSD4*BP,M*#28XY:@UC2 I\[+@)J-@Y398.G MME8'=8-[RX7!0GK+'( ZG+K7,4LM&-2K!0HO+]?0[HFF2!AJ.![LM#-0%E:Q M)LOHN6I40ZP=IO=;M2H1D M90PKUUZ5[L0Y%IV"Y@-/0LNI4\H/3QY0_GYJ^NX_K%GSA]WJ]S^O+)K2>]:H M5%=FT8B5I7VS$HKE5>,'I90,68J^_036'SFB;/[D8V7SD2.P_N,7E0^;FF#7 M%U^"79N:E _#+S,Y.;/[5:T0[/ZN,_:NV):1H!R$[Y659G3W *9#*Q2#:;)% M;0,^@>VTI_-/76JS6J#O!*8R#.X)M,"I1XIJ4_ 56<*DECK7=JH.U 9;8.U) M3ZWNKR5=:]-Q=R5TW=J=.FY8_H6_*(CH#6*,3+__&VI%S90[CGO$2/D_D@F] M-]5[8,[&4R9."L>AM+W.;72;LEMKLT2!HO,=:6 MMG_*:3:CR8P<>KO--I-X3TEZ@\5JG2D9\*'!9K5(K,/.KTHLD!O=.[^) MQ*NX3L8_[_7KI1Z"K!UQH*1@A^H7G5E^YH!67 R[=8MBSEF3"\A@&;3F^V$^ M'C&99,8*'_D*)7T-4Y]Z]L"^J2]..88VH!-+EH0',Z'P0K2A]5/T0G@,.A$> MC(=M/WL0S:.63?FR;QJSB%G#[& .,J\P_&KF40915Q$&HE<0">(L@T@<#148,H,3$+$=Y(5* M]@!3B>5@+] 1MM-"I6&9/!1#!XKO0R!K232+-Y,?2]Z6LCN9_>#\>1K5 @QO MN\RZN#> '3PJ]WX7C^2L'1H8UHXDGK,A2="9D:0734@RBB9HL.C,T&#E;-" MVU(TF9UV X0U2'(@)-G9*AM'L&3M9EV520P;#!(@B/,2UCFQN/;0<7&?XX$M MI/6NT:7:,C4VV8W2&+U!LU2,C4P&"6)609!^L [A#.(/_/Z-M6\J5^"4I4H2 M2G]K]9O0ISR^!'X#]RM]X&N'H/,0?%7I>TCYRR'V+ X= #G=#H?=.@=^+K#*GH;>$;/)#4X6V");+**S@Q'/!+3])EI]5C/F7[Z(#YNQ<;WJ@ MD[LV^V9NK17K,4?B:Z46>%6V)M>R?*>-CD%Y@8W"X/R'3I!Y^@;!?Z:A:<)D M??O&M?;JTVY2J$5UH;H9!?I0YQ$[U2\TGRL^9DY!+]]3,F+"/2?[;ADZ843) M/6MW3=VZ=>JN\Q4#.Q)?L[C=&3,KI/FQ$\50FY\&L[CN?7;1F5''V M@\_OFE^_6[FQ)B\X;]J,>7'IVZ<4CQHX8"P>O89C\<;%GL>2L1D,DT4:>(C$ M'6J!!V3);*HR&/5F\1:/ST_)3@[<,IG*F!',)&8+LX_Y@>&9?1:R9T!'A>NE M5+"]H04D@K$!B? A_$:IAYN?(\&(X.;6;LR[D(7;#I+3@\ILI?60&DUC!NOA M2@$/]*!!3NK&0HA0A>H@"7B^@F,=',=R@(<,!=[F23'C\814I0.0U8L<'K\- MO%@-]TGZ:GZ?01V[+N/_6EP5S)-$VU,(3#7=A.V(D426VS4D;@$7>1CS0:O" M($1*BVX>@KN/*>>4UX_^_>#M95TB)W=C()Y<*A"#QU4R^E>HKI(L3^R$*7XV M5 LK5@DZ%D&&8_0BP(7=RMU>V"NJED\T+B*^*>T^E#\O;013&Y>6];06,+"U MC?E *[ *KEUR3)G6^NY!HCG@MIY$,08L\B&=66>9;F..&:&.XT2;TVEU>7T^ M)PNQZJTW&L=SHH,S6CC1:#'J+156I\-J=3I]/FTE"GH];A?+,X@CVU8B7,QL%HLN&V0CX#_BI#E=$:3S^MRVBP>M\-NL0),*($5 M.8"ECCA1])=14^Y; ; M^KYMFE1I#0Z""2U*7VAS*T>]<)A'.=H-#EB_;3WZ$//')T.JE\!OPUWQN7(* M4]V@3&.W48H%GPZF M$(\R+_ F,,#KA $\ 8V4+7%Q)B\6]9-7F:2X:N=2_6FT" 3@*[*OS%IK76[= M:_W8PEVRPD1\MM=ZRF_ULU0^]+#'5Z4?GZX77/[SH'WV(S)O7JN0@V7O]NV[2^ M0\8NW,;.+WUB;7E^^<6-RK=*V8433_]A_\>Z0X=K[U9R3+/^=?_H645#80\B MR2U51G(SZ,KI*CD%BRI7]))#SW)Z/$&S#'=%U#M$$8]JK,3H!5V5S'.GD0#T MB)$M <14X:ZJQ^E8),T36^#S1PUHGO J- (C^#U%%K=(O/*1L8+]H34&UX0;6"/PDU%O02N3YY/WHR1;?1,7\1S3^9+)Y$#==(X,-((J3\N"/4-3F4FFV3NGN)' MY#7,#*:D'-F$[L]\?)6U9TYJ_X24Q(S240.FQ*,_A6_M[9:2Z8]/\?3MUSMW M$M05E30\N$X95A1?U+OK@/OS!\^]JWLMM?YH2T&YP@#0"90=S6 AEAV?.&IY MG4\FRYKN]-?CLW*\T&GG@?BENPY\&1C4.;H&%*;V :'PY9"J7/HAL0:(K#VE MJT$MW5C79) 0E08T62 =O6<5,_VUG?*&%*0G9[JM5K>8:M&-*AS1M7=^>D9\ MO,/J$E.98\B^:VJO7GTR0L4ICOCDK#IE6EN?\+^5KZ;WZ5O0J3 0B MF#2(1',(ZD VDT0ZF<]L2#2$#&4&5MVK-K@"CCW+ M[9OMR-Z"NLN)+BPS9MU+'2LR MY@1X*.)I6\>3=<;.VO(W6:(E*Q?4D$=SS,1\\2_5.5V-+1.Q_\ ]5%.TU<;7 M'-(U)\VH/WHD'&@A L%974;5E97M'E]P23 M"E)ZSV"*4O+K*^>4E$B\I9.S4_?%[J_GCA_^]HQNW=-=L*M%)_G\73(+YF!: M+41_0$=I3_6!L;)I';.+>98YQ7R-.$LM[GR-LL%=R[@=Y+[+C - M1DJBLYS@%:"Y,I;Z#38YF97'9<"ZPZN=?8;/S8R!A/HX4@!5;) MMA!7QM5RR[EF[A+W/2=P?Z2!V\)JQ+9KU=%OXN%;1NS=2BV7B1.'%B'71^0,G))_]WN;S]SSR(E]X3/[^I1-@LP3;\%!AY73RLU#2KBZ>QG_S,L9 M:3T._:IN/70_LOA9Y>]?*>\-/'8(-\: MJO<"VP9EO:[@P&P2$Y/M6$VS0)Y M()_1N;#(,[9'B:-'CY*\G)RQ)2Y'28G+W".Q!^I!0!ZR' O*2VI+-I?L+6DN M.5/"EY3H$Y.2\KR"T#<_;T=F5A;;;4&*OS$Q#L81JVR3=T%B8XH &@&T4"_G M9#F+[;M 'YK$-N)1WU62EY4/DBQ)@20F*-?Y@9,BN$PG-]:V1 \: <0MN(.(:,E## M@R"FAK37G:))*^U1?NU;= <(KLEA+ M?*8CGOKID?Y)\"*B'52=57_F2ZTAO@E1!(FB0O;*HT,_6S;YJ:YES37W/]H] M9]>!]27V44..R]MRSF^;L#8T_X4G3AG":YC9HP:M4QZ&OX,%506CGOIX_+)I MHSJ-'SBY;P6LL[[Y_,*&Q0N?>F111:]"B\DUH.OP,>^:]STS:-#6']_H/C4Q M?F?3 OA 3L6*LN=N>4U25GG/$;5C9Y/(6HO;=C,?LVN \2#--A%KDW59=D* M=-UM_72#;.-T$VQ3F5FFZ4D+F?M,2Y+6FE9[UP=WFIJ\CP6?\CP?/.9Y)>A9 MF_8HV)G&,&D)DL& @#/>9(0$+O8E%2XV(3[-R;H#DHD!K%W$[=_G*'(O0"UP MQPF[$%@@2G@:Z2,7&B6C)1UE46VHMR]7,&C8UKO]/0K[#'KX'@]S M<]/ ;0TGWU;>WUVVJ=^6A2>@'6X]VW6^\N.C4WI/[+P 2MM&]R-S5ZTRFBFB M,:0"X%[9XHF/T;[H5F.&G&.>Y JPWR$X&6LD&;9*^PH0J&.GTY"V3"6XF@22 MH*%NLQ=Z!P6GG8(/@TBDH&K+C6LTR"WM.#1.$(FJ="U\.38FJ9!<9#=!0=N@ MB.ZQJA,4[@+H7\F'4FIT1<7^NH9!\T=4-SK58$%RB 0+8M/.GU>VUFP;DCIM MX:9>8Q=N?I9$"WI\0=W@IKHE4P#=_9L%/Z,U%,'LEXDGKZB#NF.0XWEP#.D$ MAC\FF#)8\=AW$$UFCN$JBMN/A5C(GCX"*K'4]>XQ_H8@##JF%S=M]F!Q?S@5 M\8<1.[MJ6BF :X5_<6-R6'S'U>*TX(:T:A),]D/X6?*AY,&5^<>ZO4@+_'#K M9>5SV ^K>!!3X!"-2L6!+L>Q,,J24-@_R!8L_K$;> 0_X\!@+4+4C=)A6.J[ M B@B1MT)2&# =*(ZO.5C;48%0J):=*B, MK"OK;H/CP@7)%Z&0G@I9WV#E7<7R=A+L!)N$83].9<*5\H[6]W"ITI21S%+N M<\QGS7*U).@EB??XX^+<4,?8'*+79V.P)!87-Y:7'#S^'#9#GVZ'Z/5X] 0\ M_G"BV>>UV:S6)#Z8(5ETN(P0[+;P,)>?RR_G?^!9GD\*BKR;USS5Z'!;#:\7 MDU7%*(Y5L19C+[)(7!8%[2&X#:J9 5SP%>BL UVS6N:0#>0[;18Y ;*JG&C MLW)RC5N?LC_MAQU]3*8FS=K/.",DPUPNM15FT)5 M>R,U=JKS$:DM\PO7\V>\4+KJOG[]DGMM*)17C2J=U=!0+M>/N>-5] =B49E@ M'5[R>6FA'\LF2C]R(=Y&+\05%!21_NH#@'V?FXF/.% KQR/B'OZFNG2%(.;6 MF>KB%6)Y!O>4_;(=]Q0][LT, IBC65YX]J GFS*OZB1 [11P2^='-34NBFJ8 MB4P'CWNLH*DU^.BO IG Q&6X@FF7NZ)!)T.SU?ZI=(7PE+=5KY2/ #8 MI=P7<"G:"BHI[-A<9CFSF=G+-#-GF#9&B)RV,1Q#I%H#";-1';X1QL/F#?H# MM$V-&U=N:,OD*LH1<4&'^7Y(OF'BRGDOPD$+@RL6/PE[+D=FI1A^ YN5$OQ[ M";Y(:M0/UVBD5J/5LDM@!;V;=>O9=#9=_P[[CIXEZX$ML/2$B <-0="=AO6X M7K/E/#WNK'A*4"GH*?*7YE M A[!_PX GT!CEPNX#@-DHYY'DX&.98%>JM2UP)E'A$H6_\AVIG($.$O=YEC2 MA?;1,**U*FW#&L <'0%*U5CG0>WS=SQ0PW4I!]6O\_1?N^5OIZCE;Q]JR4NL MZ,P!!"RV&/M#FC:>6MRF:!:WXU2+6YK6[(NU550M;GU1B]LOX0DM;3Q.&Y^A MVMOBM+C]UK1=X;_&NI,79,# *:!K^U8VFRW%!!?>I9\FG@AP!N)4<+]D*"Z, MZQ;H'S<@?1PDS@]97'BPXD;4K:GDP!7EN)QTM,2HF@Y1J,A*0B\ M5I=KG-?D\'I-QE20P-AM54ZGP^$UI39(C,5:E6$VH0RWJRK#X]5E)#3@$?15."*J#W[6"#%-X[@D4==5\G"V9OZ=2@F4"-!IN-?U/5S0 M-$]1 MS&X1C,6)X1$SL.S!T:?G+S\";8^\?F\">BX^_.]R9(H+_Z,"]8\/^\(_]%D[ M8OYK=8_5S?[UO%D#>VX[@#N; 3[WT3LO'52Z'%3$9U#=V5?N_A0ES]UR[%UE M*Y&"[VG[$\^S/4$Z* ]H%.N","0+@^6Z'K#0;I1<(+NGD[3NTSKNKC3XBX- M75=GK>[:E/58SO;\%W*>RG\UYVB^>X5II?D1TR/F)TU/FH^8CI@I-&,ATAF- MA9A-W-G!QGU)AY-0$L%X&N4J*MSA"8))CU?--'L"#G*'VHL$N JZNCJI!5&VZO43#? M:Y88>*B("A31=:+ >*H+3J.*)TQ_O,447L>4Y8_LVZ,\=;#9Z;#JB(/Y<\'WF *I4L1,17(.EMK^R3!0[\8\:=B)3$'0RS#/P M_:U;Z>H6?)_?3)]*E$T LHCAZ+/D*?H$ED?RZ3AHQ0_RF]7G$'B!>0N]S)T& M.F %OY.;*D =: !KF#6Z';H=5D''_)OYM^[?AG];.8,D5>A%!Q:/K*+4'G=4 M!Y"D-R\QZ2>+-TTF_$Y^"0^1VT(9V-!>]%9Q)I1(KZS%UU"G&IY><"FH3G5A[%XWWI9 M7852CT'9#:($T\&>'I"MNC7MFY81L G23>N)@&PKPJ)_,'( %R<_FYC_HO&N M()RL!I:M36*WGC\&,[WE@=.17TREPYA*O]*H=%5N*D(#4 6JD.I0G=2 E@@- MTA++&K1.6".MM>Q NX1'I5T6&P&;,2*=U2").BPM8/6R0ET91@Q3H>Y^6T5, MNYXP)]SB)HDL(-UV4*O5ZLYA(EO9(:.<-2,2DFPZH&M2,SI!%*;+M M0IR 6#.%X2 3CDU##(,TO*X*@U6MG9'E9"W.+OGY&;9WU"9 52>H)0,-O)L? M.?A.I=&DX)'DYQ+I 7OM_#'EHJ\\>"KR2WCQ<^8MK$@0:DV6BZXR5W6$B=@. M/!/#)Q&6F(M9 4U"4+.WQ;41U?*K[7X]TM8Q34QW+J*-N0\W9MY+N#%I$V9$ M2O,9+LVO:6FFR"6X4:!.QX#V-M (C\!D"-I)+$=\GU0O*QY<%%B$;M%XQ9"GY>E )3):#X=EK(NMTZ2*@4>P&M@";<=H6&!\("?J)TLZ M1L)RQBVI0G>++^-&<).X+5C8^8'CJ;!377H]?%D-3UP:5LA>([%R*7@_V4T,'S_/[,8:X!\/*1XUDFT(%^$=[F$LE6$A7T3)(G2+"*42*X6Y MRA*XIEAY 8Z!==S#X:)P"3J'WKLKO#.\"]41WQ#J/TEMY:L GA? PV C(-8"3D(:"060YGL<HQ(CSB+S5%LU&,% MUI;@M:6F2WQ\O2YT[9M2RX6W+[Q-<1%@;4UU-HP>X@GJ7#; ZL^P\-OM1]I$ M]3LZDH/L;(!3$N]TQ&"MKVL1_K*!B.9'MC/IEXO,4TR/JGF__MXQWM5;/]E5 M-QP6O/O:_'XCMVW\32_$>&[Y M>V?7].ZUYJWW[\:T&P$&(@N5SOO*%AWK85$&>Q*\R^+9AF-/8Q6#J!<.B-BF MB#)QEOF$01!Z6P+>(>\!R(B\C-8Y.^$Q?VHB-]$!/P?(B(^X?U]-"S?)YQHX2"W ME]>61XE4C<6SZ]$R:')]W_L:#B@M*Y $WU."RFC,?968Y[=1238>!*%??E T M)T.=BN#H]'B]#E]B0H(_/A ,QKE=+B,62C7XQKA@<&R"WX%O&ET&\V&S'NIA MO.]=O]\P2Y"X)T=A(CO 1>+!*P(8299_ M->[35AXB*':5>U9[5OOL9O_D$G$]A/, M[HV/SD_M51:_)S$NSCEQQL;6:>R5SS^_Y:.0=RBV/2"4%XGFQ ZMX0Z1H!6Q MS1 ?/];G=_A\?JT-(O3W># 3[6 T^L?[?"K]#6ZW\3_2WP=]/D+_>)%0'VT! M$?IS $QT8.+[W'<1[+OL*"#S'1J@6'/*B6V L(8CAAL 4_].I*\N_N]I'OQ% M>C_M>6H/=-S:?NL.I(Z@L.F5 \PWW#/ #KZ1AS*\(""CQ6HU0&0%(LM8@,CQ M1B#J! ,0)<%@UYMXHUUO9BQVO0U9[7IJY0$<^!G&8'#J[?;Q:DP#8"?>3%EZ M$608^;D&@;RQ3WR*4Z%NYDX"]+%EC,T6>TBQ8A+*V=(5T>@KT= MA(KLLC#Q\+JC5$'1^C7!(ET5P^X*G#^J?.DM#[;06.G*1?AG6B(K^*.\V<4Z MC8@*H/^]&"IA&5Z?T:'4_ZLHJ@I)91HHHNI4\#V05%A$+*%",,CV[!9/%#43 M#KN#9-I>\9^3X)?$T^IV>D0/;!'"--].H79*"6!NVWM\$QY]C&0VH(4?!JJQ M5+^_ 37P#2D-&0V]&_JO06OX-2EK,M;T7M/?4&$?[Z\H&-^C8O3X2BSR\W4I M=1EUO>OZ&XKLW?Q%!=UZ%(WN5CG /M _H&!@CP&C!U8:\%12HT86MM9*O_'4 MLGB:8&'WVK3?=!I?V_0VY73.__79F7%IX''ZN M9E[-\L$U]8NZ9 [.ZI:72IY+8_[X<-M=ZQ[:I-R:NGY]1=\YVS;T[QV?7K7T MUCI>_.G?T*W=O3EUP_J*?G.V;^C7.RZ]ZK[*31#$7)^[3;M^IY6U"QU6UISV MV-6RV_W>HVE5OW?S[:MPL?E&?>3553CKS_.5HOE&_?H1SAC+Q09[1Y_AV\O1 MIT,YC+'E(#&-T0,T;8[F4VO5TK(X+2?Y:6.4?SD[5& MRLP&[N#G3-+[8O+NTR%OEO_YJF2GZ*KD)GA"HQU=E0Q$5R7OD/8"Q0SX[]+V MZ9 VH4-:%5N@4Q1;8!-!6$@<3#,&B^S2P&(^TCX"GL=!R ]\"1(RL!7/ M(?!Z!+[M&'7N8K!R!=RGX2%8 *+@Q>T(KL-B(O[6$63B-!7CZA![$&W .C.) M)N(C6AO+.;",3@*I\)R#)]MY@.>9TW 0$R3S*Y VP/< M*7@)"%[+#74;R'+%:[GNN487(>X0>*M+KA]B02A=./354]-6]EJK^FD<.8++ M\@1[#KV#Y1@'*)%%_2%&M\K$K+(1]U.CZ9## :2-(A8*=?H6^.MCCHW@@)-L M8U ;':P=7&XE:P:7"8H+C#B YJMKM7C$>L)?7NK/[]'7G6VY6ZPN">;5^PN- M[-L/5ED"J>7WS/>5XA8 3[/GT6EN/":EYSA=4F-:4.\C%';EFK869R\*"D][ M8-C#GM] H[$<8]>CO5C+-H!D683"/YA:O;"=;X$)1^!&*E@8U; S(4P,_'B^ M:@)'%R"/W6695SS>/3E^>TWU4N[AC8/Z+%V_CH1%ZL^>0LG48R57]N(V>3/" M'9.QT#&=N0&G8U&9)8N>E\.704RT3SQA$N&]?]K)=/;4I4O$]]O(SD?=N-]1 MW^_L7B)6POH")_0!,_XE!E^]C]@.&%KP#[CJB93TQG]R^S9.+"F=6%E2,K%' M07)R0=>4Y (N8_CTZK<@UI.EBD5\#M,%3N092>F)()BK>D[ M\#KLRM=9]P.IVM""QL@20*_AVGSI6$M_\M6/C"BUY?4;WK-7T_Z)ANI>Y9,-\YB,0'*(K']LP9S]DX8< M/E,NF(PF\PO0 GX56L7O8'8(!YF#PKOP7>XBO,C]"?Z)^Q'^R-E8\-,*CD!) M\"P#$6!;T+W'S7PBC_C3: 1 Z-ZC@(9@&D.\@ZK#K5K( M4*UT=WSJM)H#S2 MR[;L>NVWCSWZJTLJ@U-G)/SL-$R75[&N; 9YQ[ 1IP3LC 9NH+M,IS.Z*K% M%OCQ\17,1M-I"R:$+XS)X0MC>H2MF!)%^9KIKF9\^&15;F%FT7A']:B^Y?Z5 M XM+LQ=WJZHD?E'@(J[]:=JOZV07YJD:CG=P9#,3U:C[G$0G-^$^/4[V\=0' M2NW7M%.3WHW[]2W%9!.!['4;&09(XL$'@EZ#LN;>@X+=SKT(-0Y M,*]C15&O'V=D'48CJQ/PW,.Q*$/25V48C+H,P+"2>; MNIKO5'VU72@CZG&1&1(%Y,5=\;L:]D_^*/ZC26AV7.L_T,3ISTY')\-O;3ZX M)?S),[CVB;@Y+E&,\RQYLE$PZ$88FXTL%LM)?"VHPT,L@U563 91K^<8($D= M[Y%;.DX0. @E@T W@6T3&\3N!9@%J@71Z)TW(LP93' ME,)J@82,Y&F=41",K&29*RV7-DM[I1>E7TF\6?))(:FO-$8Z(+TB799T?JE2 M.B8Q8J)4)E%8<(DKQESZ^!&#A$?/*]'()M'P7:H1AXJP2JP)BZT=J;=&UT@T M8M4_P%8LZ$IUI2K\.;504K_4<_I-O3K;B9S\>*-_V:*F*2O]#]R_'0SKJ7HA)35SSK%N39_>TS-,%M'4C10L:I:;%L MHZ*%=$J"H'.V.08MA$9OH_GVT/+-U/*U$W0CJRX&O86BLM%\JRDNS*5%:JX. MG*O3%DV)QZ1VA"\!E+R&A]]<(,!/\3"=2P9)W$U9[C/21P6!6,H0BVQU9U+; M4B;+#U@;(+X[R58[<4:/>^"!![C/6O^'<=UJ:OTSX\;O(%XD+V!^LX%D\+$\ M7C1[S9A9D@A\21!P 29H3TQ&2?9$K"*F) 6]@>1$.PLYD$AB&=)%F"049/Z) ML-B46)7!)DW*LA9* MW:W]I4'6"=:ZI+JTZ9D-20UIJY,>2MN8T934E+8[XZFDYS-:]"=,QY*.I9W. M:,GR\1ZOE_,S/L[K?>5N.17TU_L_GY#]9 -=]];7;$S.XD[G9PQ M9'+_AY6_'%8N*8.O?'P2EC[:M=?FS5.FU%:VWGCHD=D_/;)]Z[9M#>U["IW4 M/84.F&-&JO,P,3U-W9Y+4)WG$:T'.TE?<^E-[7V-Q'"_"[>B"7C!IW*F MBT_CBVV#;&/U$VSK;,_:3ME$QFLVFA RF30758/18JXRMJ#QQX''6\5BH?=N MW#5+Y&R(3&IL2D=]F6Z23L5?V*<[K#NKTP%=KFX$/CVL^T3'ZW1J5/=,K /T MQAWC+BR^K\6R>@ON&OHS ':(ZNZ[=^.4S=,6(ZAJ!Y8U;G0S?S M"S'=(=B7#T>N7#[AX3\]J7S1=23DMVZ91,*Z?\*=ALI%+;*[<@%^,N!0W9#* MM AJ/*8508U_2Z[&PX_.J4LQI <*F:Z&86PE.QU-]RR&B]%BSUJX%FWR[(0[ MT4YVI\5Y)Z1X$G>#H,43I/C_7R'B53#]#H$VH I\PL#V(&UWQH:'O;=7]FWH M>1LX_-19*CB\,#)\;73?GZ'#QSVBHL-#4(V6,PU,.A[)$V0S@ZI(N+H-F&4X M8E)IN1RQIB0!HXDA9>L5QH>64RO*E3# #&/78HG\I)R*52T!S]LZ MFJ%_42 MB62CTTMZ42)"&0U R\WM)<&18#G^;,:?O?C3C#]GX,@C/(^G^Y''N=Z,KC<@ M1P&Q-R--HNGGX<\*_-F"/_OPYS <*9MY3CS-]]8QO:73J+<.A/(O>Z][KH3P M=^D"X,&G/F^8GH=+%\1.R1VG9[L(B\AN(A1$N!(RBC*%A!RY6VF#:(J"_\%= ML 1V7ZJ\#8N7*.\H;R^%W95SN.:7T3=H%/,AP86?+3-0CVN1>.Q M##A9QY[&96;@5+F?J/-G,( $^)8(&BLK&H"$562<>J V];P-/@>7P76@8[&Z MD4+GHD\ 3S!>P)<2X2 I=CV:XDIK:]+$D"]430&WPB1\5*PFA0=&.R]09Y9\ M!E94CEGJZCVF9V;E"EP+Q\"$Y9Z>G7N&K:1%&_&5)W&]_*!>SHC 25YEN#J& M')Q [Z +Z"H2O#Y@W&,R67S428GXI/CTM1:_W^>+%^;8[?'&)M.*><05):)C MQ!'\TNO7&K'8Y"$6+\4J)A?1^Z#F%5=OCS'FY]O=;:CM0Z/_@?4C;8&B4'$O M:V/>%S,7YZ7<5Q^ 14[TS>P7:KNYTW,RNA;T,/]VP:21?;I,')6W!+]W/?H MZ[,?@E3PT,OQ6.PSR2:]WI,,]^32F9X!I^$ W"[X,DB&R;_Q./:<=4+GOVPD MI=/CCS=+U7H],,_Q3^?GC A,"J UJ%E(W T.5? I0'<.(C6+8W S1/_(A*@ MGM3(IM;NLB5,8M6KT2^+(S:R*GRH.Z^#TP*NIX8ZD[9^8>I=Q7VZ=4^R^PM' M%G6>&%SB6EXS<_'ZTBX;9T]:SSQIF=NO**]@)NQ>E%4PS3YAVNSQ:S/B1Y;4 M/+20S$!3VM[D9F&IK!!\CV>3(O *\M/9Y0?T=A@ PW%DCB/1 MKJ:&:NH^)#7:A-[%J4TGF)CD)/UZG/X%FO[O6NZ56OIWM/19<<"CI0>P[5]X MWAI+Q^*WY:D,L%I9'8E%:!%,@M&H%_#(!:V"Q5)A91WXGA&M,>$+HJY*DC;K MF_5G](Q>;^&%J@RL %@M^@S6]N1@1<2F^Z(0B!0UP-UVT:5 MV=3]&NJQF[QLC7O-<<88']Y6CA;'A]=FPQ%NY7#N?NA:S28<5#H=#*]6_H>T MS(&VJUCU@7B^SZ(M\A6\J,D&65@V"*1[K>VR 8U@QSV,TPY6TY*H\W0-L'L2 M KE%07?'-4XY9HWS:Q ?NV;98>VT0:E@[Z'(J84:IB)O3U30YG4!*),U.K*N\3R6=-$W2>4I[JQ^_U1_O,+6_E48"I9). M?TW2^4*3=.*PI!.7X(I)>WN^EZ+YQN-\$_RWY[LH)M]+X%4MWP2<;V*<*T:" M&M_V)[8?YD0W2(=^^9X^KC&N::Y%+C9#GV//#':W=TL::!\8F&"O2\-2<%I3 MJF%B$!H,1N"6W"Z)Q0J^Q#!(D-AV!=\0"+K9E'C\D^0F5M58*_6*O%XGX 3< M6%9RX$%>P'/:LW(IUG.=F(4S4B8Y!3PA8H'")&'=%3_AP$!SG1[/G>;*VE?(R MF4H.'D$,^A5<@T?FU_!4^2J<""@H3&35,N@,'F<]M_[$GZ[#3[>A1?!]I@]^ MVB<;$5.)M="SN+G19 !"UV"H.O]:GKH/VD;V01>=/Q_=]4#178^OX'3-GMA+ M[)2=L3U&1:M].(I6^Q5%JR5I2PBR;;<89-NV2[AW_0KS8P3)^'=8+24]!P&S MA64B/6U#5N!HOB%M--FNYV*8E1WBF)4;X+O:_6F&-7N6(QJ&EV-YCU2H]'9 M#ABUL7B]M^=["6[2\G7A?-V.V_-=&I/OI6B^OB2B\"/QE_>QOJ'[8QUPLEVW M8_ VQ>#[?D-Q@SM@]CIBTV/JL!_0_ LT>O35>D@J[B&IZ5#H4&[T.LU[K(JU MW%,MM1F7VFR-37E[KI?@2"W7=)QK>AI,[)CKOV-RO=1#S=6*<[5:8GOH[2M[ MF^ O[/6+KNSALBY5<\W&N69WCEW7^Q3WUGTT91'-];<4$5F/ M>ZNH!T)^-DGC5BI(9"&^P0_D-SK\#JGI"1U1UDO]K M,>C*WX"W.B(FWY;_[6NFF\ UC2963!.K_3^MF6[2UDQMN,5LCMB4-%?^S]%< MO\9SS\CV7!T_SW5G-->O)\?DZFQ?B85T=8A(V1R8(7?!(\TXB!P0(I9A! Y ME(X&H-6(\<#Q<#IJ0>^BJY#G(>H!H9R>26*1GY7M)FMQ")Z%B(>E; 6#$+$# M(HO@U[*KL[-A*+NZWII/_D+Y:R*;K\E$#O[+DZV,)2Z\F3O]#+$2)GW>KJ$S M^\$Y>; 'N/E,0YIMO*'"MA/LX/>8MCH.\B=Y@Z^JS%ONG>ME$KTA?%#K7>[] MWLO7>C=[F[UGO*S7"PQ5/&LP%J_G(<_8JD!+6ZLLXO.'<(5%D03R[FFV%#,Z M_.7!>J?7:W:.VR+"@)@K[A//B&TB9Q%'B//$%2(KBN9Q!$7J,,,P?XR3XV%Y M_.%X5%U/P /R0\11@U0L+Y2?G0W*JK.OD0_1"_"-ZBZY7!+NS""81[X9?.RP MY>/CKHC!DA+:_COE,IP'C7^ /N7!E6\HE\_O?@WZWN>4WG'PC!?.@)WA/? O MRF[E"^51Q0_5 T(0[&>21#,=_2]L,)XJ_D@BYB M*)R@EXK-%MRF3&*G6LP9_T[55LF]IB'XL W>WUK&)'K: MWE ^8]C6[^S0^ 8,D%W.D6U_9O["]L!TB >'9+>4:',4&R1IK,GH,$EZDY'Q MZ TD$N8/<@*NM$DR&GC; E& )/0['J<\"QC)[S$[BIV$!A(^X,D#DL%(HD7J M+8YB(YABM1K]A./]SOABO]E4;CIC^MC$EIGFXI_O3:S).<7$A_(Q;>K/9^=C M").4E$&R/(Z?9![]J5Q@_>\:52^N>_(I,'+3MZ]Y_B5#V \7/W5ZV'ER]U'F.>4DQ>6 M;X;]/GY@)Z;$6$R)[^B^1P)H.?JL#WJ(TYH)"^\LSX^U JPM R\AA,EL+Y8\ MDJG8;L%'5E+Q?O@,L#L@L"^P\MX%DF0-= X56P.)2<58WV:M/(,U=83BIH1T M(^C"[R>Z'W0\6?_]5L< '103=;!81]?D75-R31#_-Y$U^<0.L3_)[E<(LY%* M&OQ73 Q/(_9OF&&RJR%Q*'/9-)@1K$<4I=EC2 .+7.A1O^+MK]S]KTL'7OW7 M6QL.+G]CP:3[7YG#]5VT8XKRU^9-/RKS?_C@.EQJW*-\KGQW8<,>V/7=U;OQ M %"$Z0,QIP3 F5/ UG;Q*&Y<-Z8'^>4(79Q&#%O&##]W.]T.M>X(V3$BUXD#&2/.SX,B+="YAE48^U MI43!^PHIN0B5((:[HZ@X?$(Z1K\'D7\QCF#5&Z[4>:N' M]'Q@[L0-+1N>1/DU#2N/[JB:-*7OPXXU:,G$ON4/+-RY=\7;6E]B2S"%+" . M;#\%7&W?DB"+A$:RS^HHMEKP%]H!>>L"D^!>H)-\%CR0$M(=Q>SCH+X$^()D MP6>0\4V!_RLDA.B8DBM!_%\BS!(?RRQYUW"-LZ..UX-WA?\1$">P@,W@ MN_'C^6?XX_SK_+?\#[R.5\=%,N^UJ\UY)'HAL93!^K!]JP^9_:_NV?XXLVGG MSM8%S"9"Z6IE.IN'*>T!2>!3V>-S>SQ>(\1]3!!,7A+AWN3 )S[<-8]BAB*_ M)T1C<9& E7E,91+=RFMR!Q98=0NL@N"#Q@5NR0-,\19_7'&\!S\Q(QY*I%U( M*O[.-IF*6M%;\%(=!,A:;'5LP_P$F]'C^DO%DR;^7Y<5U63IV]2[EUH_>Q\4\>ZYE7TDV9 M#I<'H/CZW^%\\:4DY<>G6GO"O\'$9__TFO(GI=&G/,0Z%7T\+/VD8=4C:LS? M_JRMK1O=509DO\%)T 9MM[YAD\E'N3SF'V.(]E2K:FM8#F6IEL3"SP#A@#U, M"OJ4^Q XP"JYWQ =M#/(H9>D&H/183 8D<,169TW&AAK+<=(!D<&G4L-P)EA M-$!@,1A<9XF,87 #-[Y(EML)A!V!L E% .O(?DU^*!M/D)BG"5["[4;S9*.W MGIJ'"86QT:&3DP1FS[*9EDF3Y8FFP0N'2[WVAXIQD7=53*L8F394F0^?[NXO M;E,^)'+!H+8K0F]<1X(85 $?D'_/,9"/<\8AD>=*2DHSLS(S2D2=KA3++GFY M&9F\(*2/'#WZ38_7@5G0,]H[DK4.X+.Z57)F"(SU=R,O-K>@"'%VZ #6C MW/YR_Q']F?[]AZY*D$K3L^37D_6Y73+R7P^%0)<,LC1EM:\R""598M8:3IF.;T8 M@\<8MG:6%X" M=!-[J/Q""EN>K W:$<#X]A"G)I0-&>*S3[XKBRA?!(9!O MW#=#[%&TO>B;TL%W[2A8@U[J/7#@%U..K'I^GK='YW%C+?5=$U=M>G7;]/UP M=6WMPP]-_ L:6*\;X$WNQ#[,S!PSI%:>N&"ZCSL]Z$@3+% ^B)^UO?[*R)*> M7;8^7K/NG4<62S4]TJO0NI6;NX>;.5?X4J='[_F7LCH\K[.K3#=L9G)JNNWN M97?WS2OO,7S=W7UZ8>8O!T\(AYE9@.Q,Y9N@@'NARYW<&:87](3PKT-+2H;Q M)3^=FUXS_('3=U>\P&EI: V]Y/ MGL6/)1<6X9$ %X&W1Y_XZ1Q?@I]@9N$L.^72+.^J6=3Q_>X"G %672@BAX#K ML*NA1BULJ'/J#LO0DM*AW!LW>];5#,-U&?>&^O8]^.US -DYB;PZ6GV"^1=, M2\=5$@[7G%@YHE_CS:N-_4:L/%&CGG%>>H;B.F4_LOV%#1M>V/Y(=J>U;]/ 1[F3- M2?R:^V]>N;]O^#;:&=ZNY9[XO^2/V_07WJ'\%IT/ MY__'-_WXQ&1BXC,# 'XF2^*VXG<1]%TX8PK[Q,TVMNW6U"FXKF<)?"LW'<^, M()AL[5K4$W>(!.1V.3$K=$WOS"0GF1#!-(*=Y_ &>>/']\[[\%%9S\[FI?S9 MSTX6Y[WM_ GJ/#KLKFK%@S.'U*>7/KB]V2D MK 9O, WL9>40 \JTBM*8& M\?!Y^U'H"_:2L4AY$2Y$0_BF\>B022/0BLG("#S&+61Y4@*>8+P FC4SL M8)/"8>83_CT\@P&(:5+8CL^8KGDG.-'1K4?K^PS(3TWPVSQNM]6D9X5P6+#_ MYG>]#:\#+Q&T-(G>X/;^/>P,\1KG 2N$WNC?#,9G2N^58CET?R#6]C3H]VGN,], M3NMK:#MYGET5>3^^+T2>#UII#N&9I(PXCUN-D5)$4JGPT:0<.)_P-G85S@E7 MAJ:B-(A*(VIIN8ND1JYFDE6$4EI>&A(UH18I4Q,M5>2--)74GBJ2'TVI9DD2 MDVS)UOEX[B*SJET6(L7D+I)6H"WQ>7/XBV:2#K=%-FV+2(U)BRPC=]5&H0T# M23JF+\X/JI.%^:#[?W$K'7YR21;C6D90T6@R+E,SF\SA= M'BX>>^^MC4!]-PMQG@0O!]B3Z1A %:=S]MUG)G M^JCE(+4J4'E@.Z$"Y0,X'A?DID4K!U3+ >TT&3$4O "53!:2HN!VNOD1I>YM M)5%;5.4N9E3K2RP,?Z%DH8.&\&,^-&%8%B/-,7TX[6E#8(_J-M@9HP M^7]H+<%E(>F0BT5J.AA4U\*L01;=4O!M^*7*F[0@:KNQD/(GH8D&2HZ_\IN9 M4;?:L&1P(7Q?LS#PYIEFFC][KU:./I'\-9KD,WT(7U/NH#1ASFDE@>TIU;*P M\%8;O("3: R$^\%MY2"5*PA2[BA@1C7?:F-&*0\VA^_#Y; TPV7,N5L;FR,\ MHO)H.SV"5HTB:@^B-,&,HM(<4;Z7VON:QGWP2R53XT#*T.KHP$2?(5AS9O4M M=OHDI$]3>H:7HM7X:N%7 M:IP1+:4]2C25DRC9HET^MI2PO91TC",$]$9X"C-T^#YX06,JM9=A$C+G,#DQ M:]&W:KU7*V=D_%![;^NKD5&$=F-2-:@^@_D]4DYG#,=S%]7NAPL:[7],S%O4 MX2S#1=W 4^U][!D;?A(<(3,IF9G1X*7XT^CI2 M1O65&F5P#O;8_A%ES^CHH8VC="S56"#"K1WSB.&"#E36BA\E=:02S5I=V&@N MI"Y6.M/2OJWV+)7VZ@C((MK1PYC>$49!.7@X9'"NN%ZTQ]&6(&4D0R.AZVR: M-YUQK=I8CV:SOXGRQNR.]W 9OXZI&4/':RNYWC[FH[^VWT%__5_O)(!IBH[. M4ZHT1>*BN*D\F0S2038(@7Q0!$I &>@#!H A6%H>C66:2JR1WPWJP$PP%RP M#7C1WV3)R_E-CHV+$'U-C M(_L[\KML&3G_J3WU3W>\^@MY_-1^51C82/XMB_EN7$;^-?X7UT%IV__\/Z#V M?6 Y6 76@ U@,]@&=H#'P%YP !P$SX-FCGQRJ;+8MAMO_[] !T;FL+;^0N8$[M 7J!?F 0& 9&@K%@ M M:^[@)3P3U@-J@'"\$2T @> ^!=6 3V J:L+;T!-@/G@;/@A?!R^ X. 5> M Z^#<^ ]Z4WW^;CKL0(?[-S!C: M+VM4_V/&2VH_Z\@./T5OM.YLC*;!Z>$BG(BPX;+&F(QBSVZ_QOU:6;],6=^H M?B^#"QMQ'M'O]G\_-=[YI)V%?OJ%Q#C;.R6/O1S#<62&P@+.8>8PF:&(G, < M;AU!/E1:[B&TH3.1.T+;CQ"=4>Y7G^$V9"-9+"[[GG MN77D#E;6N>=OCN76A7/".9%[&[E9Y)Z(N(WA[N'NW*R;"W$^$ ;:?L]_H#X' MK9#_@#QW;F_,_GXVL0G5SPV?RA-8=K=ERXL /_T+P!\SGS M.:XCEIBZD/"K2>TKA\SGBFO,HH;18Q8M8CYOS4''%HT9W4!.J4P( +N*)3*A ME:P"J<^2TH#_P]Z;.$919'_@5=5W]TQ/SWWFOH@1!C*$.!#,*(<<2L*1R)% MQ'"#$"(@((*"G'(&B*!"0(B(!X@0 HN"HNO!(AZ+BJZ+KKKJKJSN?EW6E:3S MJZKNF030_?W^@!^:R?2DNJ:KZM6[ZKW/B^0#\C1"?CS8F#PIN[3UY9D?S(6H MZ2A$; ^//UCYX?3W4?\H2U3>0)FVK_B)_P0%7]^?/U50?& @X^VK:* MW\PNHS42\["4(K'#':H7$J1];SJ+W"X'&\G/)%4,,V$\#[>@>X^T#N]A(3WR MHKG$K*?@?F[5NE7ZC9 =NU:R&ZHTZ_H#Z6'P^EI7;LB MV7@3UL6;2[9M&U*<7W?7^$WLLKWZV<:]^-ZG87AO(XSLK5RK_[)NK=ZZ80-D MUJZ#_%K],+T_S>P'_];'9F[8D#FNNAJPL!F/ZS =%ZD($[E^5$R'E4CK\!X: MT+_D1#B'[7'-*$:87PC?2 _3-ZVOY6\:?U==?O&0;=M*KG]H_<[KGQ$_WSC\ MG(0ZVM*$'GP910(AMETR].+_/%Z/%VNCO %J$(!JZ%=8 [^#[]BQ?1F6(C_ MPZ\&;9*'-1)MF+FW3]PY$J9WU_\R,#D;P5+]!>?],"FJ?SU^T[3;9VTKU3^) MP*1;^RKZ05@JW=I/_ZHKS)SP1$7&@Y=7K?CIX8=_6KGZ,E^F'Q"*;X.A OTO MXP955?9[:8?^63X,#(A:] -PJ.WFWOK?(C!YQ)ZI_:;N' %3HOI?^_<6!R[[ M#[E])>[D/\O(COI)'\@IW)? 3^,>3=V<*-7I9NU:8Y,Q5]$S$X)G]()>>G?X MATG_WKCFYU4K_[M:_^+2W"\>@,Y73T/G U_ L_H]O?2!\&@ON&GIE4=6_K)Z MS7]7OJ>_Q_QQ_E\6G";9O:<7_&4^_OZ9^B_<"GX$K/V%(1BDPK3"_1\Y5 M]4G@-X'IJ]<,6C+Z\;OAX#VKA)9OA>8S;.>'AX]^*+7SK$?NN(D]-WW_ XM6 M]!NWY.6ZY^Z6LK(^.C]NW$.C!O4:/J9V]G#R?868;XKX^_(!R(44UZD@I[W8 MJ)<6P#4.LN(HI+364G8.?CB/EQW46S3I!O^.>7-V M]1MA#Z97U^VJN?GA_(SN[*B*FW>E9Z1'WKPG?/_LW7/OW1GI-R"W]HDG9HX< MWXD3G[CWOB=[1[)&[CS6.S>%V8,[9V=N;UR1OV=B_E<55>DF!"1D(F\JU1T%=<]ER]OF;2D,^; M-@P]\>!?:\_O('.5U?8I\RDW'%M* -*G289),,/,V[2[.DP;_&OVLX4E19V[ MWQV]:>"H4.SQBAF+'UTXI(H;KKJB-VR;."FO[SA_:LM+\U<,75@]97T7TGM9 MVQ(NG_N!]I[5L3>/U\Y=U3OR,*'B^G$S'MJ^H%/O?JW/);IG__/SE6?O?V#8 MHKNK-ZI)Z(_'6D[,7U&Z\&[R#21CH.T;[D[N.*9P+/RPU=$9_I%&_^;K=S+= MZ>>WT\_O@/?2S[=B>3(#?YZ#];W+^"\\:#I-/O^0>1&^2*.'9=KN4^9%]#J] MYH@( D^VG>;^33.$#3YZ+J8R"$TWX#0G=X/=FM&R0RDI>?A73,E2"+HBP[&L MGUS+@D" OR8[H9/^V MI/9PITPX$6RL>V2V&0X\JG'G.,1Q=OS^D*9YCL'G@1R^%#%.%BD,?DW$*#Y" M(J/HNP@HOE09"9.@-]PP0I =R>GBI\J?'1U1.;5WU,>3W;7Y3_^^>K9,F_'GYF)I/ M".<JZKB+D PX,]4U=?]R.7W(]7O!LDRRN2X4,C- M.9IAH2*0)OJ^))!J!!BB0 M):DDN6/&46Z\Z0KQ-1&_:/B5A&PX$SS"/'PU3V>+L6RDA[+IPJC3P]*7EDU> M\'#+2.G&XD<=L^\NK['E#H-#'QK0IV<2&K0+GC@Q:^7P$7__5K^AF^^6F4^7 MS!@?*[G0!_YI[?*"BAUDUC=A0K^5ZJ@"MJ2Q+NK$VM8FHJ;>SOBHQEK=\BWC MP_MZ*7P)#6/6&BK5F2)YT%]Z.)3 .-S00=]3!O1PUFVN2ZNLF3 MZS9-&3AQTH !D_ -Y)+\W#YIP,")$P<.F!3/H.#W)3(H/H:]86D[;I3C^@R* M;HD,BH_!LVT7:-MN)(.BNSMP;?9/.)']\R'T9Q4E_Z^LH@^QC=DAJRCE M^JRBI$2_G\!R^/#_['>_V:\'?#+;\1N]T@P'?F\BP^%C.!G>\>M(6V:&0[=$ MAL/'H-ZW^_^1+\7P&[, 4B_G4F_ M-P2OZS\G\#YS%G[K>9]-]/L)V %<'9ZW8[]&9ELXD=GV(6PP5RV59+9E M7)_9=CR1V?8AV&QF>G0EF6V1CIEM1K])B7X_@;O-Y_VM?I]-]/L)V&4^[Z_T MJ]_)"30+[@8S"Z[*S'))2_PQ!5YB'"Q_RLASR>]F]H?;82IA M_T5'GV>.?KLY>F-6$7=U_D0#;3O8;.LVV_H)KE8(=L#7P-_*#<)2E_@#/XT] MLARS!&R-:JK7@X6HS>IRLQQGD06>5QP.42399.7(YL)_LG!MD&VT;8FVQE\*4";QJ"!R@4%92N]E$'* M:.6(<@9?"IQB06R8+^6K^%G\$OX4SQN!OOW?WR/;Z963LS MT3U9N[/F>UOFY*&:/';TE49TN/5V=O2:\_C?FC;J%"!6.(G$Q[I38ZQJCWA8 M1*P@BI(_$ PR,"D40C9-*[,[7':[@PD&RT+(A3\3DNK9,"PA.#U(UNS!D.@3 M/56R@*>9TQPVCCUE?]?^%SMC3PXB)N 7!38)VI,MH6/00H)BO?EA,A]&W&!^ M/ID+NUFC^YJH,".P2*4BC3.*63GIF/%XKXD2P\8;F9*ZF>XZ!XP$];.1K=LF MW1^847>/MW;4HP-#0[:\,YL;,'OVH_I'32NGW;RM=2U:NJ#'O/M?W:M'V8-& M5B@#^"N)K-"/0!26)3*??&K'O3X)BX>G* \Y3SG>1Y^S1DO,\5CU6CR]]_FW M$KU^#'RPYC=R34FO==S(1*\?7P#MO5Z'Z/='RN]N-'E8@IA#+CBRZ9SM?L[_=1';XE006'FKKKM^).E.<#C?8=@S821RZ9(\Z2/RP MP^$B@>=AFSWJ(L5 VGZ, M20Y7%$B"R/*D!XO'%SW)0SZF.J)\.*\RSQO)(V&KK?E8BR)U;XJ+ I]5!LZV MX[$2G'>TWN>-B#M])KM M]M)GV:Y7#KP_^"Z^U,"WP[,R6+^3_8SR\2XT#^@?4#%YJ,^AB/&YBV(>NINV M&D)6"_YCMIE-V*$-MCB9)]@LY"&9ZB0O#M\SJT,>WC^H7"=W"1; FG>U+2;8 M8[25D8'WC[:8V8J3V]=W*'[*R[15-[.O?YBMW &G-=[J)OR-\]B;S:PV_)0# MS9$D>XTV!'F\[6N6U"\-@!VQ,94N;(DP/C^$?G]Y +@" 2"3L'$W>;F3K6 ^O)$X/Q9% M;( LL&3%_"-P6P %PF1Q*\.5K79:&"1::3"9<+%1YR5JANX2WJ*::%-&Q*G# M3O!O*,2H$-G]/?T MG_776A\>M"H/_@CS3I_Z6F]I)G6\]7)F(=L;I( W8O-6.[<[GW:>8(XYN>5X M%/Z R^WVI4!89E%=%HOJ<[O+/%Z7Q^-54RR0E>Q50<&'S6M!JF)5MT?F1ZDK MU'IUCWI8/:-^HOY-_:\J036%N>),' M6CR4Z-V^J"=FTZ(E'NC!TY*'90^9FAKS=_O$M-JO#O\T2BX0$T)\C49QTGID M.>8>H-R63(XS'JG+3)R;/GUJ\;B"G)P>W8.UVKW3FVX8L?G(BK0GGQR_$"UM M'?;N@8PMKHH&].R=/1:^_A_=P>8H?NCS-@?OQC[P^96$[O8R' , M)S(U@56QLI\9:,4ZD(7"BH55 MJ*JP1(:R;"&ZCX!U'\'&KE Y#EF$"@FK.B++(K&G,$@8);PM?"K\3>"A8&'$ M;%2*JM LM 2=0CS"ECXA(+SEC,C_J]/F\[&-2J1YN_:"MYBAK1#T;BRY(P)J M7+-[[;/^9Z/ZG!#S8I(^O^<+7B;:\@83?026-#;J+Y!(H[8?V_Z!O-P^D J: M8C6!I&2 D)^4IE=5WRQAB8"$%"'%%NP:1,&@'_E]J$SUN?#?MLE/R\=D!JF< M.]5>G^)P<#Y_R%T?]'OPQN*J9,7M!G9HEWT#?*B7;Y1O@6^5CT4^/^-3MZG[ MU&,J:R<9/'B4AM)6&3%$17$$CQ*;TG2TE)<0>2'&QQR)A..#CJMK4+C*CC9J M_9%Y*,1SD(&U-M@MQW5+.#<0Z5$ZWMOY>=_S6?.\\SKO[[O)NS'KN <5?'V/ M_U;+%FWDX.2'(/O(A3607Z0O6G/A$9#(YTQ)Y'-^!)^ \]O1:3- !R1;(U=T M?R*7\R-,)6Q[=G.&Z+X&R9;NR)O,';G,U%BN1[TU^AV9Z/=C<+1CUG3PNGX[ M/.\%N-K46=))ORG7][LNT>\%<-+L-YWTFW)5OWA'_HMJ)#<9N?5P9ERN^MV) M#/PI6&+M8[-QJY%FJS\E6GD]\5;O \!?IGNRI['/4)\.UG1:2L=LTX>PM>&C M>W*TN7][FL_H)U@:21W;&BAGX03*V8?P'K-?BG*F_2^4LP_!"QU1SGSM*&>0 M< Y4CV6L"L;%-$&PJJJ)Q/4?#I+4I*.:,VJ%@!1(9N8#Q(3#1A&+-'?:8.:7%EZX@SAB0/>V MOS(M%(/JXA%G*JEL1$RDH&J/\E:8@NI3;23HOWN0KP\(0G>KML/>#%\_ZOK) M"K-^RL]KAD\=KC+K=T5C>;@:?A>'L(".24E$$C6\B;?N,N^Y7,- MQK0J;8G6H+$:ML^:X<.QW(*TD)_Q)@-.9.3D+)^^D<%7G9$'^ M*%P "PH*M@=8QQY-($DCE\)ADEZ?ET?!7Q/G_H">K@)GCIT,PPYON>^0OG; G*\6?*M_!'._ M_1!V5;Y9^,*!^$D8.WP'67XCK'TCO7F'9;X4[6T&'F\J+67Z"G;060P+)8 M9XD),$A#V#[TL$BBU5I&&I)1 D#0A%2!$>:7\N_RG_,,WXQ6Q#(U@"D6,30E M$I&#M7^#3GSE.6QQ5AHE4, :6;MLUG"I_"HO3"J85!*2G7U=(9?*V:"2("CQ M%$%P;.JC0*V$44&DJK?Y,&C4=PUR7R/FK^P MCE%T5BLZ:WQ3O#XN3-^TY;1^)FUC*AR;L3Z-;80N_?M7\;_XR0G-6\VDMM0/ MSP(0Q-)70TBSG;(A&]%A)$O4%LZKI P74\^]F(_/P_<4@D[@#]1.^Z$-:X? M?9@4C[.0.V056]#AO/@=]^$[WJ9WY&$MUKB#5+ES$MZ/H&8Y94&X?<=O0(=I M^QM!0?@C'GB G#A#,1V_ ,724?4J:%\+Y"%K@7L@."JWT^LL0'*1L5;"NBBM MR.#!V'"\ 9):0B-&<[KJ[2.MRJ68<; M8F).8[)S>-9UY0.T_\3?]0?1XDD^,8,[KO=H:6+$4\_-2"!OT7%T B"..D.O M>X/$B06]SJ/757B^6NCUC?1Z,/[[9_2Z"V$@;9@OLEBGP;/0$)L">%C,,DPY M@MC>AJ(DEH0F28MDW Y'W\9WX*#^ '\GS;_.? M\-_Q/_,L'R$2.Q>O(A,A!_L$,IX58_2<@>%YB^(W3N$C\0/?"%:5:V93M!)O MA'C9KYLC(C0CS@PR0P+,0,N>_?;Q-6E:K+<^HI&4%V,FO]6\U3&!COA)02#!2&"!B#EB;U$)%+#F@R'@(OD$>L[ M$@\V, N(F4<'1+U-$Q(_J4G,D*26\B0F+ZG%E\0TASA78V/K.OPSMK$QX7GB M/L CR*=,WUQC_/P;8C,8EBTW:B8("70@ @?T%,>('-];A*BW#=JX%!B&Q5P) M-XY;SQW@)!NWF-O)-7#GN!]@&Q3"<"A7!6?!6=P2^!1LAB>Y4_ 4IXAL0 MH:/(QM=5I-X >#8V=CNMME>N )?"\0K@>([ERV4%$Y_"*0J4\3.(DHAW)UD> MEM^GH 'R2!DIJ_ H$&;R$E-,*PWDB5 4)19 7BZFQSX:E*'4W';YQ9OP1@Y7 MWH27YJ9*DAJ23^F._!B+1(^[6HORZ8N?QAYP9DD%6AV "$TPVUBZ- GBET*L MBJ8Q-R>U3H:6Q&/>/X6W34A>V52>EU$;EN M.X.O%7K=B\[*._CZ73PK = 6.W:9A[++[98$K\%Q]$YQ6I*!%[1T,P-Y!C]A[@P6J@>3 D,"X M &L+=+646JIH,<)W+3\$1*P,G R\8OG1HJ@P:"D*!HJ" MGB*;)\53XAGG8;MZH.:)>4H]2SPG/:<\?&EH2:@AQ'@$N<+K$&?4"NVUUT EQ5<@P1V/KUFZ(-M^0^I/_K1.GN4KV!M^LIO]%_6C3T!O.&2W25]U0&*2L5 M1E&L=J^6SJ2'IFO+-4YK1BMC(76##2ZQG;2AF*W*=L[VN8VUV9A0%9:4") & M20C"0+G&P:ZTE.Y!CKV)F\S=Q]5S+/=UDE%B''.3ULK\? IC%7]WJ9*$+I'I MQ09%A. H%%42/2X7TV5V',N*(]1)(#Q0!@&X\L)_ZWP*S#N(=SCW'G3H7T(^ M6;,4_Q MS@F6#K6V4N&]_Z/6EF&=6CK4W[T%WDMX,4&!(G(<=J&?KP5-P#B'^XZ!]/.N MQ.H%:Z<:)TR3F?O(I\AGMGZ7MB;GA&/BV@!I_7>J%^$^FFCK#-(:_@A. P-U M9#+S-%YK!^8X)V/%X[,76K=ZF7+O5.$^@7$1"'FG4Q3+),4E24J6YG1%LU7H M5%0.I-2>(G5157\MIV35JE@@JH@>V=FT:,AG40U,IJ[X:G0ZK*9+>X#<((6J M47HUTNRE=F1?H3RE-"F,J#CM[%/240E)!A0-@1$B1S\UDM93'Q !\MBP1VDO,@=/SM#YX] M-F'2QH]NN//TO?7#EK:\/86&.#G"X\O&SX-\Z*%>.8:V"Q@ 3MBXR1!L5A,GQW6 MELKBU7E0&<.Z&(8%%@N/6;?P,%&8("LC1E4LVP!<10R97'".R%N^A";KY[)1 M=@ [DF6)4,%[6F,0$Y\4@]@C%* N@B>': /:]>I X@TD]88DXK5G(DZ/MT?0#^N-W-P^_65]>?+#' ME"?N@]6__?WXH"I*H1W45L;^ & M+\2J@4/ 8Y0M6+!:'$YGF%9RV>6OUO^ MCP#9"PPG8XD:DG/D'G(_N4*NEN^5U\C;Y'_+BESO?MM]P?TW]R]NSNEVR"P] M"?>X?5%7S&:/=G+=Y"IQC70UNHZX>!W+K"0^ET^28DZ""*3@WR&%_HG M JG%DT;%^$^6>C#W)-G'H>2]T_ -6H'7ZS]_JXUOW M,#?MOF/M[M9!Y):GAAS6,\U3#,,_D\8R\'9O4R$!L^DLR-HE)"2=9 M49"$F:' $\;(8 5+,;<\(^%+&7 L@KP@*@#; Q(C:-B(%@2VFM.2TZ(Q;B.6 M8Q>P !,@W K?ADB!B&/[D2("F"0"Q'L?L[FBGAJ",#8!P/=R"K: F^'OX,\3W,QI:@C<\XOAP MQ%0J:^(C*+[FX5F3H6NOB46PLH;:-%CZPB(CQS M%GTB6\=F8^GW56S(4S^M>X/)Z@;;( M[798+18( 6]39:'*H7@]JJ)9;&YLVT&/U]?)8@->S=J,QC:IEC?4T39;,QIW MR"O!E^ [6)P"\HHJ8I[%7FS$KO=N\#)>[WL^R>;%_WPFCM,"[4=:,.G25]I7 MY@5]FT!VHLY16F^.("L:U=@PZ_OJ:HMA!5[%UXJ*Z"\CPL&49X4TAL6 *^G-#^*TGP5YO9#N?-8 ]@=R[1KVNNAH"L4"H8TS,S3Y7I)"F*[ M%MI#&A.4O?4>FY-P?%F-JH0!2)AF4S3)8K"#+O@JDV@)F1IF#"$M:&>='D^* MO]J9GJI8HNF24X)\=:9:#3-34V *(0>"&DA,PSSJ&[53WF^R?VSM7J(5)/+B M0H#8N8(9:HY_@S@$E4"D01>&0BT6=.^!OILD?^Y.?UG]\[.G1Q]\K M?J7'6S/ZOO#DCM/<^4?GCAY\1YW^_;']V3>L&KVR"6VV/!CNDSGFJ:KGH*?/ M;4=7?QB/)F!OQK,TC&I*?\>2XCDL*:S #Q83[,5O8\EXH"!5LTT8'HR!&(7BS5J9RQJ+=XVM18)(M6K$7Q.*=>+O-6E6!W@F?G,&YCT M&+O$HC#E_Y:%[[$1X)YG@-Y,&\0LSQ ] I,-@^XE1Z>7/W!JUN+6[Y@87 +=_SRM_UV?P[RB'_GP@77PYC\LVXG7 M?PQ>_V5X9$F@+J;N=>!-X#7CLRQD"'[,QM1ZF\U>:R%'W5[!PV!!4P]L?BKY MK00TD4H-_/N+6 :6$)*&B5LB4D/P\%[6#X#$5OO]-M55K7:EEB9>]=B7=V]Z<[0^>C-:FM;WV >U_X3SHRLZZQ<.S9R]KV;RQ!<(Q1-M>!=F M(6[P4BQY(C^77\X?YEER[*I87 H)^V3+W! ;EU D,S >2S&_/6I';E9A62O6 MZWFQUJXT8;/18F56*I!5@LH-2H'23QFM5"OW*FN4[X%[M7N;>Y][F-NB]MT?KH)X/#LA!) )@4S2B(4 MKRNP38(H@PF.0!D",N(3GNR[9;RW:M"X!3EWU8VXZ?3NM<^@K7!]ZQLKNPVK MWO87U%E7]4,MS8^3H[2VE9BJOZ#RKCDV9R"80CSL+*D;+2 %$F49+&C#$2X M(52PF"-B$&$QB)741/E"4_S)BBK.%TB%R#<%5M 4*Q&" [C;E)7<"H7MR@W@ MCG)O8CF(H PY1L$D'S9N=:EN#VJW:8QLM5OS;!VMPZTCK+>9UUI_"? 3E@$ F-P:VD6D$QQ3(F_VBUEPZXM F)DJ >TYM09-*0 MEW@2D$%%IB/AD;OKAR5_MJ=NS[*5O3.'U(TL_L?%OEOZZ$_!3]$@/?K"'5^* MS,&68]AT'\3QG@>U',@D54-C>9#QC M2"/0LE:' Z4DBP+OM]9F(B5$@#WIS$J8E7 BGEX'P;KNZDZ*.JJ=1*8X 98E M7%I*=7)RJ%I+"Z?%TI:D'4S#]GQUJ?@NR>21J].X<(3BFE%X,YI6$SD;-O1( MT]-(U2:' 4.;94 8.R/(3G;1S9">O[<7\\=@0/A3'V4_J<9]ZW_Y,_C7CE0.;$6 MED'[]H,G&O4W];&F5?X@/<$VK/)U[\>M\EWD4\,J!^M(Q&_N$%8\_?YE^3N>:?IYM? Z7@_9*%!8C[X%Z&C9#@KG4T/8-WH;',<=?&!LL M.QV*0U'*#:#08T$H.\4*M]N&*H*2,MC'_PA,.+U&$RG!K?GYE>\QF$9[\ M1'(8(3@CIJQ'/'],37^KQDYL44?7YI\^9W7_CEC;LG MG^[YEUUSUXUO'4;Q MBJJ.UJ V3V96"=#E$JR@!D*UQFI-=GIZ^*"O1@@3'Q1)F3.SN2J-+#J*RUE) M,3OB?ONV1[W=\ MVQ,VI^FEJ'D31+ E^"_]%]@/IL/EL/6GSQSPEBL_/I\:?>O_XI&(U!/>XU=/ M-XB?ZJ.K_%2=_J>?JK#M&U)/$-_?F6I [[5]PS=3KT &>#!VQ^\\T!8,J6HH M5.X/N/S^ $"H7+%B26 -5MAL5K]4P4JA"K\(*JRHT=7@04TN& JHS#Y_DQ_Y M_9;4&IEODL^GDZY(]L&5K_^4%]R%\+1C; 6[;.VL6Y M6OZD[W_1W^!=_0YSH75#:>.T;5?*.%?K!AV=O6?\70"1TR*>1+>[\(XY&)M^ M@]13NEV:*K%6;/Q9$+$UG*K-AC4G3[D%X%T$'#9;N69W:9I=M;HKG%@MM'LJ M+!;-)F)RK %N0_;R BW"-1D"]C@2K'9'4Q/3'%D M.H@SOL/,$)\/>2$?_4K623Q:ZH5L^ M/Z0/FZ?7SMG=@C]9]V#Y3GCKEIJ=W/'6#2/V3*EO*4=[6BO(52.9EKL)<9'H M*"Z"Y\4''HH-<7,LZ[%8K>6JS:6J-A9/AM>';2Z?FW-6"%AQM*JB9ZY79'T5 M$ %DM5F8J'J+>I?ZH/J4VJ3R#ZM0]0 ?JW*SO-!+64D->0DGN A-+\%LY-KL M$@.HUEGX*^DDY$U#,O,"X1W']NX[[.O;4&KY+"W=^0SG'K17'GNNW6E\* MC_<=\'95:RGG(CL%KS=;*G3!_+2O& M7C YUC?74F2).<=8IEGV.GD;QY)@(;,&JZV"XZ!6 42V HK;7$^[FF3&5>.1 ML^68S,A(1GX-WP Y0)Z;!MQ>JHP[?2ZU%TFEQ8(A+3H7)V %FG2;!P$CAEJW M#(D3[_:1NV'?NMD-W/%&O4><8G7T[K3Q=UU[PAV7$N2:2@G4-E__E#U$8[OL M8&=L,"\("T7))6+]5U$6&GN:','9K2Z[W2J(BL7"V358(6,]I8)ET$1MJ[97 M.Z*Q$E:>/A>AR%E9D3UEAW9L)'\?8+UB.M( M%N/(N_%&>Q>;IG6V6BP+C<1UK"LO3$ESI:2D=XNG**RV;NQB @<"-FIT9V!EV)C>S7*0@G^O,=0]3 BC9HA9U=Y2SOPB4121.)- O":\DD:159( :Z]#@]1 MA3T]:"XU-3IM!%?$X\5F1A=(CAA41!)+;H:%V7">S3;&5I@4SKEY1+HE>\CR MFATU"S<]EKIL6$XX*=]5TK.P;$&?1<,W'*PMGC)U7L/\T@7W%_^M&?KGSIPZ ME^T\;[&X2PKWJ] O[F71BM;Y\!CLW[=4VB4NFG=PL>.65KT4EK^\C6L=@@ZQ MP_>/T??#QY^?G^?'W"07:X,7L4:3@;EOV01FFF\.L]#W<.J65'XW%@<7!Q<'UP9_ D02;W8_7*;A> M08A3TU: M6E:P)A02L4Y#TOZ)6%X4#?M:\^TD4X#H,U2S,90:?S1,K'1Z^ (R4IE"AZG4 M"8E*GTR.PT"\05\>:0.OZSL&K$EK6;IGQN$AN;&&YV8-^WSHXW/AG8^]L1S] M7/7M[_4V>+2;?ORY!T;5HX-HU?RQB_6S.?#Y\_N6GB0<%-/N>WB?2F!C;.P< M9H&(1HE3Q3G,(I'E>+Y<$+%-BL4&:\7F+.5)#*EDR&#+#$@BL5,1CV]@ M"X4-PFZ!$2!B)(&+@IW@ &!.@HO@!\ K+8E#*NXNS4:+X!BVJ6)/4G.GR(D M3"5"7/!Y$&U_G8EN;0/;7V\YPQV_LIV=^$M_=NR5W7'I8DB,6TV)<:\I,4@] M,]E^E<0@D@COS1 X&5O0TSO1-E=E8O8J^RQ[@YWU8V4B0$YDRO'L>CQN%BLA MID@!@4!Y,.0*!D.,C559P>Z?!V'(B=NY@P'1@C<@"&'%Q6EG9[H6NPZX&!>K M,C875RR-DY 4" 'HE_@HI8^+0388YU ).Y,F>T8B1!Y'KT&=7Z$N,M]PBUXS M\D:H\_*JW<1C*],3A.9F@O LV3$IRTJT04E%CHS^NY<4+ZA<13?,_-T08;6# M[HL^0_&^&* W+M5ZZ=_IU>;&P.2 N=A[;3^26 +@ !-B-Y-E9SD7BXE"$,H= MT.5P0,&A52@2PXI\!5Y_AD-,$5O.+F=_8-D4%K)6 ?*8Y:0ZH"-<0]2.&F.L MQ#][*1*Y1@DE)_!ID'!@OET-O?@LX];UW5_K>6NYX4NFIPQ.BKD*!\ OF LD MRJ/E3RGZUGE:H_K8K\3A7!N9=%542\>_(SXAOQ+Q(O$\?]H^FUY?%5F!Z8AJ M*7AV-% 9B_#M83$ V!BLMAL,'C \ ]4*2:([A.4 SS&,@A2&(?%:83]^\87- M[7#)7/45XB*#T9)E)X>-$?P_3"2:%<)_Z0=W0P\\N[_UX=ZU([(>#L[R]QT( M*]BQ+7P$G; (,E%_$(PN"!A M"@]Y/M538Z,,;3;5IPV)2^7'UY?(!U^W?AVO ?4:_D_]S>NU^)5 MG/ZAWJ+?*>W>;_OE7>B&]2TI3#^+_NJ?EF]CBEM^)\+>?X&>7XEVR<,ZR46J M+2Z-#<,4O="@: "A&?Q#V)Q9Y86%LE3!BT 1!<0QB&G"% T5P+(#,<.72,7M M&_DB?@#/[.1/\G_B?^!9/L'?VGE<*U$\?D/K@(;&035']N*7-:6K>[2,QX3U M5S3G"Z(S$BW#U!WQLV\UX\C<8%'L]EH>VK >I5+C0,'&@4+VI^%@MR<>.CHMN-L%MRB=Q_59^2,<>B= M7_JC_J./;>\+# [,Y])5(+X212DW]$+"5XSUB(L8+& $EL%*KRSQ'!Z*(LDD MR R+(Q:/A66+J7BY"-@4, YKTY@&#;6F79MI_6V=+V)J[/@'2Q=V]]_@IB\; MOH1KO][1!HQ9IS_]3;JA3VP#3\;NOIIN#-.,K,.U%(0?$$'5BJF(XT4%V"PF M(>&'MP%6Q>NBL@8A%?,[^0.8BB[R7 H_#K._#B/I,!ABF!J*[*\.Z5?IBOSP MN5_.PGKLE92.H[R:P"B1(6I]8M$ K, #IL5N*[%/%)&*H UBX]OPXZL5" %; MA2):L,GIK-'XKCR)L]S-'^+Q/]]%ZP]69+5 FY6-* .5DNF7^@:X9R2QH6?N(E;SYP]NOS*B M@U/!T -X4N6F!RJGGJH;V?X).PM06\0-RF,]!FEE\@29L3)X<*IJDIJU@B&L M&I!XLOV.)A$Y:D2R9:PBWQ-K+YB\R# N4?[V*T.(='0*=+2I&F9<;T^U.P , MV[]B)U)LV+U;:U='=/YB_U='7S^T)P:Q0=W59B E+Q5*)M%A:+RT/ M-%H;O">E@UX9X@6Q.KW>P#RG)$G"/"L#H8R5LYHE&M2T9*E&EKTU'L.'%B$N MW(3.27[:O6@DVB>M,,U4+WMD1FB1PK1TE%-(P/T<3)-^:QI\_NCZ?\W:, 1: MG_P80GV[_N/+/]D?59]XJ/XRVO%\QOL_ZF\\A1$#-21J MND95TSC<,(?MR2+6]-[0%8@8/BV#95U*8&G1R*6"#*P$19B( \1' B 9&Z!N M:8 *6F;M@&!'S3\*X+ O/H)(?UK_^Y_TR\RAIO6']6]>KSL*&525TSH?+U8M MO 5.T'?J[^N[= "KD?1YFSY*?^?#*_ Q;.TB]E&IUH?*P MRD&GRP7L#D:LZ,.( C:JE]OFOU3/WL>1A^J$K_HMM MY&?GZX:5O9N.-L:>T&^'AW^76PAS'_ER^"_]F5SX]X*597CI;E^Z MY_JV?<.AI.H&RT'+CQ;&9H$6BS Q8VX&RJCNZH!='>,<2,*?]G20 MXG#9VF52&*ZRM3*?6O[8BKI$0I/>1YU_V0=[G5R^4S__T<+=)-Z[6]O73(3MC64% M&?GRV/@>\KW)R^35MF7)W'9^B_PT_XSM=[;#Z3P(U#H<2FHMIWAK%>'I# @R MJL,(GD,727"'J[I*W:F^JS)AM0USJ:"F,DG5)>(X<::X6%PO[A1/BD(*OFP3 M&1&+BU9O/AD^MBIK*K%=V>[[B1J;VX#H,N)]\/LL3R35 )%S9K0C=J'1>U[= M<;0):G]:LK7UX @W''9[M/I9QQ#^_BDC)L]"G?L?6OU[")Z%V7!YW9S7>+ZI M5VFC_GENY^7UTX:.'$]-_6( M^T@J*P=#H3+#.2>%Y"#K,>'VJ@C&7GHMHX2=QMWN"'?C_OK':Y4JIM? H?YDNP"#W'8P$ZDU^/)2K1QVKB?.^2 M <[G); 7AKU-S6VC8)>A:)-I\J(TBF-6#,W81E[(,<#W>#:.P8NF+B[1W]W6 M-*NT=?#ME4-O'Y:S8LR_-STW5W]L4/C>46.GPD&*OO^)AZJ?"@WUEA7TOOVF M,@MT-3Q473\C;]"-?4>-PGNC .^-A7AON/"P[X[U7V]YV($\206.J6B""T^8 MBP?NVJ[.#4[D=/+!6JO"U?(,Q_F2076I/$L^)?\HL[+LJR[1QFDSM<7:>FVG MQFL$<) P>(._&^%>K?G&N SW <7R2%1)O*I(XL]KCXX.3G__S3;PY:Y7H??$ MD[M6-=54+3]6RZPH>NT0NT/_&9N'773NTCLP!!?7Z6<_7?8$['5^Z>-Q?"^Z M\P=0[]STKNS4%&Z!=8%W>?K^;'86"S5;9C=J;(>Z M%Q0$B<5=9EK<)&; L+B[=>TZ/2?;E9.3G9*:6I:6[DK#3#P0* L68"N\(#W% MXV2#6J8_- Z&NQ=W/]?]8G25Y2,N#>:GI*7E! M;ES:S+3%:>O3V+1V!_I5:K[A,3,/BJC43K;H*_X4&K]2_A.,?R\Z9?CY/K947O737 M#?!ULLH_M7V#+N"]G@%FQ/H\[86-EJ<]398C0=:>5@NAQ3/+OX2<205K/9(H M=R7;^"LY)B@C +E;:E,8?OA)RS,^G;K+<-35^4_MF19_>YI)W;H7Q2L37^N M;%+53-F%IJ*7UA;?Y:Q_<--]1\>4KJW_/;Q5?6UFV9TE*(ZP0&.Y1E*[_WK$ MA3=_'7$!\S\O%@"W8\KW@S.Q!_H+4]U/.A@?-KG]1!GC7$Z'H\SMPC::2[79 MIG."B^,$/$5FR*/#[2,@M(QDTWSU809B==3I G[14B])"/(NMX.YZ/P!\P15 MX&Q.KD0^)R/9CS54G\S/!(O!>L#8\,M)P!# V_#LFFN,42VN)&!F#Y:X% MMTE0)";$RKC:$*%^V\*;82]((L50W&>;P7A?WCAL0$ETY,2)?8,9O?,>GE;5 M<^*V83?MJ3+CL%.J9_$DB'90KUIYFUUELK7IVB/:LUJ3QFD\3W A.'J^:0Z- M',X47[K.GW0U.@\YIH,K[DFJ*N\T)J!UZ9V5-!=M.%:WFZEK7;9[J;J5&;X+ M[;CR*5-GK",[@T:B_Q0[$(2:Y%>8+)3*94D%TFO<&?E3>(%]5\)&*5!PR; ]A9TC$#["(HD)C>EALQK+KA4;AKU@%$J" [4!& M89*8<\VUNN3EI8_SF:U'&*&X'D:V;*/F=^RPJ3Z%33B:5ML@L1RG$CF0,'V M?)G(X=GAVL-Z);F>/4=)6U" J!!M'_(D7U;B1 5!;-[S)< @YIUT6$(8E- Q M&C[D-B!V&&/<8Z&9='TU3![YI;UF'D9$#$N?GO!XC]>5PJVW;VS>/$*?0;C? M -A\Y5.LZV:!:Z,439S%>?1Z*,V@^D&?PBREU\/IWRG&)[WN3Z][8!MZ!+TN MI=<4#8'RDPJ:#]A-GTRQ& TJVD=*JU*S 0JF6ZU#)>(0A $]_L0EG5O#4(>-:C3E?1:K5> M/:$RJMJM>K%KO0NY# 6BW.O&O9_!WZ[H$/!N^NJ[CKH?D[VIXA@&XO:(4Y;;^J.^X,&LU M'/+=W)4M9^ #+\U>D_Y M;?/7GEH.S[=J.J8LC29HM*5J;?Y[.I?'9F%@-XGS\ .(^FVCQL MKF6@992%*2&!6357.1L)"\(K2F2L-_^ZR-($>BE>YFY=TXPH\VO6LX?YSA-? M6E9-6;A[Z%QA54/%O%!-W0+[^+N>R:ZJ6Z1VOV'PYGZ!T1M?/G2F9O1;#U0/ MV(EJ6T>/S9EW]%T4;+U]6#B_]^(#J^'W5SZE\Z*?H?/2#9R-]:%],-])TG"Y7*"LW)0Q%R6^5.MNKW I?%>I< M%<+3="1-L2C V8S&QV[LE,,[L7+B\F-B<7%2UQ38#4C8'GDWC,*Y.9W";&[6 MP*Q164Q)%LQJUY_C4W7KWQC12ATGJWT?]*9');\VO%9)$H[HS^ =@XZ,6Y*TON?FRIOG#/ M@-BYR\.F,76;](GA=>.FOWH+4Z=/TNO?&#K4Q$+(9+-!#S27^D?/,[745T,D M> K5=UQ@0JROZ1@U9;:5/+I:3QRCO)T^.5HBPKAO=#V -BJB9U(A3=20CB*Z MA@SG5QRFM/)U!W=AT+)LG=JZKF/;JK? 7 M.@;@KYUY&NRQ[K'O\;''P'&L M7-2;[A2+P^,YXH?^6H="(18$;) 0Z!*FFB3,HG'8$I&J99OLJ2YQSR2'(E@6 M8CE(/"O7'-(;T/Y43ZIL=YF:;@)# %*/*1JK_^2#TEV#MY34+6C;_(S^YM)G M^$U\U:"7X:>;[IBV]@L7''GQ3?U]?='![9;*"605VKYF3^"1$:_ X['I69Z! MTKV>A2%VF6=98$UH32H+L;K$)3(@"^6;-+3?O3=XW(VM+EC/\RP*UFH*@T1W MK2QP+#_!-S49"(,$U\"MK["UH.8TDBH.&_EB;:YGMG)L(QA)QCIH!'C M#.^2"0P:;JU,I-V_5F1$)F30D+=(#T<'C]I58O[@X=(M)^I*GLKYU^-;7]2O MO++N!'QEX<%)975;I\ W]"A>U\A%R'_^NOZ9/NMOAYPH63_V[?WKX*)3]ZZD M<9&8'FLQ/3I!"*R(C6"QR<30U$\W'KB;2&CC-,(BR2I;_QR12D"1R<#KR3$B M9 "C,3.9)YA&YA1SD1$8?[4#6V"R1=(8SJ:4*$BA)]+$?]K1?4H7^S?!DN>JEN2'[9K4-O;#S<.&S\\7&;8&[1V:UCQXTE":&P MV=IG,#:DU>4%1>_?]A8<..K."=T3Z.B/FNCH'K#N/HK#Q6!*8MI1UVD$ M*?&PZ2,I*G4..!2;O$?9&SJL,"S$VUJ0\7QD9>?D\'9L928ENY*2DOFC48;N);^G-C]-(1]5;[1A$2-&IVPU)$Y@[$54H M0_X:_%0RO\%W9HQJ@Z^A!C4U"8< 4(60E;;_4LCUD< M)T*!@YQ$#4OJ?*#:&::2Q,D"Q&1/H^!^O4E5(+Z+VQ%Z>X[-D??6;+VA98SZ_9N9,<- M'K,)3=V8U:=V*>1=)]_X\BUX UQR["EYZHRG01QKE5HVY_KPX:9>D51;3)P MV37>X\*W0;<@*5!1;/YJGD]6K0[-SDE8CA'.9@Z\ICW42J-#_Y7@9F(CD[ , M([@9=AAY/+(Y,0/,V'X'[UL]I'K'@_K]8_3UP^J.U]T&I_;O=NM[EX=.([*Z MZX:*Z:\06!J2;.V^QT'Z9&K=^L!:3%G8*O4 G]=;Y@'8Z 'M*C^G M0J=D98'7H_ ^(-JK&)ZX;'P>[Z^;L8I%M@*NDW190A+A/_YV.S8:CD=ST>RH MXFNV5;NU0V;L>M,5#4I]:-EM\P8UAJ9LN=<^9_BC@_'D-;UR)*3?!U<6'+KE M:53=.GI&8.']+S7"MPQ;AISC:_QG0 ##8V&&91<:^$/T9!6X! 'P@LB0_&FN M @*$L&)S +-1'G"0%<()3V@K-;JOC>?[>:.PPR] M\)?O#2\7>H7+P-]=$KL1\R,S;1LQ3)D9#2((',-B+E?/+(9G.,2S;"*2 MO-4T]Z_[7H9B&!6B5P;I'^S>>!SV[\QEZ+-:9N!-1$;]'B189!58BGEB$EI! MI#T67';*WBBL):D4S1V_XF6_@VB2$4JI7E#$]MBA8FM@O,J-?24]-1>CKQ7PH2$(U( M3X%G.9:93OQXP)J9Z4Q/]]=:K2FU3F<.MA41:P2ATU!7^I!TU\6]=0;"!H&K M,O5-&H) YD2,ZUP=W9$1DH@8@1F0@8G:6"[4L6HBP; (0_9QN.CL-KUEB[[X M+/O9W$VO/CIG_:M][[RW7_?_I[KOCH^BVAZ_]VY+-MF0$$)) FP@U+3=3=E- M#$(@E-!)"$W:9'>2';.-W=D4$"01 @J(**!8, AB1U1 111%> A/[ T1;#P[ M*"JBB/ []T[)4GR/W_M\OW]\R8=SS]QR^CES9W9F=U*X]'Q2,LGJ#"8*:5>< M':9=]F<8AQY?>1!W>7K9OO/'R;KW[QQSW>$[RZX[5[.*?N4LY #2/L[N:,Y[ M'DY-+P\:'4>_#A#R1'Z-EWYSA_2\#Y2Q&-ATZNAWCND,6DUW?5^]0S]%OUF_ M7:_7H^B8**37Q1O[&AW&*<;-QNU&O5&^SHMX1.S27SFQL5]7H*]?])1_T61Y MLE:?O/N>M>O/K[_WCGLT*^ZZZUQ(LX+^I^>5.>0HN47W.NPH3&COH.+%IC6F M [$'3%J#J:.IETEC8L)AN&(W&5"LWF2 Q*%8J-)E%$'VPX?BJ6OW4"Z$.US M.&Y0OO3B&G083%$F'RAN1)UU?;4IL"&-ZQN+XK6K=1N,L:N-RB^\R-G0MH-_V-IL(XO2^N8X(I7A.+?1UCZ3 MP_O+EE.8H-ZQHZYJ^_"I#]U\&=I^V'!E8]+LDO)K^P\?[)^.[TTZOZ_/^&%3 MQ/4+W/,UCT<%IHP:6%H8A9L:6NV+IX1WT?OIKX(W'V?9:WX:=:82#S)JDXE. M$^W3:221<@Y188!O>_:6GYX8?AK^U?G-'?&['9R/=2%'\6RL:VBH/O_09J@: M]X)E'M#]DUU7]D?>IXTHC=*,3J%?N)J2HNM-;=&N2Q)M="GL#77ZLQ'MXP&P MM[53 2'TJ)LO:E!2Q\*H?KZHV,X^DNZ+)>USY"\<.*&^$RK=O<@XP;[QL[?Z M8X]MOQ)FC_SUV1[2[1FX@!Q1,Y^_/GQK>%ECPYS)'^4,R\RSE=A'#QQ_?7&% MUI_CJ?1PDV[*2%_D63)_TO#YYPKR>A3D6[-RSG\XJM0_8EB YD$1^EXS6_LR M^PW9/8-BKDDKRAB5-C)#F]CE.7S?(&/'U'@4J^W7,UKS KX/Z5$"GO!T^_8I M._$$E(SOV]%S>O>.N&/,<]!K-&+:2V!59K_I^MCXA7&:+HG1VMYFE+JP6_N= M"0G&G3$+XY)WIJ20G7AAM]XU ^/&Q9&XY_"?V\TUEFZXVW-DXC.9+;=USH#S MY8F_9D!"'"^./R[#<\7LBWS/%4/Y_I5^?IPS0VK;1MCMT#[V3@7LTUU[)VH^ M0R=#'SV[=VCH0R] .T7\&.#CP9G!#,YNY_H'9P6+B@#TIT<9T%VT>&%EY4+Z M7_/*TOIEZ?!O6?U2W_SY_J7UR]-[]4I?7K_4/W_^_,#JU0'_ZM7TO<>_SK+W M'N5?8, GL!OV';'/PM5-'EP;Q6=DL-]>^.LLNQZ0?WL!GV"?C-)9F5E]^BBS MW@9:K>S-6[L\ZY0\*]J(#,JL?G^=)2DZ^BMPD]DW;IXX@9!Q!^P;4_5)N6P& M7&V0NPQ9,&.TO&_JBT,H<5 ,@=,2QKGQ),H,.Z$,^ALK[%=/M6NCO MDA8!?8I7,CB%P>D73J(BH \S@3Z%1N@O9C8L9EXH!BZE !,8WA5X%0.7>0"I M%L5,BV+@0N=0NQ4#%XI7L/Z)#)_"5DVED.E2S'0I!EZEJ R5 :\RV(7W0I5, MKTJF427TC$93H<<-, '@-#8ZC8U.9_W36?]VM!TH[&#QM@,\1?$=%XY@+8UM M@!"! L9A-@&6,SPJ6S.- 9WT!X:AP A#K&)4@-H9W@A@T4,%C,XG8U"]&(3 M6V5BJ[K0^ 18R& 1@\44TO@$"/&)DZD6 !,8!!UQ"EN5PE:EL%4I;%4*6Y7" M5J6R5:EL52I;U9WZ""#$.4"(-( )#._*8#<&P4< ;6QF*>L9QN (!L%? ,L9 M7LGP20R?PO!IC.9T"JG7 .KH*(US@!#G.(W)D,9D2&,RI#$9TI@,:4R&-"9# M&I,ACAOJ9%R'D@WWRK@> MI1MVR+@![31\+.-1J&_4:AF/1H.C=LFX47LNZKR,QR"'Z:R,QZ+I<389-^D> MB+M5QN/0L Z61\PVBZ7 /-'-F\?X?7ZQ,<";A_B# 7^0$P6_+]M01G2( MG,C#8I\KQQ\T^V$D:';ZPSXQ*/"A;%6R" +E_BH@,59PNOT>+I1I'L_!7*? MF2NX,)T;4KF6!KEZP5=C'E==+3AYL[7080.3 'F?R'LIN6"C.<3Y0F:PC%!M M=O$AH<:7*=N SN($&/3Z@[S9'?9R/B$DFIUN+L@Y15@0$@5G"%3A?&88:Z0Z M"V#G0)!W\4X^%/('F5IF#NB'G6YJ(D:*ZA_V\>9Z070S2WC]?A==37'02 1! MG&#(D-(GUO,^4>!A-AA## <;LYEQ_75\D /_BD&>$[TP0N<[P^#C$.45\E># ME$R"ZK#' R@3%;A[_$!8YB]/%C.)SAA M.A<(\&!$GY//-K=%C\_,-X J7M[3: ;-0N!K#R7A%3S,MM2C3#"9G1-65/'F M< B"B)F2GQ.FLH:=U/CF:H@F$2B"2J)(@P 4#_+@=!%"!GP4 H.Q<()#+U?# MS15\0)H7G9F2R6"Y2P@%/%PC94%7^_CZ4( +@&@PQ04BBD*($J;3 T&_U\^H M9;M%,5"4DU-?7Y_-R='KA.#-=OJ].?]NC.HG12!P "I>ST2W0/4 QU)?UE/K M"R%FV#K.$^:JP#S %P02F8&NE"M*7M' #(4# 8_ RU%)>ZAB58WF1G^8$G;2 M@ )CLB22 @\"@$4A^! 2R ?3N9H@S]-@HS%X)?'DB2X:")0PT+^B8-3 ,!XT M4X.R*(*.JG"(ND&2#":% Y1,-8TG=1K8*A 6J8W,4X&^%QP$ZVN#D R++\0#O M%*II@$.\!FCJB+2^@?XLKR4ZF8R)(K/3'VB\@M#91F-9=9LTM+;,"?,A.5@# M'IX#@8)\G<#71])N\PU;&X0B!/JZE#IS*9=,)398H7.*5W13MMEH'"*/E_G M9U[6762\TF3C9+[*?!7A?UD_'_9P5@N+>?0(,L/UE@7^"@";B-RP"S"C,^#/#3D) -;!>1"%VQ$/+P^PZ@"Z8 M60*X &OIW+'0!N'/C^IA]RNR7@$Y84X(( ^476RM&64Q#E=>:;YH[22V(B1+ M1K7*ANLG.XRWK8] M. @_\BTY;*XF4K:Z'/CZK_"TM1JCY&45I7 M"4<"'%';F%$%DT1D-J.A_3TJM*%P1:9J!-=0XQC&=$R4(TZQ037,I-2DWC:K"K)M_;(> IL?9D>*3[/842-;_7<14!DU*2HD>G[(4R63)-M3#21](G/0Q3C7L%YI?3V,"++_Z!P/^%V*#S_ M&ABKDRTM45#DD:J%1XX,,[.@4]9>8![SL#D!EC=2)/K8RNQ+XEI08\H,HPVR M5[Q,%AJ5=7(N2GGM4:7PLJ/&B)B0Y@\.S67K M):DI72<;;8LRB;N+62O \J-1U4+A3=?7LW&.62(H\Z#9(UE19.L5B17J 19! M7E;G%-FRV7E-A+$BJ,LY0)?^9;.\C*R]3KGR9C/,"S/_VW6*_R)KH*2#)(L7 MM)[(_*GXPR?[0C7V!;7"\2Q^J$>I7ZODZ)'T#<@6:8N@JSVO7'J^4BHF MC9D \XX@2]YF8V6.XK$JQK>1G=T4B9UJA9(B,QPA25O%DRI 6RV4\E"0)0_) MN5G#J/!J95/JX-5:[V**+K4B*!)+\E^]Q90(EM8'F1ER:E)3CMBJJ6)=2JY,Y5:GG?%X^ZU[N[VHY@Z_D$5\J:-;U#>"0GR_O[2 M_8+0A=]&'[K0AWXSS.7_R)T(84*?A*5??8'TR("B M4#1('X-BD0G%H78H'B6@]B@1=4!)J"/JA#JC+B@9I:!4U!5U0]U!PS34 _5$ MZ8B^5=$']47]4'^4 5[* CER0!HK[.-S41[*1_33/0?L[(O0-:@8#4#7HH%H M$-AT,%BQ%')I&!J.1H#U1Z)1:#1<,XR%JX+Q: )PJ4D#7PR[. _K[6([,816"[F/KP/8-$(=ST3QT M YJ/%J ;T4+4A)K136@16HQ:T!*T%-V,;D'+T'*T MV*5J+;T"IT.[H#K49K MT%JL17>A=>ANK$/WHOO0>JQ'K6@#>@!M1)O0@V@S>@@;X+KX4?08>@)M04^B MK>@I]#1Z!FU#V]$.]"QZ#CV/=J(7T"X@.]B=Y";Z-WT7OH??0!^A!]A ZCC]$1] DZBHZA3]%GZ'/T M!?H2'4?_0E^AK]$WZ%OT'?H>_8!.H)/H1_03.H5^1K^@7]%I]!LZ@WY'?Z"S MZ$]T#OV%SJ,+&.%H;,0Q.!:;^)TW OWQGUP7]P/]\<9.!-GX6R<@RW8BFTX%^?A?%R [=B! M"W$1O@87XP&8?L?S(%R"!^,AN!0/Q!0>C":>A6=C#E=A)W9A'E?C&NS& KX>UV(/]F(? M]N, GH.#.(1%',9UN!XWX$8\%\_#-^#Y> &^$2_$3;@9WX07X<6X!2_!2_'- M^!:\#"_'*_"M>"6^#:_"M^,[\&J\!J_%=^*[\#I\-[X'WXOOP^OQ_;@5;\ / MX(UX$WX0;\8/X8?Q(_A1_!A^'#^!M^ G\5;\%'X:/X.WX>UX!WX6/X>?QSOQ M"W@7?A&_A'?CE_$K> ]^%>_%^_ _\'[\&CZ #^)_XM?Q(?P&?A._A=_&[^!W M\7OX??P!_A!_A _CC_$1_ D^BH_A3_%G^'/\!?X2'\?_PE_AK_$W^%O\'?X> M_X!/X)/X1_P3/H5_QK_@7_%I_!L^@W_'?^"S^$]\#O^%S^,+!-&?HR,:HB4Z MHB<&$D6BB9'$D%AB(G&D'8DG":0]220=2!+I2#J1SJ0+228I))5T)=U(=V(F M::0'Z4G222_2&]U)^I"^I!_I3S)()LDBV22'6(B5V$@NR2/YI(#8B8,4DB)R M#2DF \BU9" 91$K(8#*$E)*A9!@93D:0,C*2C"*CR1@REHPCX\D$4DXJR$12 M22:1R60*F4JFD>O(=#*#S"2SR&S"D2KB)"["DVI20]Q$(->36N(A7N(C?A(@ M5D!;F5K"2WD57D=G('68WN(6O(6G(GN0N]2-:1N\D]Y%YRGR[;%_9XXGU^ M'_WL1/#5!'DQ'/1IO&&K)B!8HVH\C0%WOBU?1BQV[=!PT&]P>3EGT.^+IK=M M0TY_D-=[!9?++^I+JH)\':_G6&,H\=?X?7RM@9-:?:F3@U5ZE]24ACQ:D9SSK#(ZSU2,UKJ]+!&.QHX:CV4[5AIV":H'PDS0]*3874&6)-U$0G[Q(\'BY*E!']1&F:R!I=91",I@M3 M&%VI<@JKG*9)S5S6:*=1B><"T WGO%Y.-]'-BYQFO%O0<9Z F].Y>(_(&?A M2/ [9!0X^4T(A?6!-R"2?J B1H;B$?S#4X/YZ68+Q0.\$'!']0'^!"0BV:? MD'GX:M' L'# R-H@_2Q.&G3YZWT25N47W='R-)K>2>]U1K#SPD+=9R']SEYG=L?#O$F<+;'7T/O/_O\HI%.K@ER'C&@HE5B M5,4PJX7^HXA51BPJDJL@-@7)4Q"'@A0J2(&"V!4D7T;R%#HV97F^PB)?H9RK MT+$I/39ECDVADZ^(FJ=,SE7$L*F(PMVFR).K(LI0GL+"JC)5*-L44?/4R0KE M/$6>/%4OA7*>LCQ?55"EPWH,X4"5Q^^L-8 /::N3CCS54AL4Y6,QY.9OYKT00EH*=*$ ,-$JG9OG@(5+X+Q^ MGRO&&P[)0<7'1> 0]:1L)!&NC_%Q 3_]A##@IA7(Q_*6=\+2:*Y:$ JLMCR' M@CD*]2/ X_9<_0BK(S]/:O*MK,G--?H#O$^2WU B%3<#)[4Q0Z@V86^UAV^( M<;;AVB$TF9T #$/E%;S4ZH=*59!GC78HG<<#B!D>0:DF@M)P.J,&0-1PI=S4 MR$C,B(@U[H@U(ZJXH-8-0%\F"AX7KQ=88RB391%D6'X%/C< ;VW =U.&:D+&$UG=6PJ&6*JBA9*C4[0&L!IFRQ@E2 ZKS M4\/%1MJLW27,8_V15@]'6MVO6IV%#IQM;+D*EF]5,9N*M8WFJ5B^BA6HF%W% M'"I6J& %%A53>10H/*QY*CVK2L6J4K&J5&PJ%9M*Q:9*:E/ELZGT;*I\-I6R M3:5L4RGGJI1S5NRB-7Y9&K\LA5>>2I//)4'GDJCSR5 M1Y[*H\TN>2J//)5'GLHCK\W.ZHH"=46!NJ) 75&@KK"K4ME56>RJ+'95%KM* MV:Y2MJN4[2IENTK9H5)VJ/HZ5!X.E8=#Y>%0>3A4'@Z5AT/EX5!Y%*H\"E4> MA2J/0I5'H;3)G-^FF[2")H"RI.3*$?0*D MCT-N"^6V1&X'2Q=[!04V^2G)*$10!X0O7 "'0M_;.8+Z:GC9_LK!D]>LO+J1,W M6K?M>OR]7:W-"1TLS9JYEF92U:JA=PGB';T^//L[]^3Z7V_[NO?V#Z:];S&I MPF(J4X4UQA*MUU1J]8FDLL+:R9)$#XR)<9/ :!7LZ;PRGS/;FF'I1PEFTM2$]F[_ MN3QIU]*6V?TZCKPN9]2JVB6K?LF?."7_N[<+9E:-*9^0-V?/O.JN-[]VM/_> MZXV_V0_?):[Z[?8M6[?7K3WUR$CGT.'9M3&WCQV5L?SDE)'+WC,<3\[\O?G1 M*8T5%KNAT[\F/-Y\$]97O6SR[^_(N7.FYT-@@= MYCV113001AN;]EJ:7K'DZ:/ ^3KZB[;:OI;>EG3EV();.LM/[OB=H4!V'7WV M$12DC^Y "&@JNR9B?$%++,B22X^Z:S,M_2U]6WNWIK?TD!E[SF6_-0&LF%S,)HXQ-S7\XUS%9]]_IE]R=-/: M]3-C[_KBP9=V-R]^=?;GGS[1]Z/]#XYR?;P_Y;H7'R^,>M_18T/NLIQ;[OY^ MER%M8&E)M&$[GYJ^:\2[I0N_W_#F ;*MPYL3]W?:0 M!PY6O#%_P&_]BYX;MQH]Z#7>-../F16_=GYF?F)-:URG8WL[+IQ] MH%V&KT5[ZOM?&_J\K=MW,N^ZF<^7V7[.A>S;"_^SY.P;OKO+FD]7E \;A"5&#L9-K5\T&<>P@5X:P=+>]IM2(PI#0>K M.%\=O4Y5_&$$?[BY>I&W=K6DT(Z8Q Y2AWD(?622/B%'[V!8NUNZ2O[K* _3 M7 HIJ22G;2YD:EY;VM+#7"5M_U=J13/N<6FZ-N-V"/J-A$;4(P>?WO3Z(?.3 MQODW/[XD_-.VL:<^?:7=[AKNQ8VNU(]?^.-@[F.++#=/6;#\2.W1@O7M=K_] M0\//]9L7^(MWW_&D::?[5\_J@R^69STV8L#I'>_/F)5"[C^;4]MMTYF-=V]. M?HU\?N/H\B_C9O\P*'7!\Z9C _=O^W3)B[/F7F_-UJQK2GQXN/D-:\@T.>M0 M0U[NFO;KVC]_S)WSZ%=?[KEE>?]7EZ4MJ7[QIBF3_>'=Q8_V7C+C8'Q2\?V+ MOIOXBM&W]_R^D4>?-R3.&(]?V>;M;PP_W6P^<^JI'ER-[GQD^Y.[D6:W= M;CL^\_3)&T[-?ZP*KSP])N;86STF/;SFT):E=5M.[C3]&H*1I42J&T6P5REHS6NUM5C^KFY(L1(9 M*D-*6!5)9%7DWY40K <)60F!R-S4Q=))B6]-8BR4$ @T1Y8U*S_WTD("=7ID M[1_?3=E3FFJ]N7%=QMK=S8_C#U)'']IZRQ3?IU']-LY\[> =B5]KRTT_#N^3 M@QQ;CQ^X8^S=[_6H2CHST)XV+F!=>&J98\DSWWQS)SK_9N7:L>GO/-)G[-PM MSW(EO_1_X^L#AV<>?2%C\;7;[]M^^//)%U[:MF_!Z3=CU_]TY_F,=Z\I3TEQ M]#DS<*2E6;L;_O>5\[ADU89IA0V?OEG&5SNZC@[ON32/9UUE9M@M^5*&9@^! M"^60.=<\/ESE$9SF\4&X@@TV7IRQYI*PZ/8'!;&1I68>;-(*VE*3'N8KJ=FT M[2HED(M 3&+'MMP,AD.B>2POUON#M=9K+(72!-M$Y6%D^J0O)[('34/RDZ87 MA4@PP)G[.OO![CX;=C3,O[U4ZHJB0_PNGIVF:0&PP=;]:I+_I5TG=RWX\:;O M/[./^U,3[W@IZIWE\^\[>_N-76+WU)X<7+[\V+NI(Q)[??>*<^X?$_B3[SYZ MS>F?5M^;\>?/U>^E?WSF]/V^+H4%N][:6!?5K4>?=(]C59\O%I5M2;EEPU^] MFC/C+=_,>:SO-_4C)YSZX=#O/TU\S__REU[CRL,?N58XG\X:V^>WQ7'GO5_V M6_?%XN$W9+7<^,WDE4_4[,FUK4HTGWND9X>[O7L6C:IS:]^?DSDC[>Q24^^_ MNF>MRO@:5X[YV9O?M_G3P[73=WQP^-&FOV8=NFFG\[ZW>IQ[Y)K!PM.W%FW? MM6U]NYE[O\ML7M;WKXJHM4>W8_/;?SS8^>N73TX(V#_?H1M1/L+O^.[5;SSS M2A?)R=^,6\$B]UXQD4MIGUD[P$+]%C.[901N^7TH-G32T!V!DI@$=TS]=]ZS M6*5R $LLL(EH[=%B_KMR$'!RN2S]NTKIW]'204U_HF*:RPI!@CY:$FXPU"[H M0IB=)* V]+"8-W6SI%J3+9VEV$E@(9,[1"D0>;D2LSAM1VV'J-,3OOGS_( ! MKH(;W&]>U_#PI\_OLUN:%M+QGMI&2_T&YR;N?ST=F^,#.X]WC3_<+V^'X^ \ MS>L[=U^AA&TIZO3OZ1VJ7=C=^[ M=]D.+W4<^V3@NS=O&_A4\]I3FZ;M/)'=^]UC-V#ZY,$F_>T)(Z('_9':N;&F M9_IG+[S_^?@M*:?CCGZ6W71HX49/^;A5X4TOSYKYV]SMEF8X+S1K?I1+V.PE145K=XL++*M,4Y?O'%]\V5;D_V8% MH86QP&J-O-2P6*PVAUH8#UZL5H*EG;3#BBKS> 2?7P@I@6=(3!CJJ34/#_KK M>/,D>E.V1MU2&3MTN-+S]]9K+<62JOFE0HT@_RFK2K3Q'YRP[XU_.J$,8N_:KQPS8)[DS6U MC=Y[U]6GWUYY[M5#.O?((\>O&^QX\)#QY-=?[A\^\^'VR]8II>I&*%7SF,6[ M)K)+E(LJ@6&A99!4:PKA"C&_-;?5VJ*\I3"D8DAN%O5KUF551QUBI>=_IN9= M8?^BL80C=EB"I>8J=U@#U5FD)?KN+:[AVD2&<$!%:^TE79L%T//)L<_](#M7//S-_O>.V7#;9QHQ*?_25_ M2?'T\^DO%/E>76#I@'[YL+[SCOCGSSZ[=Z5VW35R\N7Y_RCX)YOU_IK_CJ7 M5Q=OAV=^F[WKVR=_FM_HW#Y9U(_ZO#:-NB>^K>UMG0[>% MJ?_NU:5+*IVV:>&$09N7_T!6SSO3O+7*-"7FXQ[M"U]\[ E[X_RI2WYHG?&/ MV@W;M_NSWM.V3+E^XH1%^6=:BIY"LT8^US+AR:]7'YCS\8>-IU;^8-FP8>>: MP14IG?>+V\37#A9N&:?[P?7PD2U#1B>WO&;*[U_Y4-*S;RVZ?;MG3_ADYAL_ MIPU8WJ)_L&;Z,W%%Z2_8-LC%KFLS]D"7FP96S?_*]?$5[N!%ZW49<1J2 M#"Z? :>N"-_&M-V(Q.!:=41G;0>GR4)+@<5A==@<]+S8,]*UL*\Z,S3]7W\T MA'Z]X%O3^L\WQWU<9UK:_W(7U$?MFA^W+:'F[L$;;M[<_LWWQ#-?;(E?_-K8 M%BVZ[?0=B;< M__:9=L*SFJ>:GQOZT2=/F+KOO/[\EX] -/\_A<5NGPIE;F1S=')E86T*96YD M;V)J"C$Q-" P(&]B:@H\/"]4>7!E("]&;VYT"B]"87-E1F]N=" O07)I86Q. M87)R;W7!E("]47!E("]&;VYT1&5S M8W)I<'1O<@HO1F]N=$YA;64@+T%R:6%L3F%R_]L 0P$%!04'!@<." @.'A01%!X>'AX>'AX>'AX> M'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>_\ $0@ M7@!# P$B (1 0,1 ?_$ !\ $% 0$! 0$! ! @,$!08'" D* M"__$ +40 (! P,"! ,%!00$ !?0$" P $$042(3%!!A-180'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H MJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V M]_CY^O_$ !\! ,! 0$! 0$! 0$ ! @,$!08'" D*"__$ +41 (! M @0$ P0'!00$ $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P M%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# M 0 "$0,1 #\ ^RZ*** "BBB@ HHHH **** "BBB@#@_CYX\N?AI\+-4\96FG MQ:A-9/ HMY9"BOYDJ1GD D8W9_"O!M-_:6^,VIV$&H:;\ M7O;.X0207%O:W M*?\-$?'/_HW;7__ !O?_C5'_#1'QS_ .C=M?\ _ &]_P#C5?5E% 'RG_PT M1\<_^C=M?_\ &]_^-4?\-$?'/\ Z-VU_P#\ ;W_ .-5]644 ?*?_#1'QS_Z M-VU__P ;W_XU71_ G]H#Q5X\^+$_@+Q+X$'AFZM[*2YF29Y5G0KL*JT;J", MAP>>V/6OHFOE'P/_ ,I%O&7_ &"A_P"DUK0!]74444 >)?MQ_P#)M'B7_KK9 M_P#I5%76?LV_\D#\#_\ 8%MO_0!7)_MQ_P#)M'B7_KK9_P#I5%76?LV_\D#\ M#_\ 8%MO_0!0!Z#1110 4444 %?*/@?_ )2+>,O^P4/_ $FM:^KJ^4? _P#R MD6\9?]@H?^DUK0!]74444 >)?MQ_\FT>)?\ KK9_^E45=9^S;_R0/P/_ -@6 MV_\ 0!7)_MQ_\FT>)?\ KK9_^E45=9^S;_R0/P/_ -@6V_\ 0!0!Z#1110 4 M444 %?*/@?\ Y2+>,O\ L%#_ -)K6OJZOE'P/_RD6\9?]@H?^DUK0!]74444 M >)?MQ_\FT>)?^NMG_Z515L?L[>(O#]M\"O!4%QKNEPS1Z-;J\7(L@P65AU49X/%>'_\,5?" MS_H/^,__ ,MO_D>@#Z"_P"$I\,_]#%I'_@;'_C1_P )3X9_Z&+2/_ V/_&O MGW_ABKX6?]!_QG_X&6W_ ,CT?\,5?"S_ *#_ (S_ / RV_\ D>@#Z"_X2GPS M_P!#%I'_ (&Q_P"-'_"4^&?^ABTC_P #8_\ &OGW_ABKX6?]!_QG_P"!EM_\ MCT?\,5?"S_H/^,__ ,MO_D>@#Z"_P"$I\,_]#%I'_@;'_C7S%\.[JVO/^"A MOB^YL[B&X@?2ODDB<.K8M[4'!'!Y%;?_ Q5\+/^@_XS_P# RV_^1Z[3X.?L MX^"/A9XO/B?P_JOB*ZO#;/;;+ZXA>/:Y4DX2)3GY1WH ]EHHHH **** "BBB M@ HHHH **** "BBB@#__V0IE;F1S=')E86T*96YD;V)J"C$Q." P(&]B:@H\ M/"]4>7!E("]83V)J96-T"B]3=6)T>7!E("]);6%G90HO5VED=&@@-C<*+TAE M:6=H=" X-0HO0V]L;W)3<&%C92 O1&5V:6-E4D=""B]":71S4&5R0V]M<&]N M96YT(#@*+T9I;'1E'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX> M'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>'O_ !$( %4 0P,!(@ "$0$#$0'_ MQ ? !!0$! 0$! 0 0(#! 4&!P@)"@O_Q "U$ " 0,# @0# M!04$! 7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*" M"0H6%Q@9&B4F)R@I*C0U-C+CY.7FY^CIZO'R\_3U]O?X^?K_Q ? 0 # 0$! M 0$! 0$! 0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$! ! G< M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B7J" M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(RKR\_3U]O?X^?K_V@ , P$ A$#$0 _ /LNBN#^ M/GCRY^&GPLU3QE::?%J$UD\"BWED**_F2I&>0"1C=G\*\&TW]I;XS:G80:AI MOP"U>]L[A!)!<6]K=R1RH>C*RQ$$'U% 'UK17RG_ ,-$?'/_ *-VU_\ \ ;W M_P"-4?\ #1'QS_Z-VU__ , ;W_XU0!]645\I_P##1'QS_P"C=M?_ / &]_\ MC5'_ T1\<_^C=M?_P# &]_^-4 ?5E%?*?\ PT1\<_\ HW;7_P#P!O?_ (U7 M1_ G]H#Q5X\^+$_@+Q+X$'AFZM[*2YF29Y5G0KL*JT;J",AP>>V/6@#Z)HHH MH \2_;C_ .3:/$O_ %UL_P#TJBKK/V;?^2!^!_\ L"VW_H KD_VX_P#DVCQ+ M_P!=;/\ ]*HJZS]FW_D@?@?_ + MM_Z * /0:*** "BBB@ KY1\#_P#*1;QE M_P!@H?\ I-:U]75\H^!_^4BWC+_L%#_TFM: /JZBBB@#Q+]N/_DVCQ+_ -=; M/_TJBKK/V;?^2!^!_P#L"VW_ * *Y/\ ;C_Y-H\2_P#76S_]*HJZS]FW_D@? M@?\ [ MM_P"@"@#T&BBB@ HHHH *^4? _P#RD6\9?]@H?^DUK7U=7RCX'_Y2 M+>,O^P4/_2:UH ^KJ*** /$OVX_^3:/$O_76S_\ 2J*NL_9M_P"2!^!_^P+; M?^@"N3_;C_Y-H\2_]=;/_P!*HJV/V=O$7A^V^!7@J"XUW2X9H]&MU>.2[C5E M.P<$$Y!H ]5HK(_X2GPS_P!#%I'_ (&Q_P"-'_"4^&?^ABTC_P #8_\ &@#7 MHK(_X2GPS_T,6D?^!L?^-'_"4^&?^ABTC_P-C_QH UZ^4? __*1;QE_V"A_Z M36M?2_\ PE/AG_H8M(_\#8_\:^8OAW=6UY_P4-\7W-G<0W$#Z5\DD3AU;%O: M@X(X/(H ^M**** .6^*O@;2?B/X&OO"&N7%];V%ZT3226;JDH\N19!@LK#JH MSP>*\/\ ^&*OA9_T'_&?_@9;?_(]?3-% 'S-_P ,5?"S_H/^,_\ P,MO_D>C M_ABKX6?]!_QG_P"!EM_\CU],T4 ?,W_#%7PL_P"@_P",_P#P,MO_ )'H_P"& M*OA9_P!!_P 9_P#@9;?_ "/7TS10!\S?\,5?"S_H/^,__ RV_P#D>NT^#G[. M/@CX6>+SXG\/ZKXBNKPVSVVR^N(7CVN5).$B4Y^4=Z]EHH **** "BBB@ HH MHH **** "BBB@ HHHH __]D*96YD%!$4'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX> M'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>'A[_P 1" !> $,# 2( A$! Q$! M_\0 'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ M P4%! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R M@@D*%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+# MQ,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! M 0$! 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W M $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8 M&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ M@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G* MTM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#[+HHH MH **** "BBB@ HHHH **** .+^./C2X^'?PLUKQE:V,5_-IRQ,MO(Y17WS)& M__&J^K** /E/_ (:(^.?_ $;MK_\ X WO_P : MH_X:(^.?_1NVO_\ @#>__&J^K*\F_:/^-NB_"#P_&[11ZCK]X#]AT_?MR!UD MD(Y5!^9/ [D 'EG_ T1\<_^C=M?_P# &]_^-5O_ 4_:"\7>-/B['\/_%'@ M#_A&+G[+)<2K<-*DZ;4#*#&ZJ0""#D]JJ_LS?$3XV_%S6?\ A(=771]$\&VL MA#FWL"'O7'_+*,NS' _B?MT'.=N=I_\ RD:U'_L##_TDCH ^J**** /(/VS? M^3:/&'_7*V_]*H:U/V6?^3>O!7_8,7_T(UE_MF_\FT>,/^N5M_Z50UJ?LL_\ MF]>"O^P8O_H1H ]+HHHH Y3XM>.]'^''@/4?%>LMF*U3$,(.&N)CPD:^Y/Y# M)Z"O@?X5^$_%/[2OQMN]9\1W,QT]9!<:KA.-JCL S')'.K^V M#\1K_P"*GQ:9I=U]ALX8CQ=WC-L=_0\_(I] 3_%7VA\ _AMI_PM M^'%CX;M0DEX1Y^HW*C!GN& W'Z# 4>P% '8Z%I6G:'H]IH^D6<5G86<2PV\$ M2X6-%& !7S)I_P#RD:U'_L##_P!)(Z^J*^5]/_Y2-:C_ -@8?^DD= 'U1111 M0!Y!^V;_ ,FT>,/^N5M_Z50U4^#/C#0/ G[*'A3Q+XEO1::=;:9&&8*69V+$ M*BJ.2Q/05;_;-_Y-H\8?]&O">NHWV6\TE-LJ? M?@D#$I(ONIY]#R#P: +GP=_:2^'GQ,\0'P_IYU#2-4?)M;?4HT3[2 ,D(R,P MW <[20?3.#4G[7GQ*/PX^$=W)8W'E:WJY-CIV#\R%A\\H_W%S@_WBM?GU\2/ M!_B7X4_$2;0]1=[;4=/E6>TNX25$B9S'-&>HSC\"".HKH/BO\1_%7QR\6^&K M:YM5-[%;0:;;6\1^66X<@/(!_"7FJ'CDNT5E M.3P03D5W7Q-\&Z7\0/ VI>$-9GO+>PU%46:2T=5E79(L@VEE8#E!U!XS7A7_ M Q5\+/^@_XS_P# RV_^1Z .E_:8^'G@GXP^'+6*/Q;H6F:YI[[K.^>YC<;# M]^)P&R5/!]B/<@^=_L\_L_>'?A[\0+;Q?XC^(?AS5I;!&-E;VTZJJRL"OF,6 M;G )P,=2#VK?_P"&*OA9_P!!_P 9_P#@9;?_ "/1_P ,5?"S_H/^,_\ P,MO M_D>@#Z"_X2GPS_T,6D?^!L?^-'_"4^&?^ABTC_P-C_QKY]_X8J^%G_0?\9_^ M!EM_\CT?\,5?"S_H/^,__ RV_P#D>@#Z"_X2GPS_ -#%I'_@;'_C7S/H-W:7 MW_!1*_N;*Z@N8&T8!9(9 ZG%K&#@CBM;_ABKX6?]!_QG_P"!EM_\CUU_PB_9 MK\"_#'QG%XKT#5?$=S>QPR0B.]N(7BVN,'A(E.?QH ]JHHHH **** "BBB@ MHHHH **** "BBB@#_]D*96YD7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+# MQ,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! M 0$! 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W M $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8 M&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ M@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G* MTM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHKX>\5?\%./^";/@7Q/XD\$>-_\ @H1^P]X.\9^#M>UCPKXN\(^*OVL? M@+X>\3^%?$_A[4+C2-?\.>)- U?Q]9ZKH>O:'JMG=Z9K&CZG:6NH:9J%K<65 M[;P7,$L2@'W#17$_#GXE_#GXP^"= ^)7PD\?^"?BE\.?%EK+?>%O'_PY\5:% MXW\$^);*"[N-/GO- \5>&;_4]"UFUAO[.[LI;C3K^YBCN[6XMG=9H)47A/CA M^TY^S9^S)IFA:W^TE^T)\#OV?-&\47]UI7AG5_CA\6? 7PGTSQ%J=E;K=WNF MZ%?^/-?T"TU>_M+1TNKJST^6XN+>W=9I8TC8,0#W&BOEOX,?MR?L4_M'^++G MP%^SQ^V#^RW\>?'5GHEYXFO/!?P8_:!^$WQ1\66GAO3[O3["_P#$%SX<\#^+ M=_ MP^_9]_;&_96^.OCV/2+W7Y/!'P;_ &A?A)\3O%Z:#ILMK!J.MOX:\$^+] M-]4T"T\5Z9X-^-7Q^^%'PL\5:CX6O]0U32;'Q+8^'O'/BS0M7N] O=5T/6M, MM-8M[.33KC4-'U2RAN7N=/NXH0#Z@HJGIVHZ?K&GV&KZ1?V6J:5JEE:ZCIFI MZ==07VGZCI]] ES97]A>VTDMM>65Y;2Q7%K=6\LD%Q!(DL4CQNK&Y0 4444 M%%%% !17S_\ '/\ :R_97_9?/A=?VE_VE_V?_P!G=O&XUH^"Q\<_C+\.?A(? M%X\-G21XB/A<>/O$?A\Z^- .O:$-:.D_:QI1UK2?MWD?VC9^=ZIX$\?>!?BE MX/\ #OQ#^&7C3PG\1? 'B_3+?6_"7CGP)XCT?Q=X/\4:-=@FUU?P[XF\/WFH M:+K>F7(!-O?Z;>W-I, 3'*P!H ZRBBB@ HKYL\6?MF?L?^ O$B>#O'/[5O[- MG@OQ=)=26,?A7Q9\=/A?X=\227L(+36::'K'BFSU-[J)03);K:F5 "60"OH# M1M:T;Q%IEGK?A_5M,UW1M1A%QI^KZ-?VNJ:9?0$E1/9W]E+/:W4)96 D@E=" M00&R#0!IT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44=> ME% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?X@__ 4\ MTK4M8_X*A_\ !2"TTJQN=0NH?VXOVT]5E@M(GFECTW0OC=\3];UF^=$!*VVF M:1I]]J5[*1L@L[2>>0A(V(_V^*_R2?A!\']%_:$_X.:/VF/@/XBM(+[0OC/^ MVK_P5!^%NJVMR!Y,MEX\T;]J?PQ-N;(,;(NI^9',I5X9$26-E=%8 ']@?_!G MA\>8OBA_P21',GAWQY)I7QGTW4(T#%H8;C7?B M%XLL%1U7=/I5Q*N1)Q^&G_!ZI\9[WXB?MC?L6_LH^&H]3U;4OAQ\&_$/Q!DT M>P$DZ7_BGX^^/+?PIHNE0V<3EKG6EL?A#9O AA,B0>(+=+=R;N=*Z7_@RJ^, MVH_#S]J?]N?]C_Q=)J>D:UXO^&GA3XG6GA?41,D6E^)?@9XWU#P%XUM?(;=! M::V\?Q6TJ&^B!6>[MO#WS^9'I2^5\U_'2>V_X*+_ /!W!J6@2W=SXJ\"_"?] MHB+0[6"V4S:=I.B_L._"JY\1^(]*DE@CVIHU[\2_A3XE_M![AVBN[WQ!_] M6Q\ J_?;_@ZE_P""VWQ<_8?TSP%^Q!^R+XTNOA[\=_B[X.;XA_%OXK:'A?%? MPU^%&H:EJ>@>&] \#ZBR/'H/C+Q]J>B^();WQ';D:[X4\-Z/#/HGV'5/$^EZ M[I(!_9717^3-XM_X)"?\%\?V;/V:;O\ X*BWWQ$^)?A.31/"-M\8?&?]B?M( M>/$_:=\(^!+> Z]<>-_'&E?:8'>PTC2;F;7_ !'I#>+]7U_1M);4IM>T"V%O MJ<$/]I7_ ;2_P#!8#QK_P %1/V6/&G@_P#:!U.PU7]JC]F+4_#GAWXB>)+. MPMM)'Q.\"^++74G\ ?$R[TRQAMM+L_$EY/X?\1>'O&5KHUO!IIU71;77H;/2 MX?$UOI=H ?TGUB>)O^1<\0?]@35?_2"XK_/4_P"#I+_@M+^TI?\ [5-]_P $ MQOV./'OCGX>^&/AY#X0TKXV:U\)M0US2/B/\6/BUXWL=,U_2_A?I.L^&S#X@ M_P"$6\/Z/K7ARPO-#\.W4=QXL\7ZMK.@ZU%>6>CVMC/\H_"S]A3_ (.(/^") MOPLMO^"B=EJK:Q\)=#T>'Q;^T1^S8_QFU[XASP_#WQ D-YXLE^,WPQ>&3PW# M/I<-S))KOC/P3KGB#Q3\/KK[;KLFH6FF6FM3L >7?\&%O$+^+/#OQ4^-/C._FM-/T/X>>++2;1FTCX@:$EO>2:E#<27L>H0O91 MQV\,]S_/[_P9Q_\ *775O^S2OC/_ .I3\+*^X_\ @[G_ &WOVT?V;/\ @I/\ M&_ O[.G[7O[4'P"\$:I^Q-\-?%>I^#?@K\?OBO\ "SPKJ/BF_P#CC^T=I-]X MEOO#W@;Q9H6D7>OWNE:'HNF7>L7%G)J-QI^CZ7937+VVGVD4(!_H0?"/PQJ7 M@GX4?#'P9K1MCK'A'X>^"_#&K&SE:>T.I:!X;TW2K\VL[1Q--;&ZM)?(E:*- MI(MKF-"2H]"KX=^('[5/A+]D[_@GE<_M=?&74-4U?P]\(_V8_#?Q/\5S2WPN M?$/BW5;?P+I%S::/!J&J3_Z9XF\:^);NQT2PGO[@M>:WK%NUQ,S2NY_S,M \ M4_\ !:S_ (.6OVFOBL/AUX\\32^#_"]O#K6K^!U^)FO?#+]E[X%>$M;U#4H/ M!_AF33K"22QU37M3BM]2M;34+G0_$?C_ ,71:/JNHZA-/I^DR_V> ?ZU]%?Y M3'P#_;N_X*J_\&Z/[?WAWX"?MC>,OB'XS^$GG>%=8^*GP3\0?$:]^*'@'QO\ M'?$D]_HUM\2O@MK.LSZFV@ZOI7V+5KG1+G1$\.RZGK?A>;PEXSTX007%M9_W M&_\ !>7_ (*7_$#]@[_@FGJOQ^_9>T^^\4_$[XSS>'_!_P )?'.D>'+OQ-H? MPZT/QGX&_#%F'\/3^(HQHLOB[7/"Z:E;7]B;NPG M/W:HK_*$_9O_ ."-7_!=?_@J_P#!>P_;HMOC=J.MZ+XZU?Q-XE^'^I?M"?M' M_$;1O'WCR?3M0U#2[WQ'X&TK^R?$6GZ#H]]JEOJ>D>'KS5-2\'Z9^!OB!?_%SX:2>! M/BWXHU+Q]KGP0^.GP<\/>(=;N;+PWXBUG5]7O]"T21?AYXE\&ZUX5TG4;KPK M/K-[8:U8V5O=I>:C> 'TA_P?-?\ 'S_P3 _ZX?MH_P#HS]E&OZH/^"%'_*'S M_@G?_P!FR> ?_1%Q7\K_ /P?-?\ 'S_P3 _ZX?MH_P#HS]E&OZH/^"%'_*'S M_@G?_P!FR> ?_1%Q0!^L=?P??\'?'_!6?XV?!?Q'\.?^"A^(_$7A?Q-JFO^'/!GPJL?$%E-#J&G:!?IX?UOQ!XYM] M.>VFURUN/#&CS7S:/)X@TG4?[P:_S0/^#S[]E?XB>"?VW_@M^U_%IEY<_";X MT_!GP_\ #%/$=O#<-:Z'\4_A;JOB:ZO?#NHW2[H+*XUCP=K>A:UX?21X)=3& MF>)S:PR#1+R8 'R]\)?^#0/_ (*S_%3X3>'OBE=W_P"S!\+K[Q-X?L/$=C\+ M/B=\4/'&G_$NSM=2LQ?6NGZW:>$_A/XP\(Z-K;PR6XFTN]\8))833/:ZI)87 M=M<01^2_\$G/^"@7[8O_ 0Y_P""D%A^R[\?=3\5>$?@Z/C'I?P=_:K^ 'B[ M7#?>#O"L6OZK;::_Q7\)Q/?S:!I&L^&XM8LO'-AXN\.3)IOCKP>!!=7>HZ3J MFFW]G_0-^P-_P>?_ @O/"/@OX??\%"/@7X[\)^-M,L-*T#6OCK\$8].\:># MO$+_%/PZU.^T'Q3X2N+ZYA>?4K#PC=>/TDN;AI].T^QM66PMOV) M\%?LA?\ !O)_P6W^*7BS]M;PKX1^$?[6?Q?\1:1X3A^(M_;_ !1^-/A'Q9I= MKHF@:;X8\,M\0O@9;>.?!3>']0@T31]/T6#5?$OP_MKK4(=,C@CU"]2V#* ? MT5@@C(.0>01T(]:*^&_^"BO[:G@7_@G'^Q-\Z]?6/A3X=>#OM86YNX8==\6:MH]GJNIK'!?$ERB M:YH?PS^$_@_PW;:[:Z?J>D:7)I]U&FF:!<7EI:/I6L>-?%$VKZO#JFI '^M/ M17^;C_P16_X*L?MY_P#!-3_@I98?\$I_^"C_ (V\;>*/AYXJ^)&C_ RZT;XI M^*;KQ[KWP,^*GB^/3C\*O$G@;QS>7FJ7]U\,/'TNM^&+.XT>74Y_"\/A[Q3H M_C;1(]%:QU6#6_ZX/^"]_P#P4_U#_@E;^P3XD^,/@*'3+[X]_$[Q/I_P;^ = MGK%L;[2]-\;>(--U75]4\;ZM8>7)'>:;X#\)Z)K>O06=VHT[5/$B>&]"U!EM M-7D- '[745_D@_L-?\$]?^"Y_P#P6#NO&W[:_P )OCG\1UN_#OBO5+33/C]\ M9/VA_B%\/+_Q/XT$O]K:WX?^$.IZ,FJZI!!H%R;"VG.B67AWP)X?NY;+0;#4 M;6?2;S3M*Y+_ (*%_P#!8C_@L7I_B[X(/#?AW6/%S>%-5T[2_^$SM M6U:T\;Z!;:+XMLK]H]:D# '^O717\W__ ,/!UKKRQ>,_"NKZ5XCC&MVUU*?&<7Q!UN=_AQ\./%?Q=U >)OB3I_A;3['1=6M- M#^'GA.761XD\G6[_ ,1QP^'=-AM;8 _U+J*_R!/@5^VQ_P %*/\ @WH_X*&> M)OAA\4/$GB_Q-/\ "_Q!#IGQT_9SUCXG:WKGPA^+_A7Q;H]EXFL-=T.^OX-7 MT^PU'5]*UK2O%G@_XB:9H,'B33KJ4V&K6[6MWXF\.7?US^VI^QC_ ,' G[:_ M[-WBW_@L=^T)XTU/3OA3#X7N/CQX8^#>F_&#Q!X/\4_"WX(C?J6G>*_AW\'K M*.V\-^%O">A>#9$\3F6;Q%!\1M8\,1OXEUFSUG7+RXDN0#_5"HK^-+_@T,_X M*<_M ?M??";]H?\ 98_:2\>>(_BMXB_9L3X?>+/A=\1O&NL7?B'QM??#KQW+ MXETC5/!OB+7=0$NJ:W#X*USPY876@ZOK6HZEJTFG^+)-%>>/3/#^EPK\T_\ M!T9_P6V_:'^''QQT?_@E_P#L+>-_%/@;QL^E^%I_V@/'?PNNYX/BCJGB7XD6 MMO=>!?@=X&UC19'\0>&KN[T'5M"\1^([OP\;'Q/J\WB7PWH.G:C:6,>O66L M']X=%?Y-'QM_X);?\%\/^"47P;TC_@HKJGQ0\=^ K?3]1\)^)/B-??"S]H/Q M-XG^)/PTNM=N=/@TNX^-_AS*Z!XAT@ZQ+I7ASQ+!#J7Q#\.+2 M>4?WQ?\ ! __ (*E7W_!5C]A71OBSX]M=*TSX_\ PK\377PB^/>GZ+;&QTC4 MO%VE:;I^K:-X[T73]JI8Z7X\\,ZIIVKSV%OFRTOQ+%XET73RUCI=N[ '[:T5 M_EL?M@_\%A_V\/V,_P#@O1^U)JOA[X^_M._%[X7_ H_:4^-WASP'^R;??'W MXO7?P6UW4=8\*^)_"'PX\*2?"F'Q)>^%[KPOH?C37?#VMQ>%],\/!ISI,=OH MT=IJ;6=S!QG_ 4:_P""7_\ P<&V/P>U_P#X*B_MF_$GQ!XBGTHV/Q"\8>%? M#_QSUZX^)W[/^B:])';17EM\.] @L/!?@#PYX835(;#4M%^&>O7[^%+*XNI] M3T^WM+;6KVW /]5JO\_W_@['_P""Q/[9'P/^/8_X)U_ /QB?@O\ "S6O@]X1 M\>_$OQUX'N+NP^*7Q"@\=S>);";P2_BE72X\(^#K:WTA&O[?PM]@UOQ \\EI MJ>N'0I+O1;S]#?\ @T\_X*>_'C]N/]ES]H3]GK]HGQQXB^)_Q5_91N?!4G@O MXF>*;^XU3QKXI^%_Q-TOQ7;>'M(\3>([RYGU7Q/XA\%>(_ ^LVQ\2ZM,^JW> MBZ]XK:UKOB3X-W/P3;]I'XXZK\;+F#0[/1_B%'XQ7P?=ZG\0/'H\.VCW=QX:.L M6EO-IGVZ1=-DEAN!:Q/%_4!0 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !7^5G^P=_RMW>)/\ M)I^WU_Z=_VD*_U3*_RL_P!@[_E;N\2? M]I-/V^O_ $[_ +2% '=?#3XE:#_P28_X.M/CE?\ BCQ!:^&_A5=?'SX^0^+7 MU.2WTZQ_X0+]IKXVNM3\+_ !^*.NZXZ6[M_Q<_P#::^( UG[? M:SR2N;>+^QO"OQ&MC&XDGF2_3]ZJQ3"7S7_@\S^!-Q\/O^"F7PR^-5II]O;Z M%^T'^S5X1N+G4(ALFU#QS\+?$?B3P5X@2Z41J'>R\'-\-4BG,DCO#,D!6-;9 M-_[9?\&;WP#_ .$*_P""<'[7O[0>H:+%8ZM\=OC-K'A/2]6:./[7K?@;X+?# MBV@TJ03*#(;"R\:_$#XB6,$,C#9>6]_($"R*[@'X;?\ !F/_ ,I8OB1_V9-\ M7O\ U;'P"KY9_P"#A7XT76B_\'"'[0GQ$\;:"GQ&\._!3XJ?LU/:_#W5[M=. MTO7O!OP\^%GP@\17G@9KQM/U1=.TOQ3!S;/]3?\ M&8__ "EB^)'_ &9-\7O_ %;'P"I__!T9\(O'?[%7_!;CP;^VEH&B7$^A?&2+ MX&?M&^ -2OF==!O_ (C_ 3P?X,\5^%(KJ#;<1W&FW'@'P7XAUF%2TMM:^. M]-GADVW,<4(!]P>,/^#VO4_&WA#Q3X)UG_@F7XSP M3:7K^EW6DWT$EM)^SAY4T4EI=RQO!(/+D0F-OE8U\>/Y]7TK"&WO-8\(_$_X0ZAH&HL=OF+=:99W_B*U@*NL?D: MQ>B1'^([3 M79--^S74O)?\$"O^"WGQZ_X+$'XX?\+#_9-\)_!SPK\#-(\(0ZI\6_!_Q$\1 M:QX>\5^/?%]SJ#VG@S1?!FO^#TDLGL]#T?4M>UB\'Q#UBYT:&;P_:W.F3)X@ MMK^ _B\_9BTVV^.W_!V#/%\4%B\0Q2_\%2_VB=>DM] M&/%_P[\;>%_$=E?1I-97>A:_X:U/2M7MKR*17CEM9]/N[B*>-U9'B9U92"17 M^5Y_P5/L/%__ 2'_P"#CWQ%^TK;>%;_ /X16+]IKP?^VQX/M+4JJ_$#X>?% M+7U\6?%32=&GNYHX86U'Q'=?%7X?MYDT,5C?6DK1^5:+;L?Z_P#_ (*"?\'+ M_P#P3A\,_P#!/CXE?$#]F+]HGPW\6OV@/B]\+-=\(_!3X1:+I&KS^//#?CWQ MQX>N](T[6/BCX5OH-,E\&:-X!N;YM:\0QZ[>V+:P=*.C^&GUB]U*Q$P!_*'_ M ,&5;;QDW[&?AO5A&"4DT^UN/#/B^-)S_ Q#5?"FF.">/.2$=2*\J_X,H/#^ ME6W_ 3;_:5\50V\*ZYK/[;_ (N\/ZC=JBBXGTKPS\!O@#J.C6\L@&]H;6\\ M6:]+ C,5C>\N60*9'+?H;_P6/_93\6_MA?\ ! SQU\,_A[IUSK'Q"\*_L]_ M[XT>#M&LK*34=0UN^^#EEX.\=:WH6EV4+I/'VDT[7+#6 M-2TNZDT6/4P#_0<^+'[&/[)/QZ^)7A'XQ?'#]FSX)_&+XG> -&&@>"/&?Q0^ M''A;Q[K'A+25U*YUA+7P])XHTW5(=):/5+RZOH[FRAANX[F9Y$G4XQY?^WO^ MWG^R]_P3%_9EU7X^_M&:J_AWX>:')IW@OP;X'\):197_ (H\>>)KNPNCH'PZ M^'WA=KC3-.N=0N--TR\F$=W>:5X?T30]-OM2U?4=-TFPGN(_X?\ _@LK_P ' M+O[0WC/]N3X4_#S_ ((W_M#^(G^'?A#0=,\$ZCJ_A?P)X?\ %V@?'WXQ^,?% M:I'I&A^#?B7X%UE]9TO2;>/0?#6@:K8V%M?XO:\OB&]L/#_P 6-+^.VJ:#80Z)X4U3]HB;P-\#II]6BT2Q M8V%C#>M:?$MO"EI"THTW2QK-M%*ZRR/( 4/%7_!V1_P4%_:N\8CX&?\ !*7_ M ()VZ+INI7-\;+P_'=>'?&/[0GQ!@T6\GDM;76AX-^'MGX)\$> 6-_<0WE_> M>(#XR\+Z3&MU]OOIX3)J,/XR?\$7;CXU7?\ PBFMO#B+H,#AXM(5= M/6W _L3_ ."'_P#P4E_X)&?LL?\ !&[X&:_N_&FP?4V\5:I>^ (YS\1OB)K?C>^LKO4O TNE:5KKZMH$EAI>AF. MUTB2PT[^/+_@C_\ '/1_CK_P(W8*Q32J5=@#]P_P#@^:_X^?\ M@F!_UP_;1_\ 1G[*-?U0?\$*/^4/G_!._P#[-D\ _P#HBXK^5_\ X/FO^/G_ M ()@?],O"=AJ&L^*;S4[>T\, M6WAVQO=:T_Q#9>-UUR>TC\+7GAN2T\46VLRVHT2XBOGBS]@5_E4?\'0O[//Q M4_8E_P""R\W[6W@^.]TC0_CU=_#/]I+X.^,A90OINF_$_P"%]IX5T+Q=HR29 M:*ZU?P]XQ\(Z/XRO+6>*-AIOC31=XF65I6 /W!_;&_X,IO@AXMN-7\3?L-_M M/^+/A!?7$EU=V?PM^.^D#XD^"$D>$_9M*TGX@>'?[#\;>'-,CN%7-UKNB?$G M4_)D??/,\:[OY!_%7@;]OG_@WV_X*)>#Y/$,L7PY^/WPCG\/>.M*NO"GB.?5 M_AU\9?A3K6IW$%S:"_@BT^;Q-\+_ (A1Z#K7AG6M-UC2],U.WN+"^BN=,TCQ M!H]O)9_WP_LO?\'=O_!+3XC? [PAXG_:4\:>.?V>?CBGA^RB^(/PR;X3?$SX M@:2?%EK;PPZO/X'\6?#_ ,,^)M(U#PQJ5Z)[S0G\17'A[5X;%TM]6L+:ZB)F M_B=_X+?_ /!1D_\ !;#_ (**^"O$/[-_PS\7Q^#M(\,>"_V:?V>_">JV.G+\ M0_B1?WOC37]4CU_4M*L);N/2=4\8^+_&\FEZ)X>?6M1CT_0].T6YNY;#5=0U MFTMP#^KS_@[P^/C?$O\ X(^_L8^,_ M]=VG@7]H_]H#X.?$:2*,@KJGA35_V M?_B7X_\ #6G7T@7$D*W6J:/JHC7:)+S2K:;I ?P'_X)*_\ !SC)_P $J?V. MO#_[)WA_]A?0/BY-IOCCQUX\U_XE/\?+CX>7GBK6/&>JK#?@U\)Y?@;\1M4E#%Q<:=H/A;Q-J/CW5ID= M6@TWPO=7:.\<+PR_#W_!JI_P6;_8Y^"O[&.O?L3_ +5_QQ^'/[._BSX3?$/Q MEXT^&GB3XK>)K+P7X*\;?#_X@7MOXBU*PMO%OB">T\/6GBOP_P",[OQ"9]#N MM0L[G4M'U32[O28+Z6UU@VH!_)W_ ,%8/^"J.J_\%,OVUO"W[:WASX,6W[,W MC/PQX ^'/A6'1M%\?#XD3S^*/AKXB\1:YHGCS_A(;GP/X'V7ZVVJ:)ID6G7& MB7BVT?AJUE-_<17"VEI_37_P>P?$/7_$/AC_ ();:8MY-#X;\4^%_P!HCXAW MNG0X2PO=?FT_]GVWL+QT(+M-I5AK.J06FYL0PZQ<@ F5B/M[7_\ @[!\0^./ M^"G=E^Q?^QA^S#X%_:W^#'C?XL_#[X+?"GXEV7C[QA\-_$'BWQ'KG:VGA2QAG\(Z#<>*9+R;2KN&YC[__ (/)?V-? M%/QU_81^$/[3_@?PY+X@UC]C_P")6LW7CD6%OB>-]2&GV\<"7?B7X@:IJWC7Q1?77EJIGO[K7M=OWO+B3= M)),&!8JJ@?P@?\'C_A3P[X<_X*Y:'JVB6=A:ZCX[_9&^#7BOQ=+9V\<,^H>( MK7QC\6?!5O>:HZ(K75^OA7P=X9LDN)2\@TVST^WW^7;QHGW]_P $'O\ @YV_ M9?\ V,?V&]#_ &1?VW-+^+D&K? 5O$D7P>\;> O#%KX\MO&O@/6M:U+Q-I_@ M;4+5M5T:[\/^(_"^I:M?:-H4U^TGAN[\-KI<-SK6D3:P^!O@74M=\#:#<6^J M06EM9ZS+J/B_P]XXU#Q'>:=+J&G67C:Y\4Z#8ZE=VVC1LH!_H0_\'-G_ "K\ M>)_^OK]D7_U-_ ]?,_\ P9.Z-8P?\$[/VG_$,=O$NI:I^VEKVC7=T$4336.@ M_ WX)WVGV\DH&]XK:X\1ZG)"C$K&]W.R@&5R?IC_ (.;/^5?CQ/_ -?7[(O_ M *F_@>OG[_@RC_Y1G?M'?]GT^.?_ %0/[.E '\T/_!WGI\4?_!9/Q0;6)1<: MK^SY\"+B?;M4SW7]FZWIL;NQ(!;[/96T(9B $C0$@+7^D_\ MN>#-!@_X)V_ MM<_#V33K67PQ!^Q=\>_!S:4\,;6;Z'#\#_%>B_8&MRIB-N;!?L_E;=GE_+C; MQ7^;G_P=W?\ *9G4/^S>_@)_+Q)7^EQ^W-_R9-^V'_V:S^T'_P"JE\74 ?P- M?\&14LJ_M=_MJ0!V$,G[.'@Z62,'Y'EA^)M@D3L.[1K/,JGL)7'(K7X#_%? M7?"GPSTNZUQ]%\5-I!^V MC_V;9X3_ /5H:77Q+_P53T_Q7_P2+_X.2=1_:FG\(7A\"WO[2W@S]M+PO':1 M2^5X^\ _$S68=>^,EEHT\TMI -5N?$UW\4_"KHUR(;/5(X;B93930K( ?9/[ M6_\ P>'WW[6G[+G[0_[,/B'_ ()UZ+X:TC]H#X+_ !(^$-UXG@_:BNM:N?"K M^/O">J^&[3Q59Z1<_L]6,&IWOAF]U"WUZRL9;ZR2ZN]/AA-Y:[_M$?L7_!CQ MXPU&V^*W_!0?P!]KF.DZS\/?@%XP-BTDC0)J/AKQ)\3-%%W%"6\J.:2V\5F& MXD5!),D5LKLRV\87^@/]N'_@Y;_X)Y_ W]A[7?VC/V7_ -H?X,_M"?&_Q-X? MT/\ X4M\!+;6I[SQG/XJ\2-920CXM?#^RU'1?&WP\T'PKIT][J?B[_A(CXO;"SG]H_X(2_\%:?C+_P5Y^!OQ5^-7Q%_9?T#X >%_AWXYTK MX<^&_%'A_P")&L>,--^)WBA-$&N^,TTSP_K'@?0)O#NG>$;74O"T9NQXH\4C M4[W7KFQ*V$NB3O=@'\-/BWP5I'Q!_P"#N*3PSKL"W6E2?\%6M!URYM7YBNF\ M(_$33/%UM;7"$%9;:XNM#@ANH7!2>W>6&0%':O\ 12_X*_6D-[_P2E_X*2PS MHLB)^PQ^U/=JK $":P^"GC2^MW .?FBGMXI$/4.BD8(!K_/@T[_E<%D_[2=: MI_Z=+NO]"G_@KE_RBJ_X*4?]F'?M:_\ JA_'= '\77_!CU-(OQP_X* P!B(I M?A3\"YG7L9(/%WQ!2)OJJW$H'^^:_/K_ (/#O^4O\G_9KGP3_P#3EX^K] ?^ M#'O_ )+M^W]_V27X(?\ J8^.Z^#/^#QC3[FS_P""O%A<3QLD6K?LG?!;4+-F M&!-;1^)/B=I;2)ZJ+O3;J$D?QQ,.U '^I[IW_(/L?^O.U_\ 1"5,_#OA\7NJY\$^(X-5@T@ZC!I5S9"VN[E)Y4C/Z%4 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 5^ ?PE_P"#& M/BG^U5?_ ![O_CI\7OV@9O".O>-_A'=?"%?&7QIN?&UUXITR/0-/^!VE^,U\ M,6$GCS6!H%DWCY]5M4MM-&HZUJK0W37G[^44 ?D%_P %5O\ @BC^R7_P5^7X M)2?M+>*_CEX(U+X"MX^3P;K/P-\5>!?#&HW]E\1QX1;7],\2CQW\-?B58:C9 M0S^"M&NM*^QV.FW=C.VH?Z7+#?2PU]2_L+?L%_!?_@GQ^R+X+_8P^"&J^/M9 M^&'@E/'GV/Q%\1=6\/:S\0=8N?B)XL\1>+]=O]=U;PWX5\(^'KF[@OO$ES8: M8UCX6TZ"VTFQTRUG@NI[>:ZN?MBB@#\$_P#@F5_P;L_L4_\ !*;]H76_VE/V M>/BA^U)XR\=:]\+O$?PDO-)^,_C7X3>(O");^]MK'P/\ !+X= M:PFMPWW@O2HK.YEUZ:PCM+C4(YM-N)I;:>U_0K]O[_@G=^RW_P %+O@7>? / M]J;P1)XD\.Q7_P#;O@_Q5H=XNB>/_AMXK2VDM8/%7@/Q*MO=/I6IK;RO;7UE M=VNHZ#KEDS:=X@T?5; FVK[BHH _A^L?^#(7]EZ/QK-?ZE^W)\>[OX5K4I"DR?#6W2.X5KEH)(V%JG];?[&W[ M&'[._P"P/\!O"O[-_P"S%X$M_ ?PS\+27M\('NY]5U_Q'X@U619M9\5>+_$- MZ7U'Q#XDU:5(_M6HWDFV"UM[+2].@L=(T[3]/M?J:B@#\IO^"JG_ 1Z_9/_ M ."MOPQ\.^#?C]:>(/"7C_X?SWEU\+?C=\/9-+L_B%X&_M.2UDUC1"VKZ?J6 MD^(_!VOM96O]M>&=9LY8C)#'J&BWFB:U%#JL7Y,_\$]/^#27]BO]BWXZ^%_V M@_BO\6O'?[6GBWX=:W'XC^&OA/QCX1\/>!?ACH'B*POX[[P[XGU_PIIVH^)] M1\8^(/#$MO;W&D#4/$EIX8&IJVJ7GA:ZN(M-73?ZOZ* /PN_8-_X-]_V-/\ M@GC^V#XX_;7^"OQ,_:;\3_%3Q]HGQ'T#6- ^*/C/X5ZU\/[:S^)_B72_%6OR MZ9I7A/X,>"?$<-S9ZAI-M#H[W7BN\BM[)YX[V'4)VCN(\_\ X*??\&\W[%W_ M 5C^/WA3]HW]HOXG?M0>"_&_@_X1>'_ (+Z9I7P5\:?"CPYX5G\+>&_&'CW MQM8W]]8^.?@I\1]7EU^75?B)K5O=W5OKEKITFGVNEQ0Z5!76D>#_ SH7A339]2D@GO[C3O#^E6ND6$O!GAKP[X\^#]SXEU"YN;W4_$6B>!=3N_#.L>%[O6+NZ:?4 MM*T7QK;^%D>-#HWA_1FDNGN?ZR** /YK_P#@F;_P:_\ ["G_ 3G^,6B_M$W M7BGXB?M,?&SPCY-S\/\ 7/BK;>&M,\&?#K78XYHY/%GA/P+X>T]5;Q2%G9=. MU;Q-KWB7^P&C@O-!M]-U>+^TV_8/]O7]@O\ 9V_X*/\ [.?B;]F7]ICPW?:W MX&UR]L=>T76-!U Z-XP\!^--'CNDT'QOX,UD17":?KVDK>WD&R\M+_2-5TV^ MU'1=$(7TCQ=\0O#VHZAK%]IMW('%U)X0TKP+JX@98[/5K. M9/M+?HUXD_X-B/\ @G5>_MJ^#?VY?AUXG_:-_9_\?_#SQY\&_B'X'^%_P*\4 M?![P=\#?"VL?!#3O!VF^%]/T7P?J7P-\0^(;+0M7C\%:?/XJTV+QD/[5N=1U MMK:?3HK]88/Z*Z* /Q^_X*M?\$4?V5_^"P4GP'D_:7\?_M >!V_9Y3XG)X+' MP,\5?#GPR-3'Q7/P^;Q%_P )1_PGWPI^)IO39'X;:%_8O]DG1!;"[U;[<-1\ M^S^P??G[)W[-7@7]CK]F[X,_LN_#+5O%FN^ /@;X%TCX?>$M8\=WVCZGXPU' M1M%1TM;GQ%J'A_0?#&BW>IR"0FXFTWP_I%HY \NRB&0?H6B@ KXX_;C_ &!_ MV6_^"BWP4O?@+^U=\-K/Q_X+;4(M<\/:C!)[>&6WMO%7@3Q78[= M3\-ZY%;SSV=Q);O)8:MIMQ=:1KEAJFD7=U83?8]% '\-GB__ (,@/V=KWQ(E MUX"_;R^-/AKP@+AFDT+Q?\(? WC?Q(UJ4(2%/%>C>)OA]I:7"OM9KD^#9(W0 M%!:H6$B_LY_P3&_X-R?^"?\ _P $Q_&UE\9O"-AXQ^/7[0FEK=+X=^+_ ,:Y M]#U&Y\!?;[)=/OW^&WA'0='TGPWX4OKFU:[M_P#A(KF#7/&-O9ZEJ6FVOB:# M3+ZYLY/WWHH HZGIFFZWINH:-K.GV6K:1J]C=Z9JNE:E:P7VG:GIM_;R6M]I M^H65RDMM>65Y:RRVUU:W$4D%Q!))#*CQNRG^/K]K3_@S0_8;^-OQ)UWXA?L\ M?'+XH?LHZ?XFU:35]1^&6G^%]"^*GPWT26[N1<7]IX&T_5]8\)^)?#.FSEYS M9Z7>>*=?TS1FDBM])L[32;6WTI/[$Z* /P7_ ."4G_!O/^Q1_P $IO%FH_%W MP/?^-?CC^T)J&FZAH=I\8?BK_8R7'@W0-5BM8=4TCX>>$]!L;31O#!U2.V:/ M4MW.ER?7'_!3O\ X*2_LE_\$WOA5X'\2?MF>'_& MVM?"#X\>+-7^#-V_ACP)IGQ$T*.YU#PEK.M7VF^.O#M]J]C=7?AS7- TW6+* M6'3]+\0M=%9+6[TX6LKRK^F%?FQ_P5?_ .":WPR_X*J_L>>,/V7/B#K;^"M: M?5M-\=_"?XFVVCVVO7OPT^*7ARVU&UT'Q*-(N)[)M5TF[T[5]9\->)])M]2T MJ[U3PSKNK6EEJNF7[VE_; '\_?['?_!#O_@V^_X*CMK_ .U]^R-I_P 8/$OP MLT?XD:QX5\9?!_2O'/Q'^&WP\TKQQ'9:%XNO_#]WX2\7>']-^)^B:2-,\1Z; M-ID'A3QMI_A1;&^FTW0I%33#;:=_-S_P=;:#\*K3_@J;\+?V>/V;_#OA33-! M^!W[(GP!^ .D?#'X;66GVVE^"]='B_XG>)M ^']CH>D 0:;J">'_ ![X5N(M M+,<=TRZO:33(TMT9)/8;?_@V>_X.#_V2O$?B71?V4_B);_\ "/>(M0AM-4\4 M_LW_ +7M]\%K'Q/IEO/<6^G:CXGT?Q#KOPIU>X-G9SR3SV$]IK,ED+BYMM.D MU DM-^G/_!(C_@U*_:$^''[5W@K]L3_@ICX_\"ZU)\-?&MO\4?#GP>\*^*]4 M^)OB;Q_\4=,U)-:T/Q)\6_'&H6%KI*Z3I'B%(O$L^F:3J'BG4/%FJVMK%K6H MZ=IPU"RU4 _K4_;7_P""=_PC_P""A/[%G_#%?Q[\2?$CPG\/]5MOAA<:SK7P MDUGPMH?C2WU'X:7VC:SIL6G:EXO\'>/- CM+C4=(BAU!)_#EU)-9M(EK/:3, MEPG-_P#!+S_@EM^S]_P27^!OC7]G_P#9R\8?&+QIX-\=_%?5?C%J^I_&SQ!X M*\1^)K;Q-K'A#P7X*N;'3;SP+\/?AOI4.A1Z5X%TBX@M;K1KS4%U"YU&634Y M;::VM+/])Z* /Y_/^"C/_!N!^P__ ,%.OVF9OVJ_CW\5/VK/"/Q#G\&^$?!# MZ-\(?''PBT#P8-)\%_;O[+N%T[QG\#?'^N#4;C[?-]OE/B(VTNV+[/:6NUM_ M[B_%;XVVI/>VZ1337VH:C:M:ET2SCE(G7Z#_X*:?\$F/V0/\ @JW\ M+]%^'_[37A;5K?Q)X)EU.\^%_P 8? =]:Z#\4?AM>ZQ!'!JL6AZQ=V&IZ=JG MA_6/L]E+K7A'Q+I>L^&]2NM/TW4FT^'6=*TK4['],Z* /XD/ '_!DA^RAHOC MN'6/B+^V?\=?'?P]MM5LKQ/ ^@^ ?!/@37+W3;:X$MUI&K>.'U/Q;',FH1*+ M66^TCPIHEW!$\SVK17#0S0?V!_LY_LZ?!G]DSX*?#W]GG]G[P-IGPZ^$?POT M&#P]X0\+:6]U<"VM8F>>ZOM2U/4)[K5==U[6+Z:YU;7_ !#K-Y?:SKNL7EYJ MFJ7MU>W4TS^V44 ?@7#_ ,&Z/[$L'_!2(_\ !4-/BC^U.?C\WQVG_:$/A!O& MWPE/P>_X3.XN)+A],&@#X(#QI_PC >5@ME_PL#^U0@ .M,06/['_ +1?P.\) M_M-_L_\ QO\ V(M(\#_'SX2_$3X->,-5\(W>FV'BO3?#'Q,\):MX-U MZ_\ #5]K.DZ_I%GKUII>LW4^D76J:'K.GP7\<$MYI=_;K):R^RT4 ?B__P $ MKO\ @A=^R5_P2&\6?%_QC^S9\1/VB_&^I_&KP[X5\,^*H/CCXM^&GB6PT^P\ M(:EJVJ:;-X?B\!?"/X:7%K=SW&LW27TFHW6JPRPQP+;V]LZR22\?_P %B/\ M@@Q^S1_P6!?X>>,O'GCCQE\$_CA\+]&O?"OAOXK^"-,T?Q NJ^#+V^GU9?"7 MC3PKK+V<7B#2M)UF[O\ 5] EL-;T#4M*O-5U=1?7%IJ4UL/W0HH _#7_ ((R M_P#!#3X3?\$;K;XW7G@'XZ_$KXU^*/CY:?#VQ\9WOB[0O"_A3PS8V_PUE\83 MZ%)X=\.:-'J6J6=Y/-XXUL:A/J?BS5X9+<645M:VLD4\]U^Y5%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!17B7[2?Q_\ AW^RK\ ?C!^T?\6=3_LCX=?!7X?^)?B'XKND!>ZET[PYILUZ MNF:; JO)=ZSK=VEOHVB6$*//J&KW]E901O-<(A_''_@W[_X*8?MC?\%6?@-\ M+WN+60RV^G:. ?OW17\4O[(?\ MP86/\ 9Q9# M'_:#0 445_%#^T-_P<@_MP_";_@N;IO_ 3*\.?"O]E.]^ ]Y^V?^SO^SI+X MMUOP/\7;GXN+X)^+?B'X8:3XDU2/7K#XYZ;X-'BFRMO&NJOHE\W@)M)MI[?3 MVO\ 0]2CBN8[L _M>HK\'?\ @X7_ ."H?Q^_X),_L:?"[]HC]G/PA\'O&GC7 MQM^TWX0^"^JZ7\:] \:>(_"UOX6U_P"%?QD\<7E_I]EX%^('PXU:+7XM6^'F MBV]M=7.MW>G)IUUJD,NE37,]I=V7LO\ P0U_;_\ C)_P4S_X)]>!OVK_ (\> M&OAGX2^(GB;Q_P#$_P *W^C?"/1O%.@^"X=/\%>*+C1-*FM-.\9>,_'NN1WM MQ:1+)J$DWB.X@EN"SVUO:1D1 _7VBOXO?\ @DK_ ,'%W[;7[>?_ 5=O?V% M?B_\+OV6/#GPDMKG]H2%/$7PW\$_%K1_B,5^$]GXAN/#I?5_$_QO\8>&2UZ^ MDVPUHCP@HN5><6(TTM&T?U1_P<=?\%OOVKO^"0/B7]DK1OV:OA]^SUXXM?CS MH?QGU/Q?)\&V\ _%GX9QV<-U'XSU1M575(M8 M>=X+ VDEBL5PMT ?U-45\?\ _!/O]H'QE^U=^P[^R;^TO\1-,\,:-X[^._P! M^&'Q5\7Z3X+LM5T[PEIWB'QKX4TW7=5L_#=AKFM>(]9L]&M[N\ECT^WU/7M8 MOHK98TN=1NY0TS?8% !1110 4444 %%%% !117C'[1NL_&3PY\ ?C1XB_9XT MWP;K?QV\/_##QOKOPAT/XA:?K>J>!]>^(FC^'M0U'PGH/BFQ\-ZWX;UZ;1M; MUFVM-*O6TG7-.OH8KLW$$Y:+RW /9Z*_G]_X-]O^"S.L_P#!7C]GKXF:K\8M M ^''@/\ :=^"'CI=%^)'@GX967B#1?"5YX(\51W%_P##KQMX?T/Q=XN\;^); M*VOAI^O^&-:BOO$>HA?$'A>[OH_L-GJ^GV$'] 5 !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110!_%W_P>B_M?S_#3]CCX"_L<>'[V2#6/VG?B9=^.O&\4<3/'-\,? M@7_9.IP:7#^S)\&?^"=GB;P'^WHO[1?Q_\ _\ PTA@_&'5?B4T'C*/P_XR2+6V\''6M;_MY%UO3=/74-0^R_JA_P %6?\ M@MC^RM_P1^G^!-O^TMX _:!\$O!'Q/\ CI\5OCU\%/AE\>],^"VDW7A3PGJWPM\$?%OP9H_CSP58 M?&WQ8FJ>+_#_ (2\9:EH&N6-R_A7PH/'U[:Q%=0NI(-'O]#U+5_4/^"2'_!R M1^R3_P %5/B;)^S[!X!\:?LX_M%3Z%J'B/PS\/?'&M:/XK\-_$+3]$LS?^(K M3P%X[TFVT@ZGK^@6$=SJ]]X?UOPQX=U"ZT&UO-8T=-3M],UM=*^!_P#@W>_X M(8_L+>*_^"<'PH_::_:Q_9_\ _M)_&G]J30+[Q;')5\(Z3I^MZCKUC:+XC&H:J-*@UO^Q= T&ULOY6)O@S MHG_!-G_@YO\ AK\%/@3=W^E>"/A5_P %&?@)X=\%VVH7,VH7>E_#'XQ^+O - MQ=^#I[Z>5KS48+#P#\2;_P &KJ%Y/+J%]9PK>7TTUY--(X!_KET444 ?Y-/_ M 0M^/OPA_9>_P""XOQ4^/?QX\<:/\.?A1\,]#_;7\1^,/%FMR2"VL+"VL/% M:QV]K:V\<]_JVL:E=/!IVB:'I=M>:OK>JW5II>EV=U?74$$G]'%Y_P 'M/[' M<'Q9E\.VO['_ .T%>_!F/4GLU^**^*_ =OXTGLDN3 -7A^$\V+$6LL(^V16U MQ\3+?4/)*QRVD5SN@3^.C]A;]B[1?^"@_P#P6;\(_LE^*[S4].\#_$W]IKXQ MWWQ#O-'=X-37X>?#R;Q_\3/&]C87Z1RC2M0USPWX/U'P_I>JO'(FGZIJME<^ M5,Z)#)_=3_P6T_X-_?\ @GG+OA;H3:9K'BK1_A5H5[XH\7>#_'ABFDN_'(+'Q"FD M:G!J$T,%WIVH ']*?[,G[37P1_;%^!OP_P#VC?V=?'>F?$;X1_$S2/[7\,>) M=-$T#[H+B:QU71M9TR[CAU'0?$GA_5;:\T7Q%X>U:VM=5T76+*[T^_MHIX&6 MOYH?C?\ \%)O^"%'A#_@L'8?LP?$C_@G7XF\5_M]S_M7_ [X^DL;&*X_.K_@R-_:7\5ZA9?MJ_LB:UJTE[X/\.I\//C[\/M*GDNI&T35- M?VH*^HO^#2/_ )0O?"3_ M ++)\?O_ %8-[7R[_P 'K'_*+O\ 9]_[/X^&G_K//[4%?47_ :1_P#*%[X2 M?]ED^/W_ *L&]H _DK_X-N_^5B_5/^O[]M/_ --?C2O[!?\ @O!^W'_P23_8 M\\0?LSV?_!3?]BK7?VM]5\?Z/\5KGX.WFC_!/X*_%U? NG^&[WP!%XXMIY?B MY\2_ $N@MXAN=;\+2QQZ#%JD>I#1F;4I+1K&Q6X_CZ_X-N_^5B_5/^O[]M/_ M --?C2OT-_X/D/\ D>_^";W_ &*7[4G_ *>/@+0!_<-^Q'\0?@M\6/V0/V:? MB;^SCX!N?A9\ _'OP5^'OBSX/?#>\T#0?"UUX&^'6N>'+#4/"GA:?PWX6U;7 MO#>A2Z+I$]K8MI.A:UJFE6)A^SV-]<6\<)-&OAZUY%("DUFGC;6]!:[A*L9K82Q*I9P#_ !?? M\&UG_!*7X>?\%Z!=Z]KFEWGQI^,_QE MUKQ5J&DP^+O%VF7ECX@NM(MH_#'B_P 5^+XM'U:PUG5-8N?#46H:@FDZEJ%I MJ8!_3C^Q?_P>)?L'?M%_$GP[\,/V@?A1\1_V0+OQ7>PZ7I'Q"\4>)- ^(WPA ML-3N[B.VLK;Q=XMTBQ\,:_X4M;R6:-!KMYX+G\-Z8/-N?$&LZ+I\+WU?USVM MU;7UM;WME<07=G=P0W5I=VLT=Q;75M<1K+!<6\\3/%/!/$Z2PS1.TN>$?'FHQ>$_#WC/P_H>MW>KG0/$^C^-+WPOH=]I^@W6EZ'JVD:_=ZK- M6TQ[G4/V<_X-+_VS?&'[4_\ P2\L_AW\1-5O-<\7_LB_$G4_@-I^LZC'_AE8>%_A5X MGT+PCKT>FZAX*^,GC_Q9J>M:KK/B/38/"VCP^#TN]=EE6QA6+59[+3KK\OO$ M_P#P>V_LC:9\59] \,_L;_'WQ3\'+;4+FT;XF3>-? N@>-KZT@NXH8M4TGX4 MW5O=Z=+;WML+F\M;?5_B=HE\JK9P7MM9S7%RMA_(I_P3;_8O\/?\%!?^"S?A MK]E'QW=^(+7X5_$/XZ_&K6/B\OAS49M)O=2^''PSD\:_%+6O#TNH6[+-9P>* M+SP9IGAN.^A#76FWVJV6IV)AO[*UN8?Z\_\ @Y>_X(W_ /!/?X%_\$J_&7[1 M'[-_[,_PT^ 7Q*_9Q\6?",:9K_POT.+PY=^+/"WCOXB^%OA7K&@>/)87>3QB M=WB_3]7.EZWX>U_2YB;C1O$OAK6['4-"\0: M1<$R6&JV%S"LDT(BGE_%7_@I]_P:#\0_VBOCWX8^S MKX]\#_"M-'T[0?AQ<7VF6VK:=I7C'QSXENK73%UZ\L[VRN)-$\-67B6]TF&8 MC7ETJ[\FTG^#/^#*?QKK>M?\$[_VD/!6HZE=7NE>"?VNM9N_#]I M*_A-\,KN_LK%9&9;:RGU33+O4S:PA(O[0O\ 4+LJ9KR9V_C_ /V+/VCOV0/@ M-_P6(^.7Q<_X*P? R+X__#74/BI^T7I7CSPYJ/A6Q^)FC>$OC'X@^)EX[^._ M$'P^\330V?CW0O#US!XFTVYT2_MM1NH5U>#7++1M1U71K.RD /Z]/V;?^#T; M]B3XH>//#G@[X_\ [./QE_9OT;Q#J(TR;XBVWB3PW\7/!GA=YY"EIJ/BI--T M[P=XKMM%8;5OKW0_#'B"YT^65&>PFL4N;^W_ +%_#WB'0?%V@:)XJ\+:SIGB M+PSXETG3M>\/>(-$OK;4]'UO1-7M(;_2]6TK4;.2:TO].U&RN(+NRO+:62"Y MMYHYHG>-U8_QM_'+_@FU_P $!?\ @O);_!N[_8%^/_[-'[-7Q*\):[-K?CO1 M?V<_AGX0^&_Q5\?_ SO=!O[6[\*Z_\ 34Y/A=?Z5KNF^(H/#^H:;\1M7\! M>))='T_3]9T-;.]M=>M[K3_ZD?V(OV4M!_8>_97^#G[*/A3XB_$/XI^%/@IX M:F\)>&/&'Q3N/#5UXSG\/KJVHZCI&C7DWA/PYX6T8Z9X8LK^+PWXXGT+X._M.?&GQ9\) M)+&X,^F:3'X>_:N&@_&3X%1:?:0HFG7J^'_B-K_@3P3I]\\16TT^;7(4GMYI M+Q#_ *2E?YB7_!VEJ^I_L[_\%O?V?OCSX/AB7Q3IG[/'[-GQSTQY \4,_BKX M,-!O5O5B,=MKD^G_ !6A-LDLPDN+7PZDEM$5L;IQ_H6? M!/XD:3\8_@U\)?B[H-[::EH?Q2^&?@3XBZ/J%C+'/97VF>-O"^E^)+&[M)HB MT4MM<6VI12PO&Q1HV4J2"* /\O#_ ()I_P#*V:__ &D'_;U_](_VDJ_5/_@^ M9_Y"7_!,7_KQ_;)_]*/V6J^6/^"?'["/[<'@O_@YS;X^>,?V-?VK/"?P*/[< MW[:WBX?&GQ-^SQ\7=!^$O_"*>*K3]H!?"_B?_A8VJ>$+7P=_PCWB1M9T== U MK^V?[-UAM6TT:= M";/]K!?&;_ SX,_$;XM+X1;Q'/\ LWGP\OB=O /AOQ - ;7AH6MG1AJIM#J@ MT?538B<:?=^2 ?T7?\$,45/^"0'_ 3L"@ ']ESX;.0/[TFFL['ZEF)/J3D\ MU_G^_P#!2D8_X.S8\?\ 20G]@L_G:_LVD_K7^A?_ ,$;? ?CCX7_ /!+']@[ MX>_$OP9XK^'?C[P?^S?\/="\6^!_'7AW5_"7C#POK=EIOEWFC^(O#.OV>GZU MHFJVC_)=:?J=E:W<#_++"AXK^'S_ (*"?L(_MP>-/^#G1/CYX._8U_:L\6? MH?MT?L4^+C\:O#7[/'Q=UWX2CPIX5MOV?U\4>)S\1]+\(77@[_A'O#;:-K"Z M_K7]L_V;HYTK4AJ-S;FQNO* /]+&BBB@#_*"_P"#?/XE:!\-_P#@XP\'Q^(I M(+:U^(7Q+_:U^&NGWUPULD5IK_B3PQ\3+GP_&)+B2,I/J^L:59^'K1;.OAM=?%O]H?]GGXI_$[X)?%+X2^"/&/Q3\ M_%W0=;\#>$?#GQ7\7^'_ YX;T+Q/XFTZ_U+7? 6MPZO(G]LZ+I]VQBT@7^I MV6U^W3_P42_X+\?MZ^%M%_X)O_M)_"KXO2ZS8ZWH-EXO^%/@C]FGQ'X+^)/Q M=\0>$]0A_L;4OB+;:+H[#7].M=&OV;O"'@^^*N1;C4O''Q.T[6M*$J=&F-K\ M/=9^SN>4C%R!Q(:^*?VUO^5N'0O^TI?[$O\ ZFOP!K^U/_@W&_X)/>)O^"6W M[%>H6OQFL;&R_:=_:-\0:9\2?C-IMI<:;J/_ @NGZ7I;Z=X ^%+:SIJR6^J M7'@ZPOM9U379K6^U'38O%WBKQ):Z1?WVEVUG?7/\K'[7?["'[??\'=O[//Q^_:4_P"" M _%/PW\:66GZMXYN[O2K^ M[\+>,M*T;7+:RU.T9;K3[J:Q2"\MV6:VDDC(:@#^-_\ X-N_^5B_5/\ K^_; M3_\ 37XTK]#?^#Y#_D>_^";W_8I?M2?^GCX"UXS_ ,$!/V&/VVO@U_P7IU+X MP_%_]CO]J?X5?"22\_:X9/BE\2?V?/BUX&^'+KXET[Q/?LC?M7?M/>,_P!@*Z_9J_9B_:%_:&M? M!OAC]I"W\7W/P-^"WQ(^+4'A2?7-5^"LFB0>))O /AKQ!'H^TSQKX/UF2VC#F>:T\*:MIVA+>NT:Q6\W MC.P".[W3JG]3_P#P31^"%S/_ ,$B?V./V=_C[\.M(M&\?4;'P=\/?%.M$Q@FWL],NKDG$>#^6E_;Z-XS_:8T3PUHMQ<1RQV-]+X%^&6A7FJ3Z>7"I/Y4OC6VM;N MXAW1F:!;9G\VVD1/YE?%]Q_P75_X..?C/\+O!OCGPI\0?&'@SPU=;M U-_AI M>?!_]EKX16FJRVNG:[XZU_6K;1+70K[6&MQ)(US>ZAXM\?ZA8PWVC>$;&XM$ MDTI?]-S_ ()P?L,?#K_@G%^QO\&?V1_AM3:]X^\9W$$\]S)91:[XEOKZ;2M*$\L6AZ''I>AV[M;:;$2 ?YU/_!L^BO_ M ,'"^J,R@F.S_;%="0"58V?B.,L,]#LD=IZUJ9L=/G%AI.G7VHW1B ML[2XFC /QO\ ^#)22.']B3]L::61(HHOVHM*DEED94CCC3X2>$V>21V(5$10 M69F(55!)( )KU7_@J/\ \&]W_!.'_@J!^T;X[\6?LN_M9_"[X _MV^)-(U'X ME?$WX<^#_$W@KXG>'_'EK9ZGH^CZW\1_&WP// M#]S;Z+?:YJT6H:WX9UKQ)J=S?7=K_@T2_97^/?P"_8O_ &O/ '[4W[.OQC^! M]]XY_:"MKFS\'_'GX3^./A=J/BOPG=_"GPYHNHWEAHGC[0=!O-8T*:9;S2[F M\M+>>R,Z7%H\HE21!_.-^T3_ ,$X?^"J7_!O-_P4$U/]J+]AKX=^./BA\#[? M6?$EK\)_B=X2\":Y\5?"&L?"WQCYM_=?!KX]^#_#]UJ/B32YM%M;6TTO4M3U M>;1[/7]2T'2/&?A'Q#9:TL5OH@!^>W_!1+_@A=_P4<_X)%:=X?\ CK\4[/PM MJ?PRL/'.E:/X9_:#^ 7Q OK^Q\,^-'FN=0\)/>0WUAX.^(W@S6+LZ7)=Z1K+ M^'HM*MM4MXK&#Q!_:DMA%<_Z)/\ P;8_M[_$_P#X*#?\$P_!7Q!^-WB)_&/Q MB^#OQ&\9?L^>/_&ET9#JWC&Z\%Z9X6\4>&/$?B!G&+CQ'>>!/'7A6WU[4D>3 M^V=6L[S69C%=:A<6\/\ $K^U%_P4B_X+D?\ !P%X;\)?L8:9^RIIA\(3>.]) MUK6_#?[/_P %_B1X-\/:IXJ\,V]_#:7?Q7^(_P 4O'/C'0_"F@>'[YM1U'R= M3\1>$M'M=3BM4U%[^_LK #^_K_@BA_P3HNO^"7O_ 3[^%?[,WB74]'USXJ7 M.HZ]\4?C;K/AYFFT*[^*GCIK)]7L-&O);6SN-3TOPIH>E^'?!6GZQL;O_@I#^S9X;AM0NH:)^Q/X5U2]O\ Y?W\ M&O\ QR^.D%E8G#%LV)T*[N<%%7&IC:S$L$_TH_ACIT^C_#7X>Z1'O!OQ(\27FM(N_8-,U.VV M//$T1_TO@ H"J % & !P !P . * %HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH _GE_P"#G?\ 8:U;]M?_ ()6_%*Y\$:$^N_%;]F'6;#]I;P)86JWCZEJ M>E^!]-U;3_BAH=A!86UW=:E=7OPPUOQ3JFF:+';2'5_$>AZ#:H8IS#/%'_P: MZ_M7V7[3_P#P2#^ FB7.I6]YXV_9COO$7[-/C.UB\Q)+*V\"W46J?#?,4Q9S M$_PE\1^!K?[3&S6T]_9:C'"8VMY;:W_H8N+>WO+>>TNX(;JUNH9;>YMKB))K M>XMYT:*:">&16CEAEC9HY8I%9)$9E92I(KXB_8N_X)N?L7?\$\8OBA:?L'=4UO0UU:/3+[2?#GQ$\=^+M"\'M;P:W? M6CP^#-.\/VUU8IIMA=PSV>BZ-!8 'W'1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %8OB7Q%HO@_PYK_ (M\2:A;Z3X=\+Z) MJOB+7]5NW$=KIFBZ)8SZGJFH7,AX2WLK&UGN9G/"QQLQZ5M5YO\ &+X1^ /C MY\*?B-\$?BMHMSXD^&7Q9\&>(OA[\0/#MIK_ (D\+3Z_X.\6:7(? M!^KZ!XGTF+5=*O+JQN+K1-9TV_6WGE2&[BWDT ?P8?\ !M7\(_$O_!0S_@L! M^W9_P6%\=Z5)_'WB'Q7XNUF]N5MK.TBEU M;7KW[#IMCI^E6 M=,L+.T@^HJ "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHK.U?44TC2=4U:2-IH]+TZ]U&2%"%>5+*VEN6C1F^56=8BJ MEN 2">* -&BODW_AK+P[_P!"EK7_ (&V/^%'_#67AW_H4M:_\#;'_"@#ZRHK MY-_X:R\._P#0I:U_X&V/^%'_ UEX=_Z%+6O_ VQ_P * /K*BODW_AK+P[_T M*6M?^!MC_A1_PUEX=_Z%+6O_ -L?\* /K*BODW_ (:R\._]"EK7_@;8_P"% M'_#67AW_ *%+6O\ P-L?\* /K*BODW_AK+P[_P!"EK7_ (&V/^%'_#67AW_H M4M:_\#;'_"@#ZRHKY-_X:R\._P#0I:U_X&V/^%'_ UEX=_Z%+6O_ VQ_P * M /K*BODW_AK+P[_T*6M?^!MC_A1_PUEX=_Z%+6O_ -L?\* /K*BOF/0/VG- M!U_7=%T*'PQJ]O-K6K:;I,4\MW9M'!)J-Y#9I-(JCYMF*KY?MB_]!GP!_X0ME_\E4?\/Y?MB_ M]!GP!_X0ME_\E4?\/_P#35=UTU"/\ T]VM?VF5_%G^Q;_R=I^S MI_V5[P1_Z>[6O[3* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N9\:_\ MB;XM_P"Q9U[_ --5W735S/C7_D3?%O\ V+.O?^FJ[H _(VBBB@ HHK\G_P#@ MKU_P4PTW_@FC^SOI?C;1O#^D^-?C/\3]36VC&^T^P6^\0^,_ M$<=F\>HWOAKP=;W.F?;=.TZ:TNM5U;6M"TC^T=*@U";5+( _6#(R1D9'4=QG MIGZT5_G#_##_ (*I?\%+?V8OVK/VE?VQ?%7PIT?4?$/Q/D_9PF_:G\+>)_AE MJ.@>&['PW?\ @>WE^!=@\NGS1:S\,[GQ+\.4>/PMJ][<78OI[JVN]=L-=U)H MK.X_O*^ '[8OP@^/W[(?A#]M#2=53PY\)M>^&>J_$GQ%<:Q<022>!K;PE;ZF M/B%H^NW%J6@>\\#:OH/B#1M6FMMT,UQI$\UL&BDB) /JZBOX=?&O_!DS:S=ZE)-_:$5GI=ZD@!^SM%?PQS_\ !:?_ (+8_LH7_P ,OCK^ MV#\"+:]_9X^*M_:/HGA[Q5\)+#X9Z?J^G76FMJ2Z3X7\7Z) ?$/A;Q+=Z2DV MMZ/:>/(];NKNUM;NZ71KS3[:Y:W_ +2/@=\8O!G[0?P=^&7QP^'EW->^"?BM MX)\/>.O#4UU!):WBZ9XATZ#4(;6_M9562VU"Q:9[+4+=US!>6\\63LR0#U2B MBB@#L_AQ_P E#\!_]CGX7_\ 3Y8U^LM?DU\./^2A^ _^QS\+_P#I\L:_66@ MHHHH **** "BBB@ HHHH **** "BBB@ KP+]J[_DUS]I/_L@7QB_]5WXCKWV MO OVKO\ DUS]I/\ [(%\8O\ U7?B.@#^)2BBB@ HHK\N/^"F'[87CS]G7PYX M#^''P:B(^+?Q>N[ZVTK5DT^+5;G0-(LY['3_ #=(T^X2>VN_$6LZKJ=KI^CK M:W_?1HT?S5T-?R+:#\3? MV\?V6?&GQ:^+UQXAU2[O=#^(OA#1_CW8ZW?V/B;1M2\6:YH)U;0;'Q;91N0H MFTR6?1TU?0)[5M/N88],M]1A4:<)OZ3K3]J'P;+^RE'^U;/9W:>%1\,V^($^ MB136KZB+V*T9)O"T,[2K:-J1U]&\/12/*D)O2K2%%W!0#Z;HK^7G1/BK_P % M2/VLM,\:_'KX6^)?%FB> _"6IWT]GH?@[7-+\)Z+YFF6BW-UH'AW1II8+[QM M)IEA-'-?#4_[42\NW\E9)M1\NQB_4G_@F3^VAXF_:I^'_BCP[\2C:W'Q/^&$ MFC1:KKEE9Q6$'BSP]K4-U'I6NW-G;K'96VN+>:7J-KK4.GP6VGN?L-Y:VMJ+ MQ[6 _3VBBOQP_X*5_MK?%'X7^+_ +^S7^SE2QR75A9-8?8_L]QJ*7MJ ?L?17\P MP_:2_P""A/[!?Q.\%3?M+ZIXJ\9^!_%KM?7WA_Q/XBTKQM9:YI236K:_#X:\ M307E]+HOB701>H(M/74;:PCFDMA/97.D7%K<'^F'P[K^D^*] T/Q1H-Y%J.A M^(]'TW7M&OX"&AOM*U>SAU#3[N)@2#'\$?^GNUK^TROXL_V+?\ D[3]G3_LKW@C_P!/=K7]IE !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !7,^-?^1-\6_]BSKW_IJNZZ:N9\:_\B;X MM_[%G7O_ $U7= 'Y&T444 %?R ?\'6O@KQI96?[#?QWTW28=7\%?#_Q7\4_" M>LG4+<7NBV7BSQ+_ ,*[\5^%;'5;$E/M%GXET_P%XEBND:1(I8=$^RLR/<1E MOZ_Z\3_:%^#GP2_:#^%'BGX+?M ^'?#GBSX:?$"S&C:QH'B*\73UN9I)4-A= MZ/J4=S9:EI/B'3K[R+S0]9T6\M-9TO4H[>[TZZ@N4C< '\Q7_!-S]H+]CG_@ MH_\ MX?\%-+_ .).F^#IOAS^USX%_8DN?#?P0^+U_HVDZQXMUKX2_#FRL/%N M@:3H3ZK%-XEF\#^//#]M()= ENA-:Q:7J>Q;.^5#_2O_ ,,E_LYP?L]>)OV4 M]&^%'AKPG^SYXN\.>)?"FN_#+P,+[P+HEQH?C$W3^)[6UG\(WFBZIIDVMRWU MY<:A?:9?VE]<7%U<3R7+2S2N_P# 3^U'_P $@];\)_M+_P#!2WPY^R7XHU&7 MP;_P3ST+X/?%Q- \8ZE-?5OAS]EU272 MX+JSM=1U;1K.V/\ :D^OVQ;5?ZT_^"!O[8WQ#_;)_8%T?7_BWK=]XI^)?P>^ M(GB;X*>)?%^JR";5O%UKH.C^&/%?AC7M6GQNN]27PQXSTK0M0U&8M=ZK?:'< MZI?22WEY/+( =IJ^L?\ !.__ ((+?LV:K';0^(/AO\._B)\1M?\ $/A[PO;Q M>,/B3XJ\;_$>?PGIT;>'=,U>:WU6ZM(?[$\*V<=E<^,-;LM%TT^=YNKQM%-5^'_ ,(_B+HWC/P#X"TJ2&>TT+Q5K7CG MXFZ)\0=>/AYI8K5=8T3X'/!WA3]HW3/%6N:+\/;_Q%J?AJU\+>+]1\*G3]?\ $&G66FRZ MQ)=%BN'6'PT/$O M@K2[S2O%F@:%;V^C7OB35;*_2V5K 7,@!_:;7\C7_!SW\"OBC+K/[(W[7?AO MP3>_$'X7?!.\U[0?B;IMO!=7EAX?>X\2^&/%6@7?B.&VM[O^S_#/BE-+U;P_ MJ>NRP_8K&[M]+LKQ_.U33XI?ZY:_D+_X.,/VH_C+XT_:"_9H_P""8OPB\6ZC MX&T3XY6O@?5/B;J-EA/;BSUE]3T9IC='3A#& >'[$OAC]FS]EB7QM\5?C5\6? MB'\--1'@:'X9^-]-UGX?S:+=-JDFF*^I>'[>R\3^*K_4&@\):=I_@.Z\1P7D M>I:A-'?"%(([W^E?_@FC\#?&G[-G[!G[+?P3^(T4MKX\\#_"O28?%VFSW"7< MNB:_KEU?>)M2\./<1R30RGPW<:T^@[K>62U TX+:NUN(S7\R?_!3C_@AM\%O MV!/V,H?VN/V4?B5\9O#_ ,;/V;]3^'^J^)_%-WXL"7?BR/7?%F@>#KGQ5HG] MBV>DW?@?Q!H6N:_8ZU8/H-^EE#HL&H65S;W=YY&I)_0G_P $=_VM?&W[:7[ M/P8^,WQ-GBO?B9 ?$OP_\>ZO"D,2^(=?\!:]>:%%XEF@MXH8+>_\1Z)#I&M: MO!!##;1ZO>WXM(H[0P(H!^GM%%% '9_#C_DH?@/_ +'/PO\ ^GRQK]9:_)KX M,?!WQ!_9L_:1\/Z;)?Z7X#U%=,N[EA-+8:9XBT/Q)8> M,/#$>I1H-MO;ZR\>HP+<9 E>P^S.RR-:K)^]E>&?%+X@?LZW-Y'\$OB_XR^% MDVJ>/ETS2(OAAXQU[P^^K>)%U^^6PT6"/PO?7)U"Y&I:FBP:7.MH!)?1 VDH MGA#( ?DQ^PC^V!\ ?B;\7/VD)OBA>^&O!&L_'OQ]\/\ Q1X4\%^.Q#>Z1>:A MI/AZ#19]/MM>O[!?#LVI0Z^;<:';WLUAJNH^;;RV%D;F.>*#]LO$7@CP9XN\ M,7O@KQ3X3\.>(_!^I10P7_A;6]%T[4_#UY#;W,5[;QW&CWEO-I\JV][!!>6^ MZW/D7<$-S$4FB1U_ET^-W["/AN[O?VX_%_PKOSX6TS]F/QIHDNF^![MKG4=- MU#P9?^&8]=UZ*VUB]N;C5+;4])S/>Z>+J2^@N[>%M-?[/))#=Q?M+_P3D^-% M[XQ_8M^'OB[XG^)[2&?PQ<:_X,O?%'B74H[*.YL/#FL3V&B3:EJVJW*QSW,> ME-8V$MY-<%[J:V9Y&:X:4D SOVIOVF/@W_P3J^&7AOP3X,^&,UO>>.K3Q]=? M#SPIX1L]-TSP?INL:?)I=QJ=]XBFGOHKC3=/N-2\3VEPD.D:9J"]*BG@N+D^&]$FU&\N= M=OVMYYEM_P"V+R^MX;"PF6&\M[?39KJX39?VRQ_I1XR^$O[-7[6&@:;XA\3: M!X!^,N@PV?B#0?#WBBRU"T\0V>G)/>BP\0+X,[Z*+0]?\ $GPSO-#GOI66VMHM2^'%EX.T:)3+NC@4>,+.58]F MV'[2YF8I(\K#^C2OSI_;V_8+TO\ :]TSPYXC\.^([+P1\6/!=O/8:'KNH6TT MNCZYI%S.+J/0=?ELD;4K5+34"]WI&IV<=Y)ILMYJ"C3KL7I\D ^:?^"WMWHR M? ;X1V$\ML/$-Q\7#=Z; SQ_;'T:T\&^)(=2Z=/W:RRV@D MRS18^SO^";_BF;Q?^Q-\ M3N XEL/#.K>%L.^]A#X+\6>(/"-F0W9'LM$MGC M3_EG&RQCA:_"K]L+]C+XM_ SX%VOQ6_::^.6I?%+XB7WC#P_\._AYH5OXI\6 M^,=*T/3;JTUS7=7N;C7O&=O:ZDR'3M \FUTNPT_3]/LYIS)-5U+PY\2+CPKI\]UXD\*^%?[6@\8^"_B.);1VNHM!\# M^);;68M7NHK6?^QW\2V.LW#VVEVFJ7=O_5[3)(XYHWBE1)8I4:.2.15>.2-U M*NCHP*NCJ2K*P*LI(((- '^;EIW_ 65^)WB3Q7_ ,%#/%VD_"!KGXZ?\%&_ MA7\ _@;&?"^IW=U8>$M1\'_"F;X-^,]?\/:-;Z;+K>L:]XW2]:\\%>';1E?0 MM3U:."34M8?2K==5_J)_X)^_\$ROB=\+/^",_P 0/V4_$E_,]&TFP^'MKJM_HUW'?17OAG3O"'@<>(TL;E9;2]35 MM/A:40;YOLS]G/\ X)YZ5\#/V]_VSOVNOL'PI?PO^T19?!>'X7^&/#_@^VT[ MQ'\,+OP%X(B\/>/+D7']DP:=I[>/->0Z_?2^'KB.749U2YUGS[TF1?T[H _S M\/V#O^"POQ[_ ."/7A_XU?L??M)_LV>*_'6N:/XY\3^+=!TKQ-XMNO ?BCPK MXXU6WLK'5+'4[K5/"_B(>(O ?BF\TN+Q'8>)-->5F:[O-5TE]?T_7+>2R^L? M^"#?[.?QQ_;&_;Z^*O\ P5>^.WA^^T/PW:Z]\0_$'@G4Y],N].T;QG\4/B=9 M:UX:O['P3]IDC>_\(?#/P7JVJZ++?;;RW2_NM T]+RZU+3]8-E_8CX]^"GP: M^*LME/\ %#X2?#+XD3Z;)!+ITWCWP%X5\82V$MM(TUM)92>(=*U%[62WE9I8 M'@,;12,SQE6)->A6&GV&E65KINEV5IING6,$=M96%A;0V=E9VT*A(K>UM;=( MX+>") %CBBC2-% 55 &* /YJOVJ/^"H7[6'PF_X+7_!/]A?P?KG@R#X!^/?% M_P"S]I>O:??^"]-OO$YL/B#'8-XF@L_$DDBW-M]I+RFWE,,DUGYS^1(NV'RO MF+_@Y1_9#^-&F?%#X#?\%(_@?I.L:X?@YHGA_P ,?$631M+GUF;X>S_#GQAJ MWQ$^'OQ)U&PAM[A1X9CU'6=6TSQ'J5T$T_29=/T#[;_H^HS30_U^U'-##7 MQ;_P4?\ V4] _8W^&W[->N^&?'_Q;USP#;?$V33M:D\:'Q'JWAGQ'H_B31_" MWPO\.Z5I$6MW1U[QIH^BW\;ZCOU"UMK1=%@L]1ENFU./^LO_ ()#?LF^+/V+ MOV _@?\ !3XA1+:_$<6>O>._B!IJ/%(-#\3_ ! UV^\33>&WE@:2&:Z\,:;> MZ9X>U">&6:"?4=,NYK:5[9X37VEX0_9_^ WP^\17OB_P%\$OA%X(\6:E)++J M/BCPA\-O!OAKQ%J$LRA)I+W6]&T6RU*ZDE0!)7GN9&D4!7) Q7KE !1110!V M?PX_Y*'X#_['/PO_ .GRQK]9:_)KX/=2^'_[2WP3TK5M: M\;?#:Q@TCQ'I/AVWDN_$BZ5H^L3>(O"WB;0;&#?/VN_CF_Q_\ @]X*^&]SJ_CG]I#Q9X3E^+-W MH'AK6+2\T>+1=-&@R:9=QW4SZ;X,T[6S:&3Q'J6N30V\<,>H6MO_ &=;2.L/ M[U:!^P]96G[ S_LA:EJMK_;FH^$+B?4/$(62\T^U^)5UK0\;1ZC;C9:7$^C: M7XM2VMK<;+>YN-%M%615FE<5](?"OX&6/PN^(GQU^(5KXAN]7N/CEXLT/Q7? MZ9<6$-I#X?GT31FT6.TL[F.YF>^AN(/+F>2:*!TE5]H9'58_>* /Y6OAA^TG M^W+^P-X<\2_L[W/PA:Y0ZUJ!\(S^)O"GB+6H=$UK5T2>YN/!NK:%=PZ+XHTF M_(DU:VL4DOX!J4MQ.S@-?:?)]V_\$J_V1/B5X,\1>-/VHOCGIFLZ+XV\N!_P""IWP;^/>D?$_X4_M2_!:+ MQ1XET_P*WAV76_#>BIJNLV_ASQ3X.\0R:UX<\6W'AJQDS\0^*->UC79[E=0URWM1/;:%X>M[E+L+++9V]L[2:E MJ0_IS\%^$M%\ ^#_ KX&\.6PL_#_@[P[HWAC1;88_<:7H6G6^F6,;%0H9UM MK:/S'P"[[G/+&NFHH **** /IS]BW_D[3]G3_LKW@C_T]VM?VF5_%G^Q;_R= MI^SI_P!E>\$?^GNUK^TR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF M?&O_ ")OBW_L6=>_]-5W735S/C7_ )$WQ;_V+.O?^FJ[H _(VBBB@ HHHH * M*** "BBB@ HHHH **** "BBB@#L_AQ_R4/P'_P!CGX7_ /3Y8U^LM?DU\./^ M2A^ _P#L<_"__I\L:_66@ HHHH **** "BBB@ HHHH **** "BBB@ KP+]J[ M_DUS]I/_ +(%\8O_ %7?B.O?:\"_:N_Y-<_:3_[(%\8O_5=^(Z /XE**** " MBBB@ HHHH **** "BBB@ HHHH **** /IS]BW_D[3]G3_LKW@C_T]VM?VF5_ M%G^Q;_R=I^SI_P!E>\$?^GNUK^TR@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XP\?\ _!1_ M_@GA\*/&7B'X<_%+]O3]C#X:_$+PCJ#Z3XK\">/_ -J/X'^#?&7AC58XXY9- M,\0^%_$7CG3M;T74$BEBD>RU*QMKE8Y8W:,*ZD\?_P /8O\ @EE_TDL_8 _\ M3(_9U_\ GC5^2/[7O_!J3_P3P_;3_:7^,?[5/Q2^,O[9^@?$+XW^,+GQKXKT M;P!\0_@?I7@W3]5NK2TLY+?P]I_B+]G7Q5K=IIXBLHF2+4O$6K7(D:0M=LI5 M4^;_ /B"I_X)9?\ 1?/V_P#_ ,.G^SK_ /0JT ?O]_P]B_X)9?\ 22S]@#_Q M,C]G7_YXU'_#V+_@EE_TDL_8 _\ $R/V=?\ YXU?@#_Q!4_\$LO^B^?M_P#_ M (=/]G7_ .A5H_X@J?\ @EE_T7S]O_\ \.G^SK_]"K0!^_W_ ]B_P""67_2 M2S]@#_Q,C]G7_P">-1_P]B_X)9?])+/V /\ Q,C]G7_YXU?@#_Q!4_\ !++_ M *+Y^W__ .'3_9U_^A5H_P"(*G_@EE_T7S]O_P#\.G^SK_\ 0JT ?O\ ?\/8 MO^"67_22S]@#_P 3(_9U_P#GC5SWB[_@JW_P2XN?"?B>VMO^"DW[ MQ<7'A[ M6H(((/VQ?V>)9IYI=-N8XH88H_B*SR2R.RI'&BL[NP5020*_"+_B"I_X)9?] M%\_;_P#_ Z?[.O_ -"K1_Q!4_\ !++_ *+Y^W__ .'3_9U_^A5H ^F?^'C? M_!/3_H_#]C/_ ,2@^"/_ ,W%'_#QO_@GI_T?A^QG_P")0?!'_P";BOF;_B"I M_P""67_1?/V__P#PZ?[.O_T*M'_$%3_P2R_Z+Y^W_P#^'3_9U_\ H5: /IG_ M (>-_P#!/3_H_#]C/_Q*#X(__-Q1_P /&_\ @GI_T?A^QG_XE!\$?_FXKYF_ MX@J?^"67_1?/V_\ _P .G^SK_P#0JT?\05/_ 2R_P"B^?M__P#AT_V=?_H5 M: /IG_AXW_P3T_Z/P_8S_P#$H/@C_P#-Q1_P\;_X)Z?]'X?L9_\ B4'P1_\ MFXKYF_X@J?\ @EE_T7S]O_\ \.G^SK_]"K1_Q!4_\$LO^B^?M_\ _AT_V=?_ M *%6@#Z9_P"'C?\ P3T_Z/P_8S_\2@^"/_S<4?\ #QO_ ()Z?]'X?L9_^)0? M!'_YN*^9O^(*G_@EE_T7S]O_ /\ #I_LZ_\ T*M'_$%3_P $LO\ HOG[?_\ MX=/]G7_Z%6@#Z9_X>-_\$]/^C\/V,_\ Q*#X(_\ S<4?\/&_^">G_1^'[&?_ M (E!\$?_ )N*^9O^(*G_ ()9?]%\_;__ /#I_LZ__0JT?\05/_!++_HOG[?_ M /X=/]G7_P"A5H ^F?\ AXW_ ,$]/^C\/V,__$H/@C_\W%'_ \;_P"">G_1 M^'[&?_B4'P1_^;BOF;_B"I_X)9?]%\_;_P#_ Z?[.O_ -"K1_Q!4_\ !++_ M *+Y^W__ .'3_9U_^A5H ^F?^'C?_!/3_H_#]C/_ ,2@^"/_ ,W%'_#QO_@G MI_T?A^QG_P")0?!'_P";BOF;_B"I_P""67_1?/V__P#PZ?[.O_T*M'_$%3_P M2R_Z+Y^W_P#^'3_9U_\ H5: /L;P#_P4D_X)V6?CKP5>7G[>_P"Q;:VEKXM\ M.7-U=7/[4OP-@M[:W@UBSEGN+B>7QTD4,,,2M)++(RQQHK.[!02/TX_X>Q?\ M$LO^DEG[ '_B9'[.O_SQJ_ '_B"I_P""67_1?/V__P#PZ?[.O_T*M'_$%3_P M2R_Z+Y^W_P#^'3_9U_\ H5: /W^_X>Q?\$LO^DEG[ '_ (F1^SK_ //&H_X> MQ?\ !++_ *26?L ?^)D?LZ__ #QJ_ '_ (@J?^"67_1?/V__ /PZ?[.O_P!" MK1_Q!4_\$LO^B^?M_P#_ (=/]G7_ .A5H _?[_A[%_P2R_Z26?L ?^)D?LZ_ M_/&H_P"'L7_!++_I)9^P!_XF1^SK_P#/&K\ ?^(*G_@EE_T7S]O_ /\ #I_L MZ_\ T*M'_$%3_P $LO\ HOG[?_\ X=/]G7_Z%6@#]_O^'L7_ 2R_P"DEG[ M'_B9'[.O_P \:C_A[%_P2R_Z26?L ?\ B9'[.O\ \\:OP!_X@J?^"67_ $7S M]O\ _P##I_LZ_P#T*M'_ !!4_P#!++_HOG[?_P#X=/\ 9U_^A5H _?[_ (>Q M?\$LO^DEG[ '_B9'[.O_ ,\:C_A[%_P2R_Z26?L ?^)D?LZ__/&K\ ?^(*G_ M ()9?]%\_;__ /#I_LZ__0JT?\05/_!++_HOG[?_ /X=/]G7_P"A5H _?[_A M[%_P2R_Z26?L ?\ B9'[.O\ \\:C_A[%_P $LO\ I)9^P!_XF1^SK_\ /&K\ M ?\ B"I_X)9?]%\_;_\ _#I_LZ__ $*M'_$%3_P2R_Z+Y^W_ /\ AT_V=?\ MZ%6@#]_O^'L7_!++_I)9^P!_XF1^SK_\\:C_ (>Q?\$LO^DEG[ '_B9'[.O_ M ,\:OP!_X@J?^"67_1?/V_\ _P .G^SK_P#0JT?\05/_ 2R_P"B^?M__P#A MT_V=?_H5: /W^_X>Q?\ !++_ *26?L ?^)D?LZ__ #QJ\2_:8_X*F?\ !,;7 MOVM?!+XK:3H^CZ3^UY^S[J.J:MJFH^!->L]/TW3= M/L_B%-=W^H7]W-#:V=G:PRW-UYN9HH8D4O(ZJ":_KB_X>Q?\ !++_ *26?L ? M^)D?LZ__ #QJ_ '_ (@J?^"67_1?/V__ /PZ?[.O_P!"K1_Q!4_\$LO^B^?M M_P#_ (=/]G7_ .A5H _?[_A[%_P2R_Z26?L ?^)D?LZ__/&H_P"'L7_!++_I M)9^P!_XF1^SK_P#/&K\ ?^(*G_@EE_T7S]O_ /\ #I_LZ_\ T*M'_$%3_P $ MLO\ HOG[?_\ X=/]G7_Z%6@#]_O^'L7_ 2R_P"DEG[ '_B9'[.O_P \:C_A M[%_P2R_Z26?L ?\ B9'[.O\ \\:OP!_X@J?^"67_ $7S]O\ _P##I_LZ_P#T M*M'_ !!4_P#!++_HOG[?_P#X=/\ 9U_^A5H _?[_ (>Q?\$LO^DEG[ '_B9' M[.O_ ,\:C_A[%_P2R_Z26?L ?^)D?LZ__/&K\ ?^(*G_ ()9?]%\_;__ /#I M_LZ__0JT?\05/_!++_HOG[?_ /X=/]G7_P"A5H _IF^"7[:7['/[2^OZMX4_ M9Q_:R_9H_: \4Z#HY\0Z[X:^"7QW^%OQ6U_1= %[:Z:=:3:^!/@U\-M1@U@:CX M=LH1<7FJW]E]BENHSIYG>&Y@_<:@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@#XX_;Q_;K_9^_P""<_[-WC+]IW]I#Q'<:-X(\,-;Z7H^ MBZ1;KJ'BWQ]XTU2.Y/AWP'X+TEI8%U'Q'KLEK<&(W%Q::9I>GVNH:YKE_INB M:7J.H6W\]&D?\%>O^#A/XV:39?'/]G+_ ((<:(O[-6KP76N^&K'XJ_]&^ M,WBCPA(IFT35K/0M9\;_ Z\0VMUJEBJ7\-O8?"GQ'!>I=01:/<:E!Y%_>[' M_!1#PW#^WG_P<8_\$YOV&OB#9QZS^SQ^R7\ O%7[W6L M>(=)\)6VN>'5>'3KZ'P[KGA#X<-$^I#4%N]$\1>,=%DLX]/U6\6__K% "@*H M 4 8 ' ' X H _'[_@E)_P6%^$?_!3G1/B#X-N/AWXP_9L_:T^! M=Q'IO[0'[*WQ/6ZB\;> [L3IIUQK&DW.H:1X>OM>\+)K7FZ-<7-_X>\/^(-# MU1(;+Q)X>TEM0TB;4_URU;5M+T'2]2US7-2L-&T71K"[U35]7U6\M]/TO2M, MT^WDN[_4=1O[N2&ULK&RM8I;F[N[F6*WMH(Y)II$C1F'\G/_ 5N\,V/[#G_ M 7 _P""/O\ P4+^&.G#09_VIOBG>?L/?M.0:)=MIB>/=)\;WGA/P?X%U?Q% MIZQK8ZQ+H]CXWO\ 5[^\NI5NY7^&7@6-5EDTFREM?V1_X*@?\$ZO$7_!2[P9 M\(O@9JW[1_Q&^!7[.NG^-=5\1_M)>$/A;=3:;XG^/WA&/2X+;0/A==:OYR6. ME>&IM5>YU77+K4K37K=DM;:VA\/75Y/;ZKH@!\V_\$RO^"RNB?\ !3?]N+]O MWX-_!K3_ ;J7[+?[*FD_!^Q^$WQ2TVUUP>+?BMXA\37_CK2?'_BJZOKG6Y= M!?P#-JOA>&#X>0Z=XO6FEZ+^Z]?R;_\$4O@1\)?V8_^ M"V/_ 7%^ ?P)\$:/\.?A+\,/!_["?ASP5X.T*.1+#2=.7X17-[KW\]SJ>M:UJ&H:OJEU=:A>W-Q+_610!^)O\ P7Q_X*0_';_@ MEK^P]HO[2G[._A+X4>-/B#JGQ[^'OPJ;1OC)H?B_Q!X2_L/Q=X?\=:I?745C MX*\=_#O6%UF*[\,Z?'97#Z^UC'!->+/87#R0RV_Y-_\ #+_P#2);]A MG_PI-&_^F,5[/_P>(2)%_P $HO!%M M>T_P-^U]XWUF'Q5&_$5A>:1XV\&VNL:OJ6JP^%/$ND6VJ7USJEM?./OOX0?&KX0?M!> MM)^*?P)^*'@#XQ_#/7I]3M=$^('PQ\6Z'XX\&ZO:9J"6UW*UG?VES:3B.X@DC7^4'3(;?\ X(6_\%XK^UN[R'P=_P $ MYO\ @L6]]J5K=W]R=.\!_!C]K?1[R6^FMY[N[N8-&\/66M^(M?N+>W_X]+>3 M0OBIIELH_LOX:,UL ?K+_P %H_\ @I[X_P#^">OPP^"'@7]F/P-X-^,G[-+76-7T#6)I=8TB+QEXL\3Z)X:\5^"_$=QX=T:VU72?#L M-S8>)-*CM/$_BWP_?:A'? 5UXX&E6I\4S^#=#\1>(?%FO:3X7?6OMIT.QUKQ-KNIV^F_9D MOM5O+D23-_,+_P $P/"FH?\ !5W_ (*>_M"_\%HOB+;W.H_LW? +4/$G[)?_ M 30T'5(B^DWNB>&)[_1_B7^T!IECI?LX_#+]HSQE^RY'XZ\8>%(_B3\3OAX+ MG_A.)_A+8W%S<>.?!/AF6UO=--KJ'C>S%MH$E[<7\5C96-U>7-]::U:Q2Z!J MH!\"_!/_ (+5>$/VH/\ @LYXK_X)N?L[GX?>/?@I\(/V=/B%XT^+'QDL&U75 M=7U+X[>$O&/@O1I?!7P_UO3]?B\*W'@[PEI7B.XT_P 5ZC+HFM76K>,/M&GZ M3J6E6?ARYDU[]$O^"A'[=WP7_P"";O[*GQ&_:Q^.C:M=^$O R:9IVD>%O#B6 MLWBGQ[XT\1WT>E^%O!?AJ&]GMK4ZCJ]_*9KJ\N9DL]&T2RU?7KXBQTJY-?S: M_L:?L2?L[_\ !/G_ (.5/AW^S5^S)X+3P=\._#7_ 1TO=4O9KF?^T/$OC/Q M;J/Q\N;?7?'7C;6VCBFU[Q;KJ:?8QWVH/%!!;V5CIVCZ5::=HFEZ9IMG]&_\ M'-$6E7FI_P#!&;3OB FE-\$K[_@K5^SQ%\5O[;^SMH_]E/<2P2)JT=]C3GTI M_"5QXZ_M'[!OV M!=9?1]=\4WGPP^*#:W^TM\$_A?KILC:_$KQY\/=4UBZU35]*L[?4H+[4=/O? M ?PYO=)M+.]G\5_\(E;-;W3?U&?"[XF^!?C3\-O /Q>^&'B/3_%_PY^)_@_P M[X]\#>*=*D,NG^(/"GBO2;76]"U:U9@KK%>Z;>V\_E2I'/"SM#/'',CHO!?M M2CP /V9/VB!\51HX^&(^!OQ7'Q"'B#[$-"_X0D>!-=_X2<:M_:7_ !+QIW]B M_;/M?VS_ $7R-_G?N]U?B9_P:K?$K7?B+_P17_9OM=?OY]2N?AOXM^-7PUL; MJY?S)TT+1?BEXDUG0; N>3!I&D^(;32+%#CR-/L+2W7Y(E) /Z*Z*** "BBB M@ HHHH **** "BBB@ HHHH **** /@7_ (*/?\%'?V>/^"8?[.VI_M"?M!:C MJ=S!$+">6&W%Q+;VEQ>ZKJ^H3 M6^E:'I=O/>WLYD-I:7?X-V__ 5K_P"#C#Q?H]O\=/ 7_!"?0X?V>+S29_$N MG^$?%7Q=MK3X^7_AV5$U#3)4\-WOB_PWXY@U:72E?=HR_ 2\U.[O)X$L['>J M6MUH_&?1-)_;W_X.GOA3\"?B3"OB;X/?\$R?V.#^T5H_@._CAO\ PSU-TDG]9M 'Y6?\$KO^ M"M/P$_X*H?#+QAKO@#0_$OPD^-WP>UM?"G[07[-OQ&46_P 1OA%XF>ZU*QMQ M>JUK8-K'AW4[S1M6M=,UM=.TVZBU#2]3T77M&T+7=.O-,B_3#Q?XO\*_#_PK MXB\<^.?$>B>$/!OA'1M1\1>*/%/B34K31M \/:#I%K)>ZGJ^L:K?RP66GZ=8 M6D,MQ=7=S-'##%&SNX K^5']KKPQIW["'_!S)_P3O^/WPKCM_"_AW_@IU\.? MBK\!/VB_"^GJ;'2_&7C#P+IVFQ:)XVNK>V>WM9/$%SK&N?!U[FYN(KI[A_"E M[,%74->O;R3]7_\ @IW_ ,$N+W_@J#XC_9\\!_$S]I#XG?#/]C_X=WWBOQ)\ M>_V?_A?J%SH-U^TQK\NI>";KX>Z)XN\2PW$::7X/\+0:-XL-_"++5-0N;CQ' M;W>AG0-=TO3?$>G 'EW_ 2$_P""O,?_ 5=^+/_ 4%F\"^'/#FF?LZ_LW? M%;X:>!?V?/$UOI>N:=XY^(/A?Q#H7C$>(/&GCAM2\0ZCIIM_$&N^$FUGP38: M9H'A>^T?PKJ=G8^);:]UQ;F6#]PZ_ES_ ." /PP^'OP5_;G_ ."]?PE^$_@_ M0?A_\-?AY^UY\'_"G@KP7X8L(=,T'PYX?TCPK\2[:PTW3K.$!8XHHUW22.7G MN9WENKJ6:YFEE?\ J,H _"'_ (+T?\%)_P!J_P#X)N?!S]F#Q#^QU\./@S\4 M?BY^T3^T_P"'/V>].\*_&K1_%6JZ'>W/BSPMXEOM!MM&?PO\3_A2NF:UJ'B; M3M(TY=2USQ#)HEO9W5R;N& 8OK;\Q_\ AN;_ (/%_P#I$M^PS_X4FC?_ $QB MO;?^#I?Q#H/A'P?_ ,$G?%?BG6=+\.>&/#'_ 53^ GB'Q'XAUN^MM+T70=! MT72_$>I:OK.KZG>R0V>G:7I>GVUQ?:A?7/_!'Q1_9W\->&-&UGX@WUGI_PQ_:J\=Z__P + M*L6E\4WWARV3QM:IJJ>&8] 'A"6ZUNRUI/U/_P""9'[=W@C_ (*1_L3_ 1_ M:T\&16.F7GC[PZ+#XB^$;&:XF3P#\6/#-_ M ^O:3XN\&>*=+%QLV7@'_@G1_P4:T'Q;^T_P#LT:_J\L.F^"?A'\7O M!6FW6J_$#P(MP(EM=)LK/1K+4?"KQ/(#_8EK\#+8%[J]N2P!^K?_ 6!_P"" MGWQF_8U\6?LB?LI?L5> _AI\8/V[_P!M+XLV7A3X:>!/BKI_C#6/ /A/X9Z7 M,L/C;XF>-['P+XC\(Z]#I>GW%S:PV4W_ DFEP0Z9I_C+Q*ZZE:>#=1TZ?TS M_@IM_P %0Y_^"<_P_P#@)X(T3X3ZA^U;^V[^T_X@@^&WP$_9X^&!D\,+\0?' M-CIED?%7C&ZBU"]\3ZSX3^&&AZM?Z='<.T_B+4K4ZUIEE=:E]AMM<\4:3^;_ M /P14^&?BC_@H'^V)^T[_P %Y?CKH=_;:9\4M1UW]GG_ ()X^$O$5K)#<> ? MV7O NJ7N@:AX[M+28JMIJGCN\MKS3Q-]GBN;;5+KXIW%K/<:/XPM6K]N?B7^ MP%\$OBQ^W%^SM^W[XPU+QY=_&3]E[P#X^^'WPK\.1ZOH)^&5C9_$C3?$.D>) MO$5]X>NO#-UKDGBZ;3?$5S96VKV'BC3X(;:TL8GT^4Q2O, ?B!K/_!9W_@J' M^PSXW^&GBG_@KY_P3I^'?P1_9$^+GB_P]X(_X: _9S^*-E\1U^ WB#Q7*(-) MM?C/9)XT\6V=Q96+I+-K>MVDGA73I+*.X/A1O%6L6HT*Z_;C_@H-^WU\'/\ M@G=^R/XZ_:X^* OO%/AOP_!HFG>!_"7A26"XUSXI^.O&,\=EX&\&>%IP)[9I MO$-W*+J?5=EQ:Z7X?M-4UZ2*YM]/>&7\J?\ @Z8^+_@SPS_P2H\??L[SZ;:^ M,?C3^V+\2?@U\$OV?OAO%$]]X@\4^.[?XL^"/&USJ.BZ;;.MXTOA_3/#(;6/XYZ7\4 M?B=+-/!/;:_XN_8]^%OPNCLUO=D7D7]MK=_X@\6QWX6&."XLKFXA0(EWF, J MZS_P7"_X*R_LDV'PS_::_P""EO\ P2T\*?!/]@3XF^)/#6D:[\0/A3\1Y/&O MQB_9ZTGQK??8?#&N?%OPE!XA\0W=\]PT]A-)IY@CN(K/Q!9?#CQ#JWA?5!%("K2Z/XDT_2M5MV&UX[BSBDB>.5$=?F7 M_@@%\6+CXT?\$;?^"?WC.[O9M0N=.^!MO\,IKJYE\^=V^"7BKQ-\&!'+*6=G M:!? *P NQDVQ*)/GW4 ?L)1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10!_*=\9M0'P _X.S_V8O&/C.";3O"/[87_!/3Q-\&_A]XDG&-*O/B+X/U[Q MCXEU/PR9R6,6H167@GPY&$*Q1RW7C+P_;Q223WK1C^IW5MI'?:$/'FH:=*D/D3'P5JT4DT;QJR_U=5_GW_P#!.SX:_M@_ M\$M/^"A'P"_:E_X+D?"GX]?%GQ1\:/@E\-_V6/V7/VF-%\2)^T3HW[,GB77M M4D\&:7\)?B]%X036]4L_&WB*RUBR\*Z3K^E:EXC,]SXM\3RV=UXZO_$OBS6/ M"W^@A0!_,G_P3,_Y6$O^#@7_ +!O[#'_ *IHU_397X7?L,_L?\)?X$U?\ X3J3X:_#0^'_ !JO M_"+Z%XHU3QGX8_L75_\ 1,^,?#OAY=1_X^-)-_:_OJ_=&@#^4_\ X/$H8[C_ M ()0>#8)EWQ3?MF?!"&5,LNZ.3P?\6T==RE67^!/)\'^&O#OQ$L-:U?^VOB7XL\&^'I/L5WKNE1?V?%JTF MJ7/VK?:64\<%R\/] - 'SG^RE^R9^S]^Q#\$/"_[.'[+_@#_ (5C\&/!=YXC MU#PUX-_X2KQMXT_LV[\6^(=2\5>()O\ A(?B%XD\6>*[S^T->U?4;_R]0URZ MBM/M'V6R2VLHH+>+\0/^#L?X?>"_%_\ P16^/WBKQ+X=TS6/$7PI^(/P \8_ M#S6+RW62_P#"GB36?C5X(^'&JZKI%QQ);SZAX*\<>*?#]V%;RYK'5YUD1G6) MX_Z2Z_&S_@OU^RG\?/VV/^"5/[2'[-O[,?@/_A9GQI\?:I\$KGPGX,_X2CP9 MX,_M:'PA\>/AKXS\1/\ \)%\0?$7A3PG8_V?X:\/ZOJ6W4M=LWN_LGV.Q6YO MY[:UF /M'_@GQ\+_ )\&/V%_P!D3X:?#3P[9^%O!?AG]G;X1QZ3HUCYC1QR MZGX)T?6=7OKF>9Y+B]U/6=:U'4=9U?4;J66[U+5;^\O[N66XN)9&^PJ\<_9V M\*Z_X$_9^^!?@CQ58?V5XH\&_!SX8^%?$FF?:K*^_LW7_#W@G1-(UBP^VZ;< M7FG7GV/4;.XM_M5A=W5E<>7YMK<3P/'*WL= '\R=]_RMK:-_VAOE_P#6A-5K M]@_^"CO[!7P5_P""D_[)OQ!_93^.=S?Z+X<\7RZ1K'AKQMH@L?\ A)/AYX_\ M/W@N_"GC'P\=122TEO+.Z>;3=0TZ;RX]<\/ZKK.@23V\6J//'\+W?[''[1\O M_!Q!IG[=*?#G=^RO;_\ !-.3]G^;XI?\)?X$&SXN-\8]0\5#PE_PA!\4#XC- MG0)XK_\ MY?"+>&?F^RG6OMJM;CUC_@MA^P9\3OV^/V.++PQ^S[K>E^'/VH/ MV??C)\-_VH_V:-5UJ:&TTB7XM_":[U"33M"U*^N76SL[?7M%UG6K&RNM2672 M;37_ .Q+[5(OL5I++$ ?E7X3_P""1'_!5^\\ S_!O_@I-_P5NM_C7_P3G^$> MD#7/%7PI^'_@2ST#XH?'OX:_#C3[36K;X??&KXL:EX1TCQW8^!]1B\/+!XYL M;GX@_$O4?%.@3:MI-_K/GZA;:MI/T3_P:>>%[SP[_P $4OV?]0N[26U'C+XC M?M >*+0RQM&UU9I\7O%'AB*[4,JEHI'\-2)%(,K)'&KHQ0J:^5/CU^U9_P % MO/\ @I=\";__ ()^>%_^"6/Q"_8@\9_&[0T^%7[4O[6?Q;\'3OB7J?PH@AT_2[KQF?%?AZ;4]-M[30-=\1:KI=OJD^C6']H7>?%.E_P!. M?[+'[.O@/]D?]G'X)_LR_#&&6+P+\#_AQX7^'>@37"A;W4XO#VFPVEYKVI[6 M=6U?Q%J0O=>UB1682ZIJ-W*#AZ /?**** "BBB@ HHHH **** "BBB@ HHHH M **** /Y.?A;%%^SI_P=W?M*6WBJ^BTW3OV\_P#@GSX5\1_#==17[-_;GBOX MO:'HDND0:S MK.DZ1/X@U6/0M!AU/4;.PEUO7);.]U&+1M(CNYHGU+59=/TW4;Z/3K,37;V> MGWMTL)@M9WC_ !:_X+-_\$N/'W[=OAGX*?'[]E'XCV_P/_X*!?L:^+9/B'^S M+\4KFYEL-'U8R7%E?:Y\,O&=Y!9:BR^'O$,^F64]E<7FFZKIEM>)>Z3K.F7G MACQ/XEMI_P"?+]O7XV?\%B/^"@7[/VB?L8_M=_\ ! ;XO^(OCIX+U>T\:_#S M]I3X%_M&>(/AY\/_ '\;_#^BZCX;T/XQ^%I="\.^+_AP;S35\1:C=6&@^)? MC)K.C>3>WK6P@:W^UV(!^@__ 5NET_XY?\ !P5_P00_9\\,3#5/%_P4U;XV M_M(^.=/L?-N)O#?@Z1O#'B?0]3UG[,KG3K74;C]GW7[:V>\>.*>/V9OV MQ]"U:\_:#^&OA>^NY-'T"Z^ OC*\\'Z-=77A3QWJ<^E^#++5/$[SZI8+:^'] M7UII&\.ZGXI\=ZI_=G0!_-=_P10_Y25_\'#W_9[OPQ_]1WXG5_2C7XA?\$O/ MV0?VB?V=?VX/^"RWQ@^,?P\_X0[X=?M7?M3>!/B/\ O$7_"6^!O$'_">^#-& MT7QU::EK/]D>%O$VMZ[X6^S7&LZ;'_9WC33/#FJS?:=]O8RI#.T7[>T ?RA? M\'6?@?PO\3OAK_P2T^&WCC2_[;\%?$+_ (*?_!3P/XPT7[;J.F_VOX7\6:!X MIT'Q!I?]HZ1=Z?JVG_VAI.H7=I]MTN_LM1M?-\^RN[:YCBF3Z_\ ^(7'_@A1 M_P!&,_\ FS/[8?\ ]$%6C_P78_8L_:8_;*LO^"<$/[-OPU_X6/)\!/\ @HA\ M%?CI\6%_X3'P!X0_X13X5^$HM67Q#XISX\\5>%UUW^SVN8!_8GAHZQXCN]^; M'2+D*Y7][: /&/V>/V>_A!^RE\%OA_\ L\_ /PC_ ,(%\'OA;HTF@>!/"']O M^)_%/]A:1-J-[JTEI_;_ (TUKQ%XHU/=J&HWEQY^LZWJ%R/.\I9A#'%&G\VG M_!X?\,? WBW_ ().0_$/7_#]I?\ C3X3_M"_"V]\ >(F,L6H^'V\92:KX5\4 M6L$T,D?GZ=KFCW*1ZAIMT)K*>[L-(U%H/MVDZ?<6_P#5E7X3_P#!QC^QK^TE M^WA_P3.\7_L^_LI?#C_A:GQ>U3XM?"7Q/8>$?^$O\!^!_/T/PQKMQ>:Y??V_ M\2/%'@_PQ%]AMI$D^S3:U'>7.=EG;W$@* _8'X#_#KP3\(O@G\)/A=\-_#F MF^$? /P^^&_@SPCX/\,:1 +?3=#\/:#X>T_3M+TZUC&6*6]K!&K2R,\\\F^> MXDEGDDD;QC]NG]M[X#_\$\_V:_'W[4'[0_B+^QO!/@NT%OI>CV1@E\3^/O&- M_%/_ ,(W\/\ P7ITTL(U/Q1XDNH'AM(FDBL["SAO];U>ZL=$TO4K^U^I/#=I M<:?X=T"PNX_)N[+1=*M+J+>DGE7%M8P0S1^9$SQOLD1EWQNZ-C*,RD$_R#_\ M%]OV2O\ @L?^U%^W[^R3\1?V/_V.O /[3?[,'[(6A:5\2?"7@_XL?%CX/:-\ M*/&W[0VKZQJ]QK6K_$'X:^*OV@?A'XI\20^#M+TOP1%X<$T%KIZ7$>MVXOM4 MT;7]>TBZ /?_ /@ES^QA^T[^WA^U%IW_ 6Q_P""HN@2^%?%\FE2P?\ !/G] MCJ^%U)H/[,/PKU1)9-,^(7B#3-1AMY&^(WB/3[D:AI.?AU!JD&N^*M(3PU<>(=0\ M0Z-X?U-O$/B?1+;5]*\+ZI=ZUJ^DVL^H7 !^D_[>GC+2OAW^PY^V3X]URX6U MT?P9^RO^T#XGU*=^B6FB?"?Q9J$P5<$O(ZV_EQ1J&:65DC169@I_.K_@VU\ M:A\-O^")/[!N@:F6-WJO@;XC>/U+(4/]G_%+XY?%#XE:, K ':NC>*]/57'$ M@ E4D.#7Y.?M$?M#_P#!"_A?X.LG8O+!X M;\#>'M/\-:.+B1BSS73V.FPR7=Q(SR7%R\LTCO)(S$ ]4HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** *]U:6E]%Y%[:V]Y );>X$-U#'<1"> MTN(KNTF\N573S;6Z@AN;>3;OAN(8IHV62-&%BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *]S:6 MEXL:7=M;W20W%O=PIWF4"2&9$DC974,+%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D*96YD M%!$4 M'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX>'AX> M'AX>'A[_P 1" !5 $,# 2( A$! Q$!_\0 'P 04! 0$! 0$ M $" P0%!@<("0H+_\0 M1 @$# P($ P4%! 0 %] 0(# 01!1(A,4$& M$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B7J#A(6&AXB)BI*3E)66 MEYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3E MYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! 0$! 0 $" P0%!@<( M"0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" Q$$!2$Q!A)!40=A<1,B,H$( M%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E* M4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.D MI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T M]?;W^/GZ_]H # ,! (1 Q$ /P#[+HK@_CYX\N?AI\+-4\96FGQ:A-9/ HMY M9"BOYDJ1GD D8W9_"O!M-_:6^,VIV$&H:;\ M7O;.X0207%O:W//BQ/X"\2^!!X9NK> MRDN9DF>59T*["JM&Z@C(<'GMCUH ^B:*** /$OVX_P#DVCQ+_P!=;/\ ]*HJ MZS]FW_D@?@?_ + MM_Z *Y/]N/\ Y-H\2_\ 76S_ /2J*NL_9M_Y('X'_P"P M+;?^@"@#T&BBB@ KQW]I;XZ:1\(-&AAB@BU3Q'>C-I8&3:J)G!ED(Y"]0!U8 M\#@$CK_C/\0M)^&7@"_\4ZJ0YB'EVEMNPUS.WW(Q]>I/8 GM7PG\%? _B3]H MWXQWOB#Q9<3R:9'*+C5[M,O^P4/_2:UH ^K MJ*** /$OVX_^3:/$O_76S_\ 2J*NL_9M_P"2!^!_^P+;?^@"N3_;C_Y-H\2_ M]=;/_P!*HJL?#;QOX<^'O[+/@[Q+XHO3:V,.C6J#:I9Y7*?*B*.K'!_(DX ) MH ]EHKQ[X,?M%_#_ .*.LOHFF&^TK5>6@M-11$:X4#),95F!(')7.>O4 FJ' M[9WQ+/P^^$L]II]SY6N:]NLK/:<-&A'[V4=QA3@'LSK0!\L_M4>/]3^,OQHM MO"/A;Z%N >@5<]S7W!\$?AYIGPQ^'FG^%M/"22 MQKYM[OPN%Q>77Q1U>W!CMR]IHX<=7QB68?0 M'8#[OZ5]K4 %?*/@?_E(MXR_[!0_])K6OJZOE'P/_P I%O&7_8*'_I-:T ?5 MU%%% 'B7[%?"FMJRQ3Z);/!.GW[ M>94^21?<'MW!([T[]N/_ )-H\2_]=;/_ -*HJV/V=O$7A^V^!7@J"XUW2X9H M]&MU>.2[C5E.P<$$Y!H _.GQMX;\4?"GXC3:1?-+8:QI5PLMO(_>B M!]'\*Z:!]FTVU2 -C!D8#YG/NS$L?,O^P4/_ $FM:^E_^$I\,_\ 0Q:1 M_P"!L?\ C7S%\.[JVO/^"AOB^YL[B&X@?2ODDB<.K8M[4'!'!Y% 'UI1110! MRWQ5\#:3\1_ U]X0URXOK>PO6B:22S=4E'ER+(,%E8=5&>#Q7A__ Q5\+/^ M@_XS_P# RV_^1Z^F:* /F;_ABKX6?]!_QG_X&6W_ ,CT?\,5?"S_ *#_ (S_ M / RV_\ D>OIFB@#YF_X8J^%G_0?\9_^!EM_\CT?\,5?"S_H/^,__ RV_P#D M>OIFB@#YF_X8J^%G_0?\9_\ @9;?_(]=I\'/V'EZ@X2%AH>( MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ ! M @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,08205$' M87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66 MEYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7F MY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ _OXHHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHKY;^,_[Z)9^)K/P7\9_ MV@?A-\+O%EWX;U"[U#3[#Q!;>'/''BW0M8GT2^O])U6RL]5BLWL+F[TS4+:& MX>:SN4C /J2BO@)/^"K_ /P2UD=(X_\ @I3^P%))(RHB)^V/^SLSN[$*J(J_ M$8LS,Q 50"22 2:^E_AA^T=^SS\;21\&/CQ\&?BZ1$TY'PP^*'@CQ\1"F=T MQ_X137-6Q$N#ND/R#!R1B@#V:BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K_ M "W_ /@\Y_Y2P_#;_LR7X1?^K:^/U?ZD%?Y;_P#P><_\I8?AM_V9+\(O_5M? M'Z@"AX%_X,X/^"G_ ,0O W@WX@:'\:OV%X-&\<>%/#OC'2+74OBC\=X-3ATS MQ-I%GK5A!J$-O^S3=VD-]%:WL4=W%!>W5O'<+(D5U/&%E?\ ,;]O7_@EA_P4 M0_X(Z/IWC#PJ+:34]'M/$ MMYX?\#^*O#?BFRL-1MKL66I:'80:UI%W>#39]5MK36H;/_2)_9__ ."[W_!( M+PI\ O@EX<\0_M\_ G2]=\-_"#X:Z'KFESZGKS7FG:OI'@S1;#4K">*'092; MBSO+>:WE6,N/,C8*6&"?Y-/^#JK_ (++_L8?M^_#W]GG]F;]CWQVWQGL_AK\ M3M;^+'Q#^)]AX<\3>'O"NG:A%X2OO"/A[PEX;G\6:'H=_P")9;R#Q)K6J:UJ MNF6S:%9_V=I-M:W^I75Q=II@!_:Y_P $6OVYM?\ ^"BG_!-S]G']I[QO!!;_ M !+U_0];\%_%46EI#8V5[\1OAKXBU3P3XDUZQLH)[B&SLO%DNC0>+;6RC=4L M8==6R6*(6_EK^IU?@+_P;5? 3Q9^RQ_P1F_9NL_BS8_\(AK7CFW^(7[0.J6> MJS26[:-X0^)'B74_$_@Z_P!56Z2'^S'N_AW'X.?#?[/T&J>)K;X1_"SPOXPU7X8># MIOA?X2NELM1^.7Q^UNPFL[O4Y=>\ZQU62SU]-1LO"JZOH?@_PMH-QXAGNKOQ M$ ?ZG5%?Y1%UX\_X+-_\&P_[5'P8M/C#\0-2\5?"?QU"^MCX:VGQ1U_XE?LX M_''P+X>U#3+#QYX;T*V\16]C<>#/&_AVWU72EBU^Q\-^'?$OANZU3P[>,-8\ M-ZA<:7JO]F/_ 76^(7Q:_:._P"")!_;>_8%_: ^.OP@U3PGX;^$W[7'A;Q3 M\#/BKXX^#_B;Q7\%M?TJ&/QKH'BR\\$:[H5]>Z9H7@KQK<^-]6T#4+EQ9:WX M%A"QB\M3%( ?TC45_)'_ ,&B_P#P4-^*_P"V-^R-\?OA!^T3\8_'?QJ^-?[/ M7Q?LM8M_&/Q3\9^*?'WQ U'X3?%S16O?"T.L>+?&6KZWK>N+HWC3PE\1+&T: M2_:/2='GT/2EM[>"&T:X^0?^#P3_ (*:_'?]F[Q)^R/^RO\ LM?M _%;X#^. M]2TGQ?\ 'GXL:_\ !+XI^-?A;XTF\,W-RW@+X8:#JFL> M;T+4[CP[JVHV'Q M*U2[TB_NY;.YU#0=#OQ:^;8P3 _N:HK^>7P]^U+\0O^"/O_ 0%^'?[27[6 M/C;XF?'W]HWPQ\#?#7BK53\=1.O>$_AMX@\9>)=3UO MQ ^@^"]:\867AK4/LUY/C-^S_XKUW]K'3?#FM^)_@E\4/&_P *O$.L M>'I/@_\ %34WT'5=:\":YH.I:AHSZEIVGZ@^EW=S-8M?6-G=F SVL$B ']9E M%?YBW[.GC/\ X+P_\%Z_V5_AC^S=^S%\6?&?@[X#_LL^#F\(?'WX]_%OX]>- M]!UG]HKXX:[KFN^+7M?B#\4[6+Q5\3/'AT3P;X@\/:;HW@%8M4\/:'IME9>( M/&=X+S6_!UKIGQ?_ ,$^OVR_^"@O_!$+_@JCX4_9A^.GCCQOI?A31/C7X)^# M_P"TI\"/$OCZ_P#%'PPU+P3X^U+0XD\?>&H)[O4]#M-0L_#/B?3?B-X(\7Z) M;:?J-]8-:Z=JDL6F:MK&FL ?ZW-%?@'_ ,'-OQE^+_P$_P""0GQS^)?P+^*O MQ)^"_P 1](\?? JSTKX@?";QSXG^'/C;3+/5_BUX6TW5K73_ !7X/U31M=LK M;5-.N+BPU&"VOXHKVRGFM;E)8)7C;Y$_X-#?VBOV@OVEO^"?O[0/C/\ :-^. MOQC^/_C#1?VQO%?AC1_%?QL^)WC;XJ^)=)\-6WP4^!NJV_A[3==\=:WKVJ6& MAP:IJ^JZE#I-K=16$5_J>H7B6ZW%[?LR_M* M_L>:%^S=^U3^TA^SYH?B?X&^.-7\2:-\$/CC\3OA1I7B'5;3Q\EG::GKFG> M_%&@6>K:A;69-K;WM_#<7,-L3!'*L7RU_5UI'[8/A_\ 97_X)&?#;]M+X[ZU MKOBJR^&G[#OP>^*_C34M5UB34O%WC_Q7>?"/PC_T77?B=XG^&?[,7P4T_5]2OY_ W@+PYHFAV^JKJ/BF>WL[R M2#4H/#.N^+]7@T6;6_%FL($LIF^Q_P#@F?\ \%)_^"BW_!$?_@I3H/\ P3V_ MX*,>,?'GB/X&^*_&_A?X?^-/"_Q%\:WGQ#T?X=6OCZ>QTKP#\<_@QXWUN^NY MK7X>B6:PO]=TK3KZVT"[\-R>(C?^'+#QWI#160!_IKT444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %?Y;_ /P><_\ *6'X;?\ 9DOPB_\ 5M?' MZO\ 4@K_ "W_ /@\Y_Y2P_#;_LR7X1?^K:^/U 'H'QZ_X,^_CYX)_8U7]J7] MGO\ :HT7]HGQC%\)=!^,$WP%NO@???#/Q%JVBW_ABR\5ZSH/@OQ/;_%;XBVO MB3Q5IFGW-PNCZ3>:%X?7Q-<6@M+6XLKZ\M;-_D?_ (-E=,_X)7_$#]L_PQ\( MOV]?@W>^,/C;XJ\6Z7J/[*GC7QAXOO+CX%3>.--MEET_X<>-_AE;6MAIVH>) MM:OX9[_P=J_C'5/$WA#Q!K'V#PG-X9TO7/[&NO$/^I)^R]_R;/\ L[?]D+^$ MG_J >'Z_R[_^#F[_ ()K:M_P3G_X*#1_M!_!6QU/PA\"_P!J?6]2^,WPPUCP MN]]I*_#/XTZ5JMKJWQ)\'Z/JE@\4FA76G^)+W3_B%X,-E/8G3]+\2)IFAQI' MX3GDB /]''_@K;XNUKXFVM]8A5V02Z;]J%S;.J[;=X$D5<1@5_EH?\$3_P#@L9#_ ,$ ["XU#XGR?#"[\%:/HVO7GB#68K._A^'?Q E MU.#Q/>#06O;01Z4D+^';*5WO&*+;_P"B+^P3^U'H_P#P76_X(C^.=+U?6+"W M^,'Q3_9\^+/[)_[0%M9RV]I)X<^-]S\.;[PC>>)A:1S7@TRP\60:WX>^)^AP M2F6.UT[Q#!82"26QNHU_BB_X-F_^"@WPZ_X)5?\ !0#X[_!G]LR\_P"%+>#/ MC%H4GP9\?>)O%<5S;6_PF^-'PE\9W\>C67CO[.MQ'H^B1W=[XV\+Z_JTZ-;: M#JTVF7=_<6FCQ:I>P 'E'_!:C_@X5E_X+%_ SX3_ >U;]CW2/@'J?PH^+#? M$O3?'-I\;)_B==WUC=>#_$/A?5?":Z3$_VEO@)XEL=0A@F M34/A[=_%GXJ>%8= N(GB,$UM9^#-6MM!MUDB?-C:VZSF6022/\C_ /!6C_@Z MW^!'[&7C[X,^!_V&YO@;^W+/K-EK_B'XV:GX>\?7]WX+\*:*386O@S0_#'Q) M\%OJ_ARX\8:K=+KM[K=FMIXD30=,LM-74+2TNM8MMO\ 2_\ L:?&WX@?M)_L MK? 3]H#XH?"0_ CQO\9?AIX:^)&J_".3Q/=>,+GP/;>+;-=9T/2M0UV^\+>" MKR;5)/#]UI=_JMA=>&=-N-$U&\NM$F^UR:/<+R7QWL[C_@M/\ \'2TOPXS<^)O@]HO[3&F M_#&ZM+S2EU/1+7]GS]D&UFF^)=J4M]L,&@?$.X\ ^.KO3M0U69XFU?XC64SS':M9OX:M_A%J-[:Q3JFL3ZEK8OK<&XFFN_J;_@RG_91 MN_%7Q+_;"_;Z\903ZI<>'M-TO]G7P%K^HWMU>WE[XJ\:75A\3/C#J%R;@OYN MJVNEZ=\-(AJEQ-/>S0^*]8BRBW%PUP ?<7_![-XEU'3OV$?V2?!=I)-!HVO_ M +5LNMW]O!NCM99_"?PB\=V.EQS*FU"L*>*;YX(6!7)=7^)4G[05UX N_%VJ>._&NM>* M%N;WPQ!\%?%RV<^C:3J&E>%XYF\0W[WEGH5K2_#/4O#_B?X=>,;R&&V.^" M#P[=^+_#GBW6+^2.6WT_PYX?UN[N1#!%)!=4^+7C#3_!GA7X@_#GXC^)-0^(CW>E>)O$3:;H M$'B;0_&7B+Q9I6H>%_[1:^GTQ="U:P6[?4+^WTX _D3_ ."CW_!574/V\_\ M@H;X4_X*%^%O@9I7[/OC;PO'\&M0_P"$/LO' M#? EPTUY9:=X?TJ2U;1Y);6VT2 IJ$RO'#;?VG?\'K%U'>_\$Z_V3[V+_57? M[8.AW4?_ %SN/@;\7I4_\=<4SPI_P=9>,?C5_P %3[3]B+]DS]EKP)^TU\"_ MB'\'=1@\; M>+M*E@T'0);GX>Z+97ETPNYIKBKG_![+_P H]_V6?^SRM*_]4E\8* /NC_@T MV\.Z9HG_ 11^ >I6%I!;77B_P")G[0GB+6IH8DCDO\ 4[7XP>*?"<5W=.BA MIYTT?PQI-BLLA9UMK*WA#".&-5_CD_X.[$/A_P#X+-:SK>D-]AU2?]G_ . F MO&\@55F&JV%OKUC:7A8J0\\$&D6"1NX;"6\2'*H /[.O^#4[_E"!^RQ_V-O[ M1O\ ZT3\3:_C)_X/!O\ E,)J/_9LWP0_]&^,J /[&/\ @[ 8O_P1)^/SM]Y_ MB'^SLQQP,M\9/!Y/'U-?%O\ P90D?\.V?VE!W'[//^"(G[5L?AO3+C5KSPC<_ _QY?VMKM,T/A_PQ\:OA_<^)-3*,R[K M?1M"EO\ 5[W:2T=C8W,P5O*VG^=[_@T9_P""HO[%W[*7[/O[3O[-/[47QY^' MW[/WB/5?C-;_ !P\%ZY\5O$-AX.\(^+-&UKP%X5\$Z[I6F>)M6EM]'3Q#H5W MX'T^ZDT:\N[:_P!2L];@FT>&_P#L6I"T /,O^#WB1#^U=^Q'$"-Z?L]>/)&7 M(R$E^)!5"1UP3#( >AVG'0U^I'_!?KQ=J7AO_@V"_96T:Q:86OQ \'?\$^_" M.LB-"R-IME\,M'\>Q+<$<)"-7\$:4RNW!G6!/O.M?RY_\'-G_!1CX3?\%'?V M]M"\8_LZZIJ'BS]G_P"!GPOMO@5X0^([Z1?:;X>^(_C/2/$VN^,_B'XD\)3: MA%;W5YH5O)XT\.:#9S7%M:2WMMI%MK]M;OHVO:1>WO\ 9E_P52_9>\7_ +5? M_!LEX&\*_#[2+C7_ !Q\,?V1/V0?CUX?T2SMKR\O]3M?A-\/_ 6N^,[73;.P M@N;N]U0_#I_&$FF64%O+)>ZA';6BA&G$B '\@7_!&7_@XP_X<_\ [-'CC]GW M0OV+M)^.>I>/_C+KGQ=USXB7OQWN?AS>2-J?A#P5X0TWPR-"@^$'C<-9:);> M#Y+VWNCK8$MUK=^18V[%Y)_B7_@M)_P5ELO^"P'Q[^&'Q_F_9KTS]G7Q/X ^ M%$?PGU>WT[XFR_$UO&.E:?XL\0^*]"OKN_E^'W@!]/ET>?Q3K=I' UKJ1FAN MD/VF%85A/]%7_!I/_P %>_V4/V6_@O\ '/\ 8J_:R^,WA+X$-J'Q7N?CK\)/ M'OQ3\16WAGX>:M;^)O"GA+P?XT\$2^*]8EM] \+:GI-YX,T?Q)IEIJU[8V^O M#Q'KTMG(;O3;B.X^[_VJ/^#M23P;_P %";#]EC]A?X ?#7]N/X2:S>_#;X8^ M%?%VC?$+Q!X"UCX@?''QAKD^F:GI_@/QI;Z-XU\-:SX'6XUCPMX'[O2+A #^M+]D_QO=?$S]EG]FKXCWLWVB]^('P ^#?C>[N M/F_?W7BOX=>'->N)OF);][+?N_S$M\W))YKW^JMC)>2V5G+J-M!9ZA):V\E] M9VMT]];6MX\2-#/ &BS MW]UHW@;PGX=\':3ST6PGU&:TM;*UFOYK6RBDNY;:RM+>2 MX:1X;6WC*Q)\8_\ !1__ ()O_LY?\%2/V=+C]FK]I2+Q=8^%H_%WAWQWX:\9 M_#F_\.:/\1_ OBKP[+/''JW@_6_%?A7QKHEA-JVB7^L^%M;2^\-ZG#>^'M=U M.WCCMKTV=_9_?-% 'XX?\$K_ /@B7^S?_P $A]6^+5Y^S5\:OVI_&>A?&C3_ M Y;>+_ OQO\;?"[Q/X,AU;PI"SU74](N+U MM5N;._TJ\$%]I]Q-8:5<6'R]_P %2/\ @VA_8;_X*8_$S4?C\^N>-?V;/V@] M?BA3QG\0/A99Z'J7A[XC7%K!':VFL>/_ !K<$=CJ?B.VM(8[5O$>@:OX8UC M5((X5\076LFULVMOZ,** /Y)_P!A;_@T%_88_96^+'A'XR_&[XK_ !$_:Y\0 M^!-0L==\-^#/%GAKP_\ #[X2'Q-I>H6VHZ7K?B'P9I5]XFUGQ.FFSVD36^@: MOXRF\,7A>===T;68&BMX?ZUU5454151%4*JJ JJJC"JJC "@ 8'%+10 M!^8G_!4?_@DU^S-_P5O^%'P[^$G[2FN_%?PCIOPO^($GQ$\*>*O@OKO@SP[X MSM[^Z\.ZKX;U/0KC4/'/@#XC:3)X:UBVU&UOM3LH-#M[Z;4]!T*>+4X(;2XM MKOU3_@G5_P $]_@5_P $QOV9- _95_9YOO'6M>!=$\4>+O&5UXF^)NI>&M9\ M?>)O$7C+56U'4-1\2ZKX1\)>!]!O9K&SCTSP[I36?AG3W@\/Z'I%I=->75O- M>W'W/10!D:_H&A^*]"UKPOXGT?3/$/AOQ'I6H:%X@T#6K&VU/1];T75K2:PU M32=5TV\CFL]0TW4;&XGM+VRNH9;>ZMII8)HWC=E/\=_[4/\ P9@_L2?%SXD: MUXZ_9[_:$^+7[,.@^(M9.K7GPP'A?0?BWX(T".>:*2^TOP,^K:SX1\4Z%ILH M%RUC;:[XC\6IIB@#\-/^"47_! /]BO_ ().ZQK/Q(^& MDOC#XP_M :_I-YX>N_C9\5'TE]8T'PUJ$D$E]X>\!>'-$L;+1/"%CJ/V6 :M M?QKJ7B35(Q)976OMI#KIB?3'_!4;_@E3^SS_ ,%;/@YX!^"'[1WC+XS>"O"G MPZ^)EO\ %71-0^"7B'P1X<\0W7B&V\+>)/"*6>JW?COX=_$C39]&.F^*-0G> MWM-)L;XWT-G*-16".>VN/TSHH ^+_P#@G[^PO\)/^";_ .ROX _9$^!WB+XB M^*OAM\.=1\:ZGHFM_%;5_#.N>.+J?QWXSUWQSJZ:KJ7A#PCX&T&>&VU;Q!>V M^FK:>&K%X=.BM8;J2\N4ENYOS+_X*1?\&W_[#W_!43]I*?\ :C^/WQ4_:L\( M>/Y_ WA7X?OH_P 'O''PB\/^#AHWA!M3;3;E=/\ &GP,^(&M#4YSJMQ]NF/B M VLH2'[/96VU_,_H$HH X_QWX \&?$_P'XN^&/Q#\.:5XQ\ >/?"^M>"O&?A M37K5+W1_$GA7Q'IEQHVN:)JMJX"7%EJ>F7=S:74?REHIFV,C;6'\0W5U??VF44 ?SD_M&_P#!KG_P3+_: M(^#O[,WP*BN/C]\#OA_^RUI7Q"LO!]M\$/&?PZTO5_&^L?%&Y\(7OC/QE\5- M;^(OPD^)>H>*_&&IW7@K2'75;271(+:!I=.ALETNVTBQTO\ >_X2_"[P[\&_ MA%\,_@MX));&^UK4O#O@?PQIOA/2Y]?FL-/TO3; MS5+S3=+@DU66STK3K&XNY)WM]/M+=TMH_1Z* /Y'/VX?^#/K]A;]ISXH^)_B MW\!?BO\ $']D#5_&>H76LZ_X$\*>%O#_ ,0_A!;ZU?W-S>:CJ/A;P9J6H>%- M:\)Q7]S<^9)H6F>,CX7T](TM] T/1K4>0/K_ /X):?\ !M9^P[_P3%^)MG\? MK#6_&_[1?[0FB0WUMX,^(WQ3M]%L-'^'*:IIYTW4[[P%X&T.#^S=,\07UG-> MV9\2ZSJ'B'6[#3[ZZL=%O-+BN[\WO]$E% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !17B7[2?Q_^'?[*OP!^,'[1_Q9U/\ LCX=?!7X?^)?B'XK MND!>ZET[PYILUZNF:; JO)=ZSK=VEOHVB6$*//J&KW]E901O-<(A_''_ (-^ M_P#@IA^V-_P59^ WQQ_:8_:5^&GP0^%WPWTWXOM\-?@-HWPG\,?$/2M8U6T\ M/Z3'K7C75?%GB+QO\2/&-CXL@LG\2>%O#>FZCX<\.>#[4ZYHGB][BUD,MOIV MC@'[]T5_%+^R'_P&_A+;-^T (_$/PU\$_%K1_B*1\*;;6YO#N_5O%'QO\ &/AH_;6TV :U MM\(K]H5YA8_V<60Q_P!H- !117\4/[0W_!R#^W#\)O\ @N;IO_!,KPY\*_V4 M[WX#WG[9_P"SO^SI+XMUOP/\7;GXN+X)^+?B'X8:3XDU2/7K#XYZ;X-'BFRM MO&NJOHE\W@)M)MI[?3VO]#U*.*YCNP#^UZBOP=_X.%_^"H?Q^_X),_L:?"[] MHC]G/PA\'O&GC7QM^TWX0^"^JZ7\:] \:>(_"UOX6U_X5_&3QQ>7^GV7@7X@ M?#C5HM?BU;X>:+;VUUR_\$-?V_P#XR?\ !3/_ M ()]>!OVK_CQX:^&?A+XB>)O'_Q/\*W^C?"/1O%.@^"X=/\ !7BBXT32IK33 MO&7C/Q[KD=[<6D2R:A)-XCN();@L]M;VD9$0 /U]HK^+W_@DK_P<7?MM?MY_ M\%7;W]A7XO\ PN_98\.?"2VN?VA(4\1?#?P3\6M'^(Q7X3V?B&X\.E]7\3_& M_P 8>&2UZ^DVPUHCP@HN5><6(TTM&T?U1_P<=?\ !;[]J[_@D#XE_9*T;]FK MX??L]>.+7X\Z'\9]3\7R?'+PI\2/$L^FS_#J_P#AG:Z(GAMO /Q9^&<=G#=1 M^,]4;55U2+6'G>"P-I)8K%<+= ']35%?'_\ P3[_ &@?&7[5W[#O[)O[2_Q$ MTSPQHWCOX[_ 'X8?%7Q?I/@NRU73O"6G>(?&OA33==U6S\-V&N:UXCUFST:W MN[R6/3[?4]>UB^BMEC2YU&[E#3-]@4 %%%% !1110 4444 %%%>,?M&ZS\9/ M#GP!^-'B+]GC3?!NM_';P_\ ##QOKOPAT/XA:?K>J>!]>^(FC^'M0U'PGH/B MFQ\-ZWX;UZ;1M;UFVM-*O6TG7-.OH8KLW$$Y:+RW /9Z*_G]_P"#?;_@LSK/ M_!7C]GKXF:K\8M ^''@/]IWX(>.ET7XD>"?AE9>(-%\)7G@CQ5'<7_PZ\;>' M]#\7>+O&_B6RMKX:?K_AC6HK[Q'J(7Q!X7N[Z/[#9ZOI]A!_0%0 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 ?Q=_P#!Z+^U_/\ #3]CCX"_L<>'[V2#6/VG?B9= M^.O&\4<3/'-\,?@7_9.IP:7:;*PDO+?XA?& 3_%3QK:ZA M,'D$MWINO^+[S1SMD>&"#3H+2U;[+;P*/X=?^#M/4]=^/W_!:/\ 9O\ V;Y= M9FM/#^F?!7X"_#C1X(ECEBTC7/C%\5_&5SKNNI$4W-?7=GJ_AN&9'=XY+?0M M/"HA,A?_ $R=*TRST72]-T?3XA!8:386>F6,"XQ#9V%O':VT0P ,1PQ(@P , M#@"@#^3K]F'_ (*2?\$*OB!_P5X/[,GP9_X)V>)O ?[>B_M%_'_P/_PTA@_&'5?B4T'C*/P_XR2+6V\''6M;_MY%UO3= M/74-0^R_JA_P59_X+8_LK?\ !'Z?X$V_[2W@#]H'QP_[0<7Q+F\&'X&>%?AS MXE73%^%;^ 4\0CQ.?'WQ6^&1LFO#\1=$.C#2EUH7 M=5^W'3C!:"^_@F_P"" M:?\ RMFO_P!I!_V]?_2/]I*OU3_X/F?^0E_P3%_Z\?VR?_2C]EJ@#]COVV_^ M#JW]@S]DKX;_ +\0>$O!'Q/^.GQ6^/7P4^&7Q[TSX+:3=>%/">K?"WP1\6_ M!FC^//!5A\;?%B:IXO\ #_A+QEJ6@:Y8W+^%?"@\?7MK$5U"ZD@T>_T/4M7] M0_X)(?\ !R1^R3_P54^)LG[/L'@'QI^SC^T5/H6H>(_#/P]\<:UH_BOPW\0M M/T2S-_XBM/ 7CO2;;2#J>OZ!81W.KWWA_6_#'AW4+K0;6\UC1TU.WTS6UTKX M'_X-WO\ @AC^PMXK_P""<'PH_::_:Q_9_P# /[2?QI_:DT"^\6W.H_XY MTKP#\-;/5=6\+_#?PGX#TG5U.G>')5\(Z3I^MZCKUC:+XC&H:J-*@UO^Q= T M&ULOY6)O@SHG_!-G_@YO^&OP4^!-W?Z5X(^%7_!1GX">'?!=MJ%S-J%WI?PQ M^,?B[P#<7?@Z>^GE:\U&"P\ _$F_\&KJ%Y/+J%]9PK>7TTUY--(X!_KET444 M ?Y-/_!"WX^_"']E[_@N+\5/CW\>/'&C_#GX4?#/0_VU_$?C#Q9K?\'M/ M['<'Q9E\.VO['_[05[\&8]2>S7XHKXK\!V_C2>R2Y, U>'X3S8L1:RPC[9%; M7'Q,M]0\DK'+:17.Z!/XZ/V%OV+M%_X*#_\ !9OPC^R7XKO-3T[P/\3?VFOC M'??$.\T=W@U-?AY\/)O'_P 3/&]C87Z1RC2M0USPWX/U'P_I>JO'(FGZIJME M<^5,Z)#)_=3_ ,%M/^#?W_@GG+OA;H3:9K'BK1_A5H5[XH\7>#_'ABFDN_'(+'Q" MFD:G!J$T,%WIVH ']*?[,G[37P1_;%^!OP__ &C?V=?'>F?$;X1_$S2/[7\, M>)=-$T#[H+B:QU71M9TR[CAU'0?$GA_5;:\T7Q%X>U:VM=5T76+*[T^_MHIX M&6OYH?C?_P %)O\ @A1X0_X+!V'[,'Q(_P""=?B;Q7^WW/\ M7_ [X(8_!C>(-& M316DT?1[Z2QL8KC\ZO\ @R-_:7\5ZA9?MJ_LB:UJTE[X/\.I\//C[\/M*GDN MI&T35-?VH*^HO^#2 M/_E"]\)/^RR?'[_U8-[7R[_P>L?\HN_V??\ L_CX:?\ K//[4%?47_!I'_RA M>^$G_99/C]_ZL&]H _DK_P"#;O\ Y6+]4_Z_OVT__37XTK^P7_@O!^W'_P $ MD_V//$'[,]G_ ,%-_P!BK7?VM]5\?Z/\5KGX.WFC_!/X*_%U? NG^&[WP!%X MXMIY?BY\2_ $N@MXAN=;\+2QQZ#%JD>I#1F;4I+1K&Q6X_CZ_P"#;O\ Y6+] M4_Z_OVT__37XTK]#?^#Y#_D>_P#@F]_V*7[4G_IX^ M ']PW[$?Q!^"WQ8_9 M _9I^)O[./@&Y^%GP#\>_!7X>^+/@]\-[S0-!\+77@;X=:YX%I_#? MA;5M>\-Z%+HND3VMBVDZ%K6J:58F'[/8WUQ;QQR-^.__ 4^_P"#F#]@[_@F MM\2-2^ \NG^-/VE/C_X?,*>,_A_\(KC0(- ^'5U-'+(NC^/O'VM7JZ7I?B94 M2)[GPOHFG>)-&OAZUY%("DUFGC;6]!:[A*L9K82Q*I9P#_%] M_P &UG_!*7X>?\%Z!=Z]KFEWGQI^,_ MQEUKQ5J&DP^+O%VF7ECX@NM(MH_#'B_Q7XOBT?5K#6=4UBY\-1:AJ":3J6H6 MFI@']./[%_\ P>)?L'?M%_$GP[\,/V@?A1\1_P!D"[\5WL.EZ1\0O%'B30/B M-\(;#4[NXCMK*V\7>+=(L?#&O^%+6\EFC0:[>>"Y_#>F#S;GQ!K.BZ?"]]7] M<]K=6U];6][97$%W9W<$-U:7=K-'<6UU;7$:RP7%O/$SQ3P3Q.DL,T3M')&R MNC,K G_/K_X.??\ @@I^R/\ LP_LK6?[=W[%/PSL/@>WP\\;^$/"?QR^&_A_ M6M9F\!ZYX1\>:C%X3\/>,_#^AZW=ZN= \3Z/XTO?"^AWVGZ#=:7H>K:1K]WJ MMSIXU;3'N=0_9S_@TO\ VS?&'[4__!+RS^'?Q$U6\USQ?^R+\2=3^ VGZSJ- MREU?ZE\,5T#0O%_PQ6X=8HG2+PUI&O7WP_TV.7SI?['\&:<\MS-*\FT ]9_9 MN_X.=?\ @G!^T=\7?CI\)ETC]H/X)Q?LZ_#?XF_%/XF_$[XY>$?A=X?^&5AX M7^%7B?0O".O1Z;J'@KXR>/\ Q9J>M:KK/B/38/"VCP^#TN]=EE6QA6+59[+3 MKK\OO$__ >V_LC:9\59] \,_L;_ !]\4_!RVU"YM&^)DWC7P+H'C:^M(+N* M&+5-)^%-U;W>G2V][;"YO+6WU?XG:)?*JV<%[;6*+SP9IGAN.^A#76FWVJV6IV)AO[*UN8?Z\_^#E[_@C?_P $]_@7 M_P $J_&7[1'[-_[,_P -/@%\2OV._B+X6^% M>L:!X\EA=Y/&)W>+]/URUUSQ ^H>(K;4](3RM66VU#5(+P _K9_93_:F^"?[ M:GP ^&_[3/[/'BZ'QK\)_BCHSZMX=U80/9:A:7%G>7.EZWX>U_2YB;C1O$OA MK6['4-"\0:1<$R6&JV%S"LDT(BGE_%7_ (*??\',?["O_!-/XL:I^SU>:#\0 M_P!HKX]^&/LZ^/? _P *TT?3M!^'%Q?:9;:MIVE>,?'/B6ZM=,77KRSO;*XD MT3PU9>);W289B->72KOR;2?X,_X,I_&NMZU_P3O_ &D/!6HZE=7NE>"?VNM9 MN_#]I*_A-\,KN_LK%9&9;:RGU33+O4S:PA(O[0O]0NRIFO)G;^/ M_P#8L_:._9 ^ W_!8CXY?%S_ (*P? R+X_\ PUU#XJ?M%Z5X\\.:CX5L?B9H MWA+XQ^(/B9>._COQ!\/O$TT-GX]T+P]

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end GRAPHIC 12 chart-0e7efb26c0365e6cb47.jpg begin 644 chart-0e7efb26c0365e6cb47.jpg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

&H/!F@^%8=&U/3M-M=? MU[5M4U;Q!J5IH7U1_P %=M%^-WB7]OO_ ((L:'^SAXZ\!?"[XV:Y\5?VXM(\ M'_$KXD^!I_B3X6\ VVI_L>:S#XN\5?\ ""V_B'PHWBSQ!I/@_P#MV;PAX?NO M$.FZ1J'BDZ1_;TLFBPW\,@!^\NM>./ _AS7O"7A3Q%XP\+:%XF\>WNI:?X%\ M.:WXBTG3->\9ZCHFFR:YK%CX3TB_O(-1\1WND:/!+J^I6VC6U[/I^FQ2:ACW-IKL]OJOACP7J4,VG>+==LGN-(\-WT4EIK-W97$;1K_-5\"OV[ M_CI\:?VGO^":'PP_:.\&_L^^/?CI\(_^"DO_ 4V_8:^+'QELOA)91W.J:]^ MS)^S]JNL6/Q7^!$VJWMY??!Z^^(.AWNBZ5X[M_#UUFV3'2;/\ MI_\ @G?JJ>&/@Q_P36UZ#1/#.L_V#_P1X_X+K:S'H/BC0+/7_"FK-I?[4WBV M_&E>(O#UQY5IK7A_46C>TUK1IWCM]4TZYO+*=A'&_&?A_0_ M%OA'7]&\5>%?$FE6&N^&_$WAO5[+7= U[1=4MDO-,UC1-:TNYN].U73-1LYH MKFQU*PNI[6\M94F@GEAD#-N8QZ],=2?YGK[]3W-?R4?!?]L3_@H;\=_@O\'/ MAG^Q#XQ_98_97T[]E+_@D7^QW^V9\2]-U_\ 9[7Q)X/^+?C_ ..OPQ\2^*O! MG[/_ (%\(:;XM\,:3\%O@?HOAOX=7]GJ/BWPN=7U[P_?ZE:Z7IFG_8;)&6SX M^_X*B_\ !1+]I6/7?$O[)7CKX'?L\>$-._X(K_!?_@J=>V/Q$^#5[\7O$L7C MF\U3XM/XN^"NA7UUXI\+Z;;>'?&\O@V+0SX^UVPUV?P]HNBVVK>'O#%W?^)K MB^T@ _K,:-&(9@,J2RGNK;60LO\ =;8S)O7#[&*[L$BL/2_$OAG7M1\0Z3HO MB#1-8U7P=JL&A>*]-TO5[#4-0\+ZY=Z+IGB&VTCQ!9VES-US1];^2W]J+_@K?\ MZ^$-5_94^,^H?$'X??L7?LV M?%G]C3]D/]H7PS\0?'_[&?Q<_:*_9E^,7Q@^->A1^)?C!\*/C+^T%\-=;U3Q M9^S%X=\!6VHZ#:^%;G3_ 7KFLZC:7TNO:YJ]CI?EW<7ZK?#GQ!'X-_X+F_% MCPAX.GL'\&?M7?\ !,'X2?M'^,?[-D%WIVJ?$G]GWX_ZS\%M!\9V5TF8;J3Q M+\*_BIX>\.RZA&%FOM'\">&UEEN+>RL8[0 ZW]KS_@C[\(OVP_B9\2?'OB?] MIC]MCX5>%OCKX2\'^!OVB/@9\%?CI9>%?@A\=_#'@N :;I^G^-_"6O>"O%>I MZ.^J>'-WA7Q'=?#S7_!EQK>@M+'=/]NO-1O;W]7=*TG3M#TO3M%TFUCL-*TF MPL]+TRQM]R6]EI^GV\=I96=NNX^7#;6T,4,:@YV(-Q8Y)T:* $(!SUYQW(Z> MF#Q[XQGO2*BJ JC 7 !( & !@!0. H 4=A3J* $*@Y'//7)R/3&#D8]L8 MI:** "BBB@ HHHH **** "BBB@ HHHH **** &L,J0,$\%_F^/'B#Q#\1_$M_9Z[_"O MQ;X0\8>/_",/@^;Q?9Z]IFFWM\^M^&;2W@U+PVC2C1SJ"2VWB/2O$>@7VH:) M=_>M% 'Y>_!G_@D;^RA\#!^Q_<^#;GXM7FN_L9_$SXZ_&?P;XM\5_$#_ (2? MQ;\4OBS^TAX8UKPM\7?B)\=]?U+17O?B!XH\46VO7NH&]M'\.QV&H1V45G"F MD64&ECC_ (6?\$6/V/\ X0^#OA'X'\*:I\:9=&^"O[.'[5/[+?@]]8\?Z9?Z MA+\-?VP?&FJ>._BO/K5VGA&V-]XHMM;U:Z3PAJ\,=G;:)8B"WNM,U:2!)Z_7 M*B@#\8_B3_P0R_9)^('A+X)^$M(^)/[5_P ($^#_ .S!X1_8PU[7O@A\>+SX M;^(OC_\ LN^"K,66C?!G]H2[TSP[-8>.?"YCEU+[5=:1IOA;7C%K6K6-KJMK MIL]O96GTM+_P3,_9?A\4?$CQ'X?TKQ;X.L_B3^PMX?\ ^"=MSX/\*^(;?3?! MWA+]F_PHGBR#PYI/@C2Y](O;O1?$NCV7C#4=/LM;NM2U2WCM+;3U.E--#<37 M?Z#44 ?BM\4O^"$W[)?Q.TCP'X73XL_MC?#CP/X?_9Y^#O[+/Q0^'WPF_:0\ M0>!/!/[3WP3^!?AB/P;X!\*?M%Z#8:1+;>+9[;PTMQHVJ:YX6/@G6-5TS4M4 MT^>Z2TO#>!\'/V8?&5C_P4<_:#_:G\5>$K/P?\/?!W[+O[/O[%O[+UI9:M MIMW_ &Q\/_#FL^)_C7\8O%_]DV-W=W/A_3+[QUXK\$_#C1K#5A8:Q=)\)M0U M26R?1KW0+VZ_2FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ K+UC6])\/V,FIZWJ-GI6GQ/%')>7\Z6UNDD\@BA1I9"%#2R,J(" M#?M(_\ )*]7_P"PGX?_ /3O;T =M_PMGX:?]#UX6_\ !S:?_%T? M\+9^&G_0]>%O_!S:?_%U^55% 'ZJ_P#"V?AI_P!#UX6_\'-I_P#%T?\ "V?A MI_T/7A;_ ,'-I_\ %U^55% 'ZYZ%XR\*^)Y;B#P]XATC69K2..6YCTV^ANW@ MBF=TBDE6)B461T=4)X9E8#D5TM?#?[)G_(>\9_\ 8'T7_P!.%_7W)0 4444 M%?@?^WI_P4$_:1_9_P#VE/$_PR^'&K^#+3PII?AKP5J=G!K/@NWUF_6[US1V MO=0:2_DU*V:2-IQF&,Q 0K\@+=:_?"OY-O\ @J]_R>IXX_[$KX9_^HX] &C_ M ,/;/VR_^@_\-_\ PV]I_P#+FC_A[9^V7_T'_AO_ .&WM/\ Y1D#([U^:=13_ZB?_KA-_Z*>@#^Z?X/>)=5\9_"3X7>+]<>"76_%7PZ\$>) M-8DM;<6MM)JFN^&-+U34'M[57D6V@>[NYFA@#N(8RL8=@NX^C5XU^SG_ ,F^ M_ O_ +(Y\,/_ %!]"KV6@ HHHH **** "BBB@ HHHH **** "O!OVD?^25:O M_P!A/P__ .G>VKWFO!OVD?\ DE6K_P#83\/_ /IWMJ /S@HHHH **** /K3] MDS_D/>,_^P/HO_IPOZ^Y*^&_V3/^0]XS_P"P/HO_ *<+^ON2@ HHHH *_DV_ MX*O?\GJ>./\ L2OAG_ZCCU_637\FW_!5[_D]3QQ_V)7PS_\ 4<>@#\X**/\ MZP]3\RAEX'/S*RLHZLK*PR&!+_+DWF/RI?,&W>,+\QRHP.3Q M0 RHI_\ 43_]<)O_ $4]2U'-?LY_\F^_ O\ [(Y\,/\ U!]"KV6@ M HHHH **** "BBB@ HHHH **** "O!OVD?\ DE6K_P#83\/_ /IWMJ]YKP;] MI'_DE6K_ /83\/\ _IWMJ /YBO\ @I[^UW\:/V8!^S1X=^#_ (F^"/PLE^-G MQ+U?P]JWQG_:,T_Q)=?"'0=0\+S>";SP[\,?$&JZ%=:=8^#6^*ZZ_KK:CXWU M_4K:'0/!O@KQ9+X?27Q++I\MIN_$C]I[]I[X;_MD?LH_"76[+]FU?AG^TKXG M\/\ @/2/AIH6J>-?$GQKU2PT[X0:KX[^//[0.F>/YFT+P-HGPR^"'CA/#O@W M3O!^I>'-0\2?$GPKKEGXNL+JRU:_31=)[/\ X*$_LS?'S]ISX?\ A#PA\%/B MKX'\*:2_B&WT;XK?#/XN_#73?BA\)?B/X,U[Q#X2G'BG6M GU'0]3;Q=\('T M:]\3^%+&WUE-)\46>H:_X8U2PEN=0TR\MO,;C_@GQ\7)?$_[,_@6?]I^/Q#^ MR3^S;XJ_92^)?AGX=>+_ (;Q:A\)?@)IOPO\)^*[&RM/B9/X6^)GPZ\3>*;GQ5\1?[,US6 M=/L;[QC-H]EXD\.^%%-MJ7@WPSJ-AI?B!KC7);];7$N?VS?%&M_\%'_ O[(? M@GPW977PDL/AI\Q16TGPU\$? M$3PCK7Q.G^PZA&=6^(6A^%VN-,U/0=1BF]$C_9L^*?A+XD_MO_%_X3_%KP?X M4^(7[4MI^SPWP[O_ !/\.;KQAH?PIUGX&_#N7X?WE_XIT!]ZO M;RSTZSET5=*\Z%+F2]>'@>+_B;\?)O#NI2^(-"T6^\5'PIX1T[#7]0\;^$+ M?1)](\?Q7_AVSU6(Q>$]-V@'[W?LF?\ (>\9_P#8'T7_ -.%_7W)7PU^R8,: M]XR'IHVBCGD\7]_U/>ON6@ HHHH *_DY_P""K.T?ML^,BZ&5!X/^%Q>)<[I4 M&@$O$N.=TBY08YRPQ7]8U?R;_P#!5UF7]M7QLRL59?!?PR964D,K+X=8JRD< MAE(!4CD$ CF@#^9CX-Z1-IWQ8^/OP^^*?CGXM>#_ !K\6M+\?WFE?&7PW\7+ M;6_A;X[\$V^M:!/%XJ\%W6HS7^F?#7XG?#OPUXJ\.^&=-T6SL=+AT#1+R_T[ M3[C4=0CL6LC1/ GB#Q/\%OCK\+GF^**^.?A%\9?B?/X'_9\MOC_K&AZ];0S_ M ]T36OAQX-OOC7"_A+X:\/? M$WQAI=WH^BZAXV\;Z9INCGXA>--.ABO9])TG1KF'7?'/BFP47,KPZ+=:1 UQ M=:A:F4_80\6Z/XN_99\(2:3XZN/B-)H&K_%'PUJ_BR^NKV\U35-1LOB1XPU& MTO-7FO\ =.-0U3PWJWA[7C )9H;6SUBSMH71(1!#](>&/AGX%\&:S#KGA;P] M:Z'>6O@GPC\.;&UL9[U=$T[P9X#N]0O?">B:;X>FN9=%L$TB?4[P)>VUC'J5 MW"\=OJ%Y=0V\")>\*>#/#7P_\+1^%/".FKI&@V,GB&^M;!;BZNQ%=>(M:U?Q M/K$OVB]FN+E_M>N:UJ5Z%DF9(!<"VMUBM88(8P#^[#]G/_DWWX%_]D<^&'_J M#Z%7LM>-?LY_\F^_ O\ [(Y\,/\ U!]"KV6@ HHHH **** "BBB@ HHHH ** M** "O!OVD?\ DE6K_P#83\/_ /IWMJ]YKP;]I'_DE6K_ /83\/\ _IWMJ /S M@HHHH **** /K3]DS_D/>,_^P/HO_IPOZ^Y*^&_V3/\ D/>,_P#L#Z+_ .G" M_K[DH **** "OY-O^"KW_)ZGCC_L2OAG_P"HX]?UDU_)M_P5>_Y/4\@#^XC]G/\ MY-]^!?\ V1SX8?\ J#Z%7LM>-?LY_P#)OOP+_P"R.?##_P!0?0J]EH **** M"BBB@ HHHH **** "OS\_:8_X*I?\$]OV.?B-%\(_P!IO]JWX5_!KXD3>'-* M\71>$/&-_K%MJ[^&];N-0M=*UA8K'1;^'['>W&E:A%"WG[R]K*&11M+?H'5> M6TM9VWS6\$KX"[I(8I&P,D#1_&_P#X+M_\$A/%7P]U/2-&_;]^ 5U?RWVC316Z:GXKD>1+;5+> M6;:L'A.9ODB#2L2H4(C?-NVJW[K?V=8?\^5I_P" MO\ _&J/[-T__GRM/_ 6 MW_\ C5 '\IG_ ^+_P""7'_1\OP+_P# SQG_ /,;1_P^+_X)(/V]?@)8QWNG:3;VOFZAXOB,SPW=]+-L,W@^*,B)6CW@/N_>H55AO*?5 MO_#_ ._X(X?])!/@!_X-O$O_ ,S%?KU_9NGCI968_P"W6W_^-4?V=8?\^5I_ MX"V__P :H _(7_A_]_P1P_Z2"? #_P &WB7_ .9BC_A_]_P1P_Z2"? #_P & MWB7_ .9BOUZ_LZP_Y\K3_P !;?\ ^-4?V=8?\^5I_P" MO\ _&J /R%_X?\ MW_!'#_I()\ /_!MXE_\ F8K^./AS^UA\*O%G MA6_\*> [&UUK29_%%Q92W>EZ(]K?VZR_\(RN9+:;"R A2RC.[?^7/_P#,W7^DA_9>F_\ /A9?^ EM_P#&J/[+TW_G MPLO_ $MO_C5 '^;?_PWI^QM_P!'%_#S_P N?_YFZCF_;S_8W:&95_:+^'A9 MH954#_A)\EFC8 #_ (IOJ20*_P!)3^R]-_Y\++_P$MO_ (U1_9>F_P#/A9?^ M EM_\:H _#CX(_\ !>/_ ()!^&?@Q\(_#FM_M\_ 73]9T#X8^ =$U>PGU3Q, MD]EJ>E>$](L+^TG0^& 4FMKNWFAD4C*NA!Y%>G_\/_O^".'_ $D$^ '_ (-O M$O\ \S%?KU_9NGCI96G_ ("V_P#\:H_LZP_Y\K3_ ,!;?_XU0!\C?LH?\% _ MV-/VY'\5YVXZ;<[_+VKO^QJ@AMK>WW>1!##OQN\J*./=MSC=Y:KNQDXSG&3CJ M:GH **** "BBB@ HHHH **** "O$/VA?C?I7[/WPTO?'M[X:WKFI MV&A>&]'74_$FNWMKH^D7TZ>WU\Y?M1_!+6?CI\,;?0O"'B32_!OQ(\%>//AU M\7OA5XJUW1KOQ'X=T?XD?"CQAI?C3PQ'XI\/V&J:)?ZUX/U^33;GPIXQT[3= M7TK5YO"WB#5VT74]/UF/3[R \.T7]MW7/#N@?'BU^/G[/\ XU^&WQ<^ _PZ MT/XMWGPM^'FNV'QXD^)WP_\ &%QXIT?P;J?PC\0^%-(T&?Q#J>I>,/!GB#P- MKVA^(O#/A&[\&Z_;V>JZ])'X%UC1_&-[TWQE_:VU[X?_ ++_ ,,/C[X%^$]M MX]\6?_P!G7P[X,^&>O_$?3OA]IJ:Y^T1XC\&^'M(@\0?$8^&?%UCI6G^& MW\7+=:CJ-KX:U47ZZ>\-E;!KN)T\6^#?[._[8&I_$[]I?XD_M1ZO\!-2U[XM M? G3?@]\*Y?@[>^-H=$^&OABQU_XI:U+X,\167BKPQI6I>-+R?5/'UCJ\WQ+ MA_L66[TC2].\*/X%@U/1-0\:>-O1/B[^QB/C)^R;\ _V8O'%O\._&.A_#[Q3 M^R/??$[0O&6C3>(/ 7CWPM\ O%OP_P!?\:^'WT*_TZ[BU2W\36GA&\@T:RUV MQ%A)<3V?]KB")9B@!E:Q^W7K'P2M? &H?MD?"?0?@#H7COP7\9?$$?C/P?\ M%G_A=O@72_%GPAL3XPC^&BLVM77@#Q M?X.M(KC7HM"&N]7:_MM6NC>(/A!X/^*?P@\?_#+Q1X^^ 'Q#_: ^(,%_#+K' MA_X,:=\/M#\-^(KSX>^(_%-OI=EIGBGXG3Z7K]W->^&/!@U0:#_PC.N2:K>1 MVMWX5N?$FC\7/V-/AWX@^"WP<^!GPA\ ?"3X:_#SX2?M%?L[?&C1O FG^"]+ MT;P'HVF_"+X^>&/C-XFM?"_AG0M).F:3KVMMIFMRZ7WETB\L["7PU>RZO9:I)'%>17-O"J3I). M/@WK?P-\8+\.OAA\W?A8I#X?\6)J M/@?Q+HWCCP1-'J,'A?5+:Q&E>*O%FF:E!J:_:%?F?^P+^P[K_P"RUK?Q"\:> M.(OA7:>)_$?@CX7_ >\/Z7\)+SXNZMX#? ,VJQRZUKNI_IA0 4444 %?"7QC_ M &OOB!X5^)GC;X M'/ ?PZTWQ6DLGQ2^,6H^%=(F\5MX*:Z\%>';'1=8\(C4?'UIJ?BBQT^/[MK\ MT?CY^SM^V;HWQ&^,'C_]B'XJ_ ?P1>_M%:5X";X@CX^>#?&OBV/P%X^^'&BK MX.L?B)X(L?"%[;6_BZ#QC\/+/P[X+\2>!O$5QX8CTB]\*:3XST+Q?)-A>,/$FB_'WX%:Y^T#X;^)AT#4]%\"V/A"T MT_X?:MX9T>?4M9LK0ZCXR\7:/X_AUJ'PSI1N;[PSI&C7MUXN&CRZEX>MM7\] MU/\ :N^.NJ_M4>,?@#\*_P!G'P/XP\"_"_6?A!IGQ,^*OBW]I"Q^'NN:3;_$ M_0[7Q7J%]X5^%:_"7Q=>^+QX6\-7)NUMY/%_A\Z_J4,FE6TVGA7O8]KX0_LR M^(O T/[#TF-&\/Z;^S)^SCXD^#NO>%V\0WGB_45O]<\&?!OPYIT>D^+(_#7A M:T\26NES?#C4SJ>O7GAWPM-K!O+.^MM T\S3V-I0\/?L+?"NX_:^^,/[6GQ. M^&7P8^('CG7]1^#EW\%O&NN>!=+UWXF_"J'X;_#_ /X1G4H](\5:UI$E[X>: M\U^6\UC31X;U%$1+N:>Y\J]D84 <;H'_ 4/MO%$.F^&O#?P)\?^*/C?X=LO MV@[SX\_ GPGK&A:YXW^#,G[/7VC0;W3'D9+&S\6:M\7_ (@ZI\/M"_9_A(\- M6/Q/\&>-Y?BI;W^E^$_"'B7[+RU]_P %"_BEI]EK/@EOV1M=U7]ICPGXU\8Z M/XO^"'A[XU_#_4=&LO!'@3X1?#GXVZ]XZT/XKWFE:5I&MRS>$OBY\.?#>B^$ MKOPUH6KWOQ(\36VC:AK^+M)UC^RM+\;_ H^$^N^!_#5[\7IM'TB?5-=\-:9X@U6+4K. MPTHZG<_V,EW8*MJURR5\E^"_V+_VSO"7@'P+KWAR7]EWP-^T-X'OOCIX=U3Q M#J'CCXU_&?1/BUH/[2'A[P(_Q(^,WQ-\9ZO\/_ACXRNOCG;?$3P!X;\4V&CV M.@MX$O?"FC)\--'O/ ?AV?0)/!0!^NWP^\<:!\3O ?@KXC^%)KBX\+^/_"7A MKQMXSNKC0?%FBV.OZ//<6DA,EK/+IVHVSS6\A+P2EXF)9"3V%>=_"+ MX=:?\(?A3\,OA/I-]:7J%Y%##=WVG>"O#6E^&;*\NH;8"W MBN+JVTN.XGB@ ACEE=(AY:K7HE !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 ,4 %%%% !1110!__9 end GRAPHIC 13 chart-5f32bf9b0ca256e99b2.jpg begin 644 chart-5f32bf9b0ca256e99b2.jpg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end GRAPHIC 14 chart-986746bac297519d8c3.jpg begin 644 chart-986746bac297519d8c3.jpg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chart-f4d60677c0e25c84939.jpg begin 644 chart-f4d60677c0e25c84939.jpg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end GRAPHIC 16 chart-ff3385a010ad5ef68c1.jpg begin 644 chart-ff3385a010ad5ef68c1.jpg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end XML 17 R59.htm IDEA: XBRL DOCUMENT v3.19.3
Segment Information Disaggregated Revenue Within Reportable Segments (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Segment Reporting, Revenue Reconciling Item [Line Items]    
Revenue $ 37,341 $ 35,213
Operating Segments    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Revenue 37,345 35,217
Operating Segments | Pharmaceutical    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Revenue 33,428 31,416
Operating Segments | Pharmaceutical | Nuclear Precision Health Services [Member]    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Revenue 216 207
Operating Segments | Pharmaceutical | Pharmaceutical Distribution and Specialty [Member]    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Revenue 33,212 31,209
Operating Segments | Medical    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Revenue 3,917 3,801
Operating Segments | Medical | Cardinal Health At Home [Member]    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Revenue 471 421
Operating Segments | Medical | Medical distribution and products [Member]    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Revenue 3,446 3,380
Corporate    
Segment Reporting, Revenue Reconciling Item [Line Items]    
Revenue $ (4) $ (4)

XML 18 R3.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Statement of Comprehensive Income [Abstract]    
Net earnings/(loss) $ (4,921) $ 594
Other comprehensive income/(loss):    
Foreign currency translation adjustments and other (17) (3)
Net unrealized gain/(loss) on derivative instruments, net of tax (5) (1)
Total other comprehensive income/(loss), net of tax (22) (4)
Total comprehensive income/(loss) (4,943) 590
Less: comprehensive income attributable to noncontrolling interests (1) (1)
Total comprehensive income attributable to Cardinal Health, Inc. $ (4,944) $ 589
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Cash flows from operating activities:    
Net earnings/(loss) $ (4,921) $ 594
Adjustments to reconcile net earnings/(loss) to net cash provided by/(used in) operating activities:    
Depreciation and amortization 234 245
Impairments and (gain)/loss on sale of investments 0 2
Impairments and (gain)/loss on disposal of assets, net 1 (511)
Share-based compensation (20) (19)
Provision for bad debts 29 21
Change in operating assets and liabilities, net of effects from acquisitions and divestitures:    
(Increase)/decrease in trade receivables 229 (302)
(Increase)/decrease in inventories 356 (178)
Increase/(decrease) in accounts payable (1,812) 559
Other accrued liabilities and operating items, net 5,211 (84)
Net cash provided by/(used in) operating activities (653) 365
Cash flows from investing activities:    
Additions to property and equipment (72) (58)
Purchase of available-for-sale securities and other investments (3) (4)
Proceeds from sale of available-for-sale securities and other investments 2 1
Proceeds from Sale of Property, Plant, and Equipment 0 740
Net cash provided by/(used in) investing activities (73) 679
Cash flows from financing activities:    
Net change in short-term borrowings (2) 0
Reduction of long-term obligations (74) (1)
Net tax proceeds/(withholdings) from share-based compensation (13) (13)
Dividends on common shares (146) (150)
Purchase of treasury shares (350) (600)
Net cash used in financing activities (585) (764)
Effect of exchange rate changes on cash and equivalents (8) 2
Net increase/(decrease) in cash and equivalents (1,319) 282
Cash and equivalents at beginning of period 2,531 1,763
Cash and equivalents at end of period $ 1,212 $ 2,045
XML 20 R55.htm IDEA: XBRL DOCUMENT v3.19.3
Segment Information Narrative (Details)
$ in Millions
 3 Months Ended
Sep. 30, 2019
USD ($)
segment
Reportable_Segments
Sep. 30, 2018
USD ($)
Number of Reportable Segments | Reportable_Segments 2  
Number of operating segments | segment 2  
Project Costs On Investment And Other Spending $ 3 $ 7
naviHealth [Member]    
Pre-Tax Gain on Divestiture   $ 508
Total Opioid Litigation [Member]    
Estimated Litigation Liability $ 5,630  
XML 21 R51.htm IDEA: XBRL DOCUMENT v3.19.3
Shareholders' Equity Narrative (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Oct. 25, 2018
Class of Stock [Line Items]      
Payments for Repurchase of Common Stock $ 350 $ 600  
Final Shares Received from ASR Program     2.0
Treasury Shares      
Class of Stock [Line Items]      
Payments for Repurchase of Common Stock $ 280 $ 480  
Treasury shares acquired (using cost method), shares 6.4 9.5  
Payments for Repurchase of Common Stock $ 280 $ 480  
Treasury shares acquired, average price per share (in usd per share) $ 43.76 $ 50.45  
XML 22 R30.htm IDEA: XBRL DOCUMENT v3.19.3
Segment Information (Tables)
 3 Months Ended
Sep. 30, 2019
Segment Reporting, Revenue Reconciling Item [Line Items]  
Revenue from External Customers by Geographic Areas [Table Text Block]
The following table presents revenue by geographic area:
 
Three Months Ended September 30,
(in millions)
2019
 
2018
United States
$
36,310

 
$
34,245

International
1,035

 
972

  Total segment revenue
37,345

 
35,217

Corporate (1)
(4
)
 
(4
)
Total revenue
$
37,341

 
$
35,213

(1)
Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Revenue by Reportable Segment  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:
 
Three Months Ended September 30,
(in millions)
2019
 
2018
Pharmaceutical Distribution and Specialty Solutions (1)
$
33,212

 
$
31,209

Nuclear and Precision Health Solutions
216

 
207

Pharmaceutical segment revenue
33,428

 
31,416

Medical distribution and products (2)
3,446

 
3,380

Cardinal Health at-Home Solutions
471

 
421

Medical segment revenue
3,917

 
3,801

  Total segment revenue
37,345

 
35,217

Corporate (3)
(4
)
 
(4
)
Total revenue
$
37,341

 
$
35,213

(1)
Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services".
(2)
Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.
(3)
Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit by Reportable Segment
The following table presents segment profit by reportable segment and Corporate:
 
Three Months Ended September 30,
(in millions)
2019
 
2018
Pharmaceutical
$
398

 
$
409

Medical
170

 
135

Total segment profit
568

 
544

Corporate
(5,832
)
 
272

Total operating earnings/(loss)
$
(5,264
)
 
$
816
Assets by Reportable Segment
The following table presents total assets for each reportable segment and Corporate at:
(in millions)
September 30,
2019
 
June 30,
2019
Pharmaceutical
$
21,755

 
$
22,446

Medical
15,462

 
15,284

Corporate
1,962

 
3,233

Total assets
$
39,179

 
$
40,963
XML 23 R34.htm IDEA: XBRL DOCUMENT v3.19.3
Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)
$ in Millions
 3 Months Ended
Sep. 30, 2019
USD ($)
Restructuring Reserve [Roll Forward]  
Beginning Balance $ 72
Additions 25
Payments and other adjustments (12)
Ending Balance 85
Employee- Related Costs  
Restructuring Reserve [Roll Forward]  
Beginning Balance 64
Additions 19
Payments and other adjustments (10)
Ending Balance 73
Facility Exit and Other Costs  
Restructuring Reserve [Roll Forward]  
Beginning Balance 8
Additions 6
Payments and other adjustments (2)
Ending Balance $ 12
XML 24 R38.htm IDEA: XBRL DOCUMENT v3.19.3
Goodwill and Other Intangible Assets Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization of intangible assets $ 129 $ 133
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months 382  
Finite-Lived Intangible Assets, Amortization Expense, Year Two 442  
Finite-Lived Intangible Assets, Amortization Expense, Year Three 408  
Finite-Lived Intangible Assets, Amortization Expense, Year Four 358  
Finite-Lived Intangible Assets, Amortization Expense, Year Five $ 328  
XML 25 R17.htm IDEA: XBRL DOCUMENT v3.19.3
Financial Instruments
 3 Months Ended
Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments
10. Financial Instruments
We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.
Interest Rate Risk Management
We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes
in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.
Currency Exchange Risk Management
We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce volatility in earnings, cash flow and net investments in certain subsidiaries to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.
Commodity Price Risk Management
We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.
Fair Value Hedges
We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings. For the three months ended September 30, 2019 and 2018, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.
Cash Flow Hedges
We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.
During the three months ended September 30, 2019, we entered into a forward interest rate swap with a total notional amount of $50 million to hedge probable, but not firmly committed, future transactions associated with our debt.
Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three months ended September 30, 2019 and 2018. All gains and losses currently included within accumulated other comprehensive loss associated with our foreign exchange forward contracts to be reclassified into net earnings within the next 12 months are immaterial.
Net Investment Hedges
We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.
During three months ended September 30, 2019, we entered into a ¥64.0 billion cross-currency swap maturing in 2022.
During three months ended September 30, 2018, we entered into a €200 million cross-currency swap maturing in 2023.
Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive income/(loss) until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. There was no ineffectiveness in our net investment hedges during the three months ended September 30, 2019.
Economic (Non-Designated) Hedges
We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. The gain and losses recognized in the three months ended September 30, 2019 and 2018 were immaterial. The principal currencies managed through foreign currency contracts are the euro, Canadian dollar, British pound, Japanese yen, and Chinese renminbi.
Fair Value of Financial Instruments
The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at September 30, 2019 and June 30, 2019 approximate fair value due to their short-term maturities.
The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:
(in millions)
September 30, 2019
 
June 30, 2019
Estimated fair value
$
8,001

 
$
8,065

Carrying amount
7,991

 
8,031


The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.19.3
Long-Term Obligations and Other Short-Term Borrowings
 3 Months Ended
Sep. 30, 2019
Debt Disclosure [Abstract]  
Long-Term Obligations and Other Short-Term Borrowings
6. Long-Term Obligations and Other Short-Term Borrowings
Long-Term Debt
We had total long-term obligations, including the current portion and other short-term borrowings, of $8.0 billion at both September 30, 2019 and June 30, 2019. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $19.7 billion and $21.5 billion at September 30, 2019 and June 30, 2019, respectively.
During the three months ended September 30, 2019, we repurchased a total of $74 million of notes due in 2022 and 2047 with available cash.
Other Financing Arrangements
In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $2.0 billion commercial paper program backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility.
In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2022. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors.
Our revolving credit facility and committed receivables sales facilities require us to maintain, as of the end of every fiscal quarter from September 30, 2019 through December 2020, a consolidated net leverage ratio of no more than 4.00-to-1. The maximum permitted ratio will reduce to 3.75-to-1 in March 2021 and as of the end of every fiscal quarter thereafter. As of September 30, 2019, we were in compliance with our financial covenants.
XML 27 R29.htm IDEA: XBRL DOCUMENT v3.19.3
Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)
 3 Months Ended
Sep. 30, 2019
Earnings Per Share [Abstract]  
Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share
The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:
 
Three Months Ended September 30,
(in millions)
2019
 
2018
Weighted-average common shares–basic
296

 
305

Effect of dilutive securities:
 
 
 
Employee stock options, restricted share units, and performance share units
—

 
1

Weighted-average common shares–diluted
296

 
306
XML 28 R25.htm IDEA: XBRL DOCUMENT v3.19.3
Leases (Tables)
 3 Months Ended
Sep. 30, 2019
Leases [Abstract]  
Schedule of Lease Costs
The following table summarizes the components of lease cost:
 
Three Months Ended September 30,
(in millions)
2019
Operating lease cost
$
31

Finance lease cost


Amortization of right-of-use assets
4

Total finance lease cost
4

Variable lease cost
1

Total lease cost
$
36
Leases Supplemental Balance Sheet Information
(in millions)
September 30, 2019
Operating Leases
 
Operating lease assets
$
394

 
 
   Current portion of operating lease liabilities
103

   Operating lease liabilities
312

Total operating lease liabilities
415

 
 
Finance Leases
 
Property and equipment, net
18

 
 
Current portion of long-term obligations
5

Long-term obligations, less current portion
12

Total finance lease liabilities
$
17
Schedule of Lease Payments upplemental cash flow information related to leases:
 
Three Months Ended September 30,
(in millions)
2019
Cash paid for amounts included in the measurement of lease liabilities:


Operating cash flows paid for operating leases
$
31

Financing cash flows paid for finance lease
2

Non-cash right-of-use assets obtained in exchange for lease obligations:

New operating leases
15

New finance leases
17

Amended lease standard adoption impact as of July 1, 2019 (1) 
400
Schedule of Future Lease Payments
Future lease payments under non-cancellable leases as of September 30, 2019 were as follows:
(in millions)
Operating Leases
 
Finance Leases
 
Total
Years Ending September 30,

 

 

Remainder of 2020
$
91

 
$
4

 
$
95

2021
101

 
6

 
107

2022
79

 
4

 
83

2023
58

 
4

 
62

2024
41

 
1

 
42

Thereafter
149

 
—

 
149

Total future lease payments
519

 
19

 
538

Less: leases not yet commenced (1) 
61

 
—

 
61

Less: imputed interest
43

 
2

 
45

Total lease liabilities
$
415

 
$
17

 
$
432

(1)
As of September 30, 2019, we had certain leases that were executed but did not have control of the underlying assets; therefore, the lease liabilities and right-of-use assets are not recorded in the condensed consolidated balance sheets.
As previously disclosed in our fiscal 2019 Form 10-K under the prior accounting guidance, the future minimum rental payments for operating leases having initial or remaining non-cancelable lease terms in excess of one year at June 30, 2019 for fiscal 2020 through 2024 and thereafter were as follows: $126 million, $100 million, $76 million, $54 million, $33 million and $94 million.
XML 29 R21.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation
 3 Months Ended
Sep. 30, 2019
Share-based Payment Arrangement [Abstract]  
Share-Based Compensation
14. Share-Based Compensation
We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees.
The following table provides total share-based compensation expense by type of award:
 
Three Months Ended September 30,
(in millions)
2019
 
2018
Restricted share unit expense
$
17

 
$
14

Employee stock option expense
1

 
4

Performance share unit expense
2

 
1

Total share-based compensation
$
20

 
$
19


The total tax benefit related to share-based compensation was $4 million and $5 million for the three months ended September 30, 2019 and 2018, respectively.
Restricted Share Units
Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to restricted share units under the Plans:
(in millions, except per share amounts)
Restricted Share Units
 
Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 2019
2

 
$
51.65

Granted
2

 
42.09

Vested
(1
)
 
60.92

Canceled and forfeited
—

 
—

Nonvested at September 30, 2019
3

 
$
45.29

At September 30, 2019, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $125 million, which is expected to be recognized over a weighted-average period of two years.
Stock Options
Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.
The following table summarizes all stock option transactions under the Plans:
(in millions, except per share amounts)
Stock
Options
 
Weighted-Average
Exercise Price per
Common Share
Outstanding at June 30, 2019
6

 
$
63.78

Granted
—

 
—

Exercised
—

 
—

Canceled and forfeited
—

 
—

Outstanding at September 30, 2019
6

 
$
63.75

Exercisable at September 30, 2019
6

 
$
63.67


At September 30, 2019, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $3 million, which is expected to be recognized over a weighted-average period of one year.
The following tables provide additional detail related to stock options:
(in millions)
September 30, 2019
 
June 30, 2019
Aggregate intrinsic value of outstanding options at period end
$
10

 
$
10

Aggregate intrinsic value of exercisable options at period end
10

 
10

(in years)
September 30, 2019
 
June 30, 2019
Weighted-average remaining contractual life of outstanding options
5
 
5
Weighted-average remaining contractual life of exercisable options
5
 
5

Performance Share Units
Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
(in millions, except per share amounts)
Performance
Share Units
 
Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 2019
0.9

 
$
51.45

Granted
0.5

 
43.68

Vested
(0.1
)
 
48.40

Canceled and forfeited
(0.1
)
 
50.59

Nonvested at September 30, 2019
1.2

 
$
50.84


At September 30, 2019, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $25 million, which is expected to be recognized over a weighted-average period of three years if the performance goals are achieved.
XML 30 R63.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)
shares in Millions
 3 Months Ended
Sep. 30, 2019
$ / shares
shares
Stock Options  
Outstanding at beginning of period (in shares) | shares 6
Granted (in shares) | shares 0
Exercised (in shares) | shares 0
Canceled and forfeited (in shares) | shares 0
Outstanding at end of period (in shares) | shares 6
Exercisable at end of period (in shares) | shares 6
Weighted-Average Exercise Price per Common Share  
Outstanding at beginning of period (in usd per share) | $ / shares $ 63.78
Granted (in usd per share) | $ / shares 0
Exercised (in usd per share) | $ / shares 0
Canceled and forfeited (in usd per share) | $ / shares 0
Outstanding at end of period (in usd per share) | $ / shares 63.75
Exercisable at end of period (in usd per share) | $ / shares $ 63.67
XML 31 R40.htm IDEA: XBRL DOCUMENT v3.19.3
Leases Narative (Details) - USD ($)
$ in Millions
Jul. 01, 2019
Sep. 30, 2019
Jun. 30, 2019
Operating Leases, Future Minimum Payments Due, Next Twelve Months     $ 126
Reclassification of deferred rent in accordance with ASC 842 $ 22    
Operating Lease, Weighted Average Remaining Lease Term   6 years 2 months 12 days  
Operating Lease, Weighted Average Discount Rate, Percent   3.00%  
Operating Leases, Future Minimum Payments, Due in Two Years     100
Operating Leases, Future Minimum Payments, Due in Three Years     76
Operating Leases, Future Minimum Payments, Due in Four Years     54
Operating Leases, Future Minimum Payments, Due in Five Years     33
Operating Leases, Future Minimum Payments, Due Thereafter     $ 94
Minimum      
Lessee, Operating Lease, Term of Contract   1 year  
Maximum      
Lessee, Operating Lease, Term of Contract   23 years  
EXCEL 32 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 33 R44.htm IDEA: XBRL DOCUMENT v3.19.3
Leases Supplemental Balance Sheet Information (Details)
$ in Millions
Sep. 30, 2019
USD ($)
Leases [Abstract]  
Operating lease assets $ 394
Current portion of operating lease liabilities 103
Operating lease liabilities 312
Total operating lease liabilities 415
Net property, plant and equipment 18
Current portion of long-term debt 5
Long-term debt 12
Total finance lease liabilities $ 17
XML 34 R48.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value Measurements Narrative (Details) - Recurring - USD ($)
$ in Millions
Sep. 30, 2019
Jun. 30, 2019
Assets:    
Other investments $ 109 $ 118
Liabilities:    
Derivative Assets (Liabilities), at Fair Value, Net 95 53
Level 1    
Assets:    
Other investments 109 118
Liabilities:    
Derivative Assets (Liabilities), at Fair Value, Net 0 0
Level 2    
Assets:    
Other investments 0 0
Liabilities:    
Derivative Assets (Liabilities), at Fair Value, Net 95 53
Level 3    
Assets:    
Other investments 0 0
Liabilities:    
Derivative Assets (Liabilities), at Fair Value, Net $ 0 $ 0
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.19.3
Goodwill and Other Intangible Assets (Tables)
 3 Months Ended
Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill by Reportable Segment
The following table summarizes the changes in the carrying amount of goodwill by segment and in total:
(in millions)
Pharmaceutical
 
Medical
 
Total
Balance at June 30, 2019
$
2,663

 
$
5,715

 
$
8,378

Goodwill acquired, net of purchase price adjustments
(5
)
 
—

 
(5
)
Foreign currency translation adjustments and other
—

 
(13
)
 
(13
)
Balance at September 30, 2019
$
2,658

 
$
5,702

 
$
8,360
Schedule of Definite and Indefinite-Lived Intangible Assets
The following tables summarize other intangible assets by class at:
 
September 30, 2019
(in millions)
Gross
Intangible
 
Accumulated
Amortization
 
Net
Intangible
 
Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
 
 
 
 
 
 
 
IPR&D, trademarks and other
$
22

 
$
—

 
$
22

 
N/A
Total indefinite-life intangibles
22

 
—

 
22

 
N/A
 
 
 
 
 
 
 
 
Definite-life intangibles:
 
 
 
 
 
 
 
Customer relationships
3,555

 
1,592

 
1,963

 
13
Trademarks, trade names and patents
673

 
307

 
366

 
13
Developed technology and other
1,603

 
656

 
947

 
11
Total definite-life intangibles
5,831

 
2,555

 
3,276

 
12
Total other intangible assets
$
5,853

 
$
2,555

 
$
3,298

 
N/A
 
June 30, 2019
(in millions)
Gross
Intangible
 
Accumulated
Amortization
 
Net
Intangible
Indefinite-life intangibles:
 
 
 
 
 
IPR&D, trademarks and other
$
22

 
$
—

 
$
22

Total indefinite-life intangibles
22

 
—

 
22

 
 
 
 
 
 
Definite-life intangibles:
 
 
 
 
 
Customer relationships
3,562

 
1,517

 
2,045

Trademarks, trade names and patents
672

 
295

 
377

Developed technology and other
1,602

 
616

 
986

Total definite-life intangibles
5,836

 
2,428

 
3,408

Total other intangible assets
$
5,858

 
$
2,428

 
$
3,430
XML 36 R20.htm IDEA: XBRL DOCUMENT v3.19.3
Segment Information
 3 Months Ended
Sep. 30, 2019
Segment Reporting [Abstract]  
Segment Information
13. Segment Information
Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.
Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products.
Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment
also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.
Revenue
The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:
 
Three Months Ended September 30,
(in millions)
2019
 
2018
Pharmaceutical Distribution and Specialty Solutions (1)
$
33,212

 
$
31,209

Nuclear and Precision Health Solutions
216

 
207

Pharmaceutical segment revenue
33,428

 
31,416

Medical distribution and products (2)
3,446

 
3,380

Cardinal Health at-Home Solutions
471

 
421

Medical segment revenue
3,917

 
3,801

  Total segment revenue
37,345

 
35,217

Corporate (3)
(4
)
 
(4
)
Total revenue
$
37,341

 
$
35,213

(1)
Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services".
(2)
Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.
(3)
Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
The following table presents revenue by geographic area:
 
Three Months Ended September 30,
(in millions)
2019
 
2018
United States
$
36,310

 
$
34,245

International
1,035

 
972

  Total segment revenue
37,345

 
35,217

Corporate (1)
(4
)
 
(4
)
Total revenue
$
37,341

 
$
35,213

(1)
Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit
We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial, and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.
We do not allocate the following items to our segments: last-in first-out, or ("LIFO"), inventory charges/(credits); restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; state opioid assessment related to prior fiscal years; other (income)/expense, net; interest expense, net; loss on extinguishment of debt; and provision for income taxes.
In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $3 million and $7 million for the three months ended September 30, 2019 and 2018, respectively.
In connection with the opioid litigation as discussed further in Note 7, we recognized a pre-tax charge of $5.63 billion during the three months ended September 30, 2019, which was retained at Corporate.
In connection with the naviHealth divestiture, we recognized a pre-tax gain of $508 million during the three months ended September 30, 2018, which was retained at Corporate.
The following table presents segment profit by reportable segment and Corporate:
 
Three Months Ended September 30,
(in millions)
2019
 
2018
Pharmaceutical
$
398

 
$
409

Medical
170

 
135

Total segment profit
568

 
544

Corporate
(5,832
)
 
272

Total operating earnings/(loss)
$
(5,264
)
 
$
816


The following table presents total assets for each reportable segment and Corporate at:
(in millions)
September 30,
2019
 
June 30,
2019
Pharmaceutical
$
21,755

 
$
22,446

Medical
15,462

 
15,284

Corporate
1,962

 
3,233

Total assets
$
39,179

 
$
40,963
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.19.3
Shareholders' Equity (Tables)
 3 Months Ended
Sep. 30, 2019
Equity [Abstract]  
Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total
Accumulated Other Comprehensive Loss
The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:
(in millions)
Foreign
Currency
Translation
Adjustments
 
Unrealized
Gain/(Loss) on
Derivatives,
net of tax
 
Accumulated Other
Comprehensive
Loss
Balance at June 30, 2019
$
(95
)
 
$
16

 
$
(79
)
Other comprehensive income/(loss), before reclassifications
(17
)
 
—

 
(17
)
Amounts reclassified to earnings
—

 
(5
)
 
(5
)
Other comprehensive income/(loss), net of tax
(17
)
 
(5
)
 
(22
)
Balance at September 30, 2019
$
(112
)
 
$
11

 
$
(101
)

The sum of components may not equal the total due to rounding.
XML 39 R66.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended
Sep. 30, 2019
USD ($)
$ / shares
shares
Performance Share Units  
Nonvested at beginning of period (in shares) | shares 0.9
Granted (in shares) | shares 0.5
Vested (in shares) | shares (0.1)
Canceled and forfeited (in shares) | shares (0.1)
Nonvested at end of period (in shares) | shares 1.2
Weighted-Average Grant Date Fair Value per Share  
Nonvested at beginning of period (in usd per share) | $ / shares $ 51.45
Granted (in usd per share) | $ / shares 43.68
Vested (in usd per share) | $ / shares 48.40
Canceled and forfeited (in usd per share) | $ / shares 50.59
Nonvested at end of period (in usd per share) | $ / shares $ 50.84
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ $ 25
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 3 years
XML 40 R62.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total share-based compensation $ 20 $ 19
Restricted Share Unit    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total share-based compensation 17 14
Employee Stock Option    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total share-based compensation 1 4
Performance Share Unit    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total share-based compensation $ 2 $ 1
XML 41 R49.htm IDEA: XBRL DOCUMENT v3.19.3
Financial Instruments Narrative (Details)
€ in Millions, ¥ in Millions, $ in Millions
 3 Months Ended
Sep. 30, 2019
USD ($)
Sep. 30, 2019
JPY (¥)
Sep. 30, 2019
USD ($)
Sep. 30, 2018
EUR (€)
Derivative [Line Items]        
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments $ 0      
Cash Flow Hedging [Member]        
Derivative [Line Items]        
Foreign Currency Contract, Asset, Fair Value Disclosure     $ 50  
Currency Swap [Member]        
Derivative [Line Items]        
Foreign Currency Contract, Asset, Fair Value Disclosure   ¥ 64,000   € 200
XML 42 R41.htm IDEA: XBRL DOCUMENT v3.19.3
Leases Summary of Lease Costs (Details)
$ in Millions
 3 Months Ended
Sep. 30, 2019
USD ($)
Leases [Abstract]  
Operating Lease, Cost $ 31
Finance Lease, Right-of-Use Asset, Amortization 4
Total Finance Lease Cost 4
Variable Lease, Cost 1
Lease, Cost $ 36
XML 43 R45.htm IDEA: XBRL DOCUMENT v3.19.3
Long-Term Obligations and Other Short-Term Borrowings Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2019
Jun. 30, 2019
Debt Disclosure [Abstract]    
Debt and Lease Obligation $ 7,991 $ 8,031
Accounts Payable, Current 19,724 21,535
Notes Payable Repurchased $ 74  
Commercial Paper [Member]    
Debt Instrument [Line Items]    
Line of Credit Facility, Maximum Borrowing Capacity   2,000
Revolving Credit Facility [Member]    
Debt Instrument [Line Items]    
Line of Credit Facility, Maximum Borrowing Capacity   2,000
Short Term Credit Facilities Member | Committed Receivables Sales Facility Program [Member]    
Debt Instrument [Line Items]    
Line of Credit Facility, Maximum Borrowing Capacity   $ 1,000
ZIP 44 0000721371-19-000127-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000721371-19-000127-xbrl.zip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�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�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end XML 45 R54.htm IDEA: XBRL DOCUMENT v3.19.3
Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details) - shares
shares in Millions
 3 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Earnings Per Share [Abstract]    
Weighted Average Number Diluted Shares Outstanding Adjustment 6  
shares that would be antidilutive as a result of net loss 1  
Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)   6

XML 46 R50.htm IDEA: XBRL DOCUMENT v3.19.3
Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details) - USD ($)
$ in Millions
Sep. 30, 2019
Jun. 30, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Carrying amount $ 7,991 $ 8,031
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Estimated fair value $ 8,001 $ 8,065
XML 47 R58.htm IDEA: XBRL DOCUMENT v3.19.3
Segment Information (Assets by Reportable Segment) (Details) - USD ($)
$ in Millions
Sep. 30, 2019
Jun. 30, 2019
Segment Reporting Information [Line Items]    
Total assets $ 39,179 $ 40,963
Operating Segments | Pharmaceutical    
Segment Reporting Information [Line Items]    
Total assets 21,755 22,446
Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Total assets 15,462 15,284
Corporate    
Segment Reporting Information [Line Items]    
Total assets $ 1,962 $ 3,233
XML 48 R2.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Earnings - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Income Statement [Abstract]    
Revenue $ 37,341 $ 35,213
Cost of Goods and Services Sold 35,662 33,546
Gross margin 1,679 1,667
Operating expenses:    
Distribution, selling, general and administrative expenses 1,107 1,155
Restructuring and employee severance 30 32
Amortization and other acquisition-related costs 132 156
Impairments and (gain)/loss on disposal of assets, net 1 (511)
Litigation (recoveries)/charges, net 5,673 19
Operating earnings/(loss) (5,264) 816
Other (income)/expense, net 14 3
Interest expense, net 66 77
Earnings/(loss) before income taxes (5,344) 736
Provision for (benefit from) income taxes (423) 142
Net earnings/(loss) (4,921) 594
Less: Net earnings attributable to noncontrolling interests (1) (1)
Net earnings/(loss) attributable to Cardinal Health, Inc. $ (4,922) $ 593
Earnings/(loss) per common share attributable to Cardinal Health, Inc.:    
Basic (in shares) $ (16.65) $ 1.95
Diluted (in shares) $ (16.65) $ 1.94
Weighted-average number of common shares outstanding:    
Basic (in shares) 296 305
Diluted (in shares) 296 306
Cash dividends declared per common share $ 0.4811 $ 0.4763
XML 49 R6.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statement of Shareholders' Equity - USD ($)
shares in Thousands, $ in Millions
Total
Common Stock
Retained Earnings
Treasury Shares
AOCI Attributable to Parent
Noncontrolling Interest
Balance at beginning of period (in shares) at Jun. 30, 2018   327,000        
Balance at beginning of period at Jun. 30, 2018 $ (6,059) $ (2,730) $ (4,645)   $ 92 $ 0
Treasury, balance at beginning of period (in shares) at Jun. 30, 2018       (18,000)    
Treasury, balance at beginning of period at Jun. 30, 2018       $ (1,224)    
Statement of Stockholders' Equity            
Net Earnings/(Loss) 593   593      
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 594          
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (4)       (4)  
Employee stock plans activity, net of shares withheld for employee taxes (6) (20)   $ (26)    
Treasury Stock, Shares, Acquired       (9,500)    
Payments for Repurchase of Common Stock 600 $ 120   $ 480    
Dividends 143   143      
Stockholders' Equity, Other 2   (2)      
Balance at end of period (in shares) at Sep. 30, 2018   327,000        
Balance at end of period at Sep. 30, 2018 $ (5,913) $ (2,590) (5,097)   96 0
Treasury, balance at end of period (in shares) at Sep. 30, 2018       (27,000)    
Treasury, balance at end of period at Sep. 30, 2018       $ (1,678)    
Balance at beginning of period (in shares) at Jun. 30, 2019 327,000 327,000        
Balance at beginning of period at Jun. 30, 2019 $ (6,330) $ (2,763) (5,434)   79 (2)
Treasury, balance at beginning of period (in shares) at Jun. 30, 2019 (28,000)     (28,000)    
Treasury, balance at beginning of period at Jun. 30, 2019 $ (1,790)     $ (1,790)    
Statement of Stockholders' Equity            
Net Earnings/(Loss) (4,922)          
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest (4,921)         1
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (22)       (22)  
Employee stock plans activity, net of shares withheld for employee taxes (7) (24)   $ (31)    
Treasury Stock, Shares, Acquired       (6,400)    
Payments for Repurchase of Common Stock 350 $ 70   $ 280    
Dividends $ 141   141      
Balance at end of period (in shares) at Sep. 30, 2019 327,000 327,000        
Balance at end of period at Sep. 30, 2019 $ (903) $ (2,669) $ (371)   $ 101 $ (3)
Treasury, balance at end of period (in shares) at Sep. 30, 2019 (34,000)     (34,000)    
Treasury, balance at end of period at Sep. 30, 2019 $ (2,039)     $ (2,039)    
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.19.3
Investments Narrative (Details) - naviHealth [Member] - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended
Aug. 31, 2018
Sep. 30, 2018
Sep. 30, 2019
Jun. 30, 2019
Aug. 01, 2018
Investment [Line Items]          
Noncontrolling Interest, Ownership Percentage by Parent         98.00%
Proceeds from Divestiture of Businesses $ 737        
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners         44.00%
Partnership Indirect Ownership         100.00%
Pre-Tax Gain on Divestiture   $ 508      
Equity Method Investments     $ 329 $ 334  
XML 52 R31.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation (Tables)
 3 Months Ended
Sep. 30, 2019
Share-based Payment Arrangement [Abstract]  
Schedule of Total Share-based Compensation Expense by Type of Award
The following table provides total share-based compensation expense by type of award:
 
Three Months Ended September 30,
(in millions)
2019
 
2018
Restricted share unit expense
$
17

 
$
14

Employee stock option expense
1

 
4

Performance share unit expense
2

 
1

Total share-based compensation
$
20

 
$
19
Schedule of Stock Option Transactions Under the Plans
The following table summarizes all stock option transactions under the Plans:
(in millions, except per share amounts)
Stock
Options
 
Weighted-Average
Exercise Price per
Common Share
Outstanding at June 30, 2019
6

 
$
63.78

Granted
—

 
—

Exercised
—

 
—

Canceled and forfeited
—

 
—

Outstanding at September 30, 2019
6

 
$
63.75

Exercisable at September 30, 2019
6

 
$
63.67
Schedule of Additional Data Related to Stock Option Activity
The following tables provide additional detail related to stock options:
(in millions)
September 30, 2019
 
June 30, 2019
Aggregate intrinsic value of outstanding options at period end
$
10

 
$
10

Aggregate intrinsic value of exercisable options at period end
10

 
10

(in years)
September 30, 2019
 
June 30, 2019
Weighted-average remaining contractual life of outstanding options
5
 
5
Weighted-average remaining contractual life of exercisable options
5
 
5
Schedule of Transactions Related to Restricted Share Units Under the Plans
The following table summarizes all transactions related to restricted share units under the Plans:
(in millions, except per share amounts)
Restricted Share Units
 
Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 2019
2

 
$
51.65

Granted
2

 
42.09

Vested
(1
)
 
60.92

Canceled and forfeited
—

 
—

Nonvested at September 30, 2019
3

 
$
45.29
Schedule of Transactions Related to Performance Share Units Under the Plans
The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
(in millions, except per share amounts)
Performance
Share Units
 
Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 2019
0.9

 
$
51.45

Granted
0.5

 
43.68

Vested
(0.1
)
 
48.40

Canceled and forfeited
(0.1
)
 
50.59

Nonvested at September 30, 2019
1.2

 
$
50.84
XML 53 R35.htm IDEA: XBRL DOCUMENT v3.19.3
Restructuring and Employee Severance Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Restructuring Cost and Reserve [Line Items]    
Restructuring Costs $ 25  
Severance Costs 20 $ 29
Facility Exit and Other Costs 10 3
Enterprise Wide Cost Saving Measures [Member]    
Restructuring Cost and Reserve [Line Items]    
Restructuring Costs $ 20 $ 26
XML 54 R16.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value Measurements
 3 Months Ended
Sep. 30, 2019
Fair Value Disclosures [Abstract]  
Fair Value Measurements
9. Fair Value Measurements
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:
 
September 30, 2019
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
Other investments (1)
$
109

 
$
—

 
$
—

 
$
109

Forward contracts (2)
—

 
95

 
—

 
95

 
June 30, 2019
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
Other investments (1)
$
118

 
$
—

 
$
—

 
$
118

Forward contracts (2)
—

 
53

 
—

 
53

(1)
The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
(2) The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.
XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 56 R12.htm IDEA: XBRL DOCUMENT v3.19.3
Leases
 3 Months Ended
Sep. 30, 2019
Leases [Abstract]  
Leases
5. Leases
We primarily have operating leases for corporate offices, distribution facilities, vehicles, and equipment. We determine if an arrangement is a lease at inception by evaluating whether the arrangement conveys the right to use an identified asset and whether we obtain substantially all of the economic benefits from and have the ability to direct the use of the asset. Our lease agreements generally do not contain any material residual value guarantees or material restrictive covenants.
Beginning July 1, 2019, operating leases are included in other assets, other accrued liabilities, and deferred income taxes and other liabilities in our condensed consolidated balance sheet. Operating lease right-of-use assets and corresponding operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Operating lease expense for operating lease assets is recognized on a straight-line basis over the lease term. As most of our leases do not provide an implicit rate, we use our collateralized incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate if it is readily determinable.
Finance leases are included in property and equipment, net, current portion of long-term obligations and other short-term borrowings, and long-term obligations, less current portion in our condensed consolidated balance sheet.
Our lease agreements include leases that contain lease components and non-lease components. For all asset classes, we have elected to account for both of these provisions as a single lease component. We also, from time to time, sublease portions of our real estate property, resulting in sublease income. Sublease income and the related assets and cash flows are not material to the condensed
consolidated financial statements at or for the three months ended September 30, 2019.
We also have elected to apply a practical expedient for short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months. Short-term lease expense recognized in the three months ended September 30, 2019 was not material. In addition, we elected the package of three practical expedients permitted under the transition guidance, which include the carry forward of our leases without reassessing 1) whether any contracts are leases or contain leases, 2) lease classification and 3) initial direct costs.
Our leases have remaining lease terms from less than 1 year up to approximately 23 years. Our lease terms may include options to extend or terminate the lease when it is reasonably certain and there is a significant economic incentive to exercise that option.
The following table summarizes the components of lease cost:
 
Three Months Ended September 30,
(in millions)
2019
Operating lease cost
$
31

Finance lease cost


Amortization of right-of-use assets
4

Total finance lease cost
4

Variable lease cost
1

Total lease cost
$
36


The following tables summarizes supplemental balance sheet information related to leases:
(in millions)
September 30, 2019
Operating Leases
 
Operating lease assets
$
394

 
 
   Current portion of operating lease liabilities
103

   Operating lease liabilities
312

Total operating lease liabilities
415

 
 
Finance Leases
 
Property and equipment, net
18

 
 
Current portion of long-term obligations
5

Long-term obligations, less current portion
12

Total finance lease liabilities
$
17



The following tables summarizes supplemental cash flow information related to leases:
 
Three Months Ended September 30,
(in millions)
2019
Cash paid for amounts included in the measurement of lease liabilities:


Operating cash flows paid for operating leases
$
31

Financing cash flows paid for finance lease
2

Non-cash right-of-use assets obtained in exchange for lease obligations:

New operating leases
15

New finance leases
17

Amended lease standard adoption impact as of July 1, 2019 (1) 
400


(1)
Includes the effect of $22 million from reclassifying deferred rent as an offset in accordance with the transition guidance.
Our operating leases had a weighted-average remaining lease term of 6.2 years and a weighted-average discount rate of 3.0 percent.
Future lease payments under non-cancellable leases as of September 30, 2019 were as follows:
(in millions)
Operating Leases
 
Finance Leases
 
Total
Years Ending September 30,

 

 

Remainder of 2020
$
91

 
$
4

 
$
95

2021
101

 
6

 
107

2022
79

 
4

 
83

2023
58

 
4

 
62

2024
41

 
1

 
42

Thereafter
149

 
—

 
149

Total future lease payments
519

 
19

 
538

Less: leases not yet commenced (1) 
61

 
—

 
61

Less: imputed interest
43

 
2

 
45

Total lease liabilities
$
415

 
$
17

 
$
432

(1)
As of September 30, 2019, we had certain leases that were executed but did not have control of the underlying assets; therefore, the lease liabilities and right-of-use assets are not recorded in the condensed consolidated balance sheets.
As previously disclosed in our fiscal 2019 Form 10-K under the prior accounting guidance, the future minimum rental payments for operating leases having initial or remaining non-cancelable lease terms in excess of one year at June 30, 2019 for fiscal 2020 through 2024 and thereafter were as follows: $126 million, $100 million, $76 million, $54 million, $33 million and $94 million.
XML 57 R26.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value Measurements (Tables)
 3 Months Ended
Sep. 30, 2019
Fair Value Disclosures [Abstract]  
Fair Value, Assets and Liabilities Measured on Recurring Basis
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:
 
September 30, 2019
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
Other investments (1)
$
109

 
$
—

 
$
—

 
$
109

Forward contracts (2)
—

 
95

 
—

 
95

 
June 30, 2019
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 
 
 
 
 
 
 
Other investments (1)
$
118

 
$
—

 
$
—

 
$
118

Forward contracts (2)
—

 
53

 
—

 
53

(1)
The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
(2) The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.
XML 58 R22.htm IDEA: XBRL DOCUMENT v3.19.3
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. Investments in business entities in which we do not have control, but have the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. Refer to Note 4 for further information on our equity method investments.
References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.
Our fiscal year ends on June 30. References to fiscal 2020 and 2019 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2020 and June 30, 2019, respectively.
Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. To conform to the current year presentation, certain prior year amounts have been reclassified. In addition, financial results presented for this fiscal 2020 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2020. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2019 (the "2019 Form 10-K").
Recent Financial Accounting Standards
Recently Adopted Financial Accounting Standards
Derivatives and Hedging
In October 2018, the Financial Accounting Standards Board ("FASB") issued amended accounting guidance related to derivatives and hedging which permits the use of the Secured Overnight Financing Rate ("SOFR") Overnight Index Swap ("OIS") as a Benchmark
Interest Rate for Hedge Accounting Purposes. This guidance is effective beginning the first quarter of fiscal 2020 and must be applied on a prospective basis. The adoption did not have a material impact on our consolidated financial statements.
Leases
In February 2016, the FASB issued amended accounting guidance that requires lessees to recognize most leases on the balance sheet as a lease liability and corresponding right-of-use asset. The guidance also requires disclosures that meet the objective of enabling financial statement users to assess the amount, timing and uncertainty of cash flows arising from leases. We adopted this guidance during the first quarter of fiscal 2020 and elected the transition option which allows us to apply the guidance prospectively. The adoption resulted in the recognition of lease liabilities in the amount of $422 million and did not have a material impact on our results of operations, liquidity or debt covenant compliance under our current debt agreements. The majority of our lease spend relates to certain real estate with the remaining lease spend primarily related to vehicles and equipment. The adoption required certain changes to our systems and processes. See Note 5 for additional information regarding leases.
Recently Issued Financial Accounting Standards Not Yet Adopted
Financial Instruments - Credit Losses
In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. This guidance will be effective for us in the first quarter of fiscal 2021. We are currently evaluating the impact of adoption on our consolidated financial statements.
XML 59 R43.htm IDEA: XBRL DOCUMENT v3.19.3
Leases Summary of Minimum Lease Committments (Details)
$ in Millions
Sep. 30, 2019
USD ($)
Remainder of 2020 $ 95
2021 107
2022 83
2023 62
2024 42
Thereafter 149
Total future lease payments 538
Less: leases not yet commenced (1) 61
Less: imputed interest 45
Total lease liabilities 415
Total lease liabilities 17
Total lease liabilities 432
Operating Lease [Member]  
Remainder of 2020 91
2021 101
2022 79
2023 58
2024 41
Thereafter 149
Total future lease payments 519
Less: leases not yet commenced (1) 61
Less: imputed interest 43
Total lease liabilities 415
Finance Lease [Member]  
Remainder of 2020 4
2021 6
2022 4
2023 4
2024 1
Thereafter 0
Total future lease payments 19
Less: leases not yet commenced (1) 0
Less: imputed interest 2
Total lease liabilities $ 17
XML 60 R47.htm IDEA: XBRL DOCUMENT v3.19.3
Income Taxes Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Jun. 30, 2019
Income Taxes      
Income Tax Expense (Benefit) $ 423 $ (142)  
Effective Income Tax Rate Reconciliation, Percent 7.90% 19.40%  
Unrecognized tax benefits $ 943   $ 456
Unrecognized tax benefits that would impact effective tax rate 795   303
Unrecognized tax benefits, interest and penalties accrued 126   122
Minimum      
Income Taxes      
Estimated range of decrease in unrecognized tax benefits within the next 12 months 0    
Maximum      
Income Taxes      
Estimated range of decrease in unrecognized tax benefits within the next 12 months $ 10    
Federal | Minimum      
Income Taxes      
Open Tax Year 2008    
Total Opioid Litigation [Member]      
Income Taxes      
Estimated Litigation Liability $ 5,630    
Income Tax Expense (Benefit) 487    
Unrecognized tax benefits that would impact effective tax rate 468    
Patient Recovery Business [Member]      
Income Taxes      
Indemnification receivable 23   22
CareFusion [Member]      
Income Taxes      
Indemnification receivable $ 168   $ 165
XML 61 R64.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details) - Stock Options - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Sep. 30, 2019
Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 1 year  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 3  
Aggregate intrinsic value of outstanding options at period end 10 $ 10
Aggregate intrinsic value of exercisable options at period end $ 10 $ 10
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 5 years 5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term 5 years 5 years
XML 62 R60.htm IDEA: XBRL DOCUMENT v3.19.3
Segment Information Revenue by Geographical Segments (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Segment Revenue by Geographic [Line Items]    
Revenue $ 37,341 $ 35,213
UNITED STATES    
Segment Revenue by Geographic [Line Items]    
Revenue 36,310 34,245
Non-US [Member]    
Segment Revenue by Geographic [Line Items]    
Revenue 1,035 972
Operating Segments    
Segment Revenue by Geographic [Line Items]    
Revenue 37,345 35,217
Corporate    
Segment Revenue by Geographic [Line Items]    
Revenue $ (4) $ (4)
XML 63 R56.htm IDEA: XBRL DOCUMENT v3.19.3
Segment Information (Revenue by Reportable Segment) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Segment Reporting Information [Line Items]    
Total revenue $ 37,341 $ 35,213
Operating Segments    
Segment Reporting Information [Line Items]    
Total revenue 37,345 35,217
Operating Segments | Pharmaceutical    
Segment Reporting Information [Line Items]    
Total revenue 33,428 31,416
Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Total revenue 3,917 3,801
Corporate    
Segment Reporting Information [Line Items]    
Total revenue (4) (4)
Nuclear Precision Health Services [Member] | Operating Segments | Pharmaceutical    
Segment Reporting Information [Line Items]    
Total revenue 216 207
Pharmaceutical Distribution and Specialty [Member] | Operating Segments | Pharmaceutical    
Segment Reporting Information [Line Items]    
Total revenue 33,212 31,209
Medical distribution and products [Member] | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Total revenue 3,446 3,380
Cardinal Health At Home [Member] | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Total revenue $ 471 $ 421
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.19.3
Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2019
Sep. 30, 2018
AOCI, Net of Tax [Roll Forward]    
Balance at beginning of period $ 6,330 $ 6,059
Total other comprehensive income/(loss), net of tax (22) (4)
Balance at end of period 903 5,913
Foreign Currency Translation Adjustments    
AOCI, Net of Tax [Roll Forward]    
Balance at beginning of period (95)  
Other comprehensive income/(loss), before reclassifications (17)  
Amounts reclassified to earnings 0  
Total other comprehensive income/(loss), net of tax (17)  
Balance at end of period (112)  
Unrealized Gain/(Loss) on Derivatives, net of tax    
AOCI, Net of Tax [Roll Forward]    
Balance at beginning of period 16  
Other comprehensive income/(loss), before reclassifications 0  
Amounts reclassified to earnings (5)  
Total other comprehensive income/(loss), net of tax (5)  
Balance at end of period 11  
Accumulated Other Comprehensive Loss    
AOCI, Net of Tax [Roll Forward]    
Balance at beginning of period (79)  
Total other comprehensive income/(loss), net of tax (22)  
Balance at end of period (101)  
AOCI Attributable to Parent    
AOCI, Net of Tax [Roll Forward]    
Balance at beginning of period (79) (92)
Other comprehensive income/(loss), before reclassifications (17)  
Amounts reclassified to earnings (5)  
Balance at end of period $ (101) $ (96)
XML 65 R8.htm IDEA: XBRL DOCUMENT v3.19.3
Basis of Presentation and Summary of Significant Accounting Policies
 3 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies
1. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation
Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. Investments in business entities in which we do not have control, but have the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. Refer to Note 4 for further information on our equity method investments.
References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.
Our fiscal year ends on June 30. References to fiscal 2020 and 2019 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2020 and June 30, 2019, respectively.
Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. To conform to the current year presentation, certain prior year amounts have been reclassified. In addition, financial results presented for this fiscal 2020 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2020. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2019 (the "2019 Form 10-K").
Recently Adopted Financial Accounting Standards
Derivatives and Hedging
In October 2018, the Financial Accounting Standards Board ("FASB") issued amended accounting guidance related to derivatives and hedging which permits the use of the Secured Overnight Financing Rate ("SOFR") Overnight Index Swap ("OIS") as a Benchmark
Interest Rate for Hedge Accounting Purposes. This guidance is effective beginning the first quarter of fiscal 2020 and must be applied on a prospective basis. The adoption did not have a material impact on our consolidated financial statements.
Leases
In February 2016, the FASB issued amended accounting guidance that requires lessees to recognize most leases on the balance sheet as a lease liability and corresponding right-of-use asset. The guidance also requires disclosures that meet the objective of enabling financial statement users to assess the amount, timing and uncertainty of cash flows arising from leases. We adopted this guidance during the first quarter of fiscal 2020 and elected the transition option which allows us to apply the guidance prospectively. The adoption resulted in the recognition of lease liabilities in the amount of $422 million and did not have a material impact on our results of operations, liquidity or debt covenant compliance under our current debt agreements. The majority of our lease spend relates to certain real estate with the remaining lease spend primarily related to vehicles and equipment. The adoption required certain changes to our systems and processes. See Note 5 for additional information regarding leases.
Recently Issued Financial Accounting Standards Not Yet Adopted
Financial Instruments - Credit Losses
In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. This guidance will be effective for us in the first quarter of fiscal 2021. We are currently evaluating the impact of adoption on our consolidated financial statements.
XML 66 R4.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2019
Jun. 30, 2019
Current assets:    
Cash and equivalents $ 1,212 $ 2,531
Trade receivables, net 8,190 8,448
Inventories, net 12,458 12,822
Prepaid expenses and other 1,855 1,946
Total current assets 23,715 25,747
Property and equipment, net 2,324 2,356
Goodwill and other intangibles, net 11,658 11,808
Other Assets 1,482 1,052
Total assets 39,179 40,963
Accounts Payable, Current 19,724 21,535
Current liabilities:    
Current portion of long-term obligations and other short-term borrowings 631 452
Other accrued liabilities 2,194 2,122
Total current liabilities 22,549 24,109
Long-term obligations, less current portion 7,360 7,579
Deferred income taxes and other liabilities 8,367 2,945
Preferred shares, without par value:    
Authorized—500 thousand shares, Issued—none 0 0
Common shares, without par value:    
Authorized—755 million shares, Issued—327 million shares at September 30, 2019 and June 30, 2019, respectively 2,669 2,763
Retained earnings 371 5,434
Common shares in treasury, at cost: 34 million shares and 28 million shares at September 30, 2019 and June 30, 2019, respectively (2,039) (1,790)
Accumulated other comprehensive loss (101) (79)
Total Cardinal Health, Inc. shareholders' equity 900 6,328
Noncontrolling interests 3 2
Total shareholders' equity 903 6,330
Total liabilities and shareholders’ equity $ 39,179 $ 40,963
XML 67 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 160 368 1 false 59 0 false 11 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.cardinal.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Statements of Earnings Sheet http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings Condensed Consolidated Statements of Earnings Statements 2 false false R3.htm 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 3 false false R4.htm 1003000 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 4 false false R5.htm 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 1014000 - Statement - Condensed Consolidated Statement of Shareholders' Equity Sheet http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity Condensed Consolidated Statement of Shareholders' Equity Statements 6 false false R7.htm 1015000 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2101100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 8 false false R9.htm 2103100 - Disclosure - Restructuring and Employee Severance Sheet http://www.cardinal.com/role/RestructuringAndEmployeeSeverance Restructuring and Employee Severance Notes 9 false false R10.htm 2105100 - Disclosure - Goodwill and Other Intangible Assets Sheet http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 10 false false R11.htm 2106100 - Disclosure - Investments Sheet http://www.cardinal.com/role/Investments Investments Notes 11 false false R12.htm 2107100 - Disclosure - Leases Sheet http://www.cardinal.com/role/Leases Leases Notes 12 false false R13.htm 2108100 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Sheet http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowings Long-Term Obligations and Other Short-Term Borrowings Notes 13 false false R14.htm 2109100 - Disclosure - Commitments, Contingent Liabilities and Litigation Sheet http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigation Commitments, Contingent Liabilities and Litigation Notes 14 false false R15.htm 2110100 - Disclosure - Income Taxes Sheet http://www.cardinal.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 2111100 - Disclosure - Fair Value Measurements Sheet http://www.cardinal.com/role/FairValueMeasurements Fair Value Measurements Notes 16 false false R17.htm 2112100 - Disclosure - Financial Instruments Sheet http://www.cardinal.com/role/FinancialInstruments Financial Instruments Notes 17 false false R18.htm 2113100 - Disclosure - Shareholders' Equity Sheet http://www.cardinal.com/role/ShareholdersEquity Shareholders' Equity Notes 18 false false R19.htm 2114100 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Sheet http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthInc Earnings Per Share Attributable to Cardinal Health, Inc. Notes 19 false false R20.htm 2115100 - Disclosure - Segment Information Sheet http://www.cardinal.com/role/SegmentInformation Segment Information Notes 20 false false R21.htm 2116100 - Disclosure - Share-Based Compensation Sheet http://www.cardinal.com/role/ShareBasedCompensation Share-Based Compensation Notes 21 false false R22.htm 2201201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies 22 false false R23.htm 2303301 - Disclosure - Restructuring and Employee Severance (Tables) Sheet http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceTables Restructuring and Employee Severance (Tables) Tables http://www.cardinal.com/role/RestructuringAndEmployeeSeverance 23 false false R24.htm 2305301 - Disclosure - Goodwill and Other Intangible Assets (Tables) Sheet http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsTables Goodwill and Other Intangible Assets (Tables) Tables http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssets 24 false false R25.htm 2307301 - Disclosure - Leases (Tables) Sheet http://www.cardinal.com/role/LeasesTables Leases (Tables) Tables http://www.cardinal.com/role/Leases 25 false false R26.htm 2311301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.cardinal.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.cardinal.com/role/FairValueMeasurements 26 false false R27.htm 2312301 - Disclosure - Financial Instruments (Tables) Sheet http://www.cardinal.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.cardinal.com/role/FinancialInstruments 27 false false R28.htm 2313301 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.cardinal.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.cardinal.com/role/ShareholdersEquity 28 false false R29.htm 2314301 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables) Sheet http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncTables Earnings Per Share Attributable to Cardinal Health, Inc. (Tables) Tables http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthInc 29 false false R30.htm 2315301 - Disclosure - Segment Information (Tables) Sheet http://www.cardinal.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.cardinal.com/role/SegmentInformation 30 false false R31.htm 2316301 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.cardinal.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.cardinal.com/role/ShareBasedCompensation 31 false false R32.htm 2401402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Narrative (Details) Sheet http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails Basis of Presentation and Summary of Significant Accounting Policies Narrative (Details) Details http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies 32 false false R33.htm 2403402 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) Sheet http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceActivityRelatedToRestructuringAndEmployeeSeveranceCostsDetails Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) Details http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceTables 33 false false R34.htm 2403403 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) Sheet http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) Details http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceTables 34 false false R35.htm 2403404 - Disclosure - Restructuring and Employee Severance Narrative (Details) Sheet http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceNarrativeDetails Restructuring and Employee Severance Narrative (Details) Details 35 false false R36.htm 2405402 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) Details http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsTables 36 false false R37.htm 2405403 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) Sheet http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) Details http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsTables 37 false false R38.htm 2405404 - Disclosure - Goodwill and Other Intangible Assets Narrative (Details) Sheet http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails Goodwill and Other Intangible Assets Narrative (Details) Details 38 false false R39.htm 2406401 - Disclosure - Investments Narrative (Details) Sheet http://www.cardinal.com/role/InvestmentsNarrativeDetails Investments Narrative (Details) Details 39 false false R40.htm 2407402 - Disclosure - Leases Narative (Details) Sheet http://www.cardinal.com/role/LeasesNarativeDetails Leases Narative (Details) Details 40 false false R41.htm 2407403 - Disclosure - Leases Summary of Lease Costs (Details) Sheet http://www.cardinal.com/role/LeasesSummaryOfLeaseCostsDetails Leases Summary of Lease Costs (Details) Details 41 false false R42.htm 2407404 - Disclosure - Leases Summary of Lease Payments (Details) Sheet http://www.cardinal.com/role/LeasesSummaryOfLeasePaymentsDetails Leases Summary of Lease Payments (Details) Details 42 false false R43.htm 2407405 - Disclosure - Leases Summary of Minimum Lease Committments (Details) Sheet http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails Leases Summary of Minimum Lease Committments (Details) Details 43 false false R44.htm 2407406 - Disclosure - Leases Supplemental Balance Sheet Information (Details) Sheet http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails Leases Supplemental Balance Sheet Information (Details) Details 44 false false R45.htm 2408401 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Narrative (Details) Sheet http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails Long-Term Obligations and Other Short-Term Borrowings Narrative (Details) Details http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowings 45 false false R46.htm 2409401 - Disclosure - Commitments, Contingent Liabilities and Litigation Narrative (Details) Sheet http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails Commitments, Contingent Liabilities and Litigation Narrative (Details) Details http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigation 46 false false R47.htm 2410401 - Disclosure - Income Taxes Narrative (Details) Sheet http://www.cardinal.com/role/IncomeTaxesNarrativeDetails Income Taxes Narrative (Details) Details 47 false false R48.htm 2411402 - Disclosure - Fair Value Measurements Narrative (Details) Sheet http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements Narrative (Details) Details 48 false false R49.htm 2412402 - Disclosure - Financial Instruments Narrative (Details) Sheet http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails Financial Instruments Narrative (Details) Details 49 false false R50.htm 2412403 - Disclosure - Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details) Sheet http://www.cardinal.com/role/FinancialInstrumentsSummaryOfEstimatedFairValueOfLongTermObligationsAndOtherShortTermBorrowingsDetails Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details) Details http://www.cardinal.com/role/FinancialInstrumentsTables 50 false false R51.htm 2413402 - Disclosure - Shareholders' Equity Narrative (Details) Sheet http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails Shareholders' Equity Narrative (Details) Details 51 false false R52.htm 2413403 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) Sheet http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) Details http://www.cardinal.com/role/ShareholdersEquityTables 52 false false R53.htm 2414402 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) Sheet http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncReconciliationOfCommonSharesUsedToComputeBasicAndDilutedEpsDetails Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) Details http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncTables 53 false false R54.htm 2414403 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details) Sheet http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncNarrativeDetails Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details) Details http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncTables 54 false false R55.htm 2415402 - Disclosure - Segment Information Narrative (Details) Sheet http://www.cardinal.com/role/SegmentInformationNarrativeDetails Segment Information Narrative (Details) Details 55 false false R56.htm 2415403 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails Segment Information (Revenue by Reportable Segment) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 56 false false R57.htm 2415404 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails Segment Information (Segment Profit by Reportable Segment) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 57 false false R58.htm 2415405 - Disclosure - Segment Information (Assets by Reportable Segment) (Details) Sheet http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails Segment Information (Assets by Reportable Segment) (Details) Details http://www.cardinal.com/role/SegmentInformationTables 58 false false R59.htm 2415406 - Disclosure - Segment Information Disaggregated Revenue Within Reportable Segments (Details) Sheet http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails Segment Information Disaggregated Revenue Within Reportable Segments (Details) Details 59 false false R60.htm 2415407 - Disclosure - Segment Information Revenue by Geographical Segments (Details) Sheet http://www.cardinal.com/role/SegmentInformationRevenueByGeographicalSegmentsDetails Segment Information Revenue by Geographical Segments (Details) Details 60 false false R61.htm 2416402 - Disclosure - Share-Based Compensation Narrative (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails Share-Based Compensation Narrative (Details) Details 61 false false R62.htm 2416403 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleOfTotalShareBasedCompensationExpenseByTypeOfAwardDetails Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 62 false false R63.htm 2416404 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 63 false false R64.htm 2416405 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 64 false false R65.htm 2416406 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 65 false false R66.htm 2416407 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) Sheet http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) Details http://www.cardinal.com/role/ShareBasedCompensationTables 66 false false All Reports Book All Reports a20q110q093019form10-q.htm a20q110q93019exhibit311.htm a20q110q93019exhibit312.htm a20q110q93019exhibit321.htm a20q110q93019exhibit991.htm cah-20190930.xsd cah-20190930_cal.xml cah-20190930_def.xml cah-20190930_lab.xml cah-20190930_pre.xml chart-0e7efb26c0365e6cb47.jpg chart-5f32bf9b0ca256e99b2.jpg chart-986746bac297519d8c3.jpg chart-f4d60677c0e25c84939.jpg chart-ff3385a010ad5ef68c1.jpg http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 http://xbrl.sec.gov/invest/2013-01-31 true true XML 68 a20q110q093019form10-q_htm.xml IDEA: XBRL DOCUMENT 0000721371 2019-07-01 2019-09-30 0000721371 2019-10-31 0000721371 2018-07-01 2018-09-30 0000721371 2019-06-30 0000721371 2019-09-30 0000721371 us-gaap:TreasuryStockMember 2019-06-30 0000721371 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000721371 us-gaap:RetainedEarningsMember 2019-09-30 0000721371 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0000721371 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000721371 us-gaap:RetainedEarningsMember 2019-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2019-09-30 0000721371 us-gaap:CommonStockMember 2019-06-30 0000721371 us-gaap:CommonStockMember 2019-09-30 0000721371 us-gaap:NoncontrollingInterestMember 2019-07-01 2019-09-30 0000721371 us-gaap:NoncontrollingInterestMember 2019-06-30 0000721371 us-gaap:TreasuryStockMember 2019-09-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000721371 us-gaap:CommonStockMember 2018-09-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000721371 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0000721371 us-gaap:TreasuryStockMember 2018-06-30 0000721371 us-gaap:NoncontrollingInterestMember 2018-06-30 0000721371 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0000721371 us-gaap:TreasuryStockMember 2018-07-01 2018-09-30 0000721371 us-gaap:TreasuryStockMember 2018-09-30 0000721371 2018-09-30 0000721371 us-gaap:NoncontrollingInterestMember 2018-09-30 0000721371 us-gaap:RetainedEarningsMember 2018-09-30 0000721371 2018-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0000721371 us-gaap:RetainedEarningsMember 2018-06-30 0000721371 us-gaap:CommonStockMember 2018-06-30 0000721371 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0000721371 2019-07-01 0000721371 us-gaap:EmployeeSeveranceMember 2019-09-30 0000721371 us-gaap:EmployeeSeveranceMember 2019-07-01 2019-09-30 0000721371 us-gaap:FacilityClosingMember 2019-06-30 0000721371 us-gaap:EmployeeSeveranceMember 2019-06-30 0000721371 us-gaap:FacilityClosingMember 2019-09-30 0000721371 us-gaap:FacilityClosingMember 2019-07-01 2019-09-30 0000721371 cah:EnterpriseWideCostSavingMeasuresMember 2019-07-01 2019-09-30 0000721371 cah:EnterpriseWideCostSavingMeasuresMember 2018-07-01 2018-09-30 0000721371 cah:IPRDTrademarksandOtherMember 2019-06-30 0000721371 cah:TrademarksAndPatentsMember 2019-06-30 0000721371 us-gaap:CustomerRelationshipsMember 2019-06-30 0000721371 us-gaap:DevelopedTechnologyRightsMember 2019-06-30 0000721371 cah:MedicalMember 2019-06-30 0000721371 cah:PharmaceuticalMember 2019-07-01 2019-09-30 0000721371 cah:PharmaceuticalMember 2019-06-30 0000721371 cah:MedicalMember 2019-07-01 2019-09-30 0000721371 cah:MedicalMember 2019-09-30 0000721371 cah:PharmaceuticalMember 2019-09-30 0000721371 us-gaap:DevelopedTechnologyRightsMember 2019-09-30 0000721371 us-gaap:DevelopedTechnologyRightsMember 2019-07-01 2019-09-30 0000721371 cah:IPRDTrademarksandOtherMember 2019-09-30 0000721371 us-gaap:CustomerRelationshipsMember 2019-09-30 0000721371 cah:TrademarksAndPatentsMember 2019-09-30 0000721371 cah:TrademarksAndPatentsMember 2019-07-01 2019-09-30 0000721371 us-gaap:CustomerRelationshipsMember 2019-07-01 2019-09-30 0000721371 cah:NaviHealthMember 2018-08-01 0000721371 cah:NaviHealthMember 2018-07-01 2018-09-30 0000721371 cah:NaviHealthMember 2018-08-01 2018-08-31 0000721371 cah:NaviHealthMember 2019-06-30 0000721371 cah:NaviHealthMember 2019-09-30 0000721371 2019-07-01 2019-07-01 0000721371 srt:MinimumMember 2019-09-30 0000721371 srt:MaximumMember 2019-09-30 0000721371 cah:OperatingLeaseMember 2019-09-30 0000721371 cah:FinanceLeaseMember 2019-09-30 0000721371 cah:ASC842Member 2019-07-01 2019-07-01 0000721371 us-gaap:CommercialPaperMember 2019-06-30 0000721371 us-gaap:RevolvingCreditFacilityMember 2019-06-30 0000721371 cah:ShortTermCreditFacilitiesMember cah:CommittedReceivablesSalesFacilityProgramMember 2019-06-30 0000721371 cah:OpioidLitigationlessCuyahogaandSummitCountiesMember 2019-07-01 2019-09-30 0000721371 cah:ProductLiabilityLawsuitsMember cah:AlamedaCountyMember us-gaap:SubsequentEventMember 2019-11-01 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember cah:ClassActionLawsuitsMember cah:PrivatePartiesMember 2019-11-01 0000721371 cah:OpioidLitigationCuyahogaandSummitCountiesMember 2019-09-30 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember cah:PrivatePartiesMember 2019-11-01 0000721371 cah:OpioidLawsuitsMember us-gaap:SubsequentEventMember 2019-11-01 0000721371 cah:CVSHealthMember 2019-07-01 2019-09-30 0000721371 cah:TotalOpioidLitigationMember 2019-09-30 0000721371 cah:ProductLiabilityLawsuitsMember cah:AlamedaCountyMember us-gaap:SubsequentEventMember 2019-11-01 2019-11-01 0000721371 cah:ProductLiabilityLawsuitsMember cah:OtherJurisdictionsMember us-gaap:SubsequentEventMember 2019-11-01 0000721371 cah:OpioidLitigationlessCuyahogaandSummitCountiesMember 2019-09-30 0000721371 cah:TotalOpioidLitigationnetoftaxMember 2019-09-30 0000721371 us-gaap:SubsequentEventMember 2019-10-21 0000721371 cah:ProductLiabilityLawsuitsMember cah:OtherJurisdictionsMember us-gaap:SubsequentEventMember 2019-11-01 2019-11-01 0000721371 cah:CareFusionMember 2019-06-30 0000721371 cah:PatientRecoveryBusinessMember 2019-09-30 0000721371 cah:CareFusionMember 2019-09-30 0000721371 srt:MinimumMember us-gaap:InternalRevenueServiceIRSMember 2019-07-01 2019-09-30 0000721371 cah:PatientRecoveryBusinessMember 2019-06-30 0000721371 cah:TotalOpioidLitigationMember 2019-07-01 2019-09-30 0000721371 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000721371 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000721371 us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000721371 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000721371 us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000721371 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000721371 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000721371 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000721371 us-gaap:FairValueInputsLevel2Member 2019-06-30 0000721371 us-gaap:FairValueInputsLevel2Member 2019-09-30 0000721371 us-gaap:CurrencySwapMember 2018-09-30 0000721371 us-gaap:CurrencySwapMember 2019-09-30 0000721371 us-gaap:CashFlowHedgingMember 2019-09-30 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-06-30 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-09-30 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-09-30 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-06-30 0000721371 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2019-07-01 2019-09-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2019-07-01 2019-09-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2019-06-30 0000721371 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2019-09-30 0000721371 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-07-01 2019-09-30 0000721371 2018-10-25 0000721371 us-gaap:CorporateNonSegmentMember 2018-07-01 2018-09-30 0000721371 us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0000721371 us-gaap:NonUsMember 2019-07-01 2019-09-30 0000721371 us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0000721371 us-gaap:CorporateNonSegmentMember 2019-07-01 2019-09-30 0000721371 country:US 2019-07-01 2019-09-30 0000721371 us-gaap:NonUsMember 2018-07-01 2018-09-30 0000721371 country:US 2018-07-01 2018-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2018-07-01 2018-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2018-07-01 2018-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2019-07-01 2019-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2019-07-01 2019-09-30 0000721371 us-gaap:CorporateNonSegmentMember 2019-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2019-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember 2019-09-30 0000721371 us-gaap:CorporateNonSegmentMember 2019-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2019-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember 2019-06-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:MedicaldistributionandproductsMember 2018-07-01 2018-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:NuclearPrecisionHealthServicesMember 2019-07-01 2019-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:CardinalHealthAtHomeMember 2019-07-01 2019-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:PharmaceuticalDistributionandSpecialtyMember 2019-07-01 2019-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:PharmaceuticalDistributionandSpecialtyMember 2018-07-01 2018-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:MedicaldistributionandproductsMember 2019-07-01 2019-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:MedicalMember cah:CardinalHealthAtHomeMember 2018-07-01 2018-09-30 0000721371 us-gaap:OperatingSegmentsMember cah:PharmaceuticalMember cah:NuclearPrecisionHealthServicesMember 2018-07-01 2018-09-30 0000721371 us-gaap:PerformanceSharesMember 2019-07-01 2019-09-30 0000721371 us-gaap:PerformanceSharesMember 2019-06-30 0000721371 us-gaap:PerformanceSharesMember 2019-09-30 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2019-06-30 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2019-09-30 0000721371 us-gaap:RestrictedStockUnitsRSUMember 2018-07-01 2018-09-30 0000721371 us-gaap:PerformanceSharesMember 2018-07-01 2018-09-30 0000721371 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-09-30 0000721371 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0000721371 us-gaap:EmployeeStockOptionMember 2018-07-01 2019-06-30 0000721371 us-gaap:EmployeeStockOptionMember 2019-09-30 0000721371 us-gaap:EmployeeStockOptionMember 2019-06-30 0000721371 srt:MinimumMember us-gaap:PerformanceSharesMember 2019-07-01 2019-09-30 0000721371 srt:MaximumMember us-gaap:PerformanceSharesMember 2019-07-01 2019-09-30 pure cah:StateAG cah:segment iso4217:USD shares cah:Reportable_Segments iso4217:JPY iso4217:USD cah:plaintiff iso4217:EUR shares cah:lawsuit false --06-30 Q1 2020 0000721371 755000000 755000000 327000000 327000000 8000000000 2 500000 500000 0 0 28000000 34000000 10-Q true 2019-09-30 false 1-11373 Cardinal Health, Inc. OH 31-0958666 7000 Cardinal Place Dublin OH 43017 614 757-5000 Common shares (without par value) CAH NYSE Yes Yes Large Accelerated Filer false false false 292488354 37341000000 35213000000 35662000000 33546000000 1679000000 1667000000 1107000000 1155000000 30000000 32000000 132000000 156000000 -1000000 511000000 -5673000000 -19000000 -5264000000 816000000 -14000000 -3000000 66000000 77000000 -5344000000 736000000 -423000000 142000000 -4921000000 594000000 1000000 1000000 -4922000000 593000000 -16.65 1.95 -16.65 1.94 296000000 305000000 296000000 306000000 0.4811 0.4763 -4921000000 594000000 -17000000 -3000000 -5000000 -1000000 -22000000 -4000000 -4943000000 590000000 1000000 1000000 -4944000000 589000000 1212000000 2531000000 8190000000 8448000000 12458000000 12822000000 1855000000 1946000000 23715000000 25747000000 2324000000 2356000000 11658000000 11808000000 1482000000 1052000000 39179000000 40963000000 19724000000 21535000000 631000000 452000000 2194000000 2122000000 22549000000 24109000000 7360000000 7579000000 8367000000 2945000000 0 0 2669000000 2763000000 371000000 5434000000 2039000000 1790000000 -101000000 -79000000 900000000 6328000000 3000000 2000000 903000000 6330000000 39179000000 40963000000 327000000 2763000000 5434000000 28000000 1790000000 -79000000 2000000 6330000000 -4922000000 1000000 -4921000000 -22000000 -22000000 24000000 31000000 7000000 70000000 6000000 280000000 350000000 141000000 141000000 327000000 2669000000 371000000 34000000 2039000000 -101000000 3000000 903000000 327000000 2730000000 4645000000 18000000 1224000000 -92000000 0 6059000000 593000000 593000000 -4000000 -4000000 20000000 26000000 6000000 120000000 9000000 480000000 600000000 143000000 143000000 -2000000 2000000 327000000 2590000000 5097000000 27000000 1678000000 -96000000 0 5913000000 -4921000000 594000000 234000000 245000000 0 2000000 -1000000 511000000 20000000 19000000 29000000 21000000 -229000000 302000000 -356000000 178000000 -1812000000 559000000 -5211000000 84000000 -653000000 365000000 72000000 58000000 3000000 4000000 2000000 1000000 0 740000000 -73000000 679000000 -2000000 0 74000000 1000000 -13000000 -13000000 146000000 150000000 350000000 600000000 -585000000 -764000000 -8000000 2000000 -1319000000 282000000 2531000000 1763000000 1212000000 2045000000 <div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:13pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">1. Basis of Presentation and Summary of Significant Accounting Policies</span><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. Investments in business entities in which we do not have control, but have the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. Refer to </span><a href="#sF26386BC522F5F17861BDCB6DADF5D65" style="font-family:Arial Narrow;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Note 4</span></a><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for further information on our equity method investments.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our fiscal year ends on June 30. References to fiscal </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2020</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2020</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and June 30, </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. To conform to the current year presentation, certain prior year amounts have been reclassified. In addition, financial results presented for this fiscal </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2020</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2020</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> (the "</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> Form 10-K"). </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Financial Accounting Standards</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;font-style:italic;">Derivatives and Hedging</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In October 2018, the Financial Accounting Standards Board ("FASB") issued amended accounting guidance related to derivatives and hedging which permits the use of the Secured Overnight Financing Rate ("SOFR") Overnight Index Swap ("OIS") as a Benchmark </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Interest Rate for Hedge Accounting Purposes. This guidance is effective beginning the first quarter of fiscal 2020 and must be applied on a prospective basis. The adoption did not have a material impact on our consolidated financial statements. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-style:italic;font-weight:normal;">Leases</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In February 2016, the FASB issued amended accounting guidance that requires lessees to recognize most leases on the balance sheet as a lease liability and corresponding right-of-use asset. The guidance also requires disclosures that meet the objective of enabling financial statement users to assess the amount, timing and uncertainty of cash flows arising from leases. We adopted this guidance during the first quarter of fiscal 2020 and elected the transition option which allows us to apply the guidance prospectively. The adoption resulted in the recognition of lease liabilities in the amount of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$422 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and did not have a material impact on our results of operations, liquidity or debt covenant compliance under our current debt agreements. The majority of our lease spend relates to certain real estate with the remaining lease spend primarily related to vehicles and equipment. The adoption required certain changes to our systems and processes. </span><span style="font-family:Arial Narrow;font-size:10pt;">S</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">ee </span><a href="#s1b4f19725b5347a89ea3b6d3c65e17fb" style="font-family:Arial Narrow;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Note 5</span></a><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for additional information regarding leases.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Issued Financial Accounting Standards Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. This guidance will be effective for us in the first quarter of fiscal 2021. We are currently evaluating the impact of adoption on our consolidated financial statements.</span></div> <div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. Investments in business entities in which we do not have control, but have the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. Refer to </span><a href="#sF26386BC522F5F17861BDCB6DADF5D65" style="font-family:Arial Narrow;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Note 4</span></a><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for further information on our equity method investments.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our fiscal year ends on June 30. References to fiscal </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2020</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2020</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and June 30, </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. To conform to the current year presentation, certain prior year amounts have been reclassified. In addition, financial results presented for this fiscal </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2020</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2020</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> (the "</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> Form 10-K"). </span></div> <div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Financial Accounting Standards</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;font-style:italic;">Derivatives and Hedging</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In October 2018, the Financial Accounting Standards Board ("FASB") issued amended accounting guidance related to derivatives and hedging which permits the use of the Secured Overnight Financing Rate ("SOFR") Overnight Index Swap ("OIS") as a Benchmark </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Interest Rate for Hedge Accounting Purposes. This guidance is effective beginning the first quarter of fiscal 2020 and must be applied on a prospective basis. The adoption did not have a material impact on our consolidated financial statements. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-style:italic;font-weight:normal;">Leases</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In February 2016, the FASB issued amended accounting guidance that requires lessees to recognize most leases on the balance sheet as a lease liability and corresponding right-of-use asset. The guidance also requires disclosures that meet the objective of enabling financial statement users to assess the amount, timing and uncertainty of cash flows arising from leases. We adopted this guidance during the first quarter of fiscal 2020 and elected the transition option which allows us to apply the guidance prospectively. The adoption resulted in the recognition of lease liabilities in the amount of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$422 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and did not have a material impact on our results of operations, liquidity or debt covenant compliance under our current debt agreements. The majority of our lease spend relates to certain real estate with the remaining lease spend primarily related to vehicles and equipment. The adoption required certain changes to our systems and processes. </span><span style="font-family:Arial Narrow;font-size:10pt;">S</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">ee </span><a href="#s1b4f19725b5347a89ea3b6d3c65e17fb" style="font-family:Arial Narrow;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Note 5</span></a><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for additional information regarding leases.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Issued Financial Accounting Standards Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. This guidance will be effective for us in the first quarter of fiscal 2021. We are currently evaluating the impact of adoption on our consolidated financial statements.</span></div> 422000000 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:13pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">2. Restructuring and Employee Severance</span><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes restructuring and employee severance costs:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three months ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee-related costs (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Facility exit and other costs (2)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total restructuring and employee severance</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Facility exit and other costs primarily consist of product distribution and lease contract termination costs, lease costs associated with vacant facilities, accelerated depreciation, equipment relocation costs, project consulting fees, costs associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">During fiscal 2020 and 2019, we implemented certain enterprise-wide cost-saving initiatives affecting various functional and commercial areas intended to optimize and simplify our operating model and cost structure. We incurred </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$20 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$26 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively, in expenses related to these cost savings initiatives, which are reflected in restructuring and employee severance in the condensed consolidated statements of earnings.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Related Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Facility Exit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">and Other Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>72</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Additions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Payments and other adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(12</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Balance at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>73</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>85</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes restructuring and employee severance costs:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three months ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee-related costs (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Facility exit and other costs (2)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total restructuring and employee severance</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(2)</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Facility exit and other costs primarily consist of product distribution and lease contract termination costs, lease costs associated with vacant facilities, accelerated depreciation, equipment relocation costs, project consulting fees, costs associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs.</span></div> 20000000 29000000 10000000 3000000 30000000 32000000 20000000 26000000 <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Related Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Facility Exit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">and Other Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>72</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Additions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Payments and other adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(12</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Balance at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>73</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>85</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 64000000 8000000 72000000 19000000 6000000 25000000 10000000 2000000 12000000 73000000 12000000 85000000 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:13pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">3. Goodwill and Other Intangible Assets</span><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Goodwill</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2,663</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>5,715</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>8,378</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Goodwill acquired, net of purchase price adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Foreign currency translation adjustments and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Balance at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2,658</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>5,702</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>8,360</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial Narrow;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Intangible Assets</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following tables summarize other intangible assets by class at:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:19%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Intangible</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Intangible</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted- Average Remaining Amortization Period (Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Indefinite-life intangibles:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">IPR&amp;D, trademarks and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">N/A</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total indefinite-life intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">—</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">N/A</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Definite-life intangibles:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3,555</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,592</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,963</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>13</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Trademarks, trade names and patents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>673</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>307</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>366</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>13</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Developed technology and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,603</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>656</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>947</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>11</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total definite-life intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>5,831</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2,555</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3,276</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>12</span></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total other intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>5,853</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2,555</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3,298</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">N/A</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:43%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Intangible</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Intangible</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Indefinite-life intangibles:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">IPR&amp;D, trademarks and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total indefinite-life intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Definite-life intangibles:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3,562</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1,517</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2,045</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Trademarks, trade names and patents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>672</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>295</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>377</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Developed technology and other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1,602</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>616</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>986</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total definite-life intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>5,836</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2,428</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3,408</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total other intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>5,858</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2,428</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3,430</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Total amortization of intangible assets was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$129 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$133 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2020</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> through</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> 2024</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> is as follows: </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$382 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$442 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$408 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$358 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$328 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">.</span></div> <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2,663</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>5,715</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>8,378</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Goodwill acquired, net of purchase price adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Foreign currency translation adjustments and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Balance at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2,658</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>5,702</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>8,360</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial Narrow;font-size:10pt;"><br/></span></div> 2663000000 5715000000 8378000000 -5000000 0 -5000000 0 -13000000 -13000000 2658000000 5702000000 8360000000 <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following tables summarize other intangible assets by class at:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:19%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Intangible</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Intangible</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted- Average Remaining Amortization Period (Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Indefinite-life intangibles:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">IPR&amp;D, trademarks and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">N/A</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total indefinite-life intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">—</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">N/A</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Definite-life intangibles:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3,555</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,592</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,963</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>13</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Trademarks, trade names and patents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>673</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>307</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>366</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>13</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Developed technology and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,603</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>656</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>947</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>11</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total definite-life intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>5,831</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2,555</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3,276</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>12</span></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total other intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>5,853</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2,555</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3,298</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">N/A</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:43%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Intangible</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Intangible</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Indefinite-life intangibles:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">IPR&amp;D, trademarks and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total indefinite-life intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Definite-life intangibles:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3,562</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1,517</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2,045</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Trademarks, trade names and patents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>672</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>295</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>377</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Developed technology and other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1,602</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>616</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>986</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total definite-life intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>5,836</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2,428</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3,408</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total other intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>5,858</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2,428</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3,430</span></span></div></td><td style="vertical-align:bottom;border-bottom:2.5px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 22000000 22000000 22000000 22000000 3555000000 1592000000 1963000000 P13Y 673000000 307000000 366000000 P13Y 1603000000 656000000 947000000 P11Y 5831000000 2555000000 3276000000 P12Y 5853000000 2555000000 3298000000 22000000 22000000 22000000 22000000 3562000000 1517000000 2045000000 672000000 295000000 377000000 1602000000 616000000 986000000 5836000000 2428000000 3408000000 5858000000 2428000000 3430000000 129000000 133000000 382000000 442000000 408000000 358000000 328000000 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:13pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">4. Investments</span><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In August 2018, we sold our </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>98 percent</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> ownership interest in naviHealth Holdings, LLC ("naviHealth") to investor entities controlled by Clayton, Dubilier &amp; Rice in exchange for cash proceeds of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$737 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> (after adjusting for certain fees and expenses) and a </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>44 percent</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> equity interest in a partnership that owns </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>100 percent</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> of the equity interest of naviHealth. We also have certain call rights to reacquire naviHealth. We are accounting for this investment using the equity method of accounting and on a one-month reporting lag. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">During the three months ended September 30, 2018, we recognized a pre-tax gain of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$508 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> related to this divestiture in impairments and (gain)/loss on disposal of assets in our condensed consolidated statement of earnings. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The carrying value of this investment was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$329 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$334 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively. For the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, our proportionate share of naviHealth’s net loss, which was recorded in Other (income)/expense, net in the condensed consolidated statement of earnings, was immaterial.</span></div> 0.98 737000000 0.44 1 508000000 329000000 334000000 <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:13pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">5. Leases</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We primarily have operating leases for corporate offices, distribution facilities, vehicles, and equipment. We determine if an arrangement is a lease at inception by evaluating whether the arrangement conveys the right to use an identified asset and whether we obtain substantially all of the economic benefits from and have the ability to direct the use of the asset. Our lease agreements generally do not contain any material residual value guarantees or material restrictive covenants. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Beginning July 1, 2019, operating leases are included in other assets, other accrued liabilities, and deferred income taxes and other liabilities in our condensed consolidated balance sheet. Operating lease right-of-use assets and corresponding operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Operating lease expense for operating lease assets is recognized on a straight-line basis over the lease term. As most of our leases do not provide an implicit rate, we use our collateralized incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate if it is readily determinable. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Finance leases are included in property and equipment, net, current portion of long-term obligations and other short-term borrowings, and long-term obligations, less current portion in our condensed consolidated balance sheet. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our lease agreements include leases that contain lease components and non-lease components. For all asset classes, we have elected to account for both of these provisions as a single lease component. We also, from time to time, sublease portions of our real estate property, resulting in sublease income. Sublease income and the related assets and cash flows are not material to the condensed </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">consolidated financial statements at or for the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We also have elected to apply a practical expedient for short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months. Short-term lease expense recognized in the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> was not material. In addition, we elected the package of three practical expedients permitted under the transition guidance, which include the carry forward of our leases without reassessing 1) whether any contracts are leases or contain leases, 2) lease classification and 3) initial direct costs. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our leases have remaining lease terms from less than </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>1 year</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> up to approximately </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>23 years</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. Our lease terms may include options to extend or terminate the lease when it is reasonably certain and there is a significant economic incentive to exercise that option. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">The following table summarizes the components of lease cost:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>31</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Finance lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Amortization of right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total finance lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>36</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">The following tables summarizes supplemental balance sheet information related to leases:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>394</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">   Current portion of operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">   Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>312</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>415</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Finance Leases</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Property and equipment, net </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Current portion of long-term obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Long-term obligations, less current portion</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total finance lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial Narrow;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">The following tables summarizes supplemental cash flow information related to leases:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Operating cash flows paid for operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Financing cash flows paid for finance lease</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Non-cash right-of-use assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">New operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">New finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Amended lease standard adoption impact as of July 1, 2019 </span><span style="font-family:Arial Narrow;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:Arial Narrow;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>400</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Includes the effect of </span><span style="font-family:Arial Narrow;font-size:8pt;"><span>$22 million</span></span><span style="font-family:Arial Narrow;font-size:8pt;"> from reclassifying deferred rent as an offset in accordance with the transition guidance. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our operating leases had a weighted-average remaining lease term of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>6.2</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> years and a weighted-average discount rate of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>3.0 percent</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Future lease payments under non-cancellable leases as of </span><span style="font-family:Arial Narrow;font-size:10pt;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;"> were as follows:</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:51%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Finance Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Years Ending September 30,</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Remainder of 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>95</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>107</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>83</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>62</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>149</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>149</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total future lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>519</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>538</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Less: leases not yet commenced </span><span style="font-family:Arial Narrow;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:Arial Narrow;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>61</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Less: imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>45</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>415</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>432</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">As of September 30, 2019, we had certain leases that were executed but did not have control of the underlying assets; therefore, the lease liabilities and right-of-use assets are not recorded in the condensed consolidated balance sheets. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">As previously disclosed in our fiscal 2019 Form 10-K under the prior accounting guidance, the future minimum rental payments for operating leases having initial or remaining non-cancelable lease terms in excess of one year at </span><span style="font-family:Arial Narrow;font-size:10pt;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;"> for fiscal </span><span style="font-family:Arial Narrow;font-size:10pt;">2020</span><span style="font-family:Arial Narrow;font-size:10pt;"> through </span><span style="font-family:Arial Narrow;font-size:10pt;">2024</span><span style="font-family:Arial Narrow;font-size:10pt;"> and thereafter were as follows: </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$126 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;">, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$100 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;">, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$76 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;">, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$54 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;">, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$33 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$94 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;">.</span></div> P1Y P23Y <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">The following table summarizes the components of lease cost:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>31</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Finance lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Amortization of right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total finance lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>36</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 31000000 4000000 4000000 1000000 36000000 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Operating lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>394</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">   Current portion of operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">   Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>312</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>415</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Finance Leases</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Property and equipment, net </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Current portion of long-term obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Long-term obligations, less current portion</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total finance lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial Narrow;font-size:10pt;"><br/></span><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;"><br/></span></div> 394000000 103000000 312000000 415000000 18000000 5000000 12000000 17000000 upplemental cash flow information related to leases:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Operating cash flows paid for operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Financing cash flows paid for finance lease</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Non-cash right-of-use assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">New operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">New finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Amended lease standard adoption impact as of July 1, 2019 </span><span style="font-family:Arial Narrow;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:Arial Narrow;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>400</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span> 31000000 2000000 15000000 17000000 -400000000 22000000 P6Y2M12D 0.030 <div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Future lease payments under non-cancellable leases as of </span><span style="font-family:Arial Narrow;font-size:10pt;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;"> were as follows:</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:51%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Finance Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Years Ending September 30,</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Remainder of 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>95</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>107</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>83</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>62</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>149</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>149</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total future lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>519</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>538</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Less: leases not yet commenced </span><span style="font-family:Arial Narrow;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:Arial Narrow;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>61</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Less: imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>45</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>415</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>432</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">As of September 30, 2019, we had certain leases that were executed but did not have control of the underlying assets; therefore, the lease liabilities and right-of-use assets are not recorded in the condensed consolidated balance sheets. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">As previously disclosed in our fiscal 2019 Form 10-K under the prior accounting guidance, the future minimum rental payments for operating leases having initial or remaining non-cancelable lease terms in excess of one year at </span><span style="font-family:Arial Narrow;font-size:10pt;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;"> for fiscal </span><span style="font-family:Arial Narrow;font-size:10pt;">2020</span><span style="font-family:Arial Narrow;font-size:10pt;"> through </span><span style="font-family:Arial Narrow;font-size:10pt;">2024</span><span style="font-family:Arial Narrow;font-size:10pt;"> and thereafter were as follows: </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$126 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;">, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$100 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;">, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$76 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;">, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$54 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;">, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$33 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$94 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;">.</span></div> 91000000 4000000 95000000 101000000 6000000 107000000 79000000 4000000 83000000 58000000 4000000 62000000 41000000 1000000 42000000 149000000 0 149000000 519000000 19000000 538000000 61000000 0 61000000 43000000 2000000 45000000 415000000 17000000 432000000 126000000 100000000 76000000 54000000 33000000 94000000 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:13pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-weight:bold;">6. Long-Term Obligations and Other Short-Term Borrowings</span><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-Term Debt</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We had total long-term obligations, including the current portion and other short-term borrowings, of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$8.0 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> at both </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. </span><span style="font-family:Arial Narrow;font-size:10pt;">All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$19.7 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$21.5 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> at </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">During the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;">, we repurchased a total of </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$74 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> of notes due in 2022 and 2047 with available cash.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Financing Arrangements</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$2.0 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> commercial paper program backed by a </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$2.0 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> revolving credit facility. We also have a </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> committed receivables sales facility.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2022. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Our revolving credit facility and committed receivables sales facilities require us to maintain, as of the end of every fiscal quarter from </span><span style="font-family:Arial Narrow;font-size:10pt;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;"> through December 2020, a consolidated net leverage ratio of no more than 4.00-to-1. The maximum permitted ratio will reduce to 3.75-to-1 in March 2021 and as of the end of every fiscal quarter thereafter. </span><span style="font-family:Arial Narrow;">As of September 30, 2019, we were in compliance with our financial covenants.</span></div> 8000000000.0 19700000000 21500000000 74000000 2000000000.0 2000000000.0 1000000000.0 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:13pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">7. Commitments, Contingent Liabilities and Litigation</span><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Commitments</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">Generic Sourcing Venture with CVS Health Corporation ("CVS Health")</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>10 years</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. Due to the achievement of predetermined milestones, we are required to make quarterly payments of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$45.6 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> to CVS Health for the remainder of the initial term.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Legal Proceedings</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">We are named from time to time in </span><span style="font-family:Arial Narrow;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:Arial Narrow;font-size:10pt;"> actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a </span><span style="font-family:Arial Narrow;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:Arial Narrow;font-size:10pt;"> action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information have led, and may in the future lead, to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">From time to time, we determine that products we manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions can lead to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, action by regulators and product liability claims and lawsuits, including class actions. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our condensed consolidated statements of earnings.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;font-weight:bold;">Opioid Lawsuits </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>2,400</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> lawsuits relating to the distribution of prescription opioid pain medications. These lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as negligence, public nuisance and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the “MDL”). </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">In addition, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>21</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> state attorneys general have filed lawsuits against distributors, including us, in various state courts. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Additionally, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>43</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> state attorneys general have formed a multi-state task force to investigate the manufacturing, distribution, dispensing and prescribing practices of opioid medications. We have received requests related to the multi-state investigation, as well as separate civil investigative demands, subpoenas or requests for information from these and other state attorneys general offices. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">In October 2019, we agreed in principle to a global settlement framework with a leadership group of four state attorneys general from the multi-state task force that is designed to resolve all pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). This Settlement Framework is subject to contingencies and uncertainties as to final terms, but is the basis for our negotiation of definitive terms and documentation. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">The Settlement Framework includes (1) a cash component, pursuant to which we would pay up to </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$5.56 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> over </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>eighteen years</span></span><span style="font-family:Arial Narrow;font-size:10pt;">, (2) development and participation in a program for free or rebated distribution of opioid abuse treatment medications for a period of ten years, and (3) industry-wide changes to be specified to controlled substance anti-diversion programs. The Settlement Framework is in its early phases, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. We have included a </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$5.56 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> accrual related to the Settlement Framework in deferred income taxes and other liabilities in the condensed consolidated balance sheets and litigation (recoveries)/charges, net, in the condensed consolidated statements of earnings. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">On October 21, 2019, we and two other national distributors agreed to a </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$215 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> settlement with two Ohio counties, Cuyahoga and </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Summit, to resolve all claims in the first bellwether trial in the MDL that had been scheduled for trial in October 2019. In connection with this settlement, we have accrued </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$66 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;">, which is included in other accrued liabilities in the condensed consolidated balance sheets and litigation (recoveries)/charges, net, in the condensed consolidated statements of earnings. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">In connection with these matters, we recorded a total pre-tax charge of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$5.63 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> (</span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$5.14 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> after tax) during the three-months ended September 30, 2019 for the cash component. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. Moreover, the global Settlement Framework is in early stages and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. We will regularly review these opioid litigation matters to determine whether our accrual is adequate. We are unable to reasonably estimate the liability associated with any potential distribution of treatment medications and any incremental costs for changes to our controlled substance anti-diversion program that we may agree to under the Settlement Framework. The amount of ultimate loss may differ materially from this accrual. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">The Settlement Framework does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals. Private parties had brought approximately </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>325</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> lawsuits as of November 1, 2019. Of these, </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>97</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We will continue to vigorously defend ourselves in these matters.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">Product Liability Lawsuits</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">As of November 1, 2019, we are named as a defendant in </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>280</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>3,463</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava (IVC) filter products. Another </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>24</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> lawsuits involving similar claims by approximately </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>28</span></span><span style="font-family:Arial Narrow;font-size:10pt;"> plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. We are vigorously defending ourselves in these lawsuits.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">At September 30, 2019, we had a total of </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$414 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;">, net of estimated insurance recoveries, accrued for losses and legal defense costs related to the Cordis IVC filter lawsuits which are presented on a gross basis in the condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">to be approximately </span><span style="font-family:Arial Narrow;font-size:10pt;"><span>$836 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;">, net of estimated insurance recoveries.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">Shareholder Securities Litigation</span></div>In August 2019, the Louisiana Sheriffs' Pension &amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. We believe that the claims asserted in this complaint are without merit and intend to vigorously defend against them. Due to the early stage of this proceeding, it is not possible to reasonably estimate the amount of any possible loss or range of loss in this matter. P10Y 45600000 2400 21 43 5560000000 P18Y 5560000000 215000000 66000000 5630000000 5140000000 325 97 280 3463 24 28 414000000 836000000 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:13pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">8. Income Taxes</span><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Fluctuations in our provision for income taxes as a percentage of pre-tax earnings (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.</span></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">Opioid Settlement Framework</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In connection with the </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$5.63 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> pre-tax charge for the opioid litigation, we recorded a tax benefit of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$487 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, which is net of unrecognized tax benefits of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$468 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, reflecting our current assessment of the estimated future deductibility of the amount that may be paid. We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible that the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates. See </span><a href="#s3E77F52A990B55D8984E21DCB5CC440C" style="font-family:Arial Narrow;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Note 7</span></a><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for more information regarding these matters.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">Effective Tax Rate</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">During the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, the effective tax rate was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>7.9</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> percent and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>19.4</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> percent, respectively. The change in the effective tax rate from fiscal 2019 to fiscal 2020 is primarily due to the net effects of </span><span style="font-family:Arial Narrow;font-size:10pt;">the Settlement Framework, partially offset by the prior-year benefit of discrete tax items</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">Unrecognized Tax Benefits</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We had </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$943 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$456 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> of unrecognized tax benefits at </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively. The </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> balances include </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$795 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$303 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively, of unrecognized tax benefits that, if recognized, would have an impact on the effective tax rate.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">At </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, we had </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$126 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$122 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>zero</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and a net decrease of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$10 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, exclusive of penalties and interest.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;">Other Tax Matters</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>2008</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> through the current fiscal year. Tax laws are complex and subject to varying interpretations. Tax authorities have challenged some of our tax positions, including IRS challenges to our international transfer pricing for the periods from 2008 to 2014, and it is possible that they will challenge others. These challenges may adversely affect our effective tax rate or tax payments.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), which has been acquired by Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$168 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$165 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> at </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively, and is included in other assets in the condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition. The indemnification receivable was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$23 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$22 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> at </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively, and is included in other assets in the condensed consolidated balance sheet.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Future adjustments to the financial statements may be necessary as final tax regulations related to U.S. Tax Reform are issued. We will assess any impact as additional guidance is issued.</span></div> 5630000000 -487000000 468000000 0.079 0.194 943000000 456000000 795000000 303000000 126000000 122000000 0 10000000 2008 168000000 165000000 23000000 22000000 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:13pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">9. Fair Value Measurements</span><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Other investments (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Forward contracts (2)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>95</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>95</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Other investments (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Forward contracts (2)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div></td></tr></table>(2) The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets. <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Other investments (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Forward contracts (2)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>95</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>95</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Other investments (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Forward contracts (2)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">The other investments balance includes investments in mutual funds, which are used to offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-bottom:4px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">(2) The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets. </span></div> 109000000 0 0 109000000 0 95000000 0 95000000 118000000 0 0 118000000 0 53000000 0 53000000 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:13pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">10. Financial Instruments</span><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Interest Rate Risk Management</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Currency Exchange Risk Management</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce volatility in earnings, cash flow and net investments in certain subsidiaries to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Commodity Price Risk Management</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value Hedges</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings. For the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, there was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>no</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash Flow Hedges</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">During the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, we entered into a forward interest rate swap with a total notional amount of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$50 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> to hedge probable, but not firmly committed, future transactions associated with our debt.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. All gains and losses currently included within accumulated other comprehensive loss associated with our foreign exchange forward contracts to be reclassified into net earnings within the next 12 months are immaterial. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Net Investment Hedges</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">During three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, we entered into a </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>¥64.0 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> cross-currency swap maturing in 2022.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">During three months ended September 30, 2018, we entered into a </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>€200 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> cross-currency swap maturing in 2023.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive income/(loss) until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. There was no ineffectiveness in our net investment hedges during the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Economic (Non-Designated) Hedges</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. The gain and losses recognized in the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> were immaterial. The principal currencies managed through foreign currency contracts are the euro, Canadian dollar, British pound, Japanese yen, and Chinese renminbi.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value of Financial Instruments</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> approximate fair value due to their short-term maturities.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:43%;"/><td style="width:1%;"/><td style="width:26%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Estimated fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>8,001</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>8,065</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Carrying amount</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>7,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>8,031</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div> 0 50000000 64000000000.0 200000000 <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:43%;"/><td style="width:1%;"/><td style="width:26%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Estimated fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>8,001</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>8,065</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Carrying amount</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>7,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>8,031</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 8001000000 8065000000 7991000000 8031000000 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:13pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">11. Shareholders' Equity</span><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">During the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, we entered in an accelerated share repurchase ("ASR") program to purchase common shares for an aggregate purchase price of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$350 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and received an initial delivery of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>6.4 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> common shares having an aggregate cost of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$280 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. The average price paid per common share was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$43.76</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. The ASR program began on </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">August 20, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and is expected to conclude in the second quarter of fiscal 2020. We funded the repurchases with available cash and short-term borrowings. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">During the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, we entered in an ASR program to purchase common shares for an aggregate purchase price of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$600 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and received an initial delivery of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>9.5 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> common shares having an aggregate cost of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$480 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. The average price paid per common share was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$50.45</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. The ASR program began on August 16, 2018 and was completed on October 25, 2018 when we received the final delivery of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>2.0 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> common shares. We funded the repurchases with available cash and short-term borrowings. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated Other Comprehensive Loss</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Currency</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Translation</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Gain/(Loss) on</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Derivatives,</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Accumulated Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Loss</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(95</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(79</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Other comprehensive income/(loss), before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Amounts reclassified to earnings</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Other comprehensive income/(loss), net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Balance at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(112</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(101</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The sum of components may not equal the total due to rounding. 350000000 6400000 280000000 43.76 600000000 9500000 480000000 50.45 2000000.0 <div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated Other Comprehensive Loss</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Foreign</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Currency</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Translation</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Gain/(Loss) on</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Derivatives,</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Accumulated Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Loss</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(95</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(79</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Other comprehensive income/(loss), before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Amounts reclassified to earnings</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Other comprehensive income/(loss), net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Balance at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(112</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(101</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The sum of components may not equal the total due to rounding. -95000000 16000000 -79000000 -17000000 0 -17000000 0 5000000 5000000 -17000000 -5000000 -22000000 -112000000 11000000 -101000000 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:13pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">12. Earnings Per Share Attributable to Cardinal Health, Inc.</span><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:70%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Weighted-average common shares–basic</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>296</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>305</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Effect of dilutive securities:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee stock options, restricted share units, and performance share units</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted-average common shares–diluted</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>296</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>306</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">For the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>6 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> employee stock options, restricted share units and performance share units were excluded from the calculation of diluted shares outstanding, </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>1 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> of which would be anti-dilutive as a result of the net loss for the period. </span></div><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive for the three months ended September 30, </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> were </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>6 million</span></span>. <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:70%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Weighted-average common shares–basic</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>296</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>305</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Effect of dilutive securities:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee stock options, restricted share units, and performance share units</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted-average common shares–diluted</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>296</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>306</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 296000000 305000000 0 1000000 296000000 306000000 6000000 1000000 6000000 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:13pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">13. Segment Information</span><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;"> </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our operations are principally managed on a products and services basis and are comprised of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>two</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;font-weight:bold;">Revenue</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:</span></div><div style="line-height:120%;padding-left:4px;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical Distribution and Specialty Solutions (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>33,212</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>31,209</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Nuclear and Precision Health Solutions</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>216</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>207</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>33,428</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>31,416</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical distribution and products (2)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3,446</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3,380</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Cardinal Health at-Home Solutions</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>471</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>421</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3,917</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3,801</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">  Total segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>37,345</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>35,217</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate (3)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total revenue</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>37,341</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>35,213</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services".</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table presents revenue by geographic area:</span></div><div style="line-height:120%;padding-left:4px;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>36,310</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>34,245</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,035</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>972</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">  Total segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>37,345</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>35,217</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate (1)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total revenue</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>37,341</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>35,213</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;font-weight:bold;">Segment Profit</span></div><div style="line-height:120%;padding-left:4px;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial, and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We do not allocate the following items to our segments: last-in first-out, or ("LIFO"), inventory charges/(credits); restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; state opioid assessment related to prior fiscal years; other (income)/expense, net; interest expense, net; loss on extinguishment of debt; and provision for income taxes. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$3 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$7 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In connection with the opioid litigation as discussed further in </span><a href="#s3E77F52A990B55D8984E21DCB5CC440C" style="font-family:Arial Narrow;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">Note 7</span></a><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, we recognized a pre-tax charge of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$5.63 billion</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> during the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, which was retained at Corporate. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">In connection with the naviHealth divestiture, we recognized a pre-tax gain of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$508 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> during the three months ended September 30, 2018, which was retained at Corporate.</span></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table presents segment profit by reportable segment and Corporate:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>398</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>409</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>170</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>135</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total segment profit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>568</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>544</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(5,832</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>272</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total operating earnings/(loss)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(5,264</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>816</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:13pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>21,755</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>22,446</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>15,462</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>15,284</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,962</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3,233</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>39,179</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>40,963</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial Narrow;font-size:13pt;"><br/></span></div> 2 <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:</span></div><div style="line-height:120%;padding-left:4px;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical Distribution and Specialty Solutions (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>33,212</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>31,209</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Nuclear and Precision Health Solutions</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>216</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>207</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>33,428</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>31,416</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical distribution and products (2)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3,446</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3,380</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Cardinal Health at-Home Solutions</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>471</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>421</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3,917</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3,801</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">  Total segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>37,345</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>35,217</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate (3)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total revenue</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>37,341</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>35,213</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services".</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(3)</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div> 33212000000 31209000000 216000000 207000000 33428000000 31416000000 3446000000 3380000000 471000000 421000000 3917000000 3801000000 37345000000 35217000000 -4000000 -4000000 37341000000 35213000000 <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table presents revenue by geographic area:</span></div><div style="line-height:120%;padding-left:4px;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>36,310</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>34,245</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,035</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>972</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">  Total segment revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>37,345</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>35,217</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate (1)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total revenue</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>37,341</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>35,213</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial Narrow;font-size:8pt;">(1)</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div> 36310000000 34245000000 1035000000 972000000 37345000000 35217000000 -4000000 -4000000 37341000000 35213000000 3000000 7000000 5630000000 508000000 <div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table presents segment profit by reportable segment and Corporate:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>398</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>409</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>170</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>135</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Total segment profit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>568</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>544</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(5,832</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>272</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total operating earnings/(loss)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>(5,264</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>816</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 398000000 409000000 170000000 135000000 568000000 544000000 -5832000000 272000000 -5264000000 816000000 <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:13pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Pharmaceutical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>21,755</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>22,446</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Medical</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>15,462</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>15,284</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Corporate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1,962</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>3,233</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>39,179</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>40,963</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial Narrow;font-size:13pt;"><br/></span></div> 21755000000 22446000000 15462000000 15284000000 1962000000 3233000000 39179000000 40963000000 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:13pt;"><span style="font-family:Arial Narrow;font-size:13pt;color:#ee2724;font-style:normal;font-weight:bold;text-decoration:none;">14. Share-Based Compensation</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table provides total share-based compensation expense by type of award:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Restricted share unit expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee stock option expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Performance share unit expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total share-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The total tax benefit related to share-based compensation was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$4 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$5 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> for the three months ended </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">2018</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, respectively. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Restricted Share Units</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Restricted share units granted under the Plans generally vest in equal annual installments over </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>three years</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:52%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions, except per share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Restricted Share Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted-Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Grant Date Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Value per Share</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Nonvested at June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>51.65</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>42.09</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>60.92</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Canceled and forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nonvested at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>45.29</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">At </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$125 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, which is expected to be recognized over a weighted-average period of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>two years</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock Options</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Employee stock options granted under the Plans generally vest in equal annual installments over </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>three years</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> and are exercisable for </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>ten years</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes all stock option transactions under the Plans:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.58847736625515%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:53%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions, except per share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Stock</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted-Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Exercise Price per</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Common Share</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Outstanding at June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>63.78</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Canceled and forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Outstanding at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>63.75</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Exercisable at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1.5px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1.5px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1.5px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1.5px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1.5px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>63.67</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1.5px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">At </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$3 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, which is expected to be recognized over a weighted-average period of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>one year</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following tables provide additional detail related to stock options:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Aggregate intrinsic value of outstanding options at period end</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Aggregate intrinsic value of exercisable options at period end</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:58%;"/><td style="width:21%;"/><td style="width:2%;"/><td style="width:19%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in years)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Weighted-average remaining contractual life of outstanding options</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Weighted-average remaining contractual life of exercisable options</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>5</span></span></div></td></tr></table></div><span style="font-family:Arial Narrow;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><span style="font-family:Arial Narrow;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Performance Share Units</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">Performance share units vest over a </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>three</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>zero</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> to </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>240 percent</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:51%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions, except per share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Performance</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Share Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted-Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Grant Date Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Value per Share</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Nonvested at June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>51.45</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>43.68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>48.40</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Canceled and forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>50.59</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nonvested at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>50.84</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">At </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>$25 million</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">, which is expected to be recognized over a weighted-average period of </span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"><span>three years</span></span><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;"> if the performance goals are achieved.</span></div> <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table provides total share-based compensation expense by type of award:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Restricted share unit expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Employee stock option expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Performance share unit expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Total share-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 17000000 14000000 1000000 4000000 2000000 1000000 20000000 19000000 4000000 5000000 P3Y <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:52%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions, except per share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Restricted Share Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted-Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Grant Date Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Value per Share</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Nonvested at June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>51.65</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>42.09</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>60.92</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Canceled and forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nonvested at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>45.29</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div> 2000000 51.65 2000000 42.09 1000000 60.92 0 0 3000000 45.29 125000000 P2Y P3Y P10Y <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes all stock option transactions under the Plans:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.58847736625515%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:53%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions, except per share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Stock</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted-Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Exercise Price per</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Common Share</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Outstanding at June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>63.78</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Canceled and forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Outstanding at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>63.75</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Exercisable at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1.5px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1.5px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1.5px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1.5px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1.5px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>63.67</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1.5px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 6000000 63.78 0 0 0 0 0 0 6000000 63.75 6000000 63.67 3000000 P1Y <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following tables provide additional detail related to stock options:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Aggregate intrinsic value of outstanding options at period end</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Aggregate intrinsic value of exercisable options at period end</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:58%;"/><td style="width:21%;"/><td style="width:2%;"/><td style="width:19%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in years)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Weighted-average remaining contractual life of outstanding options</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>5</span></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Weighted-average remaining contractual life of exercisable options</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>5</span></span></div></td></tr></table></div><span style="font-family:Arial Narrow;font-size:10pt;"><br/></span></div> 10000000 10000000 10000000 10000000 P5Y P5Y P5Y P5Y 3 0 2.40 <div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#000000;">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:51%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;text-decoration:underline;">(in millions, except per share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Performance</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Share Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Weighted-Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Grant Date Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Value per Share</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Nonvested at June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>51.45</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>43.68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>48.40</span></span></div></td><td style="vertical-align:bottom;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">Canceled and forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;"><span>50.59</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">Nonvested at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cccccc;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial Narrow;font-size:8pt;font-weight:bold;"><span>50.84</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cccccc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 900000 51.45 500000 43.68 100000 48.40 100000 50.59 1200000 50.84 25000000 P3Y XML 69 R18.htm IDEA: XBRL DOCUMENT v3.19.3
Shareholders' Equity
 3 Months Ended
Sep. 30, 2019
Equity [Abstract]  
Shareholders' Equity
11. Shareholders' Equity
During the three months ended September 30, 2019, we entered in an accelerated share repurchase ("ASR") program to purchase common shares for an aggregate purchase price of $350 million and received an initial delivery of 6.4 million common shares having an aggregate cost of $280 million. The average price paid per common share was $43.76. The ASR program began on August 20, 2019 and is expected to conclude in the second quarter of fiscal 2020. We funded the repurchases with available cash and short-term borrowings.
During the three months ended September 30, 2018, we entered in an ASR program to purchase common shares for an aggregate purchase price of $600 million and received an initial delivery of 9.5 million common shares having an aggregate cost of $480 million. The average price paid per common share was $50.45. The ASR program began on August 16, 2018 and was completed on October 25, 2018 when we received the final delivery of 2.0 million common shares. We funded the repurchases with available cash and short-term borrowings.
The common shares repurchased are held in treasury to be used for general corporate purposes.
Accumulated Other Comprehensive Loss
The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:
(in millions)
Foreign
Currency
Translation
Adjustments
 
Unrealized
Gain/(Loss) on
Derivatives,
net of tax
 
Accumulated Other
Comprehensive
Loss
Balance at June 30, 2019
$
(95
)
 
$
16

 
$
(79
)
Other comprehensive income/(loss), before reclassifications
(17
)
 
—

 
(17
)
Amounts reclassified to earnings
—

 
(5
)
 
(5
)
Other comprehensive income/(loss), net of tax
(17
)
 
(5
)
 
(22
)
Balance at September 30, 2019
$
(112
)
 
$
11

 
$
(101
)

The sum of components may not equal the total due to rounding.
XML 70 R14.htm IDEA: XBRL DOCUMENT v3.19.3
Commitments, Contingent Liabilities and Litigation
 3 Months Ended
Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]  
Commitments, Contingent Liabilities and Litigation
7. Commitments, Contingent Liabilities and Litigation
Commitments
Generic Sourcing Venture with CVS Health Corporation ("CVS Health")
In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. Due to the achievement of predetermined milestones, we are required to make quarterly payments of $45.6 million to CVS Health for the remainder of the initial term.
Legal Proceedings
We become involved from time to time in disputes, litigation and regulatory matters.
We are named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.
From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information have led, and may in the future lead, to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.
From time to time, we determine that products we manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions can lead to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, action by regulators and product liability claims and lawsuits, including class actions. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.
We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.
We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.
We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our condensed consolidated statements of earnings.
Opioid Lawsuits
Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately 2,400 lawsuits relating to the distribution of prescription opioid pain medications. These lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as negligence, public nuisance and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.
The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the “MDL”).
In addition, 21 state attorneys general have filed lawsuits against distributors, including us, in various state courts.
Additionally, 43 state attorneys general have formed a multi-state task force to investigate the manufacturing, distribution, dispensing and prescribing practices of opioid medications. We have received requests related to the multi-state investigation, as well as separate civil investigative demands, subpoenas or requests for information from these and other state attorneys general offices.
In October 2019, we agreed in principle to a global settlement framework with a leadership group of four state attorneys general from the multi-state task force that is designed to resolve all pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). This Settlement Framework is subject to contingencies and uncertainties as to final terms, but is the basis for our negotiation of definitive terms and documentation.
The Settlement Framework includes (1) a cash component, pursuant to which we would pay up to $5.56 billion over eighteen years, (2) development and participation in a program for free or rebated distribution of opioid abuse treatment medications for a period of ten years, and (3) industry-wide changes to be specified to controlled substance anti-diversion programs. The Settlement Framework is in its early phases, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. We have included a $5.56 billion accrual related to the Settlement Framework in deferred income taxes and other liabilities in the condensed consolidated balance sheets and litigation (recoveries)/charges, net, in the condensed consolidated statements of earnings.
On October 21, 2019, we and two other national distributors agreed to a $215 million settlement with two Ohio counties, Cuyahoga and
Summit, to resolve all claims in the first bellwether trial in the MDL that had been scheduled for trial in October 2019. In connection with this settlement, we have accrued $66 million, which is included in other accrued liabilities in the condensed consolidated balance sheets and litigation (recoveries)/charges, net, in the condensed consolidated statements of earnings.
In connection with these matters, we recorded a total pre-tax charge of $5.63 billion ($5.14 billion after tax) during the three-months ended September 30, 2019 for the cash component. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. Moreover, the global Settlement Framework is in early stages and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. We will regularly review these opioid litigation matters to determine whether our accrual is adequate. We are unable to reasonably estimate the liability associated with any potential distribution of treatment medications and any incremental costs for changes to our controlled substance anti-diversion program that we may agree to under the Settlement Framework. The amount of ultimate loss may differ materially from this accrual. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.
The Settlement Framework does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals. Private parties had brought approximately 325 lawsuits as of November 1, 2019. Of these, 97 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We will continue to vigorously defend ourselves in these matters.
Product Liability Lawsuits
As of November 1, 2019, we are named as a defendant in 280 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 3,463 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava (IVC) filter products. Another 24 lawsuits involving similar claims by approximately 28 plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. We are vigorously defending ourselves in these lawsuits.
At September 30, 2019, we had a total of $414 million, net of estimated insurance recoveries, accrued for losses and legal defense costs related to the Cordis IVC filter lawsuits which are presented on a gross basis in the condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range
to be approximately $836 million, net of estimated insurance recoveries.
Shareholder Securities Litigation
In August 2019, the Louisiana Sheriffs' Pension & Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. We believe that the claims asserted in this complaint are without merit and intend to vigorously defend against them. Due to the early stage of this proceeding, it is not possible to reasonably estimate the amount of any possible loss or range of loss in this matter.
XML 71 R10.htm IDEA: XBRL DOCUMENT v3.19.3
Goodwill and Other Intangible Assets
 3 Months Ended
Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets
3. Goodwill and Other Intangible Assets
Goodwill
The following table summarizes the changes in the carrying amount of goodwill by segment and in total:
(in millions)
Pharmaceutical
 
Medical
 
Total
Balance at June 30, 2019
$
2,663

 
$
5,715

 
$
8,378

Goodwill acquired, net of purchase price adjustments
(5
)
 
—

 
(5
)
Foreign currency translation adjustments and other
—

 
(13
)
 
(13
)
Balance at September 30, 2019
$
2,658

 
$
5,702

 
$
8,360


Other Intangible Assets
The following tables summarize other intangible assets by class at:
 
September 30, 2019
(in millions)
Gross
Intangible
 
Accumulated
Amortization
 
Net
Intangible
 
Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
 
 
 
 
 
 
 
IPR&D, trademarks and other
$
22

 
$
—

 
$
22

 
N/A
Total indefinite-life intangibles
22

 
—

 
22

 
N/A
 
 
 
 
 
 
 
 
Definite-life intangibles:
 
 
 
 
 
 
 
Customer relationships
3,555

 
1,592

 
1,963

 
13
Trademarks, trade names and patents
673

 
307

 
366

 
13
Developed technology and other
1,603

 
656

 
947

 
11
Total definite-life intangibles
5,831

 
2,555

 
3,276

 
12
Total other intangible assets
$
5,853

 
$
2,555

 
$
3,298

 
N/A
 
June 30, 2019
(in millions)
Gross
Intangible
 
Accumulated
Amortization
 
Net
Intangible
Indefinite-life intangibles:
 
 
 
 
 
IPR&D, trademarks and other
$
22

 
$
—

 
$
22

Total indefinite-life intangibles
22

 
—

 
22

 
 
 
 
 
 
Definite-life intangibles:
 
 
 
 
 
Customer relationships
3,562

 
1,517

 
2,045

Trademarks, trade names and patents
672

 
295

 
377

Developed technology and other
1,602

 
616

 
986

Total definite-life intangibles
5,836

 
2,428

 
3,408

Total other intangible assets
$
5,858

 
$
2,428

 
$
3,430


Total amortization of intangible assets was $129 million and $133 million for the three months ended September 30, 2019 and 2018, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2020 through 2024 is as follows: $382 million, $442 million, $408 million, $358 million, and $328 million.
XML 72 R33.htm IDEA: XBRL DOCUMENT v3.19.3
Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Restructuring Charges [Abstract]    
Employee-related costs $ 20 $ 29
Facility Exit and Other Costs 10 3
Total restructuring and employee severance $ 30 $ 32
XML 73 R37.htm IDEA: XBRL DOCUMENT v3.19.3
Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2019
Jun. 30, 2019
Indefinite-lived Intangible Assets [Line Items]    
Net Intangible $ 22 $ 22
Finite-Lived Intangible Assets [Line Items]    
Gross Intangible 5,831 5,836
Accumulated Amortization 2,555 2,428
Net Intangible $ 3,276 3,408
Weighted- Average Remaining Amortization Period (Years) 12 years  
Gross Intangible, Total other intangible assets $ 5,853 5,858
Net Intangible, Total other intangible assets 3,298 3,430
IPR&D, trademarks and other    
Indefinite-lived Intangible Assets [Line Items]    
Net Intangible 22 22
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Gross Intangible 3,555 3,562
Accumulated Amortization 1,592 1,517
Net Intangible $ 1,963 2,045
Weighted- Average Remaining Amortization Period (Years) 13 years  
Trademarks, trade names and patents    
Finite-Lived Intangible Assets [Line Items]    
Gross Intangible $ 673 672
Accumulated Amortization 307 295
Net Intangible $ 366 377
Weighted- Average Remaining Amortization Period (Years) 13 years  
Developed technology and other    
Finite-Lived Intangible Assets [Line Items]    
Gross Intangible $ 1,603 1,602
Accumulated Amortization 656 616
Net Intangible $ 947 $ 986
Weighted- Average Remaining Amortization Period (Years) 11 years  
XML 74 R1.htm IDEA: XBRL DOCUMENT v3.19.3
Cover Page - shares
 3 Months Ended
Sep. 30, 2019
Oct. 31, 2019
Cover page.    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2019  
Document Transition Report false  
Entity File Number 1-11373  
Entity Registrant Name Cardinal Health, Inc.  
Entity Central Index Key 0000721371  
Current Fiscal Year End Date --06-30  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Entity Incorporation, State or Country Code OH  
Entity Tax Identification Number 31-0958666  
Entity Address, Address Line One 7000 Cardinal Place  
Entity Address, City or Town Dublin  
Entity Address, State or Province OH  
Entity Address, Postal Zip Code 43017  
City Area Code 614  
Local Phone Number 757-5000  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Title of 12(b) Security Common shares (without par value)  
Trading Symbol CAH  
Security Exchange Name NYSE  
Entity Common Stock, Shares Outstanding   292,488,354
XML 75 R5.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
shares in Thousands, $ in Millions
Sep. 30, 2019
Jun. 30, 2019
Statement of Financial Position [Abstract]    
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $ 903 $ 6,330
Preferred Shares, authorized 500 500
Preferred Shares, issued 0 0
Common Shares, authorized 755,000 755,000
Common Shares, issued 327,000 327,000
Common Shares in Treasury 34,000 28,000
XML 76 R57.htm IDEA: XBRL DOCUMENT v3.19.3
Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total operating earnings $ (5,264) $ 816
Operating Segments    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total operating earnings 568 544
Operating Segments | Pharmaceutical    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total operating earnings 398 409
Operating Segments | Medical    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total operating earnings 170 135
Corporate    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total operating earnings $ (5,832) $ 272
XML 77 R53.htm IDEA: XBRL DOCUMENT v3.19.3
Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - shares
shares in Millions
 3 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Earnings Per Share [Abstract]    
Weighted-average common shares–basic (in shares) 296 305
Effect of dilutive securities:    
Weighted Average Number Diluted Shares Outstanding Adjustment 0 1
Weighted-average common shares–diluted (in shares) 296 306
XML 78 R9.htm IDEA: XBRL DOCUMENT v3.19.3
Restructuring and Employee Severance
 3 Months Ended
Sep. 30, 2019
Restructuring Charges [Abstract]  
Restructuring and Employee Severance
2. Restructuring and Employee Severance
The following table summarizes restructuring and employee severance costs:
 
Three months ended September 30,
(in millions)
2019
 
2018
Employee-related costs (1)
$
20

 
$
29

Facility exit and other costs (2)
10

 
3

Total restructuring and employee severance
$
30

 
$
32


(1)
Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods.
(2)
Facility exit and other costs primarily consist of product distribution and lease contract termination costs, lease costs associated with vacant facilities, accelerated depreciation, equipment relocation costs, project consulting fees, costs associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs.
During fiscal 2020 and 2019, we implemented certain enterprise-wide cost-saving initiatives affecting various functional and commercial areas intended to optimize and simplify our operating model and cost structure. We incurred $20 million and $26 million for the three months ended September 30, 2019 and 2018, respectively, in expenses related to these cost savings initiatives, which are reflected in restructuring and employee severance in the condensed consolidated statements of earnings.
The following table summarizes activity related to liabilities associated with restructuring and employee severance:
(in millions)
Employee-
Related Costs
 
Facility Exit
and Other Costs
 
Total
Balance at June 30, 2019
$
64

 
$
8

 
$
72

Additions
19

 
6

 
25

Payments and other adjustments
(10
)
 
(2
)
 
(12
)
Balance at September 30, 2019
$
73

 
$
12

 
$
85
XML 79 R15.htm IDEA: XBRL DOCUMENT v3.19.3
Income Taxes
 3 Months Ended
Sep. 30, 2019
Income Tax Disclosure [Abstract]  
Income Taxes
8. Income Taxes
Fluctuations in our provision for income taxes as a percentage of pre-tax earnings (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.
Opioid Settlement Framework
In connection with the $5.63 billion pre-tax charge for the opioid litigation, we recorded a tax benefit of $487 million, which is net of unrecognized tax benefits of $468 million, reflecting our current assessment of the estimated future deductibility of the amount that may be paid. We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible that the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates. See Note 7 for more information regarding these matters.
Effective Tax Rate
During the three months ended September 30, 2019 and 2018, the effective tax rate was 7.9 percent and 19.4 percent, respectively. The change in the effective tax rate from fiscal 2019 to fiscal 2020 is primarily due to the net effects of the Settlement Framework, partially offset by the prior-year benefit of discrete tax items.
Unrecognized Tax Benefits
We had $943 million and $456 million of unrecognized tax benefits at September 30, 2019 and June 30, 2019, respectively. The September 30, 2019 and June 30, 2019 balances include $795 million and $303 million, respectively, of unrecognized tax benefits that, if recognized, would have an impact on the effective tax rate.
At September 30, 2019 and June 30, 2019, we had $126 million and $122 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.
It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of $10 million, exclusive of penalties and interest.
Other Tax Matters
We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2008 through the current fiscal year. Tax laws are complex and subject to varying interpretations. Tax authorities have challenged some of our tax positions, including IRS challenges to our international transfer pricing for the periods from 2008 to 2014, and it is possible that they will challenge others. These challenges may adversely affect our effective tax rate or tax payments.
We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), which has been acquired by Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $168 million and $165 million at September 30, 2019 and June 30, 2019, respectively, and is included in other assets in the condensed consolidated balance sheets.
As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition. The indemnification receivable was $23 million and $22 million at September 30, 2019 and June 30, 2019, respectively, and is included in other assets in the condensed consolidated balance sheet.
Future adjustments to the financial statements may be necessary as final tax regulations related to U.S. Tax Reform are issued. We will assess any impact as additional guidance is issued.
XML 80 R11.htm IDEA: XBRL DOCUMENT v3.19.3
Investments
 3 Months Ended
Sep. 30, 2019
Investments [Abstract]  
Investments
4. Investments
In August 2018, we sold our 98 percent ownership interest in naviHealth Holdings, LLC ("naviHealth") to investor entities controlled by Clayton, Dubilier & Rice in exchange for cash proceeds of $737 million (after adjusting for certain fees and expenses) and a 44 percent equity interest in a partnership that owns 100 percent of the equity interest of naviHealth. We also have certain call rights to reacquire naviHealth. We are accounting for this investment using the equity method of accounting and on a one-month reporting lag.
During the three months ended September 30, 2018, we recognized a pre-tax gain of $508 million related to this divestiture in impairments and (gain)/loss on disposal of assets in our condensed consolidated statement of earnings. 
The carrying value of this investment was $329 million and $334 million as of September 30, 2019 and June 30, 2019, respectively. For the three months ended September 30, 2019, our proportionate share of naviHealth’s net loss, which was recorded in Other (income)/expense, net in the condensed consolidated statement of earnings, was immaterial.
XML 81 R19.htm IDEA: XBRL DOCUMENT v3.19.3
Earnings Per Share Attributable to Cardinal Health, Inc.
 3 Months Ended
Sep. 30, 2019
Earnings Per Share [Abstract]  
Earnings Per Share Attributable to Cardinal Health, Inc.
12. Earnings Per Share Attributable to Cardinal Health, Inc.
The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:
 
Three Months Ended September 30,
(in millions)
2019
 
2018
Weighted-average common shares–basic
296

 
305

Effect of dilutive securities:
 
 
 
Employee stock options, restricted share units, and performance share units
—

 
1

Weighted-average common shares–diluted
296

 
306


For the three months ended September 30, 2019, 6 million employee stock options, restricted share units and performance share units were excluded from the calculation of diluted shares outstanding, 1 million of which would be anti-dilutive as a result of the net loss for the period.
The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive for the three months ended September 30, 2018 were 6 million.
XML 82 R32.htm IDEA: XBRL DOCUMENT v3.19.3
Basis of Presentation and Summary of Significant Accounting Policies Narrative (Details)
$ in Millions
Jul. 01, 2019
USD ($)
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]  
Lease Liabilities established as a Result of the adoption of ASC 842 $ 422
XML 83 R36.htm IDEA: XBRL DOCUMENT v3.19.3
Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)
$ in Millions
 3 Months Ended
Sep. 30, 2019
USD ($)
Goodwill [Line Items]  
Goodwill, Transfers $ (5)
Goodwill [Roll Forward]  
Beginning balance 8,378
Foreign currency translation adjustments and other 13
Ending balance 8,360
Pharmaceutical  
Goodwill [Line Items]  
Goodwill, Transfers (5)
Goodwill [Roll Forward]  
Beginning balance 2,663
Foreign currency translation adjustments and other 0
Ending balance 2,658
Medical  
Goodwill [Line Items]  
Goodwill, Transfers 0
Goodwill [Roll Forward]  
Beginning balance 5,715
Foreign currency translation adjustments and other 13
Ending balance $ 5,702
JSON 84 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a20q110q093019form10-q.htm": { "axisCustom": 4, "axisStandard": 23, "contextCount": 160, "dts": { "calculationLink": { "local": [ "cah-20190930_cal.xml" ] }, "definitionLink": { "local": [ "cah-20190930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "a20q110q093019form10-q.htm" ] }, "labelLink": { "local": [ "cah-20190930_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "cah-20190930_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "cah-20190930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 523, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 12, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 17 }, "keyCustom": 44, "keyStandard": 324, "memberCustom": 28, "memberStandard": 31, "nsprefix": "cah", "nsuri": "http://www.cardinal.com/20190930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.cardinal.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Goodwill and Other Intangible Assets", "role": "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssets", "shortName": "Goodwill and Other Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Investments", "role": "http://www.cardinal.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "cah:LeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Leases", "role": "http://www.cardinal.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "cah:LeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings", "role": "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowings", "shortName": "Long-Term Obligations and Other Short-Term Borrowings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - Commitments, Contingent Liabilities and Litigation", "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigation", "shortName": "Commitments, Contingent Liabilities and Litigation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - Income Taxes", "role": "http://www.cardinal.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - Fair Value Measurements", "role": "http://www.cardinal.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - Financial Instruments", "role": "http://www.cardinal.com/role/FinancialInstruments", "shortName": "Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - Shareholders' Equity", "role": "http://www.cardinal.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.", "role": "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthInc", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc.", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Condensed Consolidated Statements of Earnings", "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings", "shortName": "Condensed Consolidated Statements of Earnings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - Segment Information", "role": "http://www.cardinal.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - Share-Based Compensation", "role": "http://www.cardinal.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "role": "http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Restructuring and Employee Severance (Tables)", "role": "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceTables", "shortName": "Restructuring and Employee Severance (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Goodwill and Other Intangible Assets (Tables)", "role": "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsTables", "shortName": "Goodwill and Other Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Leases (Tables)", "role": "http://www.cardinal.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.cardinal.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - Financial Instruments (Tables)", "role": "http://www.cardinal.com/role/FinancialInstrumentsTables", "shortName": "Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - Shareholders' Equity (Tables)", "role": "http://www.cardinal.com/role/ShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)", "role": "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncTables", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income", "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - Segment Information (Tables)", "role": "http://www.cardinal.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316301 - Disclosure - Share-Based Compensation (Tables)", "role": "http://www.cardinal.com/role/ShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "I2020Q1ASC842", "decimals": "-6", "first": true, "lang": null, "name": "cah:LeaseLiabilitiesestablishedasaResultoftheadoptionofASC842", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Narrative (Details)", "role": "http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "I2020Q1ASC842", "decimals": "-6", "first": true, "lang": null, "name": "cah:LeaseLiabilitiesestablishedasaResultoftheadoptionofASC842", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)", "role": "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceActivityRelatedToRestructuringAndEmployeeSeveranceCostsDetails", "shortName": "Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)", "role": "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails", "shortName": "Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RestructuringCosts", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403404 - Disclosure - Restructuring and Employee Severance Narrative (Details)", "role": "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceNarrativeDetails", "shortName": "Restructuring and Employee Severance Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1QTD_us-gaap_RestructuringPlanAxis_cah_EnterpriseWideCostSavingMeasuresMember", "decimals": "-6", "lang": null, "name": "us-gaap:RestructuringCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:GoodwillTransfers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)", "role": "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails", "shortName": "Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:GoodwillTransfers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)", "role": "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails", "shortName": "Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405404 - Disclosure - Goodwill and Other Intangible Assets Narrative (Details)", "role": "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails", "shortName": "Goodwill and Other Intangible Assets Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "I2018Q1navi_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_cah_NaviHealthMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406401 - Disclosure - Investments Narrative (Details)", "role": "http://www.cardinal.com/role/InvestmentsNarrativeDetails", "shortName": "Investments Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "I2018Q1navi_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_cah_NaviHealthMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "lang": null, "name": "us-gaap:ReceivablesNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Leases Narative (Details)", "role": "http://www.cardinal.com/role/LeasesNarativeDetails", "shortName": "Leases Narative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Leases Summary of Lease Costs (Details)", "role": "http://www.cardinal.com/role/LeasesSummaryOfLeaseCostsDetails", "shortName": "Leases Summary of Lease Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - Leases Summary of Lease Payments (Details)", "role": "http://www.cardinal.com/role/LeasesSummaryOfLeasePaymentsDetails", "shortName": "Leases Summary of Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "cah:LesseeLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407405 - Disclosure - Leases Summary of Minimum Lease Committments (Details)", "role": "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails", "shortName": "Leases Summary of Minimum Lease Committments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "cah:LesseeLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "cah:LeasesSupplementalBalanceSheetInformationTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407406 - Disclosure - Leases Supplemental Balance Sheet Information (Details)", "role": "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails", "shortName": "Leases Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "cah:LeasesSupplementalBalanceSheetInformationTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DebtAndCapitalLeaseObligations", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408401 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)", "role": "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails", "shortName": "Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "cah:NotesPayableRepurchased", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "I2020Q1opioid_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "-6", "first": true, "lang": null, "name": "cah:OpioidTotalSettlementCuyahogaandSummitCounties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409401 - Disclosure - Commitments, Contingent Liabilities and Litigation Narrative (Details)", "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails", "shortName": "Commitments, Contingent Liabilities and Litigation Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "I2020Q1opioid_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "-6", "first": true, "lang": null, "name": "cah:OpioidTotalSettlementCuyahogaandSummitCounties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410401 - Disclosure - Income Taxes Narrative (Details)", "role": "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "3", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - Fair Value Measurements Narrative (Details)", "role": "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails", "shortName": "Fair Value Measurements Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - Financial Instruments Narrative (Details)", "role": "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "shortName": "Financial Instruments Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DebtAndCapitalLeaseObligations", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412403 - Disclosure - Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)", "role": "http://www.cardinal.com/role/FinancialInstrumentsSummaryOfEstimatedFairValueOfLongTermObligationsAndOtherShortTermBorrowingsDetails", "shortName": "Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member", "decimals": "-6", "lang": null, "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:PaymentsForRepurchaseOfCommonStock", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - Shareholders' Equity Narrative (Details)", "role": "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails", "shortName": "Shareholders' Equity Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "I2019Q1ASR", "decimals": "-5", "lang": null, "name": "cah:FinalSharesReceivedfromASRProgram", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413403 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)", "role": "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "shortName": "Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "decimals": "-6", "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)", "role": "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncReconciliationOfCommonSharesUsedToComputeBasicAndDilutedEpsDetails", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "cah:Numberofsharesexcludedfromcalculationofdilutedshares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414403 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)", "role": "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncNarrativeDetails", "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "cah:Numberofsharesexcludedfromcalculationofdilutedshares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - Segment Information Narrative (Details)", "role": "http://www.cardinal.com/role/SegmentInformationNarrativeDetails", "shortName": "Segment Information Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415403 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)", "role": "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails", "shortName": "Segment Information (Revenue by Reportable Segment) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415404 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)", "role": "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails", "shortName": "Segment Information (Segment Profit by Reportable Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember", "decimals": "-6", "lang": null, "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415405 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)", "role": "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails", "shortName": "Segment Information (Assets by Reportable Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2020Q1_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_cah_PharmaceuticalMember", "decimals": "-6", "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415406 - Disclosure - Segment Information Disaggregated Revenue Within Reportable Segments (Details)", "role": "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "shortName": "Segment Information Disaggregated Revenue Within Reportable Segments (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1014000 - Statement - Condensed Consolidated Statement of Shareholders' Equity", "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity", "shortName": "Condensed Consolidated Statement of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415407 - Disclosure - Segment Information Revenue by Geographical Segments (Details)", "role": "http://www.cardinal.com/role/SegmentInformationRevenueByGeographicalSegmentsDetails", "shortName": "Segment Information Revenue by Geographical Segments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1QTD_srt_StatementGeographicalAxis_country_US", "decimals": "-6", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416402 - Disclosure - Share-Based Compensation Narrative (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "shortName": "Share-Based Compensation Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416403 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfTotalShareBasedCompensationExpenseByTypeOfAwardDetails", "shortName": "Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416404 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails", "shortName": "Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416405 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails", "shortName": "Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "cah:AdditionalStockOptionPlanDataTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember", "decimals": "-6", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416406 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails", "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "-6", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416407 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)", "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1015000 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "role": "http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Restructuring and Employee Severance", "role": "http://www.cardinal.com/role/RestructuringAndEmployeeSeverance", "shortName": "Restructuring and Employee Severance", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a20q110q093019form10-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 59, "tag": { "cah_ASC842Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ASC 842", "label": "ASC 842 [Member]", "terseLabel": "ASC 842" } } }, "localname": "ASC842Member", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfLeasePaymentsDetails" ], "xbrltype": "domainItemType" }, "cah_AdditionalStockOptionPlanDataTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A disclosure of additional data related to all stock option activity", "label": "Additional Stock Option Plan Data [Table Text Block]", "terseLabel": "Schedule of Additional Data Related to Stock Option Activity" } } }, "localname": "AdditionalStockOptionPlanDataTableTextBlock", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "cah_AlamedaCountyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Alameda County [Member]", "label": "Alameda County [Member]", "terseLabel": "Alameda County [Member]" } } }, "localname": "AlamedaCountyMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_Amortizationandotheracquisitionrelatedcosts": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Amortization and other acquisition-related costs", "terseLabel": "Amortization and other acquisition-related costs" } } }, "localname": "Amortizationandotheracquisitionrelatedcosts", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Basis of Presentation and Summary of Significant Accounting Policies [Abstract]", "label": "Basis of Presentation and Summary of Significant Accounting Policies [Abstract]" } } }, "localname": "BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract", "nsuri": "http://www.cardinal.com/20190930", "xbrltype": "stringItemType" }, "cah_CVSHealthMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CVS Health [Member]", "label": "CVS Health [Member]", "terseLabel": "CVS Health" } } }, "localname": "CVSHealthMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_CardinalHealthAtHomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cardinal Health At Home [Member]", "label": "Cardinal Health At Home [Member]", "terseLabel": "Cardinal Health At Home [Member]" } } }, "localname": "CardinalHealthAtHomeMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_CareFusionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CareFusion [Member]", "label": "CareFusion [Member]", "terseLabel": "CareFusion [Member]" } } }, "localname": "CareFusionMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_CashComponentForSettlementFrameworkTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash Component For Settlement Framework, Term", "label": "Cash Component For Settlement Framework, Term", "terseLabel": "Cash Component For Settlement Framework, Term" } } }, "localname": "CashComponentForSettlementFrameworkTerm", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "durationItemType" }, "cah_ClassActionLawsuitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Class Action Lawsuits [Member]", "label": "Class Action Lawsuits [Member]", "terseLabel": "Class Action Lawsuits [Member]" } } }, "localname": "ClassActionLawsuitsMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_CommittedReceivablesSalesFacilityProgramMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.", "label": "Committed Receivables Sales Facility Program [Member]", "terseLabel": "Committed Receivables Sales Facility Program [Member]" } } }, "localname": "CommittedReceivablesSalesFacilityProgramMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_EnterpriseWideCostSavingMeasuresMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Enterprise Wide Cost Saving Measures", "label": "Enterprise Wide Cost Saving Measures [Member]", "terseLabel": "Enterprise Wide Cost Saving Measures [Member]" } } }, "localname": "EnterpriseWideCostSavingMeasuresMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_ExercisablePeriodOfPlansInYears": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The instrument's contractual term.", "label": "Exercisable period of plans, in years", "terseLabel": "Exercisable period of plans (in years)" } } }, "localname": "ExercisablePeriodOfPlansInYears", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "cah_FacilityExitAndOtherCosts": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceActivityRelatedToRestructuringAndEmployeeSeveranceCostsDetails": { "order": 2.0, "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.", "label": "Facility Exit and Other Costs", "terseLabel": "Facility Exit and Other Costs" } } }, "localname": "FacilityExitAndOtherCosts", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceActivityRelatedToRestructuringAndEmployeeSeveranceCostsDetails", "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_FinalSharesReceivedfromASRProgram": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Final Shares Received from ASR Program", "label": "Final Shares Received from ASR Program", "terseLabel": "Final Shares Received from ASR Program" } } }, "localname": "FinalSharesReceivedfromASRProgram", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "cah_FinanceLeaseImputedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Finance Lease Imputed Interest", "label": "Finance Lease Imputed Interest", "terseLabel": "Less: imputed interest" } } }, "localname": "FinanceLeaseImputedInterest", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_FinanceLeaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finance Lease", "label": "Finance Lease [Member]", "terseLabel": "Finance Lease [Member]" } } }, "localname": "FinanceLeaseMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "domainItemType" }, "cah_IPRDTrademarksandOtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "IPR&D,TrademarksandOther [Member]", "terseLabel": "IPR&D, trademarks and other" } } }, "localname": "IPRDTrademarksandOtherMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cah_IndemnificationReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.", "label": "Indemnification Receivable", "terseLabel": "Indemnification receivable" } } }, "localname": "IndemnificationReceivable", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_InvestigationbyMultitateTaskForce": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Investigation by Multitate Task Force", "label": "InvestigationbyMultitateTaskForce", "terseLabel": "InvestigationbyMultitateTaskForce" } } }, "localname": "InvestigationbyMultitateTaskForce", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "cah_LawsuitTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lawsuit Type [Axis]", "label": "Lawsuit Type [Axis]", "terseLabel": "Lawsuit Type [Axis]" } } }, "localname": "LawsuitTypeAxis", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "stringItemType" }, "cah_LeaseLiabilitiesestablishedasaResultoftheadoptionofASC842": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lease Liabilities established as a Result of the adoption of ASC 842", "label": "Lease Liabilities established as a Result of the adoption of ASC 842", "terseLabel": "Lease Liabilities established as a Result of the adoption of ASC 842" } } }, "localname": "LeaseLiabilitiesestablishedasaResultoftheadoptionofASC842", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_LeasePaymentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Table Text Block] for Lease Payments [Table]", "label": "Lease Payments [Table Text Block]", "terseLabel": "Schedule of Lease Payments" } } }, "localname": "LeasePaymentsTableTextBlock", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "cah_LeasesSupplementalBalanceSheetInformationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Table Text Block] for LeasesSupplementalBalanceSheetInformation [Table]", "label": "LeasesSupplementalBalanceSheetInformation [Table Text Block]", "terseLabel": "Leases Supplemental Balance Sheet Information" } } }, "localname": "LeasesSupplementalBalanceSheetInformationTableTextBlock", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "cah_LeasesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Leases [Text Block]", "label": "Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LeasesTextBlock", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "cah_LesseeFinanceLeaseLiabilityNotYetCommencedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee Finance Lease Liability Not Yet Commenced, Amount", "label": "Lessee Finance Lease Liability Not Yet Commenced, Amount", "terseLabel": "Less: leases not yet commenced (1)" } } }, "localname": "LesseeFinanceLeaseLiabilityNotYetCommencedAmount", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LesseeLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee Lease Liability Payments Due After Year Five", "label": "Lessee Lease Liability Payments Due After Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LesseeLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee Lease Liability Payments Due Year Five", "label": "Lessee Lease Liability Payments Due Year Five", "terseLabel": "2024" } } }, "localname": "LesseeLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LesseeLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee Lease Liability Payments Due Year Four", "label": "Lessee Lease Liability Payments Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LesseeLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee Lease Liability Payments Due Year Three", "label": "Lessee Lease Liability Payments Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LesseeLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee Lease Liability Payments Due Year Two", "label": "Lessee Lease Liability Payments Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LesseeLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee Lease Liability Payments Remainder Of Fiscal Year", "label": "Lessee Lease Liability Payments Remainder Of Fiscal Year", "terseLabel": "Remainder of 2020" } } }, "localname": "LesseeLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LesseeOperatingLeaseLiabilityNotYetCommencedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Lessee Operating Lease Liability Not Yet Commenced, Amount", "label": "Lessee Operating Lease Liability Not Yet Commenced, Amount", "terseLabel": "Less: leases not yet commenced (1)" } } }, "localname": "LesseeOperatingLeaseLiabilityNotYetCommencedAmount", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_LitigationTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Litigation Type [Axis]", "label": "Litigation Type [Domain]", "terseLabel": "Litigation Type [Domain]" } } }, "localname": "LitigationTypeDomain", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_LossContingencyAccrualNetofInsuranceRecoveries": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Loss Contingency Accrual, Net of Insurance Recoveries", "label": "Loss Contingency Accrual, Net of Insurance Recoveries", "terseLabel": "Loss Contingency Accrual, Net of Insurance Recoveries" } } }, "localname": "LossContingencyAccrualNetofInsuranceRecoveries", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_LossContingencyLawsuitsNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Lawsuits, Number", "label": "Loss Contingency, Lawsuits, Number", "terseLabel": "Loss Contingency, Lawsuits, Number" } } }, "localname": "LossContingencyLawsuitsNumber", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "cah_MaximumQuarterlyPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Maximum Quarterly Payment for pharmaceutical sourcing venture if certain milestones are achieved.", "label": "Maximum Quarterly Payment", "terseLabel": "Maximum quarterly payment" } } }, "localname": "MaximumQuarterlyPayment", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_MedicalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical [Member]", "label": "Medical Member", "terseLabel": "Medical" } } }, "localname": "MedicalMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_MedicalSegmentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical Segment [Axis]", "label": "Medical Segment [Axis]", "terseLabel": "Medical Segment [Axis]" } } }, "localname": "MedicalSegmentAxis", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" ], "xbrltype": "stringItemType" }, "cah_MedicalSegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Medical Segment [Axis]", "label": "Medical Segment [Domain]", "terseLabel": "Medical Segment [Domain]" } } }, "localname": "MedicalSegmentDomain", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" ], "xbrltype": "domainItemType" }, "cah_MedicaldistributionandproductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical distribution and products [Member]", "label": "Medical distribution and products [Member]", "terseLabel": "Medical distribution and products [Member]" } } }, "localname": "MedicaldistributionandproductsMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_NaviHealthMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "naviHealth [Member]", "label": "naviHealth [Member]", "terseLabel": "naviHealth [Member]" } } }, "localname": "NaviHealthMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/InvestmentsNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_Netproceedstaxwithholdingsfromsharebasedcompensation": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.", "label": "Net proceeds/(tax withholdings) from share-based compensation", "terseLabel": "Net tax proceeds/(withholdings) from share-based compensation" } } }, "localname": "Netproceedstaxwithholdingsfromsharebasedcompensation", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cah_NotesPayableRepurchased": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Principal Amount of Notes Payable Repurchased during the year", "label": "Notes Payable Repurchased", "terseLabel": "Notes Payable Repurchased" } } }, "localname": "NotesPayableRepurchased", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_NuclearPrecisionHealthServicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nuclear Precision Health Services [Member]", "label": "Nuclear Precision Health Services [Member]", "terseLabel": "Nuclear Precision Health Services [Member]" } } }, "localname": "NuclearPrecisionHealthServicesMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_NumberofStateAttorneysGeneralfilinglawsuits": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of State Attorneys General filing lawsuits", "label": "Number of State Attorneys General filing lawsuits", "terseLabel": "Lawsuits Against Distributors" } } }, "localname": "NumberofStateAttorneysGeneralfilinglawsuits", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "cah_Numberofsharesexcludedfromcalculationofdilutedshares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares excluded from calculation of diluted shares", "label": "Number of shares excluded from calculation of diluted shares", "terseLabel": "Weighted Average Number Diluted Shares Outstanding Adjustment" } } }, "localname": "Numberofsharesexcludedfromcalculationofdilutedshares", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncNarrativeDetails" ], "xbrltype": "sharesItemType" }, "cah_OperatingLeaseImputedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating Lease Imputed Interest", "label": "Operating Lease Imputed Interest", "terseLabel": "Less: imputed interest" } } }, "localname": "OperatingLeaseImputedInterest", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_OperatingLeaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating Lease", "label": "Operating Lease [Member]", "terseLabel": "Operating Lease [Member]" } } }, "localname": "OperatingLeaseMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "domainItemType" }, "cah_OpioidLawsuitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Opioid Lawsuits [Member]", "label": "Opioid Lawsuits [Member]", "terseLabel": "Opioid Lawsuits [Member]" } } }, "localname": "OpioidLawsuitsMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_OpioidLitigationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Opioid Litigation", "label": "Opioid Litigation [Axis]", "terseLabel": "Tax Matters Agreement [Axis]" } } }, "localname": "OpioidLitigationAxis", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "cah_OpioidLitigationCuyahogaandSummitCountiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Opioid Litigation, Cuyahoga and Summit Counties", "label": "Opioid Litigation, Cuyahoga and Summit Counties [Member]", "terseLabel": "Cuyahoga and Summit County [Member]" } } }, "localname": "OpioidLitigationCuyahogaandSummitCountiesMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_OpioidLitigationlessCuyahogaandSummitCountiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Opioid Litigation, less Cuyahoga and Summit Counties", "label": "Opioid Litigation, less Cuyahoga and Summit Counties [Member]", "terseLabel": "Opioid Litigation, less Cuyahoga and Summit Counties [Member]" } } }, "localname": "OpioidLitigationlessCuyahogaandSummitCountiesMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_OpioidSettlementFrameworkMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Opioid Settlement Framework [Member]", "label": "Opioid Settlement Framework [Member]", "terseLabel": "Opioid Settlement Framework [Member]" } } }, "localname": "OpioidSettlementFrameworkMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_OpioidTotalSettlementCuyahogaandSummitCounties": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Opioid Total Settlement, Cuyahoga and Summit Counties", "label": "Opioid Total Settlement, Cuyahoga and Summit Counties", "terseLabel": "Opioid Total Settlement, Cuyahoga and Summit Counties" } } }, "localname": "OpioidTotalSettlementCuyahogaandSummitCounties", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_OtherJurisdictionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Jurisdictions [Member]", "label": "Other Jurisdictions [Member]", "terseLabel": "Other Jurisdictions [Member]" } } }, "localname": "OtherJurisdictionsMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_PartnershipIndirectOwnership": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Partnership Indirect Ownership", "label": "Partnership Indirect Ownership", "terseLabel": "Partnership Indirect Ownership" } } }, "localname": "PartnershipIndirectOwnership", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "percentItemType" }, "cah_PatientRecoveryBusinessMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Patient Recovery Business [Member]", "label": "Patient Recovery Business [Member]", "terseLabel": "Patient Recovery Business [Member]" } } }, "localname": "PatientRecoveryBusinessMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_PharmaceuticalDistributionandSpecialtyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pharmaceutical Distribution and Specialty [Member]", "label": "Pharmaceutical Distribution and Specialty [Member]", "terseLabel": "Pharmaceutical Distribution and Specialty [Member]" } } }, "localname": "PharmaceuticalDistributionandSpecialtyMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_PharmaceuticalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pharmaceutical [Member]", "label": "Pharmaceutical Member", "terseLabel": "Pharmaceutical" } } }, "localname": "PharmaceuticalMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "cah_PharmaceuticalSegmentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pharmaceutical Segment [Axis]", "label": "Pharmaceutical Segment [Axis]", "terseLabel": "Pharmaceutical Segment [Axis]" } } }, "localname": "PharmaceuticalSegmentAxis", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" ], "xbrltype": "stringItemType" }, "cah_PharmaceuticalSegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Pharmaceutical Segment [Axis]", "label": "Pharmaceutical Segment [Domain]", "terseLabel": "Pharmaceutical Segment [Domain]" } } }, "localname": "PharmaceuticalSegmentDomain", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" ], "xbrltype": "domainItemType" }, "cah_PlaintiffTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plaintiff Type [Axis]", "label": "Plaintiff Type [Axis]", "terseLabel": "Plaintiff Type [Axis]" } } }, "localname": "PlaintiffTypeAxis", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "stringItemType" }, "cah_PlaintiffTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Plaintiff Type [Axis]", "label": "Plaintiff Type [Domain]", "terseLabel": "Plaintiff Type [Domain]" } } }, "localname": "PlaintiffTypeDomain", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_PreTaxGainonDivestiture": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Pre-Tax Gain on Divestiture", "label": "Pre-Tax Gain on Divestiture", "terseLabel": "Pre-Tax Gain on Divestiture" } } }, "localname": "PreTaxGainonDivestiture", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/InvestmentsNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_PrivatePartiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Private Parties [Member]", "label": "Private Parties [Member]", "terseLabel": "Private Parties [Member]" } } }, "localname": "PrivatePartiesMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from sales of available-for-sale securities and other investments.", "label": "Proceeds from sale of available-for-sale securities and other investments", "terseLabel": "Proceeds from sale of available-for-sale securities and other investments" } } }, "localname": "Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cah_ProductLiabilityLawsuitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product Liability Lawsuits [Member]", "label": "Product Liability Lawsuits [Member]", "terseLabel": "Product Liability Lawsuits [Member]" } } }, "localname": "ProductLiabilityLawsuitsMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_ProjectCostsOnInvestmentAndOtherSpending": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.", "label": "Project Costs On Investment And Other Spending", "terseLabel": "Project Costs On Investment And Other Spending" } } }, "localname": "ProjectCostsOnInvestmentAndOtherSpending", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_Purchaseofavailableforsalesecuritiesandotherinvestments": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow from purchases of available-for-sale securities and other investments.", "label": "Purchase of available-for-sale securities and other investments", "negatedLabel": "Purchase of available-for-sale securities and other investments" } } }, "localname": "Purchaseofavailableforsalesecuritiesandotherinvestments", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cah_ReclassificationofdeferredrentinaccordancewithASC842": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Reclassification of deferred rent in accordance with ASC 842", "label": "Reclassification of deferred rent in accordance with ASC 842", "terseLabel": "Reclassification of deferred rent in accordance with ASC 842" } } }, "localname": "ReclassificationofdeferredrentinaccordancewithASC842", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LeasesNarativeDetails" ], "xbrltype": "monetaryItemType" }, "cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]", "label": "Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Definite and Indefinite-Lived Intangible Assets" } } }, "localname": "ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "cah_SegmentRevenuebyGeographicLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Segment Revenue by Geographic [Table]", "label": "Segment Revenue by Geographic [Line Items]", "terseLabel": "Segment Revenue by Geographic [Line Items]" } } }, "localname": "SegmentRevenuebyGeographicLineItems", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueByGeographicalSegmentsDetails" ], "xbrltype": "stringItemType" }, "cah_SegmentRevenuebyGeographicTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Segment Revenue by Geographic [Table]", "label": "Segment Revenue by Geographic [Table]", "terseLabel": "Segment Revenue by Geographic [Table]" } } }, "localname": "SegmentRevenuebyGeographicTable", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueByGeographicalSegmentsDetails" ], "xbrltype": "stringItemType" }, "cah_Sharesthatwouldbeantidilutiveasaresultofnetloss": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "shares that would be antidilutive as a result of net loss", "label": "shares that would be antidilutive as a result of net loss", "terseLabel": "shares that would be antidilutive as a result of net loss" } } }, "localname": "Sharesthatwouldbeantidilutiveasaresultofnetloss", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncNarrativeDetails" ], "xbrltype": "sharesItemType" }, "cah_ShortTermCreditFacilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other short-term credit facilities and an unsecured line of credit", "label": "Short Term Credit Facilities Member", "terseLabel": "Short Term Credit Facilities Member" } } }, "localname": "ShortTermCreditFacilitiesMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_SummaryofMinimumLeasePaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Summary of Minimum Lease Payments [Abstract]", "label": "Summary of Minimum Lease Payments [Abstract]" } } }, "localname": "SummaryofMinimumLeasePaymentsAbstract", "nsuri": "http://www.cardinal.com/20190930", "xbrltype": "stringItemType" }, "cah_TaxMatterAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tax Matter [Axis]", "label": "Tax Matter [Axis]", "terseLabel": "Tax Matter [Axis]" } } }, "localname": "TaxMatterAxis", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "cah_TaxMatterDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Tax Matter [Axis]", "label": "Tax Matter [Domain]", "terseLabel": "Tax Matter [Domain]" } } }, "localname": "TaxMatterDomain", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_TaxMattersAgreementDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Tax Matters Agreement [Axis]", "label": "Tax Matters Agreement [Domain]", "terseLabel": "Tax Matters Agreement [Domain]" } } }, "localname": "TaxMattersAgreementDomain", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_TotalFinanceLeaseCost": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/LeasesSummaryOfLeaseCostsDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total Finance Lease Cost", "label": "Total Finance Lease Cost", "totalLabel": "Total Finance Lease Cost" } } }, "localname": "TotalFinanceLeaseCost", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "cah_TotalLeaseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total Lease Liability", "label": "Total Lease Liability", "terseLabel": "Total lease liabilities" } } }, "localname": "TotalLeaseLiability", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_TotalLeaseLiabilityNotYetCommencedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total Lease Liability Not Yet Commenced, Amount", "label": "Total Lease Liability Not Yet Commenced, Amount", "terseLabel": "Less: leases not yet commenced (1)" } } }, "localname": "TotalLeaseLiabilityNotYetCommencedAmount", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_TotalLeaseLiabilityPaymentsDue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total undiscounted Lease Liability Payments Due for both operating and financing leases", "label": "Total Lease Liability Payments Due", "terseLabel": "Total future lease payments" } } }, "localname": "TotalLeaseLiabilityPaymentsDue", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_TotalLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total Lease Liability Undiscounted Excess Amount", "label": "Total Lease Liability Undiscounted Excess Amount", "terseLabel": "Less: imputed interest" } } }, "localname": "TotalLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "cah_TotalOpioidLitigationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Total Opioid Litigation", "label": "Total Opioid Litigation [Member]", "terseLabel": "Total Opioid Litigation [Member]" } } }, "localname": "TotalOpioidLitigationMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_TotalOpioidLitigationnetoftaxMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Total Opioid Litigation, net of tax", "label": "Total Opioid Litigation, net of tax [Member]", "terseLabel": "Opioid Settlement Framework [Member]" } } }, "localname": "TotalOpioidLitigationnetoftaxMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "cah_TrademarksAndPatentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Trademarks And Patents Member", "terseLabel": "Trademarks, trade names and patents" } } }, "localname": "TrademarksAndPatentsMember", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "cah_VestingPeriodinyearsforShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vesting Period in years for Shares", "label": "Vesting Period in years for Shares", "terseLabel": "Vesting Period in years for Shares" } } }, "localname": "VestingPeriodinyearsforShares", "nsuri": "http://www.cardinal.com/20190930", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "integerItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueByGeographicalSegmentsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r343" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r344" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r345" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r345" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r345" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r346" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r345" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r345" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r345" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r345" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r341" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "invest_InvestmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investment [Line Items]", "terseLabel": "Investment [Line Items]" } } }, "localname": "InvestmentLineItems", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://www.cardinal.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "invest_InvestmentTable": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investment [Table]", "terseLabel": "Investment [Table]" } } }, "localname": "InvestmentTable", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://www.cardinal.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_CondensedFinancialStatementsCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Condensed Financial Statements, Captions [Line Items]", "terseLabel": "Statement of Stockholders' Equity" } } }, "localname": "CondensedFinancialStatementsCaptionsLineItems", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r98", "r111" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByGeographicalSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByGeographicalSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case Type" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r116", "r186", "r188", "r336" ], "lang": { "en-US": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/LeasesNarativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/LeasesNarativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/LeasesNarativeDetails", "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/LeasesNarativeDetails", "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedFinancialStatementsTable": { "auth_ref": [ "r82", "r236" ], "lang": { "en-US": { "role": { "label": "Condensed Financial Statements [Table]", "terseLabel": "Condensed Consolidated Statement of Shareholders' Equity" } } }, "localname": "ScheduleOfCondensedFinancialStatementsTable", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByGeographicalSegmentsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r115", "r186", "r187", "r335", "r339", "r340" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByGeographicalSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts Payable, Current" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r38", "r43", "r44", "r245" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.", "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Foreign Currency Translation Adjustments" } } }, "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r39", "r43", "r44", "r245" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest.", "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Unrealized Gain/(Loss) on Derivatives, net of tax" } } }, "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r41", "r42", "r43" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r40", "r43", "r44", "r245" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "AOCI Attributable to Parent" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r84" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net earnings/(loss) to net cash provided by/(used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r193", "r216", "r219" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total share-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfTotalShareBasedCompensationExpenseByTypeOfAwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r73", "r130", "r137" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r92" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r40", "r43", "r44", "r245" ], "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r102", "r310", "r324" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r4", "r36" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r195", "r218" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfTotalShareBasedCompensationExpenseByTypeOfAwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r83" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r232", "r233" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r21", "r75" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and equivalents at end of period", "periodStartLabel": "Cash and equivalents at beginning of period", "terseLabel": "Cash and equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net increase/(decrease) in cash and equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging [Member]" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "auth_ref": [ "r266" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "terseLabel": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments" } } }, "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r169" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r158", "r166" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments, Contingent Liabilities and Litigation" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r182" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Cash dividends declared per common share" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]", "terseLabel": "Common shares, without par value:" } } }, "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common Shares, authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)", "terseLabel": "Common Shares, issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r14" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Authorized\u2014755 million shares, Issued\u2014327 million shares at September 30, 2019 and June 30, 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r47", "r49", "r50" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive income attributable to Cardinal Health, Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r47", "r49", "r239", "r248" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total comprehensive income/(loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate", "verboseLabel": "Corporate" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByGeographicalSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r60" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of Goods and Services Sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrencySwapMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.", "label": "Currency Swap [Member]", "terseLabel": "Currency Swap [Member]" } } }, "localname": "CurrencySwapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtAndCapitalLeaseObligations": { "auth_ref": [ "r315", "r330" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term and long-term debt and lease obligation.", "label": "Debt and Lease Obligation", "terseLabel": "Debt and Lease Obligation", "verboseLabel": "Carrying amount" } } }, "localname": "DebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsSummaryOfEstimatedFairValueOfLongTermObligationsAndOtherShortTermBorrowingsDetails", "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r171" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowings" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r10", "r11", "r12", "r311", "r312", "r323" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r277" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Estimated fair value" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsSummaryOfEstimatedFairValueOfLongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r28" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r321" ], "lang": { "en-US": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r321" ], "lang": { "en-US": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r28", "r78", "r176", "r179", "r180", "r181", "r281", "r282", "r284", "r322" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "auth_ref": [ "r225" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "terseLabel": "Estimated range of decrease in unrecognized tax benefits within the next 12 months" } } }, "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.", "label": "Deferred Tax and Other Liabilities, Noncurrent", "terseLabel": "Deferred income taxes and other liabilities" } } }, "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r73", "r100" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "auth_ref": [ "r249" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.", "label": "Derivative Assets (Liabilities), at Fair Value, Net", "terseLabel": "Derivative Assets (Liabilities), at Fair Value, Net" } } }, "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative, Name [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r258", "r259", "r261", "r262" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r256", "r258", "r261" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilityNotionalAmount": { "auth_ref": [ "r251", "r252", "r254" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payments on the derivative liability.", "label": "Derivative Liability, Notional Amount", "terseLabel": "Foreign Currency Contract, Asset, Fair Value Disclosure" } } }, "localname": "DerivativeLiabilityNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r81", "r250", "r253", "r254", "r256", "r257", "r260", "r261", "r264", "r265", "r267" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "verboseLabel": "Developed technology and other" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r186" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "verboseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/InvestmentsNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r182", "r320" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "terseLabel": "Dividends" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r55", "r85", "r88", "r89", "r90", "r91", "r94", "r318", "r332" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in shares)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Earnings/(loss) per common share attributable to Cardinal Health, Inc.:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r55", "r85", "r88", "r89", "r90", "r91", "r94", "r318", "r332" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in shares)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r95" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Earnings Per Share Attributable to Cardinal Health, Inc." } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthInc" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r278" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and equivalents" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r80", "r222", "r223" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r217" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r217" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r216" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, Tax Benefit", "terseLabel": "Tax benefit related to share-based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Employee- Related Costs" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r214" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options", "verboseLabel": "Employee Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfTotalShareBasedCompensationExpenseByTypeOfAwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r175" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r22", "r103", "r119" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity Method Investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FacilityClosingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Facility Closing [Member]", "terseLabel": "Facility Exit and Other Costs" } } }, "localname": "FacilityClosingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryOfEstimatedFairValueOfLongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r268", "r269", "r270", "r274" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryOfEstimatedFairValueOfLongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r189", "r190", "r191", "r269", "r305" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryOfEstimatedFairValueOfLongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r268", "r269", "r271", "r272", "r275" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r189", "r190", "r191", "r269", "r306" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r189", "r190", "r191", "r269", "r307" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryOfEstimatedFairValueOfLongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r189", "r190", "r191", "r269", "r308" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "auth_ref": [ "r276" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.", "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementInputsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails", "http://www.cardinal.com/role/FinancialInstrumentsSummaryOfEstimatedFairValueOfLongTermObligationsAndOtherShortTermBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r273", "r275" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r289", "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Total lease liabilities", "verboseLabel": "Total finance lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails", "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r289" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Current portion of long-term debt" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r289" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Long-term debt" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "terseLabel": "Total future lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in remainder of fiscal year following latest fiscal year ended.", "label": "Finance Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "Remainder of 2020" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r291", "r297" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Financing cash flows paid for finance lease" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r288" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under finance lease.", "label": "Finance Lease, Right-of-Use Asset", "terseLabel": "Net property, plant and equipment" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r290", "r294", "r303" ], "calculation": { "http://www.cardinal.com/role/LeasesSummaryOfLeaseCostsDetails": { "order": 1.0, "parentTag": "cah_TotalFinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Finance Lease, Right-of-Use Asset, Amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "Financial Instruments" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r136" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r138" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Five" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r138" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Four" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r138" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Three" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r138" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Two" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r131", "r133", "r136", "r140", "r309" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r136", "r309" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Intangible" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r131", "r135" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "verboseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r136" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Net Intangible" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Weighted- Average Remaining Amortization Period (Years)" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": { "auth_ref": [ "r73" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.", "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "negatedTerseLabel": "Impairments and (gain)/loss on disposal of assets, net" } } }, "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r159" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "Gain (Loss) Related to Litigation Settlement", "negatedTerseLabel": "Litigation (recoveries)/charges, net" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r123", "r124" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Other Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r125" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "negatedTerseLabel": "Foreign currency translation adjustments and other" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillTransfers": { "auth_ref": [ "r126" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of transfers into (out of) an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Transfers", "terseLabel": "Goodwill, Transfers" } } }, "localname": "GoodwillTransfers", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r59" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross margin" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r256", "r263" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r256" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r256" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r79" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Earnings/(loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/InvestmentsNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r231" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r76", "r101", "r230" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Income Tax Expense (Benefit)", "verboseLabel": "Provision for (benefit from) income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r72" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Increase/(decrease) in accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r72" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "(Increase)/decrease in inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities, net of effects from acquisitions and divestitures:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r72" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedTerseLabel": "Other accrued liabilities and operating items, net" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r72" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedTerseLabel": "(Increase)/decrease in trade receivables" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r132", "r139" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r139" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Net Intangible" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r132", "r139" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Gross Intangible, Total other intangible assets" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r129", "r134" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Net Intangible, Total other intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.", "label": "Intangible Assets, Net (Including Goodwill)", "terseLabel": "Goodwill and other intangibles, net" } } }, "localname": "IntangibleAssetsNetIncludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r52", "r99", "r280", "r283", "r319" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense, net" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]", "terseLabel": "Federal" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r2", "r34", "r122" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentHoldingsScheduleOfInvestmentsTextBlock": { "auth_ref": [ "r338" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for investment holdings. This includes the information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments.", "label": "Investment Holdings, Schedule of Investments [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentHoldingsScheduleOfInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments [Abstract]" } } }, "localname": "InvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r268" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Other investments" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseArrangementTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement, Type [Axis]", "terseLabel": "Lease Arrangement, Type [Axis]" } } }, "localname": "LeaseArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseArrangementTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement, Type [Domain]", "terseLabel": "Lease Arrangement, Type [Domain]" } } }, "localname": "LeaseArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r301", "r303" ], "calculation": { "http://www.cardinal.com/role/LeasesSummaryOfLeaseCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Lease, Cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r301" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Costs" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "terseLabel": "Total future lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "Remainder of 2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r293" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lessee, Operating Lease, Term of Contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesNarativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r19", "r314", "r327" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r25" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationReserve": { "auth_ref": [ "r29", "r159" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.", "label": "Estimated Litigation Liability", "terseLabel": "Estimated Litigation Liability", "verboseLabel": "litigation settlement liability recorded" } } }, "localname": "LitigationReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails", "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r12" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-term Debt and Lease Obligation", "terseLabel": "Long-term obligations, less current portion" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as current.", "label": "Long-term Debt and Lease Obligation, Current", "terseLabel": "Current portion of long-term obligations and other short-term borrowings" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r28" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r28", "r170" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermPurchaseCommitmentPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Long-term Purchase Commitment, Period", "terseLabel": "Long-term Purchase Commitment, Period" } } }, "localname": "LongtermPurchaseCommitmentPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r167", "r168" ], "lang": { "en-US": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r167", "r168" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r167", "r168" ], "lang": { "en-US": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.", "label": "Loss Contingency, Number of Plaintiffs", "terseLabel": "Number of plaintiffs" } } }, "localname": "LossContingencyNumberOfPlaintiffs", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossOnSaleOfInvestments": { "auth_ref": [ "r57", "r58", "r73", "r316", "r333" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The difference between the carrying value and the sale price of an investment. A loss would be recognized when the sale price of the investment is less than the carrying value of the investment. This element refers to the Loss included in earnings and not to the cash proceeds of the sale.", "label": "Loss on Sale of Investments", "terseLabel": "Impairments and (gain)/loss on sale of investments" } } }, "localname": "LossOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r33", "r313", "r326" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Noncontrolling Interest, Ownership Percentage by Parent" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r70" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r70" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by/(used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r70", "r71", "r74" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by/(used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r45", "r48", "r54", "r74", "r93", "r317", "r331" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Earnings/(Loss)", "totalLabel": "Net earnings/(loss) attributable to Cardinal Health, Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r45", "r48", "r242", "r247" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 }, "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Less: comprehensive income attributable to noncontrolling interests", "negatedTerseLabel": "Less: Net earnings attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the quantification of the effect of adopting the new accounting standard or change in accounting principle expected by the entity to have a significant effect on the entity's financial statements.", "label": "New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification", "negatedTerseLabel": "Amended lease standard adoption impact as of July 1, 2019" } } }, "localname": "NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Financial Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Non-US [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationRevenueByGeographicalSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of Reportable Segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OpenTaxYear": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "documentation": "Tax year that remains open to examination under enacted tax laws, in CCYY format.", "label": "Open Tax Year", "terseLabel": "Open Tax Year" } } }, "localname": "OpenTaxYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "gYearListItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Total operating earnings", "totalLabel": "Operating earnings/(loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings", "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r295", "r303" ], "calculation": { "http://www.cardinal.com/role/LeasesSummaryOfLeaseCostsDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating Lease, Cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r289" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total lease liabilities", "verboseLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails", "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r289" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r289" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r292", "r297" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows paid for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r288" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r300", "r303" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesNarativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r299", "r303" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesNarativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r285", "r286" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "Operating Leases, Future Minimum Payments Due, Next Twelve Months" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesNarativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r285", "r286" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Five Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesNarativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r285", "r286" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Four Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesNarativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r285", "r286" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Three Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesNarativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r285", "r286" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Two Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesNarativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r285", "r286" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Operating Leases, Future Minimum Payments, Due Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesNarativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r98", "r111" ], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByGeographicalSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r5", "r6", "r7", "r26" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Prepaid expenses and other" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r23" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other Assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r43", "r51" ], "calculation": { "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "verboseLabel": "Other comprehensive income/(loss), before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax": { "auth_ref": [ "r39" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax", "terseLabel": "Net unrealized gain/(loss) on derivative instruments, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r37", "r279" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments and other" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r46", "r49", "r51", "r175" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive income/(loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income/(loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r46", "r49", "r239", "r240", "r244" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r62" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income)/expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r66" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Purchase of treasury shares", "terseLabel": "Payments for Repurchase of Common Stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r68", "r147" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedLabel": "Payments and other adjustments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r66" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends on common shares" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r65" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Additions to property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Share Units", "verboseLabel": "Performance Share Unit" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfTotalShareBasedCompensationExpenseByTypeOfAwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]", "terseLabel": "Preferred shares, without par value:" } } }, "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Shares, authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred Shares, issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r13" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Authorized\u2014500 thousand shares, Issued\u2014none" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r63" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from Divestiture of Businesses" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": { "auth_ref": [ "r82" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from (Repayments of) Short-term Debt", "terseLabel": "Net change in short-term borrowings" } } }, "localname": "ProceedsFromRepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r64" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from Sale of Property, Plant, and Equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r45", "r48", "r69", "r102", "r112", "r239", "r241", "r243", "r247", "r248" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net earnings/(loss)", "totalLabel": "Net earnings/(loss)", "verboseLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r8", "r9", "r143", "r329" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r56", "r120" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision for bad debts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r15", "r20", "r328", "r337" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables, Net, Current", "terseLabel": "Trade receivables, net" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r43", "r44", "r51" ], "calculation": { "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTerseLabel": "Amounts reclassified to earnings" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "terseLabel": "AOCI, Net of Tax [Roll Forward]" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "auth_ref": [ "r107", "r109" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "terseLabel": "Assets by Reportable Segment" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "auth_ref": [ "r106", "r109" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r106", "r109" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Segment Profit by Reportable Segment" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "auth_ref": [ "r105", "r109" ], "lang": { "en-US": { "role": { "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]", "verboseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r105", "r109" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]", "terseLabel": "Revenue by Reportable Segment" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r67" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Reduction of long-term obligations" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Share Units", "verboseLabel": "Restricted Share Unit" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfTotalShareBasedCompensationExpenseByTypeOfAwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring and Employee Severance" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeverance" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r73", "r146", "r151", "r155" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 }, "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceActivityRelatedToRestructuringAndEmployeeSeveranceCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "totalLabel": "Total restructuring and employee severance", "verboseLabel": "Restructuring and employee severance" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings", "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceActivityRelatedToRestructuringAndEmployeeSeveranceCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringChargesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring Charges [Abstract]" } } }, "localname": "RestructuringChargesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails", "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCosts": { "auth_ref": [ "r73" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Costs", "terseLabel": "Additions", "verboseLabel": "Restructuring Costs" } } }, "localname": "RestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails", "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r147", "r152" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r182", "r325" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r53", "r97", "r98", "r110" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenue", "verboseLabel": "Total revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings", "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByGeographicalSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r298", "r303" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "New financing leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r298", "r303" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "New Operating Leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r43" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount" } } }, "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Schedule of Total Share-based Compensation Expense by Type of Award" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r268", "r269" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r131", "r135" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of Future Lease Payments" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r127", "r128" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r127", "r128" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill by Reportable Segment" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r139", "r141" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.", "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]", "terseLabel": "Schedule of Transactions Related to Performance Share Units Under the Plans" } } }, "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r149", "r150", "r153" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails", "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r149", "r150", "r153" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Summary of Restructuring and Employee Severance" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r147", "r154" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r96", "r102", "r104", "r108", "r127" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r195", "r218" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfTotalShareBasedCompensationExpenseByTypeOfAwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r198" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of Transactions Related to Restricted Share Units Under the Plans" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r198", "r210", "r212" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Option Transactions Under the Plans" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r30", "r77", "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r180", "r181", "r182" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r93" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r117" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]" } } }, "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Revenue Reconciling Item [Line Items]", "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]" } } }, "localname": "SegmentReportingRevenueReconcilingItemLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r61", "r121" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Distribution, selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r73", "r146", "r151", "r155" ], "calculation": { "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceActivityRelatedToRestructuringAndEmployeeSeveranceCostsDetails": { "order": 1.0, "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance Costs", "verboseLabel": "Employee-related costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceActivityRelatedToRestructuringAndEmployeeSeveranceCostsDetails", "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r72" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "negatedLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r196" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Canceled and forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Canceled and forfeited (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested at end of period (in shares)", "periodStartLabel": "Nonvested at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted Share Units", "verboseLabel": "Performance Share Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested at end of period (in usd per share)", "periodStartLabel": "Nonvested at beginning of period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-Average Grant Date Fair Value per Share", "verboseLabel": "Weighted-Average Grant Date Fair Value per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r208" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r208" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfTotalShareBasedCompensationExpenseByTypeOfAwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r201" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r201" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at end of period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r204" ], "lang": { "en-US": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Canceled and forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r204" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Canceled and forfeited (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r218" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of outstanding options at period end" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r200", "r218" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period (in shares)", "periodStartLabel": "Outstanding at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Stock Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of period (in usd per share)", "periodStartLabel": "Outstanding at beginning of period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise Price per Common Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r192", "r197" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToRestrictedShareUnitsUnderPlansDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfTotalShareBasedCompensationExpenseByTypeOfAwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r196" ], "lang": { "en-US": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Target performance goal (as a percent)", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails", "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllTransactionsRelatedToPerformanceShareUnitsUnderPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r218" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of exercisable options at period end" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAdditionalDataRelatedToStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r102", "r127", "r145", "r148", "r156", "r334" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]", "verboseLabel": "Operating and Reportable Segment" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationAssetsByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationSegmentProfitByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r32", "r175" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesNarativeDetails", "http://www.cardinal.com/role/LeasesSummaryOfLeasePaymentsDetails", "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesNarativeDetails", "http://www.cardinal.com/role/LeasesSummaryOfLeasePaymentsDetails", "http://www.cardinal.com/role/LeasesSummaryOfMinimumLeaseCommittmentsDetails", "http://www.cardinal.com/role/SegmentInformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r13", "r14", "r175", "r182", "r202" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareBasedCompensationScheduleOfAllStockOptionTransactionsUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r13", "r14", "r182", "r194", "r211" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "negatedTerseLabel": "Employee stock plans activity, net of shares withheld for employee taxes" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r14", "r17", "r18", "r118" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Cardinal Health, Inc. shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r237", "r238", "r246" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "negatedPeriodEndLabel": "Balance at end of period", "negatedPeriodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total shareholders' equity", "verboseLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r185" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "terseLabel": "Stockholders' Equity, Other" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]", "terseLabel": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsConsolidationItemsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.", "label": "Subsegments Consolidation Items [Axis]", "terseLabel": "Subsegments Consolidation Items [Axis]" } } }, "localname": "SubsegmentsConsolidationItemsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.", "label": "Subsegments Consolidation Items [Domain]", "terseLabel": "Subsegments Consolidation Items [Domain]" } } }, "localname": "SubsegmentsConsolidationItemsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "domainItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Subsegments [Domain]", "terseLabel": "Subsegments [Domain]" } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails", "http://www.cardinal.com/role/SegmentInformationRevenueByReportableSegmentDetails", "http://www.cardinal.com/role/SegmentInformationTables" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r304" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r304" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesAndLitigationNarrativeDetails", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxCreditCarryforwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Tax Credit Carryforward [Line Items]", "terseLabel": "Income Taxes" } } }, "localname": "TaxCreditCarryforwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardTable": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.", "label": "Tax Credit Carryforward [Table]", "terseLabel": "Income Taxes" } } }, "localname": "TaxCreditCarryforwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "terseLabel": "Treasury shares acquired, average price per share (in usd per share)" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r31", "r183" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Shares" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r31", "r183" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "negatedPeriodEndLabel": "Treasury, balance at end of period (in shares)", "negatedPeriodStartLabel": "Treasury, balance at beginning of period (in shares)", "terseLabel": "Common Shares in Treasury" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r14", "r175", "r182" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "negatedTerseLabel": "Treasury Stock, Shares, Acquired", "terseLabel": "Treasury shares acquired (using cost method), shares" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity", "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r31", "r183", "r184" ], "calculation": { "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Common shares in treasury, at cost: 34 million shares and 28 million shares at September 30, 2019 and June 30, 2019, respectively", "negatedPeriodEndLabel": "Treasury, balance at end of period", "negatedPeriodStartLabel": "Treasury, balance at beginning of period" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets", "http://www.cardinal.com/role/CondensedConsolidatedStatementOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r175", "r182", "r183" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "terseLabel": "Payments for Repurchase of Common Stock" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfLeasePaymentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/RestructuringAndEmployeeSeveranceLiabilitiesAssociatedWithRestructuringAndEmployeeSeveranceActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r221", "r227" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r224" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized tax benefits, interest and penalties accrued" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r228" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r296", "r303" ], "calculation": { "http://www.cardinal.com/role/LeasesSummaryOfLeaseCostsDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable Lease, Cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LeasesSummaryOfLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/LongTermObligationsAndOtherShortTermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r91" ], "calculation": { "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncReconciliationOfCommonSharesUsedToComputeBasicAndDilutedEpsDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Weighted Average Number Diluted Shares Outstanding Adjustment" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncReconciliationOfCommonSharesUsedToComputeBasicAndDilutedEpsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]", "terseLabel": "Effect of dilutive securities:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncReconciliationOfCommonSharesUsedToComputeBasicAndDilutedEpsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r87", "r91" ], "calculation": { "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncReconciliationOfCommonSharesUsedToComputeBasicAndDilutedEpsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted-average common shares\u2013diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings", "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncReconciliationOfCommonSharesUsedToComputeBasicAndDilutedEpsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r86", "r91" ], "calculation": { "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncReconciliationOfCommonSharesUsedToComputeBasicAndDilutedEpsDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average common shares\u2013basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings", "http://www.cardinal.com/role/EarningsPerShareAttributableToCardinalHealthIncReconciliationOfCommonSharesUsedToComputeBasicAndDilutedEpsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Weighted-average number of common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.cardinal.com/role/CondensedConsolidatedStatementsOfEarnings" ], "xbrltype": "stringItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8475-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r117": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r157": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r158": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r166": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r185": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r231": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=d3e5283-111683" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=117331979&loc=d3e41228-113958" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r276": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13,16)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e604059-122996" }, "r338": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r341": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r342": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r343": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r344": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r345": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r346": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r83": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" } }, "version": "2.1" } XML 85 R27.htm IDEA: XBRL DOCUMENT v3.19.3
Financial Instruments (Tables)
 3 Months Ended
Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount
The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:
(in millions)
September 30, 2019
 
June 30, 2019
Estimated fair value
$
8,001

 
$
8,065

Carrying amount
7,991

 
8,031
XML 86 R23.htm IDEA: XBRL DOCUMENT v3.19.3
Restructuring and Employee Severance (Tables)
 3 Months Ended
Sep. 30, 2019
Restructuring Charges [Abstract]  
Summary of Restructuring and Employee Severance
The following table summarizes restructuring and employee severance costs:
 
Three months ended September 30,
(in millions)
2019
 
2018
Employee-related costs (1)
$
20

 
$
29

Facility exit and other costs (2)
10

 
3

Total restructuring and employee severance
$
30

 
$
32


(1)
Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods.
(2)
Facility exit and other costs primarily consist of product distribution and lease contract termination costs, lease costs associated with vacant facilities, accelerated depreciation, equipment relocation costs, project consulting fees, costs associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs.
Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance
The following table summarizes activity related to liabilities associated with restructuring and employee severance:
(in millions)
Employee-
Related Costs
 
Facility Exit
and Other Costs
 
Total
Balance at June 30, 2019
$
64

 
$
8

 
$
72

Additions
19

 
6

 
25

Payments and other adjustments
(10
)
 
(2
)
 
(12
)
Balance at September 30, 2019
$
73

 
$
12

 
$
85
XML 87 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 88 R42.htm IDEA: XBRL DOCUMENT v3.19.3
Leases Summary of Lease Payments (Details) - USD ($)
$ in Millions
 3 Months Ended
Jul. 01, 2019
Sep. 30, 2019
Operating cash flows paid for operating leases   $ 31
Financing cash flows paid for finance lease   2
New Operating Leases   15
New financing leases   $ 17
ASC 842    
Amended lease standard adoption impact as of July 1, 2019 $ 400  
XML 89 R46.htm IDEA: XBRL DOCUMENT v3.19.3
Commitments, Contingent Liabilities and Litigation Narrative (Details)
$ in Millions
 3 Months Ended
Nov. 01, 2019
StateAG
plaintiff
lawsuit
Sep. 30, 2019
USD ($)
Oct. 21, 2019
USD ($)
Subsequent Event      
Loss Contingencies [Line Items]      
Opioid Total Settlement, Cuyahoga and Summit Counties     $ 215.0
Opioid Litigation, less Cuyahoga and Summit Counties [Member]      
Loss Contingencies [Line Items]      
litigation settlement liability recorded   $ 5,560.0  
Cash Component For Settlement Framework, Term   18 years  
Cuyahoga and Summit County [Member]      
Loss Contingencies [Line Items]      
litigation settlement liability recorded   $ 66.0  
Opioid Lawsuits [Member] | Subsequent Event      
Loss Contingencies [Line Items]      
Loss Contingency, Lawsuits, Number 2,400    
Lawsuits Against Distributors | StateAG 21    
InvestigationbyMultitateTaskForce | StateAG 43    
CVS Health      
Loss Contingencies [Line Items]      
Long-term Purchase Commitment, Period   10 years  
Maximum quarterly payment   $ 45.6  
Minimum      
Loss Contingencies [Line Items]      
Loss Contingency Accrual, Net of Insurance Recoveries   414.0  
Maximum      
Loss Contingencies [Line Items]      
Loss Contingency Accrual, Net of Insurance Recoveries   836.0  
Alameda County [Member] | Product Liability Lawsuits [Member] | Subsequent Event      
Loss Contingencies [Line Items]      
Loss Contingency, Lawsuits, Number | lawsuit 280    
Number of plaintiffs | plaintiff 3,463    
Other Jurisdictions [Member] | Product Liability Lawsuits [Member] | Subsequent Event      
Loss Contingencies [Line Items]      
Loss Contingency, Lawsuits, Number | plaintiff 24    
Number of plaintiffs | plaintiff 28    
Total Opioid Litigation [Member]      
Loss Contingencies [Line Items]      
litigation settlement liability recorded   5,630.0  
Opioid Settlement Framework [Member]      
Loss Contingencies [Line Items]      
litigation settlement liability recorded   $ 5,140.0  
Private Parties [Member] | Opioid Lawsuits [Member] | Subsequent Event      
Loss Contingencies [Line Items]      
Loss Contingency, Lawsuits, Number | lawsuit 325    
Class Action Lawsuits [Member] | Private Parties [Member] | Opioid Lawsuits [Member] | Subsequent Event      
Loss Contingencies [Line Items]      
Loss Contingency, Lawsuits, Number | lawsuit 97    
XML 90 R65.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) - Restricted Share Units
shares in Millions
 3 Months Ended
Sep. 30, 2019
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 2 years
Restricted Share Units  
Nonvested at beginning of period (in shares) | shares 2
Granted (in shares) | shares 2
Vested (in shares) | shares (1)
Canceled and forfeited (in shares) | shares 0
Nonvested at end of period (in shares) | shares 3
Weighted-Average Grant Date Fair Value per Share  
Nonvested at beginning of period (in usd per share) | $ / shares $ 51.65
Granted (in usd per share) | $ / shares 42.09
Vested (in usd per share) | $ / shares 60.92
Canceled and forfeited (in usd per share) | $ / shares 0
Nonvested at end of period (in usd per share) | $ / shares $ 45.29
XML 91 R61.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation Narrative (Details)
$ in Millions
 3 Months Ended
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Tax benefit related to share-based compensation $ 4 $ 5
Stock Options    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Award vesting period (in years) 3 years  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 3  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 1 year  
Exercisable period of plans (in years) 10 years  
Restricted Share Units    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Award vesting period (in years) 3 years  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 125  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 2 years  
Performance Share Units    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Vesting Period in years for Shares 3  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 25  
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition 3 years  
Performance Share Units | Minimum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Target performance goal (as a percent) 0.00%  
Performance Share Units | Maximum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Target performance goal (as a percent) 240.00%  

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